Conditions: Hidradenitis Suppurativa Acne Inversa
Keywords: Avacopan ChemoCentryx Skin Disease Inflammatory nodule Abscess Sinus formation Fistula formation
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 435
Healthy volunteers: no

Brief summary:
Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

Detailed description:
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 study in subjects with moderate to severe Hidradenitis Suppurativa.

The study is multicenter and will consist of three subject groups. Subjects will be randomized 1:1:1 to a treatment of 10mg avacopan twice daily, 30 mg avacopan twice daily or placebo twice daily for 12 weeks.

Following the 12 weeks double-blind treatment period, subjects on placebo will be re-randomized 1:1 to receive 10 mg or 30 mg avacopan twice daily for additional 24 weeks. Subjects treated with avacopan will continue to receive the same dose (either 10 mg or 30 mg twice daily) for additional 24 weeks.

Subjects will be on study treatment for 36 weeks and will be followed for 44 weeks for assessment of safety and efficacy.

Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.

Primary efficacy analysis will be at 12 weeks.

Arms:
arm 1: Placebo twice daily (BID) for Period 1 of the study arm 2: Avacopan 10 mg twice daily (BID) for Period 1+2 of the study arm 3: Avacopan 30 mg twice daily (BID) for Period 1+2 of the study arm 4: Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2. arm 5: Treatment period 2, subjects randomized to placebo during period 1 were rerandomized 1:1 to receive 10 mg or 30 mg avacopan BID in period 2.

Interventions: intervention 1: Avacopan intervention 2: Placebo
Intervention descriptions: intervention 1: Active treatment intervention 2: Placebo

Protocol document:
Prot_000.pdf: 
A vac o pa n ( C C X 1 6 8)  
 
Pr ot oc ol C L 0 1 6 _ 1 6 8 
3 1 J ul y 2 0 1 9 
 
A me n d me nt 2. 0 
C he m o Ce ntr y x, I n c.  
C O N FI D E N TI A L  
Pa ge 1  of 8 7  
P R O T O C O L 
Pr ot oc ol A me n d me nt 2 . 0 
 
TI T L E P A G E  
St u d y Title:  A Ra n d o mize d, D o u ble- Bli n d, Place b o- C o ntr olle d, Parallel 
Gr o u p, P hase 2 St u d y t o E val uate t he Safet y a n d Efficac y of 
A vac o pa n i n S u bjects wit h M o derate t o Se vere Hi dra de nitis 
S u p p urati va 
Pr ot oc ol N u m ber:  C L 0 1 6 _ 1 6 8  
I n vesti g ati o n al Pr o d uct: A vac o pa n  (f or merl y C C X 1 6 8) 
I n dic ati o n: Treat me nt of s u bjects wit h Hi dra de nitis S u p p urati va 
S p o ns or:  C he m o Ce ntr y x, I n c.  
De vel o p me nt P h ase:  2  
I N D n u m ber 1 3 9 9 3 3 
E u dr a C T n u m ber  2 0 1 8- 0 0 2 3 5 1- 1 5 
S p o ns or's Res p o nsi b le 
Me dic al Officer:  
 
C he m o Ce ntr y x, I n c.  
 
S p o ns or Si g n at or y: 
 
Ori gi n al : 
A me n d me nt 1. 0 : 
A me n d me nt 2. 0 : 
1 9 Oct o ber 2 0 1 8 
1 9 M arc h  2 0 1 9 
3 1 J ul y 2 0 1 9 
 
T he i nf or mati o n c o ntai ne d herei n is t he pr o pert y of t he S p o ns or a n d ma y n ot be re pr o d u ce d, 
p u blis he d, or discl ose d t o ot hers wit h o ut writte n a ut h orizati o n of t he S p o ns or. 
T his st u d y will be c o n d u cte d acc or di n g t o t he pri n ci ples of G o o d Cli nical Practice as 
descri be d i n I nter nati o nal C o nfere nce o n H ar m o nizati o n g ui deli nes, i ncl u di n g t he arc hi vi n g 
of esse ntial d oc u me nts. 
P P D
P P D
P P D


Avacopan (CCX168) 
Protocol CL016_168 
31 July 2019 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 2 of 87 
INVESTIGATOR SIGNATORY PAGE 
Protocol Number: CL016_168 
Protocol Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 
Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe 
Hidradenitis Suppurativa 
I agree: 
•
To assume responsibility for the proper conduct of the study at this site.
•
To conduct the study in compliance with this protocol, any future amendments, and
with any other study conduct procedures provided by ChemoCentryx, Inc.
•
Not to implement any deviations from or changes to the protocol without agreement
from the Sponsor and prior review and written approval from the Institutional Review
Board (IRB)/Ethics Committee (EC), except where necessary to eliminate an
immediate hazard to the subjects, or for administrative aspects of the study (where
permitted by all applicable regulatory requirements).
•
That I am thoroughly familiar with the appropriate use of the investigational drug(s),
as described in this protocol, and any other information provided by the Sponsor
including, but not limited to the following: the current version of the Investigator’s
Brochure prepared by ChemoCentryx, Inc. and approved product label, if applicable.
•
That I am aware of and will comply with current International Conference on
Harmonisation (ICH)/Food and Drug Administration (FDA) good clinical practices
(GCP) guidelines and all regulatory requirements.
•
To ensure that all persons assisting me with the study are adequately informed about
the investigational drug(s) and their study-related duties and function as described in
the protocol.
__________________________________ 
___________________ 
Principal Investigator  
Date 
__________________________________ 
Printed Name 
Address*_____________________________________________________________ 
____________________________________________________________________ 
Phone Number* ___________________________________________ 
* If the address or phone number needs to be changed during the course of the study, this will
be done by the Investigator, with written notification to the Sponsor, and will not require (a)
protocol amendment(s).


A vac o pa n ( C C X 1 6 8)  
Pr ot oc ol C L 0 1 6 _ 1 6 8 
3 1 J ul y 2 0 1 9 
A me n d me nt 2. 0 
C he m o Ce ntr y x, I n c.  
C O N FI D E N TI A L  
Pa ge 3  of 8 7  
S P O N S O R C O N T A C T I N F O R M A TI O N  
Pr ot oc ol N u m ber:  C L 0 1 6 _ 1 6 8 
Pr ot oc ol Title:  A R a n d o mize d, D o u ble- Bli n d, Place b o- C o ntr olle d, Parallel Gr o u p, P hase 2 
St u d y t o E v al uate t he Saf et y a n d Efficac y of A vac o pa n i n S u bjects wit h M o derate t o Se vere 
Hi dra de nitis S u p p urati va 
Me dical Offi cer  
 
Vice Presi de nt Cli nical De vel o p me nt  a n d Tra nsl ati o nal Me dici ne 
C he m o Ce ntr y x, I n c.  
 
 
 
 
Cli nical O perati o ns 
Ma na g er  
 
C he m o Ce ntr y x, I n c.  
 
 
 
 
P P D
P P D
P P D
P P D


A v a c o p a n ( C C X 1 6 8) 
3 1 J ul y 2 0 1 9 
S P O N S O R SI G N A T U R E F O R A P P R O V A L 
P r ot o c ol N u m b e r: C L 0 1 6 1 6 8 
Pr ot o c ol C L 0 1 6 1 6 8 
A m e n d m e nt 2. 0 
P r ot o c ol Title: A R a n d o mi z e d, D o u bl e- Bli n d, Pl a c e b o- C o ntr oll e d, P ar all el Gr o u p, P h as e 2 
St u d y t o E v al u at e t h e S af et y a n d Effi c a c y of A v a c o p a n i n S u bj e cts wit h M o d er at e t o S e v er e 
Hi dr a d e nitis S u p p ur ati v a 
Vi c e Pr esi d e nt, Cli ni c al D e v el o p m e nt 
a n d Tr a nsl ati o n al M e di ci n e 
D at e 
C h e m o C e ntr y x, I nc. 
C O N FI D E N TI A L 
P a g e 4 of 8 7 
P P D
P P D


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 5 of 87 
PROTOCOL AMENDMENT 2.0: SUMMARY OF CHANGES 
1. The protocol Title Page was updated with the new amendment number and date. 
2. Collection of the Dermatology Life Quality Index (DLQI) and the Work Productivity and 
Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) scores were 
updated throughout the document. 
3. Period 1 has been defined to refer to the blinded, placebo-controlled 12-week treatment period. 
Period 2 has been defined to refer to the 24-week, active treatment period. 
4. Scars have been updated to include the term “hypertrophic” where appropriate throughout the 
document. 
5. SYNOPSIS - Secondary and Other Objectives and Section 2.2 Secondary Objectives and Other 
Objectives have been updated to prioritize the objectives. 
6. SYNOPSIS - Secondary Efficacy Endpoints and Section 8.5.2 Secondary Endpoints have been 
updated to prioritize four main secondary efficacy endpoints. All other previous secondary 
efficacy endpoints were relocated to SYNOPSIS - Other Efficacy Endpoints and Section 8.5.3 
Other Endpoints.  
7. SYNOPSIS - Other Efficacy Endpoints and Section 8.5.3 Other Endpoints have been added. 
8. SYNOPSIS - Study Interventions/Methodology and Section 4.4 Removal of Subjects from 
Therapy have been updated to include details on discontinuation of study medication due to 
inadequate or worsening response during the 24-week active treatment period. 
9. SYNOPSIS - Study Interventions/Methodology and Section 3.1 Stratification and 
Randomization have been updated to state that not more than 20% of enrolled subjects will be 
on allowed concomitant antibiotic therapy. 
10. SYNOPSIS - Criteria for Inclusion and Section 4.1 Inclusion Criteria have been updated to 
indicate the requirement of subjects to have at least 5 inflammatory nodules and abscesses at 
Screening in Inclusion #5 and to clarify contraception methods in Inclusion #7. 
11. SYNOPSIS - Criteria for Exclusion and Section 4.2 Exclusion Criteria have been updated to 
clarify medicines with potential therapeutic impact on HS in Exclusion #9. 
12. STUDY SCHEMA has been updated to clarify the two treatment periods. 
13. TIME AND EVENTS TABLE has been updated: 
a. To add a urine pregnancy test for women of childbearing potential on Day 1; 
b.To add collection of DLQI and WPAI:SHP scores (in Patient-Reported Outcomes) and 
Health-Economic Information; 
c. To clarify the collection of AEs at Screening; 
d.To clarify the maximum number of days allowed to exceed the Screening period; 
e. To update PK blood sample collection for timepoints up to 3 hours following dosing; 
f. To add study procedures to Week 24 and 32 visits; 
g.To add exploratory biomarker plasma sample collection at Day 1, Week 12, and Week 36 or 
Early Termination visits; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 6 of 87 
h. To add optional photography to all visits. 
14. LIST OF ABBREVIATIONS AND ACRONYMS has been updated to include missing 
acronyms. 
15. Section 5.7 Concomitant Therapy and Restrictions has been updated to clarify concomitant use 
of treatments with potential impact on HS including systemic antibiotics, antiseptics, 
analgesics, wound care, and lesion intervention methods. 
16. Section 6 STUDY PROCEDURES has been updated to harmonize study procedures with Time 
and Events Table in Sections 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 6.10, 6.11, 6.12, 6.13 
and 6.14. 
17. Section 7.1.1 Location and Extent of Hidradenitis Suppurativa Assessment has been updated to 
specify that the same Investigator should assess the lesions at each visit to assure consistency. 
18. Section 7.1.7 Health-Economic Information has been added. 
19. Section 7.2.3.3 Adverse Events of Special Interest (AESI) has been added. 
20. Section 7.2.4 Serious Adverse Event Reporting has been updated to include the new email 
contact for Serious Adverse Event reporting. 
21. Section 7.4 Exploratory Biomarker Assessments has been added to allow collection of plasma 
blood samples for biomarker assessments. 
22. Section 7.5 Photographic Assessments has been updated to specify the different uses of the 
photographs. 
23. Section 8.1 Timing of Analyses has been updated to describe the primary and final analyses. 
24. Section 8.4.1 Modified Intent-to-Treat Population has been updated to define the modified 
intent-to-treat populations. 
25. Section 8.4.3 Safety Population has been updated to define the safety populations. 
26. Section 8.8.1 General Approach has been updated to clarify on the non-responder and missing 
data analyses. 
27. Section 8.8.2 Analysis of Primary Efficacy Endpoint has been updated. 
28. Section 8.8.3 Analysis of Secondary and Other Efficacy Endpoints in Period 1 and 
Section 8.8.4 Analysis of Secondary and Other Efficacy Endpoints in Period 2 have been 
added. 
29. Section 8.8.12 Covariates and Subgroups has been updated to include new variables for the 
analysis of the efficacy endpoints. 
30. Section 8.9 Interim Analyses has been updated to include a potential futility analysis.


A vac o pa n ( C C X 1 6 8)  
 
Pr ot oc ol C L 0 1 6 _ 1 6 8 
3 1 J ul y 2 0 1 9 
 
A me n d me nt 2. 0 
C he m o Ce ntr y x, I n c.  
C O N FI D E N TI A L  
Pa ge 7  of 8 7  
T A B L E O F C O N T E N T S  
I N V E S TI G A T O R SI G N A T O R Y P A G E ......................................................................................... 2 
S P O N S O R C O N T A C T I N F O R M A TI O N  ....................................................................................... 3 
S P O N S O R SI G N A T U R E F O R A P P R O V A L  ................................................................................. 4 
S T U D Y S Y N O P SI S  ...................................................................................................................... 1 2 
S T U D Y S C H E M A ......................................................................................................................... 2 1 
TI M E A N D E V E N T S T A B L E ...................................................................................................... 2 2  
LI S T O F A B B R E VI A TI O N S A N D A C R O N Y M S  ...................................................................... 2 5 
1.  
I N T R O D U C TI O N ...................................................................................................... 2 8 
1. 1.  
C o m ple me nt a n d A vac o p a n ........................................................................................ 2 8  
1. 2.  
Pre vi o us Cli nical St u dies  ............................................................................................ 2 9 
1. 3.  
Rati o nale f or t he St u d y  ............................................................................................... 3 0 
2.  
O BJ E C TI V E S  ............................................................................................................. 3 1 
2. 1.  
Pri mar y O bj ecti ves  ..................................................................................................... 3 1 
2. 2.  
Sec o n dar y a n d Ot her O bj ecti ves  ................................................................................ 3 1 
3.  
S T U D Y D E SI G N  ....................................................................................................... 3 2 
3. 1.  
Stratificati o n a n d Ra n d o mizati o n  ............................................................................... 3 2 
3. 2.  
St u d y Treat me nts  ........................................................................................................ 3 3 
3. 3.  
St u d y Fl o w  .................................................................................................................. 3 4 
3. 4.  
Scie ntific Rati o nale f or St u d y Desi g n  ........................................................................ 3 4 
3. 5.  
Rati o nale f or D ose Sel ecti o n  ...................................................................................... 3 5 
4.  
S T U D Y P O P U L A TI O N  ............................................................................................. 3 6 
4. 1.  
I n cl usi o n Criteria ........................................................................................................ 3 6 
4. 2.  
E x cl usi o n Criteria  ....................................................................................................... 3 7 
4. 3.  
Scree n Fail ures  ............................................................................................................ 3 8 
4. 4.  
Re m o val of S u bjects fr o m T hera p y  ............................................................................ 3 9 
5.  
S T U D Y D R U G/ T R E A T M E N T  ................................................................................. 4 0 
5. 1.  
Pr o d uct C haracteristics  ............................................................................................... 4 0 
5. 2.  
D oses a n d Re gi me ns ................................................................................................... 4 0  
5. 3.  
Dr u g S u p pl y ................................................................................................................ 4 1  
5. 3. 1.  
Pac ka gi n g a n d La b eli n g  .............................................................................................. 4 1 
5. 3. 2.  
St ora ge  ........................................................................................................................ 4 1 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 8 of 87 
5.4. 
Blinding ......................................................................................................................41 
5.5. 
Drug Accountability ...................................................................................................42 
5.6. 
Treatment Compliance ................................................................................................42 
5.7. 
Concomitant Therapy and Restrictions ......................................................................43 
6. 
STUDY PROCEDURES ............................................................................................45 
6.1. 
Screening and Enrollment ...........................................................................................45 
6.2. 
Study Day 1 ................................................................................................................46 
6.3. 
Study Week 2 (Day 15) ..............................................................................................47 
6.4. 
Study Week 4 (Day 29) ..............................................................................................48 
6.5. 
Study Week 8 (Day 57) ..............................................................................................49 
6.6. 
Study Week 12 (Day 85) ............................................................................................50 
6.7. 
Study Week 16 (Day 113) ..........................................................................................51 
6.8. 
Study Week 20 (Day 141) ..........................................................................................52 
6.9. 
Study Week 24 (Day 169) ..........................................................................................54 
6.10. 
Study Week 28 (Day 197) ..........................................................................................55 
6.11. 
Study Week 32 (Day 225) ..........................................................................................56 
6.12. 
Study Week 36 (Day 253) ..........................................................................................57 
6.13. 
Study Week 44 (Day 309) ..........................................................................................58 
6.14. 
Early Termination Visit ..............................................................................................58 
7. 
STUDY ASSESSMENTS ..........................................................................................59 
7.1. 
Efficacy Assessments .................................................................................................59 
7.1.1. 
Location and Extent of Hidradenitis Suppurativa Assessment ...................................59 
7.1.2. 
Sartorius and Modified Sartorius Scores ....................................................................59 
7.1.3. 
International Hidradenitis Suppurativa Severity Score System ..................................60 
7.1.4. 
Hidradenitis Suppurativa-Physician Global Assessment (HS-PGA) .........................60 
7.1.5. 
Global Assessment of Skin Pain .................................................................................61 
7.1.6. 
Health-Related Quality of Life Assessments ..............................................................61 
7.1.7. 
Health-Economic Information ....................................................................................61 
7.2. 
Safety Assessments .....................................................................................................61 
7.2.1. 
Physical Examinations and Vital Signs ......................................................................61 
7.2.2. 
Clinical Safety Laboratory Assessments ....................................................................62 
7.2.3. 
Adverse Events ...........................................................................................................62 
7.2.3.1. 
Adverse Event Severity Assessment ..........................................................................63 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 9 of 87 
7.2.3.2. 
Causality Assessment .................................................................................................63 
7.2.3.3. 
Adverse Events of Special Interest (AESI) ................................................................63 
7.2.3.4. 
Serious Adverse Events ..............................................................................................64 
7.2.3.5. 
SARs and SUSARs .....................................................................................................64 
7.2.3.6. 
Laboratory Abnormalities ...........................................................................................65 
7.2.3.7. 
Pregnancies .................................................................................................................65 
7.2.4. 
Serious Adverse Event Reporting ...............................................................................65 
7.3. 
Pharmacokinetic Assessments ....................................................................................66 
7.4. 
Exploratory Biomarker Assessments ..........................................................................66 
7.5. 
Photographic Assessments..........................................................................................66 
7.6. 
Study Completion and Withdrawal ............................................................................67 
8. 
STATISTICAL CONSIDERATIONS .......................................................................67 
8.1. 
Timing of Analyses .....................................................................................................67 
8.2. 
Statistical Hypotheses .................................................................................................67 
8.3. 
Sample Size Determination ........................................................................................68 
8.4. 
Analysis Populations ..................................................................................................68 
8.4.1. 
Modified Intent-to-Treat Population ...........................................................................68 
8.4.2. 
Per-Protocol Population ..............................................................................................68 
8.4.3. 
Safety Population ........................................................................................................68 
8.5. 
Efficacy Endpoints ......................................................................................................69 
8.5.1. 
Primary Endpoint ........................................................................................................69 
8.5.2. 
Secondary Efficacy Endpoints ....................................................................................69 
8.5.3. 
Other Efficacy Endpoints ...........................................................................................69 
8.6. 
Safety Endpoints .........................................................................................................70 
8.7. 
Pharmacokinetic Endpoints ........................................................................................70 
8.8. 
Statistical Analysis Methodology ...............................................................................71 
8.8.1. 
General Approach .......................................................................................................71 
8.8.2. 
Analysis of Primary Efficacy Endpoint ......................................................................72 
8.8.3. 
Analysis of Secondary and Other Efficacy Endpoints in Period 1 .............................72 
8.8.4. 
Analysis of Secondary and Other Efficacy Endpoints in Period 2 .............................73 
8.8.5. 
Safety Analyses ..........................................................................................................73 
8.8.6. 
Pharmacokinetic Analysis ..........................................................................................74 
8.8.7. 
Subject Disposition .....................................................................................................74 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 10 of 87 
8.8.8. 
Demographics and Baseline Characteristics ...............................................................74 
8.8.9. 
Prior and Concomitant Medications ...........................................................................74 
8.8.10. 
Study Drug Exposure and Compliance .......................................................................74 
8.8.11. 
Handling of Missing Data ...........................................................................................75 
8.8.12. 
Covariates and Subgroups ..........................................................................................75 
8.9. 
Interim Analyses .........................................................................................................75 
9. 
STUDY COMPLETION AND TERMINATION ......................................................75 
9.1. 
Study Completion .......................................................................................................76 
9.2. 
Study Termination ......................................................................................................76 
10. 
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..................................................................................................76 
10.1. 
Regulatory, Ethical, and Study Oversight Considerations .........................................76 
10.1.1. 
Informed Consent .......................................................................................................76 
10.1.2. 
Study Discontinuation and Closure ............................................................................77 
10.1.3. 
Confidentiality and Privacy ........................................................................................77 
10.1.4. 
Future Use of Stored Specimens and Data .................................................................77 
10.1.5. 
Key Roles and Study Governance ..............................................................................78 
10.1.5.1. 
Investigator Responsibilities .......................................................................................78 
10.1.5.2. 
Sponsor and Its Designees ..........................................................................................78 
10.1.5.3. 
Institutional Review Boards/Ethics Committees ........................................................78 
10.1.6. 
Safety Oversight and Data Monitoring Committee ....................................................79 
10.1.7. 
Study Monitoring ........................................................................................................79 
10.1.8. 
Quality Assurance and Quality Control ......................................................................80 
10.1.9. 
Data Handling and Record Keeping ...........................................................................80 
10.1.9.1. 
Data Collection and Management Responsibilities ....................................................80 
10.1.9.2. 
Study Records Retention ............................................................................................81 
10.1.10. 
Protocol Deviations ....................................................................................................81 
10.1.11. 
Protocol Modifications ...............................................................................................81 
10.1.12. 
Study Registration, Use of Information and Publication ............................................82 
11. 
BENEFIT/RISK ASSESSMENT ...............................................................................82 
11.1. 
Non-Clinical Evaluation .............................................................................................82 
11.2. 
Clinical Evaluation .....................................................................................................83 
11.3. 
Summary Benefit-Risk Statement ..............................................................................85 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 11 of 87 
12. 
REFERENCES ...........................................................................................................86 
 
LIST OF TABLES 
Table 1: 
Avacopan/Placebo Treatment for the Three Study Groups ........................................34 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 12 of 87 
STUDY SYNOPSIS 
Name of Sponsor 
ChemoCentryx, Inc. 
Name of Active Ingredient 
Avacopan (formerly CCX168) 
Study Number:  
CL016_168 
Title 
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate 
the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis 
Suppurativa 
Study centers 
Multi-centers 
Study period 
29 months 
Phase of development 
Phase 2 
Background 
Hidradenitis suppurativa (HS), also called acne inversa, is a chronic inflammatory skin disease 
characterized by inflammatory nodule, abscess, sinus and fistula formation, and scarring of the 
skin, most commonly in apocrine gland rich areas such as the axilla, inframammary area, 
inguinal area, perineum, and perianal area. Therapy for subjects with HS includes local and 
systemic antibiotics, pain medication, and anti-TNF-α agents such as adalimumab. Acitretin is 
used in early stage disease. Other drugs such as cyclosporin A, dapsone, and isotretinoin have 
been used with limited success. 
Studies have shown that HS is a neutrophil-driven disease, and that complement activation with 
the production of terminal fragment C5a may be important in the pathogenesis of the disease. 
The C5a-C5aR signaling axis is essential in mediating neutrophil activation and migration. 
Avacopan, an orally administered selective C5a receptor (C5aR) inhibitor, was shown to be 
effective and safe in a Phase 2 study in subjects with anti-neutrophil cytoplasmic autoantibody 
(ANCA)-associated vasculitis (AAV) and is being tested in a Phase 3 clinical trial in subjects 
with AAV. Since avacopan selectively blocks the C5aR, it has the potential to be an effective 
therapy for subjects with HS. Hence, the clinical hypothesis of this trial is to test whether 
avacopan is effective in treating subjects with moderate to severe HS. 
Study Description 
The study is a randomized, double-blind, placebo-controlled, three-group Phase 2 trial in 
approximately 390 subjects with moderate to severe hidradenitis suppurativa (Hurley Stage II or 
III). Subjects will be randomized 1:1:1 to a treatment of 10 mg avacopan twice daily, 30 mg 
avacopan twice daily or placebo for 12 weeks. Other systemic treatments for HS including anti-
TNF-α treatments are prohibited. Stable antibiotic therapy with doxycycline or minocycline is 
allowed as specified in the protocol. Subjects treated with 10 mg or 30 mg avacopan twice daily 
during the blinded, placebo-controlled 12-week treatment period (Period 1) will be followed by 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 13 of 87 
an additional 24-week, active treatment period (Period 2) during which they will continue to 
receive the same dose regimen, either 10 mg or 30 mg avacopan twice daily. Subjects on 
placebo who complete Period 1 will be re-randomized 1:1 to receive 10 mg or 30 mg avacopan 
twice daily in Period 2. During Period 2 the treatment assignment to 10 mg or 30 mg twice 
daily will not be disclosed to the subject, study site personnel or the Sponsor. Thereafter, all 
subjects will be followed without study drug for 8 weeks before they exit the study. 
Objectives 
Primary Objectives: 
1. Evaluation of the efficacy of avacopan compared to placebo in subjects with Hurley Stage II 
or III hidradenitis suppurativa (HS) based on subjects achieving a Hidradenitis Suppurativa 
Clinical Response (HiSCR) after 12 weeks of treatment. HiSCR is defined as at least a 50% 
reduction in abscess and inflammatory nodule count and no increase in abscess count and no 
increase in draining fistula count at Week 12 relative to baseline. 
2. Evaluation of the safety of avacopan compared to placebo in these subjects based on the 
adverse event incidence, changes from baseline in laboratory parameters, and vital signs. 
Secondary and Other Objectives: 
1. Evaluation of the efficacy of avacopan compared to placebo in these subjects include: 
a. The subject’s global assessment of skin pain numeric rating scale (NRS), 
b. The modified Sartorius score, and 
c. Achieving an AN count of 0, 1, or 2. 
2.  Assessment of patient-reported outcomes including health-related quality-of-life changes 
based on the Short Form-36 version 2 (SF-36 v2), the EuroQOL-5D-5L (EQ-5D-5L), the 
Hidradenitis Suppurativa Quality of Life (HiSQOL) Index, the Dermatology Life Quality 
Index (DLQI), and the Work Productivity and Activity Impairment Questionnaire: Specific 
Health Problem (WPAI:SHP) with avacopan compared to placebo. 
3. Evaluation of the pharmacokinetic profile of avacopan in subjects with HS. 
4. Evaluation of the safety and efficacy of avacopan treatment from Day 1 by each timepoint 
up to Week 44 in subjects with HS. 
5. Evaluation of the efficacy of avacopan compared to placebo in these subjects include: 
a. The Sartorius score, International HS Severity Scoring System (IHS4) score, HS 
Physician Global Assessment (HS-PGA), 
b. Proportion of subjects who experienced flare, who experienced loss of response during 
Period 2, who received oral antibiotic rescue therapy or lesion intervention, and who 
received disallowed opioid pain therapy, and 
c. The duration of flare in days.  
6. Evaluation of health-economic information. 
Endpoints 
Endpoints will be evaluated by treatment group. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 14 of 87 
Primary Efficacy Endpoint 
The proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at 
Week 12. A response is defined as a reduction of at least 50% in abscess and inflammatory 
nodule count with no increase in abscess count and no increase in draining fistula count 
compared to baseline. 
Secondary Efficacy Endpoints: 
1. Reduction of IHS4 score relative to baseline at Week 12; 
2. Proportion of subjects achieving at least 30% reduction and at least 1 unit reduction from 
Day 1 in the subject’s global assessment of skin pain (NRS30) in subjects with a Day 1 
NRS of at least 3, evaluated at Week 12; weekly averages of daily pain will be calculated 
based on subjects’ daily diary recording of the worst pain experienced in the previous 24 
hours; 
3. Change from Day 1 to Week 12 in the modified Sartorius score to quantify the severity 
change of HS; 
4. Proportion of subjects with baseline Hurley Stage II who achieved an abscess and 
inflammatory nodule count of 0, 1, or 2 at Week 12. 
Other Efficacy Endpoints: 
The following efficacy endpoints will be analyzed from Day 1 to each timepoint up to Week 44, 
where applicable: 
1. Proportion of subjects achieving HiSCR; 
2. Proportion of subjects achieving at least 30% reduction and at least 1 unit reduction from 
Day 1 in the subject’s global assessment of skin pain (NRS30), in subjects with a Day 1 
NRS of at least 3; 
3. Proportion of subjects with baseline Hurley Stage II who achieved an abscess and 
inflammatory nodule count of 0, 1, or 2; 
4. Change from Day 1 in inflammatory nodule count, abscess count, draining fistula count, and 
total AN count; 
5. Change from Day 1 in the Sartorius score, modified Sartorius score, IHS4 score, and HS-
PGA to quantify the severity change of HS; 
6. Change from Day 1 in patient-reported outcomes: SF-36 v2, EQ-5D-5L, HiSQOL and 
DLQI; 
7. Proportion of subjects who experienced flare, defined by at least a 25% increase in AN 
counts with a minimum increase of 2 AN lesions relative to Day 1; 
8. Duration of flare in days (calculated from the day when flare is observed to the day prior to 
the observation that flare is no longer present; of note, there could be multiple periods that 
flares are observed, in which case, the total days from the multiple periods will be used); 
9. Proportion of subjects who experience at least 25% increase in draining fistula counts with a 
minimum increase of 2 draining fistula counts relative to Day 1; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 15 of 87 
10. During Period 2, Proportion of subjects with a loss of response, (LOR) defined as loss of at 
least 50% of AN count improvement achieved from Period 1; 
11. Time to LOR during Period 2; 
12. Proportion of subjects who received oral antibiotic rescue therapy; 
13. Proportion of subjects who start disallowed opioid pain therapy; 
14. Proportion of subjects who undergo lesion intervention due to HS; 
15. Number of lesion interventions due to HS; 
16. Health-economic information: 
a. WPAI:SHP: Change from Day 1 to each timepoint during Period 1and Change from 
Week 12 to each timepoint during Period 2 and including the follow-up period; 
b. Hospitalizations (cumulative): Number of Hospitalizations total and due to HS, 
Number of days hospitalized, Number of days missed from work;  
c. Emergency or Urgent Care visits (cumulative): Number of visits total and due to HS, 
Number of days (or hours where applicable) missed from work; 
d. Lesion interventions for HS: Number of days (or hours where applicable) missed from 
work due to HS lesion interventions. 
Safety endpoints: 
1. Subject incidence of treatment-emergent serious adverse events, adverse events, and 
withdrawals due to adverse events; 
2. Change from Day 1 and shifts from Day 1 in all safety laboratory parameters; 
3. Change from Day 1 in vital signs and significant changes in physical examination 
abnormalities. 
Number of Subjects/Sample Size Assumptions: 
The study will enroll approximately 390 subjects. The proportion of subjects in the placebo 
control group achieving a HiSCR at Week 12 is estimated to be approximately 30%. The 
attrition rate throughout the trial is estimated to be approximately 7%. A sample size of 
approximately 130 subjects per treatment group (390 in total) at a Type I error rate of two-sided 
α = 0.05 provides approximately 90% power to detect a 20% superiority of avacopan compared 
to the placebo control group in HiSCR at Week 12, assuming an HiSCR at Week 12 of 50% in 
the avacopan group. 
Study Interventions/Methodology 
Eligible adult subjects (at least 18 years of age) with moderate to severe hidradenitis 
suppurativa (Hurley Stage II or III) as specified by the eligibility criteria are allowed to enter 
the study. 
In Period 1, subjects will be randomized 1:1:1 to receive 10 mg avacopan twice daily, 30 mg 
avacopan twice daily or matching placebo for 12 weeks in a double-blind, placebo-controlled 
manner. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 16 of 87 
To obtain balance across treatment groups, a stratified randomization scheme will be 
implemented. The stratification factors and strata within each factor are listed below. Eligible 
subjects will be randomized with equal chance (i.e., 1:1:1) to one of the three treatment groups 
within each stratum based on a non-dynamic, list-based blocked randomization scheme. 
1. Hurley Stage (Stage II vs. III): 
a. Stage II disease: one or more widely separated recurrent abscesses with tract 
formation and scars, or 
b. Stage III disease: multiple interconnected tracts and abscesses across an entire area, 
with diffuse or near diffuse involvement. 
2. Concomitant antibiotic therapy (Yes vs. No) 
a. Concomitantly treated with doxycycline or minocycline as the only allowed antibiotic 
treatment for HS, or 
b. No concomitant antibiotic therapy. 
3. Anti-TNF-α treatment (Treatment naïve vs. Previous treatment): 
a. Did not previously receive anti-TNF-α drug such as adalimumab or infliximab (anti-
TNF-α drug naïve), or 
b. Previously (but no longer) received an anti-TNF-α drug and 
• completed anti-TNF-α treatment but may have relapsed, or 
• was intolerant to anti-TNF-α treatment, or 
• previously failed to respond or inadequately responded to anti-TNF-α treatment. 
Not more than 20% of subjects will be in stratum 2a. 
Subjects will be screened for eligibility based on the stage of the disease and their health status. 
The Screening period will be up to 28 days. The primary efficacy analysis can occur when the 
last enrolled subject has completed the Week 12 visit. After Period 1, all subjects will continue 
into Period 2 with an additional 24-week treatment with either 10 mg or 30 mg avacopan twice 
daily. The treatment assignment to 10 mg or 30 mg twice daily will not be disclosed to the 
subject, study site personnel or the Sponsor. Thereafter, all subjects will be followed for 8 
weeks. 
All subjects will visit the study center during the 28-day Screening period, and, if eligible, on 
Day 1 and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, and 44 of the study. Study drug will be 
dispensed at the study site and subjects will take the first dose of study drug, i.e., avacopan or 
matching placebo, while at the study center. Following the first dose, subjects will take study 
drug twice daily which will continue for 12 weeks (84 days). Thereafter, all subjects will take 
avacopan study drug for 24 weeks (168 days), after which all subjects will be followed for 
8 weeks (56 days) without taking study medication. Study procedures at each visit day are 
detailed in the Time and Events Table. 
Subjects will be discontinued from the study when all the Study Week 44 visit procedures have 
been completed. 
Subjects who experience a flare of HS or need HS lesion intervention during the study will be 
treated by the Investigator as outlined in Section 5.7 Concomitant Therapy and Restrictions. 
These subjects will be requested to remain in the study and to complete all study procedures if 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 17 of 87 
possible. During this time, subjects may continue to receive the study drug if deemed clinically 
feasible by the Investigator as described in Section 5.7. 
Discontinuation of study medication due to inadequate or worsening response in Period 2: 
Unless prohibited for safety reasons, deemed inappropriate by the Investigator, or subject 
withdraws consent, all subjects are allowed to enter Period 2. Subjects in Period 2 will 
discontinue taking study medication if at two consecutive protocol-specified visits ≥14 days 
apart, the AN count increases by more than 50% compared to the AN count at Week 12. 
However, these subjects will be requested to remain in the study and to complete all study 
procedures if possible. 
Criteria for Inclusion 
1. Aged at least 18 years of age; 
2. Clinical diagnosis of HS (Hurley Stage II or III), confirmed by a dermatologist, for at least 
6 months prior to Screening. Hurley Stage II disease is defined as having one or more 
widely separated recurrent abscesses with tract formation and scars; Stage III disease is 
defined as having multiple interconnected tracts and abscesses across an entire anatomical 
area, with diffuse or near diffuse involvement. 
3. HS lesions are present in at least 2 distinct anatomic areas (e.g., left and right axilla; or left 
axilla and left inguino-crural fold), one of which is Hurley Stage II or Hurley Stage III; 
4. Inadequate or loss of response to a systemic course of antibiotics of 90 days. However, a 
subject who has completed less than 90 days of antibiotic treatment may be allowed into the 
study upon discussion with the Medical Monitor if: 1) the subject has demonstrated 
intolerance to or contraindication for antibiotics to treat HS, or 2) it was determined by the 
Investigator that an antibiotic course of at least 28 days to treat HS did not benefit the 
subject and a continued antibiotic therapy would therefore not be indicated.  
Inadequate or loss of response is defined if the following was observed despite antibiotic 
treatment: 
a. Progression of Hurley Stage (i.e., the Hurley Stage of at least one affected anatomic 
region progressed from I→II, II→III, or I→III); 
b. Subject required at least one intervention (e.g., incision and drainage or intralesional 
injection of corticosteroid); 
c. Subject experienced pain interfering with activities of daily living, with unsatisfactory 
relief from over-the-counter analgesics (e.g., ibuprofen or acetaminophen); 
d. Subject experienced pain requiring opioids, including tramadol; 
e. Subject experienced drainage interfering with activities of daily living (e.g., requires 
multiple dressing changes and/or changes of clothes daily); 
f. Subject experienced an increase in the number of anatomic regions affected by HS; 
g. Subject experienced at least one new abscess or one new draining fistula. 
5. Must have at least 5 inflammatory nodules or abscesses at Screening; 
6. Must agree to use a topical antiseptic daily over the course of the study; topical antiseptics 
may include but are not limited to chlorhexidine, triclosan, benzoyl peroxide, or diluted 
bleach in bath water; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 18 of 87 
7. Female subjects of childbearing potential may participate if adequate contraception is used 
during the study and for at least three months after study completion. Adequate 
contraception is defined as resulting in a failure rate of less than 1% per year (combined 
estrogen and progestogen [oral, intravaginal, or transdermal], or progestogen-only hormonal 
contraception where inhibition of ovulation is the primary mode of action [oral, injectable, 
or implantable], intra-uterine device, intra-uterine hormone releasing system, bilateral tubal 
occlusion, vasectomized partner, or true [absolute] sexual abstinence, i.e., in line with the 
preferred and usual lifestyle of the subject). Male subjects with partners of childbearing 
potential may participate in the study if they had a vasectomy at least 6 months prior to 
randomization or if adequate contraception as defined above is used during the study and for 
at least three months after study completion. In addition, a barrier method (i.e., condom, 
cervical cap, or diaphragm) must be used during intercourse between a male study subject 
and a female partner of childbearing potential; 
8. Willing and able to give written Informed Consent and to comply with the requirements of 
the study protocol; 
9. Judged by the Investigator to be otherwise fit for the study, based on medical history, 
physical examination (including electrocardiogram [ECG]), and clinical laboratory 
assessments. Subjects with clinical laboratory values that are outside of normal limits (other 
than those specified in the Exclusion Criteria) and/or with other abnormal clinical findings 
that are judged by the Investigator not to compromise subject participation in the study, may 
be entered into the study. 
Criteria for Exclusion 
1. Pregnant or breast-feeding; 
2. Any other skin disease that may interfere with the assessment of HS, such as a viral or 
fungal skin infection; 
3. Rapidly progressive, expanding HS within 30 days prior to Screening; 
4. More than 20 draining fistulae at Screening; 
5. Any anti-TNF-α treatment for HS or for other conditions prior to Day 1 visit will be 
prohibited. Exception: Subjects who were previously treated with an anti-TNF-α drug and 
discontinued treatment >12 weeks prior to Day 1 visit are allowed for enrollment; 
6. Systemic antibiotics are generally excluded. Exception: subjects on systemic antibiotic 
treatment with doxycycline or minocycline who have been on a stable dose for at least 28 
days prior to Day 1. After a pre-specified percentage of subjects on these permissible 
antibiotic treatments have been enrolled, no further enrollment of such subjects will be 
allowed; 
7. Topical antibiotics use within 14 days prior to Day 1; 
8. Have started a topical prescription medicine for HS within 14 days prior to Screening or is 
anticipated to start during the screening period. Topical prescription medicine for HS other 
than topical antibiotics that was started >14 days prior to Screening is allowed; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 19 of 87 
9. With the exception of permissible antibiotic treatment regimens, have received a systemic 
medicine for HS or with a potential therapeutic impact on HS, including systemic antibiotic 
therapy, biologics and other systemic therapies such as methotrexate, cyclosporine, 
retinoids, and fumaric acid esters, etc., within a minimum of 30 days or 5 half-lives 
(whichever is longer) after taking the last dose; 
10.  Have received within 14 days prior to Day 1 visit or is expected to require during the study 
oral or transdermal opioid analgesics (except for tramadol) for any reason; non-opioid 
analgesics are allowed if the subject is on a stable dose for at least 14 days prior to the Day 
1 visit (“as needed” dosing is not considered to be a stable dose); 
11. Currently taking a strong inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, such as 
carbamazepine, phenobarbital, phenytoin, rifampin, or St. John’s wort; 
12. Any of the following within 12 weeks prior to Screening: symptomatic congestive heart 
failure requiring prescription medication, unstable angina (unless successfully treated with 
stent or bypass surgery), clinically significant cardiac arrhythmia, myocardial infarction or 
stroke; 
13. History or presence of any form of cancer within the 5 years prior to Screening, with the 
exception of excised basal cell or squamous cell carcinoma of the skin, or carcinoma in situ 
such as cervical or breast carcinoma in situ that has been excised or resected completely and 
is without evidence of local recurrence or metastasis; 
14. Evidence of tuberculosis based on interferon γ release assay (IGRA); 
15. HBV, HCV, or HIV viral screening test done at Screening or within 6 weeks prior to 
screening showing evidence of active or chronic viral infection; 
16. Received a live vaccine within 4 weeks prior to Screening; 
17. WBC count less than 3500/μL, or neutrophil count less than 1500/μL, or lymphocyte count 
less than 500/µL before start of dosing; 
18. Evidence of hepatic disease: AST, ALT, alkaline phosphatase, or bilirubin >3 times the 
upper limit of normal before the start of dosing; 
19. Clinically significant abnormal electrocardiogram (ECG) during Screening which, in the 
opinion of the Investigator, may place the subject at unacceptable risk for study 
participation; 
20. Known hypersensitivity to avacopan or inactive ingredients of the avacopan capsules 
(including gelatin, polyethylene glycol, or macrogolglycerol hydroxystearate [EP, European 
Pharmacopoeia (EP)] known also as polyoxyl 40 hydrogenated castor oil [NF, National 
Formulary]) or Cremophor® RH 40; 
21. Participated in any clinical study of an investigational product within 30 days prior to 
Screening or within 5 half-lives after taking the last dose; 
22. History or presence of any medical condition or disease which, in the opinion of the 
Investigator, may place the subject at unacceptable risk for study participation. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 20 of 87 
Study Drug, Dose, and Mode of Administration 
Study subjects will receive active avacopan or placebo capsules as study drug. The study drug 
consists of hard gelatin capsules containing 10 mg avacopan or placebo administered orally. 
Avacopan and placebo bottles and capsules will be identical in appearance. 
Subjects will be asked to take 3 capsules of study drug orally with water and preferably with 
food every morning, and 3 capsules with water and preferably with food in the evening 
approximately 12 hours after the morning dose, as instructed. Study drug will be taken for 36 
weeks (252 days) continuously.  


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 21 of 87 
STUDY SCHEMA 
 
 
 
 
Period 1 
 
Period 2 
 
 
 
Screening  
 
 
Double-Blind Treatment 
 
 
Active Treatment  
 
 Follow-up  
 
Eligibility 
Assessments 
 
 
 
Group A: Placebo b.i.d. 
Group B: Avacopan 10 mg b.i.d. 
Group C: Avacopan 30 mg b.i.d. 
 
 
Avacopan 10 mg b.i.d. 
Avacopan 30 mg b.i.d. 
Avacopan 10 mg b.i.d. 
Avacopan 30 mg b.i.d. 
 
No study 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Duration 
≤ 28 days 
 
84 days 
(12 weeks)  
 
168 days (24 weeks) 
 
56 days 
(8 weeks) 
Study 
Visits 
One or more 
visits to 
complete 
screening 
procedures 
 
Day 1 and, Weeks 2, 4, 8 and 12 
 
Weeks 16, 20, 24, 28, 
32, 36 
 
Week 44 
 
/ -
--
--
--


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 22 of 87 
TIME AND EVENTS TABLE 
 
Screening 
Period 1 
Double-Blind Treatment 
Period 2 
Active Treatment  
Follow-
up 
Study Week1 
≤4 weeks1 
 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
44 
Study Day1 
≤28 days1 
1 
15 
29 
57 
85 
113 
141 
169 
197 
225 
253 
309 
 
-7 
days 
 
 
 
 
 
 
 
 
 
 
 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review 
inclusion/exclusion 
criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics, 
medical history, 
prior treatments  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical 
examination2 
X 
 
X3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Vital signs 
X 
 
X3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum pregnancy 
test for women of 
childbearing 
potential 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
  
Urine pregnancy 
test for women of 
childbearing 
potential 
 
 
X3 
 
 
 
 
 
 
 
 
 
 
 
HIV, HBV, HCV 
testing 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening for 
tuberculosis4 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
12-Lead ECG 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
Serum chemistry 
incl. Liver 
Function Tests, 
Hematology 
X 
 
X3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
 
X3 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Biomarker plasma 
sample collection15 
 
 
X15 
 
 
 
X 
 
 
 
 
 
X 
 
Stratification and 
randomization 
 
 
X 
 
 
 
X10 
 
 
 
 
 
 
 
Record location 
and number of HS 
inflammatory 
nodules, abscesses, 
fistulae, and scars 
X 
 
X3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Record Hurley 
Stage 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject global 
assessment of skin 
pain daily diary 
recording5  
 
X3→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→X 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 23 of 87 
 
Screening 
Period 1 
Double-Blind Treatment 
Period 2 
Active Treatment  
Follow-
up 
Study Week1 
≤4 weeks1 
 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
44 
Study Day1 
≤28 days1 
1 
15 
29 
57 
85 
113 
141 
169 
197 
225 
253 
309 
 
-7 
days 
 
 
 
 
 
 
 
 
 
 
 
 
Record items for 
the Sartorius and 
modified Sartorius 
scores calculation6 
 
 
X3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Photograph 
selected lesions12  
 
 
X12 
X 
X12 
X 
X12 
X12 
X 
X 
X12 
X 
X12 
X 
Record IHS4 
score7  
 
 
X3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
HS-PGA14 
 
 
X3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
SF-36 v2 and EQ-
5D-5L Patient-
Reported 
Outcomes8  
 
 
X3 
 
X 
 
X 
X 
 
 
X 
 
X 
X 
HiSQOL Index8 
Health-Economic 
Information13  
 
 
X3
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Study drug 
dispensing 
 
 
X3 
 
  
  
X 
  
  
X  
 
  
 
 
Study drug 
compliance 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Study drug 
accountability11 
 
 
 
 
 
 
X11 
 
 
X11 
 
 
X11 
 
PK plasma sample 
collection9 
 
 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
X 
Concomitant 
medications 
X 
 
X 
X  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse event 
assessment 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
1Screening period may be exceeded by up to 3 days. Week 1 through 36 visits may occur within a ± 2-day window. 
The Week 44 visit may occur within a ± 4-day window. 
2Physical examination will include body weight measurements. Height will be measured only at Screening. 
3These procedures must be performed before taking the first dose of blinded study drug (avacopan or placebo). 
4Screening for tuberculosis: see exclusion criteria for specifics. 
5Subjects will record the maximum severity pain on a numeric rating scale from 0 (no skin pain) to 10 (skin pain as 
bad as can be imagined) in a daily diary from one week prior to Day 1 through the Week 44 visit. 
6Twelve body areas will be evaluated to calculate the Sartorius and modified Sartorius scores: left and right axillae, 
left and right inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, 
perianal area, perineal area, and other. The presence of nodules, abscesses, fistulae, scars, and other findings will 
be recorded. The longest distance between two lesions and whether lesions are separated by normal skin will be 
recorded. 
7IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of 
draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4–10 signifies 
moderate HS and a score of 11 or higher signifies severe HS. 
8“Patient-reported outcomes” (PROs) include the SF-36 v2, EQ-5D-5L, HiSQOL, DLQI, and WPAI-SHP 
questionnaires. The SF-36 v2 and EQ-5D-5L instruments are widely accepted global non-disease-specific tools to 
measure changes in subjects’ health-related quality of life. The HiSQOL index (an HS-specific instrument) and 
DLQI instruments are designed to measure the impact of HS or skin disease on subjects’ quality of life. The 
WPAI:SHP assesses the effect of general and specific health conditions on productivity losses. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 24 of 87 
9 PK blood sample will be collected prior to the morning dose on Day 1 and at 0.5, 1, 2, and 3 (+/- 5 minutes) hours 
following dosing. Single PK samples will be collected pre-dosing at the subsequent visits as indicated. The date 
and time of the PK sample collection will be recorded. The date and time of the last dose of study drug prior to the 
PK sample collection will also be recorded. On study visit days when PK samples are collected, it is preferable 
that the subjects take the morning dose of study drug at the site following the collection of PK samples. PK will be 
performed in up to 150 subjects participating in the study. The Sponsor will continuously assess the number of 
subjects enrolled in the PK group. If at any point during enrollment, the number of PK subjects is below the 
required number, PK samples will be considered mandatory for the remaining subjects to be enrolled in the study. 
Additional consenting will be requested from subject for collection of PK samples. 
10 Subjects on placebo who complete the blinded, placebo-controlled 12-week period (Period 1) will be re-
randomized 1:1 to receive 10 mg or 30 mg avacopan twice daily during the 24-week active treatment period 
(Period 2). 
11At Week 12, 24, and 36 visits, full drug accountability will be conducted on returned study drug. 
12If consented, photography will be used for the purpose of publications and lesion assessment comparison. If 
feasible, it is recommended that photographs be taken at every visit. 
13Health-economic information include hospitalizations, emergency or urgent care visits, and lesion interventions 
due to HS. The WPAI:SHP questionnaire administration will follow the Patient-Reported Outcomes schedule. 
14HS-PGA is an ordinal scale specific to HS that categorizes subjects into clear, minimal, mild, moderate, severe, or 
very severe disease. 
15Biomarker plasma sample will be collected at Day 1, Week 12, and Week 36 or Early Termination visits in 
subjects who consented and at study sites adequately equipped to perform the collection. For Day 1, the biomarker 
sample collection must be done before the subject takes the first dose of study drug. 
 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 25 of 87 
LIST OF ABBREVIATIONS AND ACRONYMS 
AAV 
ANCA-associated vasculitis 
AE 
adverse event 
AESI 
adverse event of special interest 
aHUS 
atypical hemolytic uremic syndrome 
ALT 
alanine aminotransferase 
AN 
abscess and inflammatory nodule (count) 
ANA 
antinuclear antibodies 
ANC 
absolute neutrophil count 
ANCA 
anti-neutrophil cytoplasmic autoantibody 
ANCOVA 
analysis of covariance 
AST 
aspartate aminotransferase 
AT 
Aminotransferase 
ATC 
Anatomic Therapeutic Chemistry 
AUC 
area under the plasma concentration-time curve 
b.i.d. 
twice daily 
BVAS 
Birmingham Vasculitis Activity Score 
C3 
complement component 3 
C3a 
complement component 3a fragment 
C4a 
complement component 4a fragment 
C5a 
complement component 5a fragment 
C5aR 
receptor for C5a 
C5b-9 
membrane attack complex or terminal complement complex 
CA 
competent authority 
Cmax 
maximum (maximal) plasma concentration 
Cmin 
minimum plasma concentration 
CMH 
Cochran-Mantel-Haenszel 
CPK 
creatine phosphokinase 
CRA 
Clinical Research Associate 
CRF 
Case Report Form 
CRO 
clinical research organization 
CSR 
clinical study report 
CYP3A4 
cytochrome P450 3A4 
DLQI  
Dermatology Life Quality Index 
DMC 
data monitoring committee 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
electronic case report form 
EDC 
electronic data capture 
EIA  
enzyme immunoassay 
EP 
European Pharmacopoeia 
EQ-5D-5L 
EuroQuality of Life-5 Domains-5 Levels 
FDA 
Food and Drug Administration 
g 
Gram 
GCP 
Good Clinical Practice 
HBV 
hepatitis B virus 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 26 of 87 
HCV 
hepatitis C virus 
hERG 
potassium channel encoded by the human ether-à-gogo related gene 
HiSCR 
hidradenitis suppurativa clinical response 
HiSQOL 
Hidradenitis Suppurativa Quality of Life 
HIV 
human immunodeficiency virus 
HS 
hidradenitis suppurativa 
HS-PGA  
Hidradenitis Suppurativa-Physician Global Assessment 
ICH 
International Conference on Harmonisation 
IC50 
concentration associated with 50% inhibition 
Ig 
Immunoglobulin 
IgAN 
immunoglobulin A nephropathy 
IGRA 
interferon γ release assay 
IHS4 
International HS Severity Scoring System 
IND 
Investigational New Drug 
INR 
International normalized ratio 
IRB 
Institutional Review Board 
IRT 
interactive response technology 
ITT 
intent-to-treat 
IV 
intravenous(ly) 
kDa 
Kilodalton 
kg 
Kilogram 
LOCF 
last observation carried forward 
LOR 
loss of response 
MAC 
membrane attack complex 
MCP-1 
monocyte chemoattractant protein-1, also known as CCL2 
MedDRA 
Medical Dictionary for Regulatory Activities 
Mg 
Milligram 
mITT 
modified intent-to-treat 
mL 
Milliliter 
MPO 
myeloperoxidase  
MSS  
modified Sartorius score 
N 
Number 
NF 
National Formulary 
NRI 
Non-Responder Imputation 
NRS 
numeric rating scale 
NRS30 
proportion of subjects achieving at least 30% reduction and at least 1 unit 
reduction from baseline in the subject’s global assessment of skin pain on a 
numeric rating scale 
PCR 
polymerase chain reaction 
PK 
pharmacokinetic(s) 
PP 
Per-protocol 
PRO 
patient-reported outcome 
PT 
prothrombin time 
QA 
quality assurance 
QC 
quality control 
QT/QTc 
Q-T interval on ECG; corrected Q-T interval 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 27 of 87 
RBC 
red blood cell(s) 
RNA 
ribonucleic acid 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SAR 
serious adverse reaction 
SD 
standard deviation 
SEM 
standard error of the mean 
SF-36 v2 
Short Form-36 version 2.0 
SOP 
standard operating procedure 
SUSAR 
suspected unexpected serious adverse reaction 
TB 
tuberculosis 
TBili 
total bilirubin 
TCC 
terminal complement complex, also known as membrane attack complex 
ULN 
upper limit of normal 
WBC 
white blood cell 
WHODD 
World Health Organization Drug Dictionary 
WPAI:SHP 
Work Productivity and Activity Impairment Questionnaire: Specific Health 
Problem 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 28 of 87 
1. 
INTRODUCTION 
1.1. Complement and Avacopan 
The activation of the complement pathway generates biologically active fragments of 
complement proteins, e.g., C3a, C4a and C5a anaphylatoxins, and the C5b-9 membrane attack 
complex (MAC) or terminal complement complex (TCC), all of which mediate inflammatory 
responses by inducing leukocyte chemotaxis, activating macrophages, neutrophils, platelets, 
mast cells and endothelial cells and by increasing vascular permeability, cytolysis, and tissue 
injury. 
C5a is one of the most potent pro-inflammatory mediators of the complement system, being at 
least 100 times more potent than C3a. This 12 to 14.5 kD polypeptide, along with a C5b 
fragment, is produced by enzymatic cleavage of a C5 precursor during activation of any of the 3 
complement pathways. C5a induces expression of adhesion molecules and chemotactic 
migration of neutrophils, eosinophils, basophils, and monocytes. It also mediates inflammatory 
reactions by causing smooth muscle contraction, increasing vascular permeability, inducing 
basophil and mast cell degranulation, and inducing release of lysosomal proteases and oxidative 
free radicals. The anaphylactic and chemotactic effects of C5a are mediated through its 
interaction with the C5aR, a G protein-coupled receptor expressed on human neutrophils, 
monocytes, basophils, eosinophils, renal glomerular tissues, and lung smooth muscle and 
endothelial cells. 
Avacopan (formerly CCX168) is an orally administered, small molecule, selective inhibitor of 
the complement 5a receptor (C5aR). 
As measured in vitro, avacopan functionally inhibits C5a-mediated chemotaxis, displaces 
[125I]-C5a from human C5aR, and inhibits C5a-mediated increase in cytoplasmic calcium levels 
with a potency (IC50) of 0.2 to 0.9 nM in buffer (Bekker et al, 2016). 
Avacopan was also evaluated for its ability to inhibit the C5a-mediated chemotaxis of 
neutrophils in freshly isolated human whole blood. Avacopan produced 50% inhibition (IC50) of 
C5a-mediation neutrophil migration in this assay at a concentration of 1.7 nM; 90% inhibition 
(A10 value) occurred at an avacopan concentration of 15.4 nM. Avacopan also inhibits C5aR in 
cynomolgus monkeys and hamsters with potencies similar to that observed with human whole 
blood. However, avacopan possesses moderate potency for rabbit C5aR (IC50 ~ 1.4 µM) and 
lacks affinity for mouse, rat, or dog C5aR (IC50 >10 µM). 
The efficacy of avacopan was assessed using genetically-modified mice where the mouse C5aR 
coding region was substituted for the human C5aR coding region. In these studies, intravenous 
injection of mouse anti-myeloperoxidase (anti-MPO) IgG into the human C5aR knock-in mice 
caused glomerulonephritis in a manner mimicking anti-neutrophil cytoplasmic autoantibody 
(ANCA) disease in humans. At daily oral doses of 30 mg/kg avacopan, a marked inhibition of 
anti-MPO induced glomerulonephritis was documented histologically, as assessed by the number 
of necrotic and crescent-containing glomeruli. These results were consistent with reduced 
protein, leukocytes, and red blood cells in the urine, and reduced serum blood urea nitrogen and 
creatinine in mice receiving avacopan (Xiao et al, 2014). 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 29 of 87 
1.2. 
Previous Clinical Studies 
Five Phase 1 studies and four Phase 2 studies with avacopan have previously been completed. 
Avacopan was generally well tolerated in these studies. A Phase 3 study in subjects with AAV 
previously completed enrollment but follow up is ongoing and the study remains blinded. 
Another Phase 2 study in subjects with C3 glomerulopathy is currently enrolling and is also 
blinded. 
Results from a mass balance study (CL004_168) showed that avacopan was mostly metabolized 
in the liver; in vitro metabolism studies showed that avacopan was primarily metabolized 
through cytochrome P450 3A4 (CYP3A4). 
Avacopan did not show evidence of a detrimental effect on QT/QTc based on results from an 
intensive ECG study (CL007_168). 
Co-administration of the strong CYP3A4 enzyme inducer rifampicin in study CL008_168 
resulted in an approximately 93% reduction of systemic exposure of avacopan, which may result 
in a loss of efficacy of avacopan. Therefore, the use of strong CYP3A4 enzyme inducers with 
avacopan is an exclusion criterion for this study. Co-administration of the strong CYP3A4 
enzyme inhibitor itraconazole resulted in a 119% increase of systemic exposure of avacopan. 
Concomitant use of avacopan with strong CYP3A4 enzyme inhibitors should be used with 
caution. 
Two Phase 2 clinical trials in 109 subjects with ANCA-associated vasculitis (AAV) were 
conducted. The first study in 67 subjects (CL002_168) included three dose groups: 30 mg 
avacopan twice daily plus low dose prednisone (20 mg/day), 30 mg avacopan twice daily plus no 
prednisone, and placebo plus full dose prednisone (60 mg/day). All subjects received either IV 
cyclophosphamide or rituximab as standard of care treatment. Avacopan, alone or with low dose 
prednisone, was associated with a rapid onset of action based on improvements in a global 
disease activity index (the Birmingham Vasculitis Activity Score, BVAS), and improvements in 
renal parameters such as albuminuria, and health-related quality of life measurements over a 12-
week treatment period (Jayne et al, 2017). The steady state mean avacopan plasma concentration 
was approximately 204 ng/mL in these subjects, corresponding to >95% projected inhibition of 
the C5aR in the circulation. Avacopan also showed a favorable safety profile in this study. 
The second study in 42 subjects (CL003_168) included three dose groups: 10 mg avacopan twice 
daily plus full dose prednisone (60 mg), 30 mg avacopan twice daily plus full dose prednisone, 
and placebo plus full dose prednisone. All subjects received either IV cyclophosphamide or 
rituximab as standard of care treatment. Avacopan appeared to be safe when added on top of full 
dose prednisone plus cyclophosphamide or rituximab, and the efficacy data support 30 mg 
avacopan twice daily as the therapeutic dose in AAV. Refer to the Investigator’s Brochure for 
more details. 
An open-label Phase 2 clinical trial in 7 subjects with IgA nephropathy (IgAN) has been 
conducted (CL005_168). Results showed that avacopan therapy was associated with 
improvement in proteinuria over a 12-week treatment period; 3 of 7 subjects showed 
approximately 50% decrease in either urinary protein:creatinine ratio (UPCR) or 
albumin:creatinine ratio (UACR). An open-label Phase 2 clinical trial in 6 subjects with atypical 
hemolytic uremic syndrome (aHUS) was conducted (CL006_168). Results showed that serum 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 30 of 87 
collected from subjects dosed with avacopan caused a mean percent reduction of 82% in 
thrombus size compared to baseline in an ex vivo assay. 
A Phase 2 clinical trial with a target enrollment of approximately 88 subjects with C3 
glomerulopathy is ongoing (CL011_168). The study remains blinded. 
A Phase 3 clinical trial with a target enrollment of approximately 300 subjects with AAV 
previously completed enrollment and follow up is ongoing (ADVOCATE, CL010_168). In this 
study in subjects with AAV, avacopan (or placebo) is compared with standard of care 
glucocorticoids as added medications to background therapy of either rituximab or 
cyclophosphamide followed by azathioprine. The study remains blinded. 
The Reference Safety Information section of the Investigator’s Brochure has been updated to 
include the potential risk of urticaria, angioedema, and of hepatotoxicity, and to state that general 
gastrointestinal adverse events (e.g., nausea, diarrhea) observed in Phase 2 AAV studies have 
been observed in the ongoing Phase 3 CL010_168 study at approximately the same frequency 
and severity. Further, as a result of the DMC review of safety data from all completed and 
ongoing studies of avacopan, the frequency of monitoring of hematology has been increased to 
monthly and rules for pausing administration of blinded study drug have been modified. 
A benefit and risk assessment of avacopan is presented in Section 11; detailed information about 
non-clinical and clinical trials with avacopan is presented in the Investigator’s Brochure. Results 
from nonclinical and clinical studies conducted to date showed a positive risk-benefit profile of 
avacopan in treatment of subjects with HS (Section 11). 
1.3. 
Rationale for the Study 
Hidradenitis suppurativa (HS), also called acne inversa, is a chronic inflammatory skin disease 
characterized by inflammatory nodule, abscess, sinus and fistula formation, and scarring of the 
skin, most commonly in apocrine gland rich areas such as the axilla, inframammary area, 
inguinal area, perineum, and perianal area. In its moderate and severe forms, HS is debilitating 
and causes significant discomfort, pain, anxiety and depression, as well as impairment of quality 
of life. The exact cause of HS has not been identified, although genetic defects in the gene 
encoding for gamma-secretase have been described in subjects with HS. Potential target proteins 
include Notch, E-cadherin, and nicastrin. Notch plays an important role in hair follicle 
development, and a defect in Notch may lead to formation of epidermal cysts, dysregulation of 
normal T-cell mediated immune responses, and suppression of Toll-like receptor-4-induced pro-
inflammatory macrophage mediated cytokine responses (Radtke et al, 2010; Wang et al, 2010). 
Smoking and obesity have been associated with HS (Prens and Deckers, 2015). 
Therapy for subjects with HS includes local and systemic antibiotics, pain medication, and anti-
TNF-α agents such as adalimumab. Acitretin is used in early stage disease. Other drugs such as 
cyclosporin A, dapsone, and isotretinoin have been used with limited success (Napolitano et al, 
2017). In more advanced cases, a multifaceted approach may be adopted, where surgical therapy 
is used to remove the chronic components of HS which are not expected to respond to medical 
therapy (e.g., scarring, fistulas, and sinus tracts), and long-term systemic medical therapy is used 
to treat the acute or sub-chronic manifestations of HS (e.g., abscesses and inflammatory 
nodules). 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 31 of 87 
Studies have shown that HS is a neutrophil-driven disease, and that complement activation with 
the production of terminal fragment C5a may be important in the pathogenesis of the disease 
(Kanni et al, 2018). The C5a-C5aR signaling axis is essential in mediating neutrophil activation 
and migration. Recently it is has been reported that circulating C5a and C5b-9 levels were 
significantly greater in HS patients, further adding to the relevance of C5a-C5aR an important 
mechanistic contributor to the disease process. More importantly, plasma from HS patients 
activates neutrophils (CD11b upregulation) ex vivo, and this activation can be blocked by a 
neutralizing antibody against C5a (IFX-1; Kanni T, et al. 2018), suggesting that C5a may be a 
critical factor in driving neutrophil activation and infiltration in the diseased tissue in HS 
patients. An anti-C5a agent, IFX-1, has shown efficacy in a Phase 2 study, suggesting a role for 
C5a blocking agents in the treatment of HS (Guo et al, 2017). 
Avacopan, an orally administered, C5a receptor (C5aR) selective agent, was shown to be 
effective and safe in a Phase 2 study in subjects with AAV (Jayne et al, 2017) and is being tested 
in a Phase 3 clinical trial in subjects with AAV. Since HS is a neutrophil-driven disease and 
avacopan selectively blocks the C5aR, the activation of which leads to neutrophil attraction, 
avacopan has the potential to be an effective therapy for patients with HS. Hence, the clinical 
hypothesis of this trial is to test whether avacopan is effective in treating patients with moderate 
to severe HS. 
This clinical trial will be conducted in compliance with the protocol, good clinical practice 
(GCP), and applicable regulatory requirements. 
2. 
OBJECTIVES 
2.1. Primary Objectives 
The primary objectives of this study include: 
1. Evaluation of the efficacy of avacopan compared to placebo in subjects with Hurley Stage II 
or III hidradenitis suppurativa (HS) based on subjects achieving a Hidradenitis Suppurativa 
Clinical Response (HiSCR) after 12 weeks of treatment. HiSCR is defined as at least a 50% 
reduction in abscess and inflammatory nodule count with no increase in abscess count and no 
increase in draining fistula count at Week 12 relative to baseline. 
2. Evaluation of the safety of avacopan compared to placebo in these subjects based on the 
adverse event incidence, changes from baseline in laboratory parameters, and vital signs. 
2.2. Secondary and Other Objectives 
The secondary and other objectives of this study include: 
1. Evaluation of the efficacy of avacopan compared to placebo in these subjects include: 
a. The subject’s global assessment of skin pain numeric rating scale (NRS), 
b. The modified Sartorius score, and 
c. Achieving an AN count of 0, 1, or 2. 
2. Assessment of patient-reported outcomes including health-related quality-of-life changes 
based on the Short Form-36 version 2 (SF-36 v2), the EuroQOL-5D-5L (EQ-5D-5L), the 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 32 of 87 
Hidradenitis Suppurativa Quality of Life (HiSQOL) Index, the Dermatology Life Quality 
Index (DLQI), and the Work Productivity and Activity Impairment Questionnaire: Specific 
Health Problem (WPAI:SHP) with avacopan compared to placebo. 
3. Evaluation of the pharmacokinetic profile of avacopan in subjects with HS. 
4. Evaluation of the safety and efficacy of avacopan treatment from Day 1 by each timepoint up 
to Week 44 in subjects with HS. 
5. Evaluation of the efficacy of avacopan compared to placebo in these subjects include: 
a. The Sartorius score, International HS Severity Scoring System (IHS4) score, HS 
Physician Global Assessment (HS-PGA), 
b. Proportion of subjects who experienced flare, who experienced loss of response during 
Period 2, who received oral antibiotic rescue therapy or lesion intervention, and who 
received disallowed opioid pain therapy, and 
c. The duration of flare in days. 
6. Evaluation of health-economic information. 
3. 
STUDY DESIGN 
The study is a randomized, double-blind, placebo-controlled, three-group Phase 2 trial in 
approximately 390 subjects with moderate to severe hidradenitis suppurativa (Hurley Stage II or 
III). Subjects will be randomized 1:1:1 to a treatment of 10 mg avacopan twice daily, 30 mg 
avacopan twice daily or placebo for 12 weeks. Other systemic treatments for HS including anti-
TNF-α treatments are prohibited. Stable antibiotic therapy with doxycycline or minocycline is 
allowed as specified in the protocol. Subjects treated with 10 mg or 30 mg twice daily during the 
blinded, placebo-controlled 12-week treatment period (Period 1) will be followed by an 
additional 24-week,  active treatment period (Period 2) during which they will continue to 
receive the same dose regimen, either 10 mg or 30 mg avacopan twice daily. Subjects on placebo 
who complete Period 1 will be re-randomized 1:1 to receive 10 mg or 30 mg avacopan twice 
daily in Period 2. During Period 2 the treatment assignment to 10 mg or 30 mg twice daily will 
not be disclosed to the subject, study site personnel or the Sponsor. Thereafter, all subjects will 
be followed for 8 weeks without study drug before they exit the study. 
To obtain balance across treatment groups, a stratified randomization scheme will be 
implemented. The stratification factors and strata within each factor are listed below. 
3.1. Stratification and Randomization 
1. Hurley Stage (Stage II vs. III) 
a. Stage II disease: one or more widely separated recurrent abscesses with tract formation 
and scars, or 
b. Stage III disease: multiple interconnected tracts and abscesses across an entire area, 
with diffuse or near diffuse involvement. 
2.  Concomitant  antibiotic therapy (Yes vs. No) 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 33 of 87 
a. Concomitantly treated with doxycycline or minocycline as the only allowed antibiotic 
treatment for HS, or 
b. No concomitant antibiotic therapy. 
3. Anti-TNF-α treatment (Treatment naïve vs. Previous treatment): 
a. Did not previously receive anti-TNF-α drug such as adalimumab or infliximab (anti-
TNF-α drug naïve), or 
b. Previously (but no longer) received an anti-TNF-α drug and 
• completed anti-TNF-α treatment but may have relapsed, or 
• was intolerant to anti-TNF-α treatment, or 
• previously failed to respond or inadequately responded to anti-TNF-α treatment. 
Not more than 20% of subjects will be in stratum 2a as described above. 
Eligible subjects will be randomized with equal chance (i.e., 1:1:1) to one of the three treatment 
groups within each stratum based on a non-dynamic, list-based blocked randomization scheme. 
1) Placebo twice daily 
2) Avacopan 10 mg twice daily 
3) Avacopan 30 mg twice daily 
3.2. Study Treatments 
Treatments for each group are shown in Table 1. 
The treatment period is 36 weeks (252 days), followed by an 8-week (56 days) follow-up period 
without taking study medication. Subjects will be randomized 1:1:1 to receive placebo, 10 mg 
avacopan or 30 mg avacopan b.i.d. for the blinded, placebo-controlled treatment for the first 
12 weeks (Period 1). Subjects randomized to 10 mg and 30 mg avacopan in Period 1 will 
continue with the same drug regimen during the next 24-week active drug treatment period 
(Period 2). Subjects randomized to placebo in Period 1 will be re-randomized to receive either 10 
mg or 30 mg avacopan b.i.d. in Period 2. Study treatment-group specific drug kits will be 
dispensed at relevant study visits. Detailed information about the study drug kits, dispensation 
and accountability is available in the Study Pharmacy Manual. 
Study drug will be taken as described in Section 5.2. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 34 of 87 
Table 1: 
Avacopan/Placebo Treatment for the Three Study Groups 
 
Period 1 
(12-Week Placebo-
Controlled Treatment)  
Period 2 
(24-Week Active Drug 
Treatment)  
Group A 
Placebo 
Kit # 1  
Re-randomized  
50% to Kit # 2 
50% to Kit # 3 
Group B 
10 mg Avacopan 
Kit # 2 
Kit # 2 
Group C 
30 mg Avacopan 
Kit # 3 
Kit # 3 
3.3. Study Flow 
Subjects will be screened for eligibility based on the stage of the disease and their health status. 
The Screening period will be up to 28 days. The primary efficacy analysis can occur when the 
last enrolled subject has completed the Week 12 visit. After the blinded, placebo-controlled 12-
week treatment period, all subjects will continue with a 24-week active treatment with 10 mg 
avacopan twice daily or 30 mg avacopan twice daily. After Week 36, all subjects will be 
followed for 8 weeks without receiving study medication. 
All subjects will visit the study center during the 28-day Screening period, and, if eligible, on 
Day 1 and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, and 44 of the study. Study drug will be 
dispensed at the study site and subjects will take the first dose of study drug, i.e., avacopan or 
matching placebo, while at the study center. Preferably, on visit days subject should take their 
dose while on-site. Following the first dose, subjects will take study drug twice daily, which will 
continue for 12 weeks (84 days). Thereafter, all subjects will take avacopan study drug for 24 
weeks (168 days), after which they will be followed for 8 weeks (56 days) without taking study 
drug. Study procedures at each visit day are detailed in the Time and Events Table. 
Subjects will exit the study when all the Study Week 44 visit procedures have been completed. 
Subjects who experience a flare of HS during the study will be treated by the Investigator, which 
may include a maximum 1-week course of antibiotic rescue treatment with doxycycline or 
minocycline or intralesional Kenalog rescue injections (triamcinolone acetonide, 10 mg total 
maximum per subject within a period no longer than 1 week). These subjects will be requested to 
remain in the study and to complete all study procedures if possible. During this time, subjects 
may continue to receive the study drug, if deemed clinically feasible by the Investigator. 
3.4. Scientific Rationale for Study Design 
The aim of this study is to determine whether avacopan is effective in subjects with moderate to 
severe hidradenitis suppurativa. The placebo-controlled study design allows evaluation of 
whether or not avacopan treatment will yield superior efficacy compared to placebo. A certain 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 35 of 87 
proportion of subjects will be allowed to have concomitant treatment for HS with doxycycline or 
minocycline. 
There is well-documented precedence of placebo-controlled trials in HS as previous adalimumab 
Phase 2 and 3 studies were conducted as placebo-controlled studies. 
3.5. Rationale for Dose Selection 
Single doses of 1 mg up to 100 mg avacopan were studied in a Phase 1 study (CL001_168) in 
48 healthy volunteers. Once daily doses of 1, 3, and 10 mg avacopan, and twice daily doses of 
30 mg and 50 mg for up to 7 days were studied in the multiple dose period of the study. 
Doses from 3 mg up to 100 mg twice daily for 7 days were tested in 16 healthy volunteers in 
Phase 1 study CL007_168, and 30 mg (single dose and twice daily doses for 17 days) in 
32 healthy volunteers in Phase 1 study CL008_168. Further, 64 healthy Japanese and Caucasian 
male subjects were tested in both fed and fasted states at doses up to 100 mg/day (CCX1101). 
All these avacopan doses were found to be safe in these studies. 
A dose of 30 mg avacopan twice daily given for 12 weeks was studied in clinical trial 
CL002_168 in subjects with AAV. This dose regimen was shown to be effective and well 
tolerated in study CL002_168. Doses of 10 mg and 30 mg avacopan twice daily given for 
12 weeks were studied in clinical trial CL003_168 in subjects with AAV and found to be well 
tolerated. Refer to the Investigator’s Brochure for details. 
A dose of 30 mg avacopan twice daily is being studied in a Phase 3 clinical trial in AAV 
(CL010_168). 
A dose of 30 mg avacopan twice daily has been selected for this study in HS based on experience 
with this dose regimen in subjects with AAV. This dose regimen is lower than the maximum 
dose regimen of 100 mg twice daily tested in study CL007_168. A dose regimen of 30 mg 
avacopan twice daily provides a trough (Cmin) plasma avacopan concentration of approximately 
204 ng/mL; this concentration was shown to provide at least 95% C5aR blockade of blood 
neutrophils continuously throughout the day based on ex vivo C5a-induced CD11b upregulation 
assays conducted in whole blood samples obtained from subjects in Phase 1 clinical trial 
CL001_168. This level of C5aR coverage is deemed appropriate to achieve optimal 
pharmacology. 
A dose of 10 mg avacopan twice daily has been selected to determine the lower dose range that 
could still elicit significant clinical effects. It is anticipated that both avacopan dose regimens 
would be well tolerated in subjects with HS. At steady state, plasma levels for the 10 mg twice 
daily dose regimen result in at least 90% C5aR inhibition on blood neutrophils continuously 
throughout the day. 
Based on the favorable safety profile observed in the long-term toxicology studies (26 weeks in 
rats and 44 weeks in cynomolgus monkeys; see Investigator’s Brochure), and on the safety and 
tolerability results from the clinical trials conducted to date, 10 mg and 30 mg avacopan twice 
daily are considered appropriate doses to test in this clinical trial. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 36 of 87 
4. 
STUDY POPULATION 
Eligible adult subjects (at least 18 years of age) with moderate to severe hidradenitis suppurativa 
(Hurley Stage II or III) on standard-of-care therapy as specified by the inclusion and exclusion 
criteria, are allowed to enter the study. 
4.1. Inclusion Criteria 
Subjects must meet all of the following inclusion criteria in order to enter the study: 
1. Aged at least 18 years of age; 
2. Clinical diagnosis of HS (Hurley Stage II or III), confirmed by a dermatologist, for at least 
6 months prior to Screening. Hurley Stage II disease is defined as having one or more widely 
separated recurrent abscesses with tract formation and scars; Stage III disease is defined as 
having multiple interconnected tracts and abscesses across an entire anatomical area with 
diffuse or near diffuse involvement; 
3. HS lesions are present in at least 2 distinct anatomic areas (e.g., left and right axilla; or left 
axilla and left inguino-crural fold), one of which is Hurley Stage II or Hurley Stage III; 
4. Inadequate or loss of response to a systemic course of antibiotics of 90 days. However, a 
subject who has completed less than 90 days of antibiotic treatment may be allowed into the 
study upon discussion with the Medical Monitor if: 1) the subject has demonstrated 
intolerance to or contraindication for antibiotics to treat HS, or 2) it was determined by the 
Investigator that an antibiotic course of at least 28 days to treat HS did not benefit the subject 
and a continued antibiotic therapy would therefore not be indicated.  
Inadequate or loss of response is defined if the following was observed despite antibiotic 
treatment: 
a. Progression of Hurley Stage (i.e., the Hurley Stage of at least one affected anatomic 
region progressed from I→II, II→III, or I→III); 
b. Subject required at least one intervention (e.g., incision and drainage or intralesional 
injection of corticosteroid); 
c. Subject experienced pain interfering with activities of daily living, with unsatisfactory 
relief from over-the-counter analgesics (e.g., ibuprofen or acetaminophen); 
d. Subject experienced pain requiring opioids, including tramadol; 
e. Subject experienced drainage interfering with activities of daily living (e.g., requires 
multiple dressing changes and/or changes of clothes daily); 
f. Subject experienced an increase in the number of anatomic regions affected by HS; 
g. Subject experienced at least one new abscess or one new draining fistula. 
5. Must have at least 5 inflammatory nodules or abscesses at Screening; 
6. Must agree to use a topical antiseptic daily over the course of the study; topical antiseptics 
may include but are not limited to chlorhexidine, triclosan, benzoyl peroxide, or diluted 
bleach in bath water; 
7. Female subjects of childbearing potential may participate if adequate contraception is used 
during the study and for at least three months after study completion. Adequate contraception 
is defined as resulting in a failure rate of less than 1% per year (combined estrogen and 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 37 of 87 
progestogen [oral, intravaginal, or transdermal], or progestogen-only hormonal contraception 
where inhibition of ovulation is the primary mode of action [oral, injectable, or implantable], 
intra-uterine device, intra-uterine hormone releasing system, bilateral tubal occlusion, 
vasectomized partner, or true [absolute] sexual abstinence, i.e., in line with the preferred and 
usual lifestyle of the subject). Male subjects with partners of childbearing potential may 
participate in the study if they had a vasectomy at least 6 months prior to randomization or if 
adequate contraception as defined above is used by their female partners of childbearing 
potential during the study and for at least three months after study completion.  In addition, a 
barrier method (i.e., condom, cervical cap, or diaphragm) must be used during intercourse 
between a male study subject and a female partner of childbearing potential; 
8. Willing and able to give written Informed Consent and to comply with the requirements of 
the study protocol; 
9. Judged by the Investigator to be otherwise fit for the study, based on medical history, 
physical examination (including electrocardiogram [ECG]), and clinical laboratory 
assessments. Subjects with clinical laboratory values that are outside of normal limits (other 
than those specified in the Exclusion Criteria) and/or with other abnormal clinical findings 
that are judged by the Investigator not to compromise subject participation in the study may 
be entered into the study. 
4.2. Exclusion Criteria 
Subjects will be excluded from study participation if any of the following criteria are met: 
1. Pregnant or breast-feeding; 
2. Any other skin disease that may interfere with the assessment of HS, such as a viral or fungal 
skin infection; 
3. Rapidly progressive, expanding HS within 30 days prior to Screening; 
4. More than 20 draining fistulae at Screening; 
5. Any anti-TNF-α treatment for HS or for other conditions prior to Day 1 visit will be 
prohibited. Exception: subjects who were previously treated with an anti-TNF-α drug and 
discontinued treatment >12 weeks prior to Day 1 visit are allowed for enrollment; 
6. Systemic antibiotics are generally excluded. Exception: subjects on systemic antibiotic 
treatment with doxycycline or minocycline who have been on a stable dose for at least 
28 days prior to Day 1. After a pre-specified percentage of subjects on these permissible 
antibiotic treatments have been enrolled, no further enrollment of such subjects will be 
allowed; 
7. Topical antibiotics use within 14 days prior to Day 1; 
8. Have started a topical prescription medicine for HS within 14 days prior to Screening or is 
anticipated to start during the Screening period. Topical prescription medicine for HS other 
than topical antibiotics that was started >14 days prior to Screening is allowed; 
9. With the exception of permissible antibiotic treatment regimens, have received a systemic 
medicine for HS or with a potential therapeutic impact on HS, including systemic antibiotic 
therapy, biologics and other systemic therapies such as methotrexate, cyclosporine, retinoids, 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 38 of 87 
and fumaric acid esters, etc., within a minimum of 30 days or 5 half-lives (whichever is 
longer) after taking the last dose; 
10. Have received within 14 days prior to the Day 1 visit, or is expected to require during the 
study, oral or transdermal opioid analgesics (except for tramadol) for any reason; non-opioid 
analgesics are allowed if the subject is on a stable dose for at least 14 days prior to the Day 1 
visit (“as needed” dosing is not considered to be a stable dose); 
11. Currently taking a strong inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, such as 
carbamazepine, phenobarbital, phenytoin, rifampin, or St. John's wort; 
12. Any of the following within 12 weeks prior to Screening: symptomatic congestive heart 
failure requiring prescription medication, unstable angina (unless successfully treated with 
stent or bypass surgery), clinically significant cardiac arrhythmia, myocardial infarction or 
stroke; 
13. History or presence of any form of cancer within the 5 years prior to Screening, with the 
exception of excised basal cell or squamous cell carcinoma of the skin, or carcinoma in situ 
such as cervical or breast carcinoma in situ that has been excised or resected completely and 
is without evidence of local recurrence or metastasis; 
14. Evidence of tuberculosis based on interferon γ release assay (IGRA); 
15. HBV, HCV, or HIV viral screening test done at Screening or within 6 weeks prior to 
Screening showing evidence of active or chronic viral infection; 
16. Received a live vaccine within 4 weeks prior to Screening; 
17. WBC count less than 3500/μL, or neutrophil count less than 1500/μL, or lymphocyte count 
less than 500/µL before start of dosing; 
18. Evidence of hepatic disease: AST, ALT, alkaline phosphatase, or bilirubin >3 times the upper 
limit of normal before the start of dosing; 
19. Clinically significant abnormal electrocardiogram (ECG) during Screening which, in the 
opinion of the Investigator, may place the subject at unacceptable risk for study participation; 
20. Known hypersensitivity to avacopan or inactive ingredients of the avacopan capsules 
(including gelatin, polyethylene glycol, or macrogolglycerol hydroxystearate [EP] known 
also as polyoxyl 40 hydrogenated castor oil [NF] or Cremophor® RH 40); 
21. Participated in any clinical study of an investigational product within 30 days prior to 
Screening or within 5 half-lives after taking the last dose; 
22. History or presence of any medical condition or disease which, in the opinion of the 
Investigator, may place the subject at unacceptable risk for study participation. 
4.3. Screen Failures 
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
subsequently randomized to receive a study intervention or dosed with any study drug. A 
minimal set of screen failure information is required to ensure transparent reporting of screen 
failure participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to queries from regulatory authorities. Minimal 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 39 of 87 
information includes demography, screen failure details, eligibility criteria, and any serious 
adverse event (SAE). 
Individuals who do not meet the criteria for participation in this trial (screen failure) may 
potentially be rescreened. These cases need to be discussed with the Medical Monitor. 
4.4. Removal of Subjects from Therapy 
Investigators must clearly distinguish between discontinuation of study drug treatment and 
withdrawal from the study. Subjects who discontinue study drug treatment or who initiate 
medication changes (including those prohibited by the protocol) will not be automatically 
withdrawn from the study but all efforts must be made to continue to follow the subjects for all 
regularly scheduled visits. All safety and efficacy assessments should be completed. 
Investigators must take appropriate measures to make sure that subjects are motivated to comply 
with all requirements of the protocol in order to minimize the amount of missing data, including 
subjects who discontinue study treatment early or initiate medication changes (including those 
prohibited by the protocol). If subjects are not followed, they should complete all safety and 
efficacy assessments required for the Early Termination visit. Investigators and their staff must 
take measures to actively maintain contact with their subjects in the study, such as telephone 
calls, texts, or emails between visits, and offers for transportation support to visit the study site. 
Subjects may be withdrawn from the study for only one of the following reasons: 
1. Subject withdrawal of consent to contribute additional outcome information; 
2. Subject non-compliance with dosing or diary completion; 
3. Loss to follow-up. 
Subjects may discontinue study drug treatment for any of the following reasons: 
1. Subject withdrawal of consent; 
2. The Investigator may discontinue study drug treatment if, in his/her clinical judgment, it is in 
the best interest of the subject; 
3. The Sponsor may request discontinuation of study drug treatment for safety reasons. If a 
subject develops any of the following lab abnormalities: 
If a subject develops ALT or AST >3x ULN, additional testing should be performed immediately 
and repeated in one week to assay for total and fractionated serum bilirubin concentration, serum 
albumin concentration, and prothrombin time or INR, in addition to repeat transaminase (ALT, 
AST) testing. In addition, if a subject develops Grade 3 or greater increased hepatic 
transaminases (>5 times the upper limit of normal), or if a subject develops Grade 2 or greater 
increased transaminases (>3 times the upper limit of normal) with elevation of bilirubin to >2 
times the upper limit of normal, dosing with study drug must be paused in this subject. 
Study medication must be permanently discontinued (FDA Guidance 2009) if any of the 
following markers of hepatic injury and/or impaired liver synthetic function are observed, and 
cannot be attributed to a reversible etiology unrelated to study medication (e.g., cholelithiasis): 
• 
ALT or AST >8x ULN 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 40 of 87 
• 
ALT or AST >5x ULN for more than 2 weeks 
• 
ALT or AST >3x ULN and (Total Bilirubin >2x ULN or INR >1.5) 
• 
ALT or AST >3x ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) 
If a subject develops Grade 3 or greater leukopenia (WBC count <2 x 109/L) or neutropenia 
(<1 x 109/L), or Grade 4 lymphopenia (<0.2 x 109/L), then study drug (avacopan or placebo) 
must be paused in this subject. In addition, if a subject develops Grade 2 leukopenia (WBC count 
<3 x 109/L, but ≥2 x 109/L), the subject must be followed closely for infection and for further 
significant reduction (reduction by an additional 0.5 x 109/L or more, or to <2 x 109/L) in WBC 
count; if either occurs, then study drug must be paused in this subject. Study drug may be 
resumed only if the abnormal value returns to normal and the Investigator deems resumption to 
be appropriate. 
If a subject develops Grade 3 or worse CPK increase (>5 times the upper limit of normal), dosing 
with study drug must be paused in this subject. Study drug may be resumed only if the CPK 
returns to normal levels. 
Discontinuation of study medication due to inadequate or worsening response in Period 2: 
Unless prohibited for safety reasons, deemed inappropriate by the Investigator, or subject 
withdraws consent, all subjects are allowed to enter Period 2. Subjects in Period 2 will 
discontinue taking study medication if at two consecutive protocol-specified visits ≥14 days 
apart, the AN count increases by more than 50% compared to the AN count at Week 12. 
However, these subjects will be requested to remain in the study and to complete all study 
procedures if possible. In the event of early withdrawal from the study, the tests and evaluations 
listed for the Early Termination visit in Section 6.14 will be performed, whenever possible. Data 
collected at this visit will be designated as an “Early Termination” visit in the electronic data 
capture (EDC) system. The Sponsor should be notified of all study drug treatment and study 
withdrawals in a timely manner. 
5. 
STUDY DRUG/TREATMENT 
5.1. Product Characteristics 
The study drug consists of hard gelatin capsules containing 10 mg avacopan or placebo 
administered orally. Avacopan and placebo bottles and capsules will be identical in appearance. 
The capsules are manufactured under current good manufacturing practice. 
5.2. Doses and Regimens 
Subjects will be asked to take 3 capsules of study drug orally with water and preferably with 
food every morning, and 3 capsules with water and preferably with food in the evening 
approximately 12 hours after the morning dose, as instructed. Study drug will be taken for 
36 weeks (252 days) continuously. Study drug will be dispensed as outlined in the Time and 
Events Table. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 41 of 87 
Subjects will be asked to bring all bottles of study drug, whether empty or not, to the study center 
at each study visit for study drug compliance/accountability check. 
If a subject misses a dose, the missed dose should be taken as soon as possible. If it is close to 
the time for their next dose (within 3 hours), the missed dose should not be taken and the next 
dose should be taken at the regular time. 
On study visit days it is preferable that the subjects take the morning dose of study drug at the 
site following the collection of PK samples, if applicable to that visit. 
5.3. Drug Supply 
5.3.1. 
Packaging and Labeling 
Study drug will be packaged in treatment assignment-specific kits and provided to the study sites 
for dispensing. Capsules containing 10 mg avacopan and/or identical placebo capsules will be 
packaged in plastic bottles with child-resistant screw caps. Each kit will include 3 bottles. Each 
bottle will contain 180 capsules with a label including, at minimum, the study number, bottle 
number, dosing instructions, storage instructions, and Sponsor name and address. 
5.3.2. 
Storage 
Study drug, both avacopan and placebo, capsules should be stored according to label 
instructions. Access should be restricted to pharmacy staff or to the designated responsible 
member of the Investigator’s staff, and to the study monitor. 
5.4. Blinding 
This study is double-blind. Blinding of the study will be achieved by the following measures: 
1. The study drug kits, bottles and capsule appearance for avacopan and placebo will be 
identical; 
2. Limited access to the randomization code: Sponsor personnel, study site personnel, study 
subjects, personnel responsible for study monitoring, and biostatisticians and data managers 
involved in data analysis of the study will remain blinded to treatment assignment for the 
duration of the study; 
3. While laboratory personnel conducting the PK assays will not be blinded to treatment 
assignment, unblinded avacopan plasma concentration results will not be shared with the 
study site personnel or study staff who have direct contact with study sites during the study; 
4. Data that could potentially be unblinding, i.e., WBC and neutrophil count data within the 
normal range (i.e., values outside the normal range will be made available for safety 
monitoring) will not be made available to study site personnel, study subjects, personnel 
responsible for study monitoring, and biostatisticians and data managers during the study 
unless required for safety monitoring. Investigators, however, will be provided with safety 
laboratory data reports, flagging abnormally high and low values to make informed decisions 
regarding subject care. 
Treatment assignments for individual subjects in the blinded portion of the study will remain 
blinded to the study team, Investigators, and subjects until after the study database has been 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 42 of 87 
cleaned and locked. Designated study staff will be provided with instructions regarding how to 
unblind an individual subject’s treatment assignment if it becomes medically necessary. An 
individual subject treatment assignment may be unblinded only in the case of an adverse event 
that requires knowledge of the study drug received by the subject in order to provide appropriate 
treatment or management of the adverse event. The study monitor and Sponsor should be 
consulted or notified as soon as possible in the event that unblinding of an individual subject’s 
treatment assignment occurs prior to study completion. 
When the last subject has completed the double-blind treatment period, an unblinded analysis of 
the double-blind treatment period will be conducted. All data collected in the double-blind 
treatment period will be cleaned and locked before the analysis. To maintain the blinding of 
treatment assignment in the active treatment period, the Sponsor will designate a contract 
research organization (CRO) to conduct the analysis. The analysis results will be communicated 
to the Sponsor with aggregated data only (i.e., by treatment group without disclosing treatment 
assignment for individual subjects). In the event it becomes necessary to identify the treatment 
assignment for an individual subject for safety analysis, the treatment assignment can be 
disclosed on an individual basis. If occurred, these events will be documented. 
An external data monitoring committee (DMC) will be constituted for the study (see 
Section 10.1.6). The DMC members will review data periodically over the course of the study in 
an unblinded manner. The membership and the primary responsibilities of the DMC will be 
defined in a charter that will also provide procedures for data review, documentation, and 
communication of recommendations. 
5.5. Drug Accountability 
The Investigator or designee is responsible for maintaining complete accountability including 
dates and quantities of study product(s) received, accurate inventory on an ongoing basis as well 
as dispensation and returned medication records. Periodically throughout the study, a Sponsor 
representative, usually the study monitor, will verify and inventory the used, unused, and 
partially used study drug. The Investigator or designee must retain all unused and/or expired 
study supplies until the study monitor has confirmed the accountability data. 
With Sponsor approval following drug accountability, unused study drug can be destroyed per 
site SOP or policy. Unused study drug may also be returned to the Sponsor or its designee for 
destruction with appropriate documentation. The documentation of such disposition/destruction 
should be maintained in the pharmacy files to be reviewed by a Sponsor representative. 
At the termination of the study, a final drug accountability review and reconciliation must be 
performed and any discrepancies must be investigated and their resolution documented. 
Please refer to the Study Pharmacy Manual for further instruction regarding study drug 
receiving, handling, storage and return/destruction. 
5.6. Treatment Compliance 
The avacopan and placebo capsules will be self-administered by participating study subjects. The 
first dose of study drug on Day 1 will be taken in the presence of study site personnel. Subjects 
will be provided with dosing instructions at the start of the study and will be encouraged by 
study site personnel to take the study drug according to the instructions for the duration of the 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 43 of 87 
study. The study drug dispensed will be checked and a capsule count will be done at Weeks 12, 
24, and 36 of any remaining avacopan or placebo capsules returned. This information will be 
recorded and entered into the EDC system. The study subjects will be required to maintain a 
record of daily drug administration in a daily diary. 
Avacopan plasma concentration measurements over the course of the study may also be used to 
assess subject compliance. Any events of non-compliance to the protocol will be documented in 
the study records. 
5.7. Concomitant Therapy and Restrictions 
No new treatment for HS (other than the study drug) may be introduced during the study period 
with the exceptions as outlined below. 
All concomitant medications taken during the course of the study must be recorded meticulously 
on the concomitant medication pages in the EDC. 
Anti- TNF-α Therapy, Systemic or Other Treatments with Potential Impact on HS: 
Concomitant anti-TNF-α treatment during the trial is prohibited. Subjects who were previously 
treated with any anti-TNF-α drug and discontinued treatment >12 weeks prior to Day 1 visit 
would be allowed for enrollment. 
Anti-TNF-α agents comprise five different FDA-approved drugs: adalimumab (Humira®), 
infliximab (Remicade®), entanercept (Enbrel®), golimumab (Simponi®), and certolizumab 
(Cimzia®). Of these anti-TNF-α agents, adalimumab, golimumab, and certolizumab share the 
longest mean terminal half-lives of 14 days as specified in their respective prescribing 
information labels. Subjects entering the trial need to be anti-TNF-α treatment-naïve or must 
have discontinued anti-TNF-α treatment for at least 12 weeks (which provides a washout period 
of over 5 times the half-life of any anti-TNF-α agent). 
With the exception of permissible antibiotic treatment regimens, systemic or other treatments 
with a potential therapeutic impact on HS, including systemic antibiotic therapy, biologics and 
other systemic therapies such as methotrexate, cyclosporine, retinoids, and fumaric acid esters, 
etc., are prohibited. 
Antibiotic Therapy: Concomitant use of oral antibiotic therapy for treatment of HS is generally 
not allowed. Systemic antibiotics (doxycycline or minocycline only) for the treatment of HS are 
permissible only for those subjects whose randomization was appropriately stratified for 
antibiotic use (see Section 3.1 Stratification and Randomization). During the study, the dose(s) of 
these drugs for the treatment of HS may not be increased. A systemic antibiotic must not be 
started for the treatment of HS during the course of the trial (treatment for a condition other than 
HS is allowed).  However, the Investigators will be allowed to reduce the dose(s) or discontinue 
these ongoing antibiotic treatments during the study. Any dose changes in these treatments 
during the study must be recorded in the EDC system. 
Antibiotic rescue medication may be initiated at Week 4 or Week 8, if a subject experiences an 
increase in their AN count such that the total count is greater than or equal to 150% of their 
baseline AN count. For example, if a subject has a baseline (= Day 1) AN count of 15, antibiotic 
rescue therapy may be allowed with a minimum AN count of 23 (1.5 x 15 = 22.5) at Week 4 or 
8. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 44 of 87 
Subjects who qualify may initiate treatment with minocycline or doxycyline up to 100 mg b.i.d. 
The dosing regimen must remain stable throughout study participation. Rescue antibiotic therapy 
must be captured in the source document and on the appropriate eCRF. 
Antiseptic Therapy: All subjects must use a topical antiseptic daily over the course of the study; 
topical antiseptics may include but are not limited to chlorhexidine, triclosan, benzoyl peroxide, 
or dilute bleach in bath water. 
Wound Care: Concomitant use of wound care dressings on HS wounds is allowed. 
Lesion Intervention: In the event that an acutely painful lesion occurs that requires an immediate 
intervention, physicians will have the option to perform protocol-allowed interventions. All 
study visit evaluations must occur before any interventions are performed. Any lesion that 
undergoes an intervention will be documented in the source. The site will be required to count 
any lesion that undergoes an intervention as permanently present from the date of the 
intervention, and must account for it in the source and on the appropriate eCRF. 
Lesions that receive lesion interventions will be reported as adverse events. 
Only two types of interventions are allowed: injection with intralesional triamcinolone acetonide 
suspension (intralesional Kenalog rescue injections, i.e., triamcinolone acetonide, 10 mg total 
maximum per subject within a period no longer than 1 week) and incision and drainage. 
If incision and drainage is performed, the required over-the-counter antiseptic wash should 
continue to be used. New systemic and topical therapies following incision and drainage 
(including antibiotics), are prohibited. Concomitant use of wound care dressings is allowed. 
Subjects should continue using any allowed ongoing oral and topical therapies during the study. 
During Period 1, a total of two protocol-allowed interventions are permissible. An intervention 
can occur on maximally two different lesions at the same visit or on the same lesion at two 
different study visits. The same lesion cannot be treated two times at the same visit. If a subject 
requires more than two interventions within the first 12 weeks, then they must discontinue taking 
study medication. However, these subjects will be requested to remain in the study and to 
complete all study procedures if possible. 
During Period 2, maximally two interventions every 4 weeks are permitted. An intervention can 
occur on two different lesions at the same visit or on the same lesion at two different study visits. 
Within each 4-week period, the same type of intervention cannot be used two times on the same 
lesion. If a subject requires more than two interventions within a 4-week period or has two of the 
same interventions on the same lesion within that period, the subject must discontinue taking 
study medication. However, these subjects will be requested to remain in the study and to 
complete all study procedures if possible. 
Analgesic Therapy: Subjects may receive non-opioid analgesics and also tramadol during the 
study. Any dose changes need to be recorded in the EDC. Oral and transdermal opioid analgesics 
(except for tramadol) for any reason are disallowed.  
CYP3A4 Metabolism: Drugs that are strong inducers of the CYP3A4 enzyme, such as 
carbamazepine, phenobarbital, phenytoin, rifampin or St. John’s wort are prohibited during the 
study because these drugs may substantially reduce the plasma concentrations of avacopan and 
reduce its effectiveness. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 45 of 87 
Substances that are strong inhibitors of CYP3A4, such as boceprevir, clarithromycin, conivaptan, 
indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, 
posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole, and grapefruit 
juice should be avoided during the study, because these may modestly increase (~2-fold) the 
plasma concentrations of avacopan. However, these are not absolutely contra-indicated. If these 
must be used concomitantly with avacopan, subjects should be monitored carefully for any 
untoward side effects. 
All concomitant medications taken during the course of the study must be recorded meticulously 
on the concomitant medication pages in the EDC. 
6. 
STUDY PROCEDURES  
6.1. Screening and Enrollment 
Informed consent must be obtained prior to performance of any study-specific tests or 
evaluations. Screening should occur within 28 days and not exceed 31 days prior to 
randomization. Subjects will undergo the following evaluations to determine their eligibility for 
study participation: 
• Recording of demographic data and relevant medical history in the EDC; 
• Recording of all prior medications and treatments for HS from diagnosis to Screening in 
the EDC; 
• Recording of all other concomitant medications on the Screening day(s) in the EDC, 
including alcohol intake, recreational drug use, non-prescription medications, herbal 
preparations or special diets; 
• A physical examination will be performed (see Section 7.2.1); body weight and height 
will be measured; 
• Vital signs will be obtained as detailed in Section 7.2.1; temperature, sitting blood 
pressure, and heart rate will be measured after at least 3 minutes of rest; 
• Serum pregnancy test (in women of childbearing potential); 
• Virology assessments as detailed in Section 7.2.2, unless done within 6 weeks prior to 
Screening; 
• Tuberculosis exclusion based on interferon γ release assay (IGRA); 
• 12-lead ECG to exclude any clinically significant findings; 
• Serum chemistry and hematology tests according to Section 7.2.2; 
• A urine sample will be collected for urinalysis (see Section 7.2.2); 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars and the Hurley Stage of HS will be recorded; 
• Any pre-treatment adverse events (occurring during the Screening visit) will be recorded. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 46 of 87 
Results from certain tests that have been performed prior to Screening may be used to determine 
study eligibility if these tests were performed as part of the practice of medicine and were done 
whether or not study entry was contemplated, such as for diagnosis or treatment of the subject’s 
condition. Results from the prior tests must be recorded in the EDC. 
After all Screening procedures have been completed and the subject satisfies all eligibility 
criteria: 
• The study schedule will be discussed with the subject and the schedule will be provided 
to the subject to ensure compliance with the study visits. 
• Subjects will be issued a daily diary on Day -7 along with instructions on how to record 
skin pain in the daily diary and will be asked to start recording their skin pain starting that 
day (one week prior to the Day 1 visit). 
6.2. Study Day 1 
If eligible for the study, the subject will visit the study center on Day 1. The following 
procedures will be performed before taking the first dose of study drug: 
• Stratification and randomization in the IRT system; 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• Urine pregnancy test (in women of childbearing potential); 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements;  
• Biomarker plasma sample will be collected (see Section 7.4); 
• The date and time of collection of the PK sample will be recorded; 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Lesions will be selected and baseline photography will be completed; 
• Items for the Sartorius and modified Sartorius scores will be collected (see Section 7.1.2); 
• IHS4 score will be calculated (see Section 7.1.3); 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• Subjects will be asked to complete the SF-36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms; 
• Compliance with daily recording of skin pain in daily diary starting one week prior to 
Day 1 will be checked and retraining provided, if necessary; 
• Any pre-treatment adverse events (from time of the Screening visit) will be recorded. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 47 of 87 
Thereafter, the following procedures will be performed: 
• Study drug will be provided to the subject with dosing instructions (see Section 5.2); 
• The subject will be asked to take the first dose of study drug while at the study center; 
• The time of the dosing of study drug will be recorded; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any post-dosing adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 2 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug, as instructed. On study visit days, it is preferable that the 
subjects take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit, and 
− Continue taking all their other concomitant medications as usual. 
6.3. Study Week 2 (Day 15) 
The Study Week 2 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for shipment to the central laboratory for serum 
chemistry, hematology, and PK measurements; the date and time of collection of the PK 
sample will be recorded; 
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded; 
• If the subject has not yet taken the morning dose of study drug for this day, the subject 
will be asked to take the dose; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of skin pain and drug dosing in diaries will be checked 
and re-training provided if necessary; 
• Items for the Sartorius and modified Sartorius scores will be collected; 
• IHS4 score will be calculated; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 48 of 87 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• The study site personnel will make sure the subject is taking the study drug as instructed; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 4 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit, and 
− Continue taking all their other concomitant medications as usual. 
6.4. Study Week 4 (Day 29) 
The Study Week 4 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements; the date and time of 
collection of the PK sample will be recorded; 
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded; 
• If the subject has not yet taken the morning dose of study drug for this day, the subject 
will be asked to take the dose; 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of skin pain and study drug dosing in diaries will be 
checked and retraining provided, if necessary; 
• Items for the Sartorius and modified Sartorius scores will be collected; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 49 of 87 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• Subjects will be asked to complete the SF-36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms; 
• The study site personnel will make sure the subject is taking the study drug as instructed; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 8 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and 
− Continue taking all their other concomitant medications as usual. 
6.5. Study Week 8 (Day 57) 
The Study Week 8 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements; the date and time of 
collection of the PK sample will be recorded; 
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded; 
• If the subject has not yet taken the morning dose of study drug for this day, the subject 
will be asked to take the dose; 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 50 of 87 
• Compliance with daily recording of pain and study drug dosing in diaries will be checked 
and retraining provided, if necessary; 
• Items for the Sartorius and modified Sartorius scores will be collected; 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• The study site personnel will make sure the subject is taking the study drug as instructed 
and that the subject has adequate study drug for dosing until the following visit; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug administration in daily diary; 
− Come to the study center for the Week 12 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and 
− Continue taking all their other concomitant medications as usual. 
6.6. Study Week 12 (Day 85) 
The Study Week 12 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements; the date and time of 
collection of the PK sample will be recorded; 
• Biomarker plasma sample will be collected; 
• A 12-lead ECG will be taken to exclude any clinically significant findings; 
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded; 
• If the subject has not yet taken the morning dose of study drug for this day, the subject 
will be asked to take the dose;  


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 51 of 87 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed;  
• Compliance with daily recording of pain in diaries will be checked and re-training 
provided, if necessary; 
• Items for the Sartorius and modified Sartorius scores will be collected; 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• Subjects will be asked to complete the SF-36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms; 
• Drug accountability will be performed; the returned bottles of study drug will be checked 
to make sure the subject is taking the study drug as instructed; 
• Study drug will be dispensed. Note: At this visit, subjects who were assigned to placebo 
arm will be re-randomized to receive 10 mg or 30 mg avacopan twice a day; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 16 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and 
− Continue taking all their other concomitant medications as usual. 
6.7. Study Week 16 (Day 113) 
The Study Week 16 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 52 of 87 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements; the date and time of 
collection of the PK sample will be recorded; 
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded; 
• If the subject has not yet taken the morning dose of study drug for this day, the subject 
will be asked to take the dose; 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain and study drug dosing in diaries will be checked 
and re-training provided, if necessary; 
• Items for the Sartorius and modified Sartorius scores will be collected; 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• Subjects will be asked to complete the SF-36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms; 
• The study site personnel will make sure the subject is taking the study drug as instructed; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 20 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and 
− Continue taking all their other concomitant medications as usual. 
6.8. Study Week 20 (Day 141) 
The Study Week 20 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 53 of 87 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements; the date and time of 
collection of the PK sample will be recorded; 
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded; 
• If the subject has not yet taken the morning dose of study drug for this day, the subject 
will be asked to take the dose; 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain in diaries will be checked and re-training 
provided, if necessary; 
• Items for the Sartorius and modified Sartorius scores will be collected; 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• The study site personnel will make sure the subject is taking the study drug as instructed 
and that the subject has adequate study drug for dosing until the following visit; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 24 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and 
− Continue taking all their other concomitant medications as usual. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 54 of 87 
6.9. Study Week 24 (Day 169) 
The Study Week 24 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for serum chemistry, hematology, and serum pregnancy 
test (in women of childbearing potential); 
• Drug accountability will be performed; the returned bottles of study drug will be checked 
to make sure the subject is taking the study drug as instructed; 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain in diary will be checked and re-training 
provided, if necessary; 
• Study drug will be dispensed; 
• Items for the Sartorius and modified Sartorius scores will be collected; 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 28 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and 
− Continue taking all other concomitant medications as usual. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 55 of 87 
6.10. Study Week 28 (Day 197) 
The Study Week 28 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements; the date and time of 
collection of the PK sample will be recorded; 
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded; 
• If the subject has not yet taken the morning dose of study drug for this day, the subject 
will be asked to take the dose; 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain and study drug dosing in diaries will be checked 
and re-training provided, if necessary; 
• Items for the Sartorius and modified Sartorius scores will be collected; 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• Subjects will be asked to complete the SF-36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms; 
• The study site personnel will make sure the subject is taking the study drug as instructed; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 32 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 56 of 87 
− Take the study drug as instructed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and 
− Continue taking all their other concomitant medications as usual. 
6.11. Study Week 32 (Day 225) 
The Study Week 32 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for serum chemistry, hematology, and serum pregnancy 
test (in women of childbearing potential); 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain in dairy will be checked and re-training 
provided, if necessary; 
• Items for the Sartorius and modified Sartorius scores will be collected; 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA; 
• The study site personnel will make sure the subject is taking the study drug as instructed 
and that the subject has adequate study drug for dosing until the following visit; 
• Study personnel will record health-economic information; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain and study drug dosing in daily diary; 
− Come to the study center for the Week 36 study visit; 
− Store the study drug in a cool and dry place according to label instructions for the 
duration of the study; 
− Take the study drug as instructed. On study visit days, it is preferable that the subjects 
take the morning dose of study drug at the site following the collection of PK 
samples, if applicable to that visit; and 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 57 of 87 
− Continue taking all their other concomitant medications as usual. 
6.12. Study Week 36 (Day 253) 
The Study Week 36 visit must occur within ± 2 days of the scheduled date. During this visit, the 
following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• Blood samples will be collected for serum chemistry, hematology, serum pregnancy test 
(in women of childbearing potential), and PK measurements; the date and time of 
collection of the PK sample will be recorded; 
• Biomarker plasma sample will be collected; 
• The date and time of the last dose of study drug prior to collection of the PK sample will 
be recorded; 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Compliance with daily recording of pain and study drug dosing in diaries will be checked 
and re-training provided, if necessary; 
• Items for the Sartorius and modified Sartorius scores will be collected; 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• Subjects will be asked to complete the SF-36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms; 
• Drug accountability will be performed on the returned bottle(s) of study drug; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will be reminded to: 
− Record severity of skin pain in daily diary; 
− Come to the study center for the Week 44 study visit; and 
− Continue taking all their other concomitant medications as usual. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 58 of 87 
6.13. Study Week 44 (Day 309) 
The Study Week 44 (follow-up) visit must occur within ± 4 days of the scheduled date. During 
this visit, the following study procedures will be performed: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• A 12-lead ECG will be taken to exclude any clinically significant findings; 
• Blood samples will be collected for serum chemistry, hematology and PK measurements; 
the date and time of collection of the PK sample will be recorded; 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Items for the Sartorius and modified Sartorius scores will be collected; 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA; 
• Study personnel will record health-economic information; 
• Subjects will be asked to complete the SF-36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms; 
• The completed daily diary will be collected; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded; 
• After all study procedures have been completed, the subject will exit the study. 
6.14. Early Termination Visit 
If a subject will be withdrawn early from the study, the following termination procedures must 
be completed whenever possible: 
• A physical examination including body weight; 
• Vital signs (temperature, sitting blood pressure, heart rate) after at least 3 minutes of rest; 
• A 12-lead ECG will be taken to exclude any clinically significant findings; 
• Blood samples for serum chemistry, hematology, and serum pregnancy test (in women of 
childbearing potential), and PK measurements; the date and time of collection of the PK 
sample will be recorded; 
• Biomarker plasma sample will be collected; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 59 of 87 
• A urine sample will be collected for urinalysis; 
• The anatomic location and number of HS inflammatory nodules, abscesses, fistulae, and 
hypertrophic scars will be recorded; 
• Follow-up photography of lesions will be completed; 
• Items for the Sartorius and modified Sartorius scores will be collected if the prior visit 
where this assessment was made was more than 2 weeks before; 
• IHS4 score will be calculated; 
• The Investigator will complete the HS-PGA, if the prior visit where these assessments 
were made was more than 2 weeks before; 
• Study personnel will record health-economic information; 
• Subjects will be asked to complete the SF-36 v2, EQ-5D-5L, HiSQOL, DLQI, and 
WPAI:SHP forms, if the prior visit where these assessments were made was more than 2 
weeks before; 
• Drug accountability will be performed on the returned bottles of study drug; 
• Completed daily diary will be collected; 
• Any changes in concomitant medication use will be recorded, including alcohol intake, 
recreational drug use, non-prescription medications, herbal preparations or special diets; 
• Any adverse events will be recorded. 
7. 
STUDY ASSESSMENTS 
7.1. Efficacy Assessments 
7.1.1. 
Location and Extent of Hidradenitis Suppurativa Assessment 
The location and extent of HS will be assessed at visits in the Time and Events Table by 
recording the anatomic location(s) of the disease, as well as the number of HS inflammatory 
nodules, abscesses, fistulae, and hypertrophic scars in each of the locations in the EDC. All study 
Investigators will receive study specific training to assess HS lesions. 
The same Investigator should assess the lesions at each visit to assure consistency. Study sites 
should schedule all visits for the same subject such that the same Investigator is available to 
assess the lesions of that subject. 
The information regarding location and extent of HS involvement will be used to determine the 
Hurley Stage and also to calculate the HiSCR at post-baseline visits. The HiSCR will be 
calculated programmatically in the EDC. 
7.1.2. 
Sartorius and Modified Sartorius Scores 
Twelve body areas will be evaluated at visits specified in the Time and Events Table to calculate 
the Sartorius and modified Sartorius scores: 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 60 of 87 
• left and right axillae, 
• left and right inframammary areas, 
• intermammary area, 
• left and right buttocks, 
• left and right inguino-crural folds, 
• perianal area and perineal area, and 
• other (specify). 
A score of 4 indicates the least severe disease, and higher scores indicate increasingly severe 
disease. There is no upper limit in the score (Sartorius et al, 2003; Sartorius et al, 2009). 
The presence of nodules, abscesses, fistulae, hypertrophic scars, and other findings will be 
recorded in the EDC. The longest distance between two lesions and whether lesions are 
separated by normal skin will also be recorded. 
7.1.3. 
International Hidradenitis Suppurativa Severity Score System 
The International Hidradenitis Suppurativa Severity Score (IHS4) is simple to calculate and has 
been validated with the use of existing physician-derived outcomes such as HS-PGA, Hurley 
classification, MSS or Expert Opinion classification) and patient-reported outcome measure 
(DLQI). IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses 
multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or 
less signifies mild HS, a score of 4–10 signifies moderate HS and a score of 11 or higher 
signifies severe HS. 
7.1.4. 
Hidradenitis Suppurativa-Physician Global Assessment (HS-PGA) 
The HS-PGA is an ordinal scale specific to HS that categorizes subjects into clear, minimal, 
mild, moderate, severe, or very severe disease, and it was used successfully in a phase 2 
interventional clinical trial. A recently developed six stage PGA was defined as follows (Kimball 
et al, 2012): 
• Clear: no inflammatory or non-inflammatory nodules 
• Minimal: Only the presence of non-inflammatory nodules 
• Mild: Less than 5 inflammatory nodules or 1 abscess or draining fistula and no 
inflammatory nodules 
• Moderate: Less than 5 inflammatory nodules or one abscess or draining fistula and one or 
more inflammatory nodules or 2–5 abscesses or draining fistulae and less than ten 
inflammatory nodules 
• Severe: 2–5 abscesses or draining fistulae and ten or more inflammatory nodules 
• Very severe: More than 5 abscesses or draining fistulae 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 61 of 87 
7.1.5. 
Global Assessment of Skin Pain 
Subjects will record the maximum severity pain on a numeric rating scale from 0 (no skin pain) 
to 10 (skin pain as bad as can be imagined) in a daily diary from one week prior to Day 1 
through the Week 44 visit. 
The weekly average of the maximum severity pain for visits designated in the Time and Events 
Table will be calculated programmatically. 
7.1.6. 
Health-Related Quality of Life Assessments 
The SF-36 v2 and EQ-5D-5L instruments are widely accepted global non-disease-specific tools 
to measure changes in subjects’ health-related quality of life. The HiSQOL index (an HS-specific 
instrument) and DLQI instruments are designed to measure the impact of HS or skin disease on 
subjects’ quality of life. Forms for these instruments will be completed by study subjects at visits 
specified in the Time and Events Table. Proven translations will be used for non-English 
speaking subjects, whenever possible. 
Study site personnel will facilitate completion of the questionnaires by the subjects, but will not 
complete the forms for the subjects. The administrator will establish a rapport with the subject, 
emphasize the importance of completing the form, and serve to answer questions and address 
concerns. Subjects should complete the questionnaires before seeing the Investigator at the visit. 
7.1.7. 
Health-Economic Information 
The WPAI:SHP (https://www.cdisc.org/foundational/qrs) assesses the effect of general and 
specific health conditions on productivity losses. Scores are calculated for four areas: percent 
work time missed due to HS, percent impairment while working due to HS, percent overall work 
impairment due to HS, and percent activity impairment due to HS. Forms for this instrument will 
be completed by study subjects at visits specified in the Time and Events Table to measure 
changes from baseline in work productivity and activity impairment. 
Other health-economic information will be recorded by the study personnel on the appropriate 
CRFs such as details on Hospitalizations (i.e., Number of Hospitalizations total and due to HS, 
Number of days hospitalized, Number of days missed from work), Emergency or Urgent Care 
visit (i.e., Number of visits total and due to HS, Number of days (or hours where applicable) 
missed from work), Lesion interventions for HS (i.e., Number of days (or hours where 
applicable) missed from work due to HS lesion interventions). 
7.2. Safety Assessments 
7.2.1. 
Physical Examinations and Vital Signs 
A physical examination (including evaluation of general appearance/mental status, head, eyes, 
ears, nose, throat, and the following body systems: dermatologic, cardiovascular, respiratory, 
gastrointestinal, musculoskeletal and neurologic) will be performed at visits indicated in the 
Time and Events Table. Findings must be recorded in the source documents. 
Any new or worsening findings upon physical examination need to be recorded as adverse 
events. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 62 of 87 
Body weight will be measured as part of the physical examinations. Height needs to be recorded 
only at Screening. BMI will be calculated in the EDC from the body weight and height 
measurements. 
Vital signs and 12-Lead ECG will be measured during Screening and on each scheduled study 
day as indicated in the Time and Events Table. Sitting blood pressure, pulse rate, and body 
temperature will be measured. All vital signs assessments will be performed after the subject has 
rested for at least three minutes. 
7.2.2. 
Clinical Safety Laboratory Assessments 
The following tests will be performed at the visits identified in the Time and Events Table. 
• Hematology: At the central laboratory hemoglobin, hematocrit, RBC count, WBC count 
with differential, platelet count, mean cell hemoglobin, mean cell hemoglobin 
concentration, mean corpuscular volume; 
• Serum Chemistry: At the central laboratory, liver panel (total and fractionated bilirubin, 
lactate dehydrogenase, aspartate aminotransferase [AST], alanine aminotransferase 
[ALT]), renal panel (blood urea nitrogen, creatinine), creatine phosphokinase (CPK), 
albumin, sodium, potassium, magnesium, bicarbonate, chloride, calcium, inorganic 
phosphorus, glucose, total protein, alkaline phosphatase, total cholesterol, uric acid, 
serum amylase, and serum lipase; 
• Coagulation: PT and INR will be performed only if ALT and/or AST >3x ULN; 
• Urinalysis: At the central laboratory, nitrite, blood, and protein, will be tested. If positive, 
microscopy will be performed; 
• Virology (measured only at Screening and may be measured at the local laboratory): 
hepatitis B surface antigen, hepatitis C antibodies, HIV 1 and 2 antibodies; virology tests 
done within 6 weeks prior to Screening are acceptable for eligibility assessment; results 
from prior virology tests performed at the local laboratory must be recorded in the EDC 
system; 
• TB screen: Interferon γ release assay (IGRA) through the central laboratory. 
7.2.3. 
Adverse Events 
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of 
a drug in humans, whether or not considered drug-related. An adverse event could therefore be 
any unfavorable and/or unintended sign (including abnormal laboratory findings), symptom, or 
disease temporally associated with the use of the drug, whether or not considered related to the 
drug. This definition includes intercurrent illnesses or injuries and exacerbation of pre-existing 
conditions. 
An unexpected adverse event is an adverse event that is not identified in nature, severity, or 
frequency in the current Investigator’s Brochure, or that is of greater severity than expected 
based on the information in the Reference Safety Information listing within the Investigator’s 
Brochure. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 63 of 87 
All adverse events occurring in subjects who have been randomized to treatment will be recorded 
in the EDC system and will be reported in accordance with regulatory requirements. Adverse 
events reported prior to commencement of administration of study drug will be considered pre-
treatment events. 
All adverse events will be monitored until resolution or, if the adverse event is determined to be 
chronic, until a cause is identified. If an adverse event remains unresolved at the conclusion of 
the study, a clinical assessment will be made by the Investigator and the Sponsor’s Medical 
Monitor to determine whether continued follow-up of the adverse event is warranted. 
7.2.3.1. 
Adverse Event Severity Assessment 
The severity of each adverse event will be determined by the Investigator using the following 
scale: 
• Mild (Grade 1): no limitation of usual activities 
• Moderate (Grade 2): some limitation of usual activities  
• Severe (Grade 3): inability to carry out usual activities 
• Life-threatening (Grade 4): an immediate risk of death 
• Death (Grade 5) 
7.2.3.2. 
Causality Assessment 
The relationship of study drug to an adverse event will be determined by the Investigator and 
Sponsor based on the following definitions: 
• Probably Not Related: the adverse event was more likely explained by causes other than 
study drug.  
• Possibly Related: there is evidence for a reasonable possibility that study drug 
administration caused the adverse event. 
7.2.3.3. 
Adverse Events of Special Interest (AESI) 
The following findings, as defined below, must be reported as AEs and will be considered 
adverse events of interest (AESI): 
Infections:  
For medically important infections, the organisms involved in the infection need to be 
determined whenever possible and be documented in the EDC. All local and national vaccination 
recommendations should be followed. 
Hepatic Transaminase Elevation: 
• Grade 3 or greater increased ALT or AST (>5 times the upper limit of normal)  
• Grade 2 or greater increased ALT or AST (>3 times the upper limit of normal) with 
elevation of bilirubin to >2 times the upper limit of normal or INR >1.5 
Neutropenia, Lymphopenia, and Leuokopenia: 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 64 of 87 
• Grade 3 or greater neutropenia (<1 x 109/L) 
• Grade 4 lymphopenia  (<0.2 x 109/L) 
• Grade 3 or greater leukopenia (WBC count <2 x 109/L) 
Creatine Phosphokinase Elevation: 
• Grade 3 or greater CPK increase (>5 times the upper limit of dosing) 
Hypersensitivity Reactions:  
• urticaria  
• angioedema 
Malignancies: 
• Any malignancies will be reported as AEs. 
HS Lesion Interventions: 
• Lesion interventions as described in Section 5.7 will be recorded as AE. 
7.2.3.4. 
Serious Adverse Events 
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose: 
• Results in death; 
• Is life-threatening (i.e., the subject was, in the opinion of the Investigator, at immediate 
risk of death from the event as it occurred); 
• Requires or prolongs hospitalization; 
• Results in persistent or significant disability or incapacity; 
• Is a congenital anomaly or birth defect; 
• Is an important and significant medical event that, based on appropriate medical 
judgment, may jeopardize the subject and/or may require medical or surgical intervention 
to prevent one of the other outcomes defining serious. 
Elective surgery already known during Screening to occur in the course of the study, and elective 
hospitalizations for convenience of the subject which are clearly unrelated to any medical 
condition, and agreed upon between the Investigator and the subject prior to randomization, will 
not have to be reported as SAEs. 
7.2.3.5. 
SARs and SUSARs 
A serious adverse reaction (SAR) is defined as an SAE for which there is at least a reasonable 
possibility that the study drug caused the event. 
A suspected unexpected serious adverse reaction (SUSAR) is defined as an SAE for which there 
is at least a reasonable possibility that the study drug caused the event, and the SAE is 
”unexpected”, i.e., not described in terms of nature, severity, or frequency in the Reference 
Safety Information within the current Investigator’s Brochure. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 65 of 87 
”Reasonable possibility” means that there is evidence to suggest a causal relationship between 
the study drug and the adverse event. Within the reporting requirements, the following examples 
illustrate the types of evidence that would suggest a causal relationship: 
• A single occurrence of an event that is uncommon and known to be strongly associated 
with drug exposure (e.g., angioedema, hepatic injury, Stevens-Johnson Syndrome); 
• One or more occurrences of an event that is not commonly associated with drug 
exposure, but is otherwise uncommon in the population exposed to the drug (e.g., tendon 
rupture); 
• An aggregate analysis of specific events observed in a clinical trial (such as known 
consequences of the underlying disease or condition under investigation or other events 
that commonly occur in the study population independent of drug therapy) that indicates 
those events occur more frequently in the drug treatment group than in a concurrent or 
historical control group. 
Events related to the underlying disease, such as relapses or worsening of disease will not be 
considered as SUSARs, unless there is a reasonable possibility that avacopan use was associated 
with these events. 
7.2.3.6. 
Laboratory Abnormalities 
Safety laboratory tests are performed frequently over the course of the study. Laboratory reports 
with abnormal findings will be reviewed by the Investigator. The Medical Monitor will review 
notably abnormal laboratory results according to the Safety Monitoring Plan. The Investigator 
will be advised to follow subjects with notably high liver panel tests closely and to take 
appropriate steps, such as potentially discontinuing study drug, in case the abnormalities persist. 
Please see Section 4.4 for guidance on laboratory abnormalities (white blood cell count, 
neutrophil count, lymphocyte count, AST or ALT and other lab abnormalities of impaired liver 
function or hepatic toxicity, CPK increase) that would prompt pausing or permanently 
discontinuing study drug. 
7.2.3.7. 
Pregnancies 
Any pregnancies that occur in female subjects or partners of male study subjects must be 
reported to the Safety team within 24 hours of awareness as indicated in Section 7.2.4. All 
pregnancies must be followed up until conclusion and the outcome of the pregnancy reported 
within 24 hours of awareness to the Safety team as indicated in Section 7.2.4. 
7.2.4. 
Serious Adverse Event Reporting 
Any serious adverse event occurring from Screening through the end of the follow-up period, 
whether or not considered study related, will be reported immediately (within 24 hours) to the 
Safety team. Reporting is done by completing the SAE form in the EDC system. If it is not 
possible to access the EDC system, the Investigator will send an email to the clinical safety 
mailbox (see information below) of the Clinical Research Organization (CRO) or call their 
regional SAE hotline and fax the completed SAE report form within 24 hours of awareness. 
Contact details are as follows: 


A vac o pa n ( C C X 1 6 8)  
 
Pr ot oc ol C L 0 1 6 _ 1 6 8 
3 1 J ul y 2 0 1 9 
 
A me n d me nt 2. 0 
C he m o Ce ntr y x, I n c.  
C O N FI D E N TI A L  
Pa ge 6 6  of 8 7  
C R O Cli nical Safet y  e-m ail :   
 
C R O S A E h otli ne: 
 
C R O Facsi mile:  
 
A n y me di cati o n or ot her t hera pe utic meas ures us e d t o treat t he e ve nt, i n a d diti o n t o t he o utc o me 
of t he a d verse e v e nt , will be rec or de d i n t he E D C s yste m. 
F oll o w- U p Re p orts: 
T he I n vesti gat or m ust c o nti n ue t o f oll o w t he s u bject u ntil t he S A E has s u bsi de d or u ntil t he 
c o n diti o n bec o mes c hr o nic i n nat ure, sta bilizes (i n t he case of persiste nt i m pair me nt) , or t he 
s u bject dies.  
Wit hi n 2 4 h o urs of recei pt of f oll o w- u p i nf or mati o n, t he I n vesti gat or m ust u p date t he S A E f or m 
electr o nicall y i n t he E D C s yste m f or t h e st u d y a n d s u b mit a n y s u p p orti n g d oc u me ntati o n (e. g., 
s u bject disc har ge s u m mar y or a ut o ps y re p orts) t o t he C R O Cli nical Safet y t ea m via fa x  or e -
mail. If it is n ot p ossi ble t o access t he E D C s yste m, refer t o t he pr oce d ures o utli ne d a b o ve f or 
i nitial re p orti n g of S A Es. 
T he S p o ns or or its re pr ese ntati ves will re p ort all S U S A Rs t o nati o nal healt h a ut h orities a n d 
ce ntral et hics c o m mittees i n a n e x pe dite d ma n ner i n acc or d a nce wit h Cli nical Trial Directi ve, 
Articles 1 6 a n d 1 7, I C H G ui deli ne E 2 A a n d E N T R C T 3 o n t he re p orti n g of all S U S A Rs. 
I n v esti gat ors will f or war d a n y s afet y c o m m u nicati o n as a p plica ble t o t heir local et hics 
c o m mittees.  
7. 3.  P h ar m ac o ki ne tic Assess me nts 
C o nce ntrati o ns of a v ac o p a n  (a n d meta b olites) will be deter mi ne d i n plas ma acc or di n g t o t he 
sc he d ule i n t he Ti me a n d E ve nts Ta ble . The d ate a n d ti me of t he last d ose of st u d y dr u g pri or t o 
t he sa m ple c ollecti o ns m ust be rec or d e d i n t he E D C s yste m . T he dat e a n d ti me of t he P K sa m ple 
c ollecti o n m ust als o be rec or de d. 
T otal plas ma c o nce ntrati o ns of a vac o p a n  (a n d meta b olites) will be deter mi ne d usi n g v ali date d 
a nal yti cal met h o ds.  
7. 4.  E x pl or at or y Bi o m ar ker Assess me nts  
S u bjects  w h o c o nse nte d will ha ve t heir plas ma c ollecte d f or bi o mar k er ass ess me nts i ncl u di n g f or 
e x a m ple c o m ple me nt fra g me nts i nfla m mat or y c he m o ki ne a n d c yt o ki nes.  T he c ollecti o n will 
occ ur acc or di n g t o t he s c he d ule i n t he  Ti me a n d E ve nts Ta ble. 
7. 5.  P h ot o gr a p h ic Assess me nts 
P h ot o gra p hs of aff ecte d s ki n a n d lesi o ns will be ta ke n t o d oc u me nt t he c h a n ges i n vis ual 
a p pear a nce a n d se v erit y o ver t he c o urse of st u d y treat me nt  i n s u bjects w h o c o nse nte d . 
I n v esti gat ors will use t hese p h ot o gr a p hs t o c o m pare t heir c urre nt a n d pri or lesi o n assess me nts. I n 
rare cases, t h e I n vesti gat or ma y us e a n a n o n y mize d p h ot o gra p h t o c o ns ult wit h t he st u d y tea m t o 
ass ure acc ur ac y a n d c o nsiste nc y of t he assess me nts.  
P P D
P P D
P P D


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 67 of 87 
In selected cases, anonymized photographs may be used to communicate potential treatment 
effects in a publication. 
7.6. Study Completion and Withdrawal 
The Week 44 visit will be the last study say for all subjects. Procedures for this day will be 
completed per the Time and Events Table. Each subject’s condition will be evaluated by the 
Investigator at the end of the clinical trial and subjects will be returned to standard of care 
medical treatment, at the Investigator’s discretion. For early withdrawals from the study, the 
procedures for the Early Termination visit will be performed, when possible (see Section 6.14). 
8. 
STATISTICAL CONSIDERATIONS 
8.1. Timing of Analyses 
Primary Analysis: This study consists of a 12-week placebo-controlled, double-blind treatment 
period (Period 1), followed by a 24-week active treatment period (Period 2). When the last 
subject has completed or dropped out of Period 1, an unblinded analysis of the data collected 
from Period 1 can be conducted. 
To maintain the blinding of treatment assignment in Period 2, the analysis results will be 
conducted by a CRO and only aggregated results by treatment will be available to the Sponsor. 
Treatment assignment for individual subjects will not be disclosed to the subject, study site 
personnel at the site, or the Sponsor until the end of the study. 
Final Analysis: When all subjects have completed all of the Week 44 assessments or the last 
subject has dropped out of Period 2, a final analysis will be conducted on all data collected in the 
study. 
8.2. Statistical Hypotheses 
The primary efficacy objective is to evaluate the efficacy of avacopan compared to placebo in 
subjects with Hurley Stage II or III HS based on subjects achieving a Hidradenitis Suppurativa 
Clinical Response (HiSCR) after 12 weeks of treatment. To address this objective, the following 
hypotheses will be tested using the data collected from Period 1 after the last subject has 
completed Period 1: 
• The null hypothesis (H0) is that the avacopan group is not different from the placebo 
control group when comparing the HiSCR rate at Week 12. 
• The alternative hypothesis (H1) is that the avacopan group is different from the placebo 
control group when comparing the HiSCR rate at Week 12. 
To address the multiplicity issue with two dose groups, a fixed hierarchical testing sequence will 
be employed. The hypothesis testing will test the avacopan 30 mg vs. placebo first. If the test is 
significant at the α = 0.05 level, the avacopan 10 mg vs. placebo will be tested at the α = 0.05 
level. If the test of avacopan 30 mg vs. placebo is not significant at the α = 0.05 level, the 
avacopan 10 mg vs. placebo will be tested as an exploratory analysis. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 68 of 87 
8.3. Sample Size Determination 
The study will enroll approximately 390 subjects. In two Phase 3 clinical trials with adalimumab 
(PIONEER I and II; Kimball et al, 2016a), the proportions of subjects in the placebo control 
group achieving a HiSCR at Week 12 were 26.0% and 27.6%, respectively. Hence, if the control 
group only receives placebo, one may assume a HiSCR at Week 12 of approximately 30%. The 
average HiSCR at Week 12 in the adalimumab groups in PIONEER I and II were 41.8% and 
58.9%, respectively with an average of approximately 50% (Kimball et al, 2016a). The attrition 
rate throughout the trial is estimated to be approximately 7%. A sample size of approximately 
130 subjects per treatment group (390 in total) at a Type I error rate of α = 0.05 (two-sided) 
provides approximately 90% power to detect a 20% superiority of avacopan compared to the 
placebo control group in HiSCR at Week 12, assuming an HiSCR at Week 12 of 50% in the 
avacopan group. 
8.4. Analysis Populations 
8.4.1. 
Modified Intent-to-Treat Population 
For the purposes of efficacy data analysis, the Modified Intent-to-Treat (mITT) population will 
be used. This population will include all subjects who are randomized and received at least one 
dose of study drug. The efficacy population will be analyzed according to the treatment group 
each subject is randomized to. The mITT population will be the primary analysis population for 
the efficacy analysis. 
The mITT populations are defined for the two treatment periods as the following: 
• The mITT1 Population in Period 1 is defined as all subjects who are randomized at 
baseline and have received at least one dose of study drug during Period 1. 
• The mITT2 Population in Period 2 is defined as all subjects who have received at 
least one dose of study drug during Period 2. 
8.4.2. 
Per-Protocol Population 
The Per-Protocol (PP) population will consist of all randomized subjects who receive at least one 
dose of study drug and do not have protocol deviations that could significantly affect the 
interpretation of the results for the primary endpoints. Subjects’ inclusion/exclusion from the PP 
population will be determined and documented prior to the database lock and unblinding. 
8.4.3. 
Safety Population 
The Safety Populations are defined as the following: 
• The Safety Population in Period 1 is defined as all subjects who are randomized at 
baseline and have received at least one dose of study drug during Period 1. 
• The Safety Population in Period 2 is defined as all subjects who received at least one 
dose of avacopan during Period 2. 
• The All Avacopan Treated Population is defined as all subjects who receive at least 
one dose of avacopan in any treatment period. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 69 of 87 
The Safety Populations will be analyzed according to the assigned treatment group. In the event 
that a subject receives a treatment regimen that does not correspond to the assigned treatment, 
the subject will be included in the analysis group of the treatment actually received. 
8.5. Efficacy Endpoints 
8.5.1. 
Primary Endpoint 
The primary endpoint is the proportion of subjects achieving Hidradenitis Suppurativa Clinical 
Response (HiSCR) at Week 12. 
This endpoint is considered appropriate because it was able to measure meaningful 
improvements in HS subjects in previous studies (Kimball et al, 2014; Zouboulis et al, 2015; 
Kimball et al, 2016b). This endpoint was also used successfully in two Phase 3 clinical trials 
with adalimumab (Kimball et al, 2016a). 
8.5.2. 
Secondary Efficacy Endpoints 
Secondary efficacy endpoints include: 
1. Reduction of IHS4 score relative to baseline at Week 12; 
2. Proportion of subjects achieving at least 30% reduction and at least 1 unit reduction from 
Day 1 in the subject’s global assessment of skin pain (NRS30) in subjects with a baseline 
NRS of at least 3, evaluated at Week 12; weekly averages of daily pain will be calculated 
based on subjects’ daily diary recording of the worst pain experienced in the previous 
24 hours; 
3. Change from Day 1 to Week 12 in the modified Sartorius score to quantify the severity 
change of HS; 
4. Proportion of subjects with baseline Hurley Stage II who achieved an abscess and 
inflammatory nodule count of 0, 1, or 2 at Week 12. 
8.5.3. 
Other Efficacy Endpoints 
The following efficacy endpoints will be analyzed from Day 1 to each timepoint up to Week 44, 
where applicable: 
1. Proportion of subjects achieving HiSCR; 
2. Proportion of subjects achieving at least 30% reduction and at least 1 unit reduction from 
Day 1 in subject’s global assessment of skin pain (NRS30), in subjects with a Day 1 NRS of 
at least 3; 
3. Proportion of subjects with baseline Hurley Stage II who achieved an abscess and 
inflammatory nodule count of 0, 1, or 2; 
4. Change from Day 1 in inflammatory nodule count, abscess count, draining fistula count, and 
total AN count; 
5. Change from Day 1 in the Sartorius score, modified Sartorius score, IHS4 score, and HS-
PGA to quantify the severity change of HS; 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 70 of 87 
6. Change from Day 1 in patient-reported outcomes: SF-36 v2, EQ-5D-5L, HiSQOL, and  
DLQI; 
7. Proportion of subjects who experienced flare, defined as an at least 25% increase in AN 
counts with a minimum increase of 2 AN lesions relative to Day 1; 
8. Duration of flare in days (calculated from the day when flare is observed to the day prior to 
the observation that flare is no longer present; of note, there could be multiple periods that 
flares are observed, in which case, the total days from the multiple periods will be used); 
9. Proportion of subjects who experience at least 25% increase in draining fistula counts with a 
minimum increase of 2 draining fistula counts relative to Day 1; 
10. During Period 2, Proportion of subjects with a loss of response (LOR), defined as loss of at 
least 50% of AN count improvement achieved from Day 1 to Week 12; 
11. Time to LOR during Period 2; 
12. Proportion of subjects who received oral antibiotic rescue therapy; 
13. Proportion of subjects who start disallowed opioid pain therapy; 
14. Proportion of subjects who undergo lesion intervention due to HS; 
15. Number of lesion interventions due to HS; 
16. Health-economic information: 
a. WPAI:SHP: Change from Day 1 to each timepoint during Period 1 and Change from 
Week 12 to each timepoint during Period 2 and including the follow-up period; 
b. Hospitalizations (cumulative): Number of Hospitalizations total and due to HS, Number 
of days hospitalized, Number of days missed from work; 
c. Emergency or Urgent Care visits (cumulative): Number of visits total and due to HS, 
Number of days (or hours where applicable) missed from work; 
d. Lesion interventions for HS (cumulative): Number of days (or hours where applicable) 
missed from work due to HS lesion interventions. 
8.6. Safety Endpoints 
Safety endpoints include: 
1. Subject incidence of treatment-emergent serious adverse events, adverse events, and 
withdrawals due to adverse events; 
2. Change from Day 1 and shifts from Day 1 in all safety laboratory parameters; 
3. Change from Day 1 in vital signs and significant changes in physical examination 
abnormalities. 
8.7. Pharmacokinetic Endpoints 
Avacopan (and its metabolite) plasma concentrations will be used to calculate the following PK 
parameters on Day 1 and trough plasma concentrations (Cmin) over the course of the clinical trial. 
Cmax 
Maximum plasma concentration 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 71 of 87 
Tmax 
Time of maximum plasma concentration  
AUC0-6h Area under the plasma concentration-time curve from Time 0 to Hour 6 on Day 1 
8.8. Statistical Analysis Methodology 
8.8.1. 
General Approach 
All study data will be summarized by treatment using descriptive statistics. Categorical variables 
will be reported as frequency and percent (e.g., gender, race). Continuous variables will be 
reported as number of subjects, mean, standard deviation, median, minimum, and maximum 
(e.g., age, weight). All summaries, statistical analyses, and individual subject data listings 
described below will be completed using Version 9.3 or later of the SAS Statistical Analysis 
System (SAS Institute, Inc. Cary, NC). 
All statistical testing will be two-sided, with the Type I error rate at α = 0.05.  
Baseline is defined as the last value prior to start of dosing with study drug (typically the Day 1 
pre-dose value). 
Non-Responder Analysis: For non-responder analysis, the following imputation rules will be 
applied to categorical and continuous efficacy variables, respectively: 
• Categorical Efficacy Variables: Non-Responder Imputation (NRI) will be used as the 
primary analysis. Last Observation Carried Forward (LOCF) will be the secondary 
approach for the non-responder analysis. 
• Continuous Efficacy Variables: LOCF will be used as the primary analysis. The valid 
assessments from last visit prior to the visit the subject was considered a non-
responder will be carried forward to the end of study for continuous efficacy 
variables. Baseline efficacy evaluations will not be carried forward.  
The following are examples for subjects who will be counted as non-responder:  
• Concomitant anti-TNF-α treatment or other treatments with clinically relevant impact 
on HS; 
• Antibiotic rescue therapy; 
• Non-protocol specified lesion intervention, or higher than permitted frequency or 
number of pre-specified lesion interventions. Protocol-specified lesion interventions 
will not be counted as Non-responder. 
Concomitant therapy that would qualify a subject as non-responder will be reviewed prior to 
database lock. More details will be provided in the Statistical Analysis Plan (SAP). 
Missing Data Analysis: For missing data analysis, the following imputation rules will be applied 
to categorical and continuous efficacy variables, respectively: 
• Categorical Efficacy Variables: NRI will be the primary approach for categorical 
variables. The NRI analysis will count subjects who have missing values at a specific 
visit as non-responders for that visit. LOCF will be the secondary approach for the 
missing data analysis. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 72 of 87 
• Continuous Efficacy Variables: LOCF will be the primary approach for continuous 
efficacy variables of missing data. The LOCF analyses will have their valid efficacy 
assessments from the previous visits to impute missing data at later visits. Baseline 
efficacy evaluations will not be carried forward. 
Lesions that received intervention (incision and drainage, or intralesional injection) will be 
counted as permanently present from the date of the intervention. 
Details of the statistical analysis will be provided in a separate statistical analysis plan (SAP), 
which will be finalized prior to database lock. 
8.8.2. 
Analysis of Primary Efficacy Endpoint 
The primary efficacy endpoint, the proportion of subjects achieving HiSCR at Week 12 will be 
tested using the Cochran-Mantel-Haenszel (CMH) test, stratified by Hurley Stage (Stage II vs. 
III), concomitant  antibiotic therapy with allowed antibiotics (Yes vs. No) and anti-TNF drug use 
(Treatment naïve vs. Previous treatment). The hierarchical testing procedure will be used for the 
comparisons of the 10 mg avacopan vs. placebo and 30 mg avacopan vs. placebo to maintain the 
overall Type I error at 0.05. The 30 mg avacopan vs. placebo will be tested first: if the p-value is 
less than or equal to 0.05, then 10 mg avacopan vs. placebo will be tested at the α = 0.05 level. If 
the test of avacopan 30 mg vs. placebo is not significant at the α = 0.05 level, the 10 mg 
avacopan vs. placebo will be tested as an exploratory analysis. The two-sided 95% confidence 
intervals for the difference in proportions (avacopan minus placebo control) will be calculated 
using the stratified Newcombe hybrid-score method. The primary efficacy analysis will be 
carried out in the mITT1 Population. In addition, the primary efficacy endpoint will be analyzed 
in the Per-Protocol Population. 
The proportion of subjects achieving HiSCR at Week 12 will be calculated as those subjects 
having at least a 50% reduction from baseline in abscess and inflammatory nodule count, with no 
increase in abscess count and no increase in draining fistula count number at Week 12 divided by 
the total number of subjects randomized to the particular treatment group. 
8.8.3. 
Analysis of Secondary and Other Efficacy Endpoints in Period 1 
The Secondary and Other Efficacy Endpoints for Period 1 will be tested separately for the 10 mg 
and 30 mg avacopan groups at Type I error at 0.05. The analyses will be carried out in the 
mITT1 Population. Analysis of other efficacy endpoints will be conducted from Day 1 to each 
timepoint. 
Categorical variables of change from Day 1 to Week 12 will be analyzed using CMH test 
stratified for baseline Hurley Stage (Stage II vs. III), concomitant antibiotic therapy with allowed 
antibiotics (Yes vs. No) and anti-TNF-α drug use (Treatment naïve vs. Previous treatment) 
similar to the analysis of the primary efficacy endpoint. 
Continuous variables will be analyzed using a mixed effects model for repeated measures. This 
model will include treatment group, visit, treatment-by-visit interaction, and randomization strata 
(Hurley Stage II or Hurley Stage III, previous anti-TNF-α drug use or anti-TNF-α drug naïve, 
concomitant antibiotic therapy use or not) as factors, and baseline as covariate. Subjects will be 
considered as repeated measure units over visits. Testing p-values, point estimates and 
corresponding 95% confidence intervals will be estimated for the difference between the 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 73 of 87 
avacopan group and the placebo control group across 12 weeks using linear contrast from the 
model. 
For the analysis of subject’s global assessment of skin pain (NRS30) up to Week 12, subjects 
who received analgesics of disallowed pain therapy will be counted as non-responder for 
categorical variables. For continuous variables, LOCF applies. Hereby, the last pain assessment 
is carried forward from the start day of the analgesics or day of the intervention until 14 days 
after the stop of analgesic use or day of the intervention. Concomitant medication for treatment 
of pain will be reviewed. Disallowed pain therapy will be determined by a blinded data review 
prior to database lock. 
The test of 10 mg vs. 30 mg avacopan groups will be conducted at each timepoint for the 
endpoint of the proportion of subjects achieving HiSCR and the secondary endpoints. A detailed 
Type I management plan for the secondary endpoint testing will be provided in SAP. 
8.8.4. 
Analysis of Secondary and Other Efficacy Endpoints in Period 2 
The efficacy data for secondary and other endpoints by timepoint in Period 2 will be summarized 
using the mITT2 population.  Analysis of other efficacy endpoints will be conducted from Day 1 
to each timepoint. 
For the analysis of time to loss of response (LOR), the treatment difference between the 10 mg 
and 30 mg avacopan groups will be analyzed using the stratified log-rank test with baseline 
randomization stratification factors as the stratification variables. 
8.8.5. 
Safety Analyses 
All subjects who are randomized and received at least one dose of study drug will be included in 
the safety population. 
All clinical safety and tolerability data will be summarized by treatment group and listed by 
treatment group and by subject. 
All reported adverse events will be coded using MedDRA and listed by System Organ Class, 
Preferred Term, and verbatim term. 
• Treatment-emergent adverse events will be summarized and listed by treatment group by 
System Organ Class and Preferred Term, by relatedness and by maximum severity. 
• Treatment-emergent serious adverse events and adverse events leading to withdrawal will 
be summarized by treatment group. 
Individual vital signs and change from baseline in vital signs will be summarized by treatment 
group and listed by treatment group, subject, and study visit. 
Laboratory data will be listed by treatment group, subject, and study visit. Abnormal laboratory 
values will be flagged. Laboratory data (actual values and change from baseline) will be 
summarized by treatment group and study visit. Shift tables will be generated for shifts in 
laboratory parameters by study visit. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 74 of 87 
8.8.6. 
Pharmacokinetic Analysis 
Individual plasma concentrations of avacopan and significant metabolites will be listed, plotted, 
and summarized descriptively and graphically. PK analysis may be performed in a subject subset 
only. The following parameters will be determined, where possible: 
Cmax 
Maximum plasma concentration 
Tmax 
Time of maximum plasma concentration  
AUC0-3h Area under the plasma concentration-time curve from Time 0 to Hour 3 on Day 1 
Cmin 
Trough level plasma concentrations at post-Day 1 visits 
The relationship between PK parameters (e.g., Cmin) and efficacy endpoints such as HiSCR may 
also be evaluated. 
8.8.7. 
Subject Disposition 
The number of subjects who were screened, who screen failed (by reason), who were 
randomized, who completed Week 12, Week 36, and Week 44 of the study, respectively, and 
who withdrew early from the study, along with the reasons for withdrawal, will be presented by 
treatment group. 
8.8.8. 
Demographics and Baseline Characteristics 
All subject baseline characteristics and demographic data, i.e., age, sex, race, ethnicity, weight, 
height, body mass index, anatomic location of HS, number of inflammatory nodules, abscesses, 
draining fistulae and hypertrophic scars, Hurley Stage of HS, HS disease duration (from time of 
diagnosis), subject’s global assessment of skin pain NRS, Sartorius and modified Sartorius 
scores, IHS4 score, and HS-PGA, previous systemic treatment, previous antibiotic treatment, 
previous TNF inhibitor use, prior surgery for HS, SF-36 v2, EQ-5D-5L, and HiSQOL index will 
be summarized and listed by treatment group. 
Physical examination abnormalities, medical history, previous and concomitant medications 
(including HS medication use) at study entry will be summarized and listed by treatment group. 
8.8.9. 
Prior and Concomitant Medications 
All medications will be coded using the World Health Organization Drug Dictionary (WHODD). 
All prior (within 12 months of Screening for HS medications, and within 6 months of Screening 
for all other medications) and concomitant medications (including HS medications) will be 
summarized and listed by WHODD Anatomic Therapeutic Chemistry (ATC) classification and 
preferred term. 
8.8.10. 
Study Drug Exposure and Compliance 
Subject drug exposure will be calculated comparing the daily drug diary, study drug dispensing 
and return records, as well as avacopan plasma concentrations over the course of the study. The 
study drug exposure (duration, total dose, and average daily dose) and compliance will be 
summarized for the double-blind and active treatment periods separately. Individual subject data 
listings will also be provided. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 75 of 87 
8.8.11. 
Handling of Missing Data 
For binary variables, non-response imputation will be used for missing data (primary approach). 
Sensitivity analyses will include last observation carried forward (LOCF) and multiple 
imputation. For continuous variables, LOCF and observed without adjustment for missing data 
will be performed as sensitivity analyses. Baseline data will not be carried forward. 
8.8.12. 
Covariates and Subgroups 
The analysis of the efficacy endpoints may be adjusted by the following variables in the form of 
covariate analysis, stratified analysis, and/or subgroup analysis: 
• Randomization stratification variables 
− Hurley Stage II vs. Hurley Stage III 
− Concomitant  antibiotic therapy (Yes vs. No) 
− Anti-TNF-α treatment (Treatment naïve vs. Previous treatment) 
• Sex 
• BMI 
• Baseline weight 
• Age at diagnosis of HS 
• Age at study entry 
• Duration of HS 
• Subject’s age, race, and ethnicity  
• Baseline inflammatory nodule count 
• Baseline abscess count 
• Baseline draining fistula count 
• Baseline Sartorius and modified Sartorius scores 
• Baseline AN count 
• Geographic distribution  
8.9. Interim Analyses 
An interim analysis for futility may be conducted (for example, if enrollment is much slower 
than expected) by an independent statistical data center when at least 30% of the planned study 
participants have completed Period 1 of the study. This interim futility analysis will not affect the 
Type I error of the overall study.  Based upon the futility analysis, it is possible that the low dose 
of avacopan or the entire study may be stopped. The details regarding the futility analysis 
boundaries will be provided in the SAP. 
9. 
STUDY COMPLETION AND TERMINATION 
The primary analysis can be performed when all subjects have completed at least the Week 12 
visit. Another analysis will be performed when all subjects have completed the full study. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 76 of 87 
9.1. Study Completion 
A subject has completed the study when s/he has completed the study procedures per protocol. 
9.2. Study Termination 
The end of study is defined as the last study visit of the last clinical trial subject. 
The study will be terminated early if there is an insurmountable safety concern that cannot be 
addressed by protocol amendment. This will be determined in conjunction with the DMC. In this 
case, the Investigators, competent authorities (CAs), IRB/ECs will be notified expeditiously and 
appropriate measures taken to safeguard the study subjects. 
10. 
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS 
10.1. Regulatory, Ethical, and Study Oversight Considerations 
10.1.1. 
Informed Consent 
A properly executed, written, and appropriately explained Informed Consent Form, in 
compliance with the Declaration of Helsinki, ICH GCP, and US Code of Federal Regulations for 
Protection of Human Subjects (21 CFR 50.25[a,b], CFR 50.27, and CFR Part 46, Subpart A), 
will be signed by each subject prior to entering the trial. Consent forms will be provided to 
subjects in their native language and will describe in detail the study intervention, study 
procedures, and risks. 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 
the study and continues throughout the individual’s study participation. Consent forms will be 
approved by the applicable IRB or EC and the participant will be asked to read and review the 
document. The Investigator or the Investigator’s designee will explain the clinical trial to the 
participant and answer any questions that may arise. A verbal explanation will be provided in 
terms suited to the participant’s comprehension of the purposes, procedures, and potential risks 
of the study and of their rights as research participants. Participants will have the opportunity to 
carefully review the written consent form and ask questions prior to signing. The participants 
should have the opportunity to discuss the study with their family or surrogates or think about it 
prior to agreeing to participate. The participant will sign the informed consent document prior to 
any procedures being done specifically for the study. Participants must be informed that 
participation is voluntary and that they may withdraw from the study at any time, without 
prejudice. The rights and welfare of the participants will be protected by emphasizing to them 
that the quality of their medical care will not be adversely affected if they decline to participate 
in this study. A copy of the informed consent document will be given to the participants for their 
records. The informed consent process will be documented in the source document (including the 
date), and the form signed, before the participant undergoes any study-specific procedures. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 77 of 87 
10.1.2. 
Study Discontinuation and Closure 
Determination of unexpected, significant, or unacceptable risk to participants may warrant 
termination or suspension of the clinical trial. Written notification, documenting the reason for 
study suspension or termination, will be provided by the Sponsor or its designee to Investigators 
and applicable regulatory agencies/competent authorities. If the study is prematurely terminated 
or suspended, the Principal Investigator will promptly inform study participants and the 
applicable IRB/EC, and will provide the reason(s) for the termination or suspension. Study 
participants will be contacted, as applicable, and be informed of changes to study visit schedule. 
The study may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the applicable IRBs/ECs and regulatory agencies/competent authorities. 
10.1.3. 
Confidentiality and Privacy 
Participant confidentiality and privacy is strictly held in trust by the participating investigators, 
their staff, and the Sponsor and its designees. This confidentiality is extended to cover testing of 
biological samples in addition to the clinical information relating to participants. Therefore, the 
study protocol, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the study or the data will be released to any unauthorized 
third party without prior written approval of the Sponsor. 
All research activities will be conducted in as private a setting as possible. 
The study monitor, other authorized representatives of the Sponsor, representatives of the 
IRB/EC, regulatory agencies/competent authorities may inspect all documents and records 
required to be maintained by the Investigator, including but not limited to, medical records 
(office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical 
study sites will permit access to such records. 
The study participant’s contact information will be securely stored at each clinical site for 
internal use during the study. At the end of the study, all records will continue to be kept in a 
secure location for as long a period as dictated by the reviewing IRB/EC, Institutional policies, 
or Sponsor requirements. 
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored at the Sponsor’s designated CRO. This will not 
include the participant’s contact or identifying information. Rather, individual participants and 
their research data will be identified by a unique study identification number. The study data 
entry and study management systems used by clinical sites and by the CRO’s staff will be 
secured and password protected. At the end of the study, all study databases will be de-identified 
and archived at the Sponsor’s designated CRO. 
10.1.4. 
Future Use of Stored Specimens and Data 
Data collected for this study will be analyzed and stored at the Sponsor’s designated CRO. At the 
end of the study, these data will be transferred to the Sponsor or to a Sponsor-delegated storage 
location. 
Biological samples collected from study participants will be shipped from the study sites to the 
CRO’s central laboratory for analysis. Plasma samples collected for PK analysis will be shipped 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 78 of 87 
from the CRO’s central laboratory to the Sponsor’s designated PK laboratory for analysis. Once 
the assays are completed, the data verified, and all analyses completed, the samples will be 
destroyed. 
10.1.5. 
Key Roles and Study Governance 
10.1.5.1. Investigator Responsibilities 
The Investigator and site staff will be the primary contact for the study subjects. The Investigator 
and its staff will communicate all relevant study-related information to the subjects and conduct 
all study-specific procedures including collection of blood and urine samples. The Investigator 
agrees that neither s/he nor any of the study staff will supply study drug to any persons other than 
those enrolled in the study. 
Prior to trial initiation, the Investigator will provide the Sponsor with a fully executed and signed 
FDA Form 1572, a Financial Disclosure Form, and a curriculum vitae. Financial Disclosure 
Forms will also be completed for all sub-Investigators listed on the Form 1572 who will be 
involved directly in the treatment or evaluation of research subjects in this trial. 
The study will be conducted in accordance with the Declaration of Helsinki (amended by the 59th 
World Medical Association General Assembly, October 2008) and GCP according to ICH 
guidelines. Specifically, the study is based on adequately performed laboratory and animal 
experimentation; the study will be conducted under a protocol reviewed by a properly constituted 
IRB/EC; the study will be conducted by scientifically and medically qualified persons; the 
benefits of the study are in proportion to the risks; the rights and welfare of the subjects will be 
respected; and each subject or his/her legal guardian will give his/her written Informed Consent 
before any protocol-specific tests or evaluations are performed. 
The Investigator agrees to complete a subject identification register, which will be used for the 
purpose of long term follow-up, if needed. This form will be treated as confidential, and will be 
filed by the Investigator in a secure locked place. Otherwise, all reports and communications 
relating to the study will identify participants by initials and/or assigned number only. 
10.1.5.2. Sponsor and Its Designees  
This clinical trial will be sponsored by ChemoCentryx, Inc. ChemoCentryx will designate to its 
CRO several clinical trial activities including those related to study oversight, clinical, medical 
and safety monitoring, site communication, data management, safety laboratory measurements, 
statistical analysis, report writing, and site contract and investigator payment. The Sponsor will 
maintain oversight by having regular meetings with its designated CRO. The Sponsor will also 
designate measurement of plasma PK samples to a CRO that will use validated methods for 
measurements of avacopan and metabolites. 
10.1.5.3. Institutional Review Boards/Ethics Committees 
Prior to initiating the study, the Investigator will obtain written confirmation from the IRB/EC 
that the IRB/EC was properly constituted and met the definition of all United States Code of 
Federal Regulations Title 21, Section 312.3(b) and Part 56, and/or the applicable local, regional 
or national Regulatory requirements. A copy of the confirmation will be provided to the Sponsor. 
The Principal Investigator will provide the IRB/EC with all appropriate materials, including the 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 79 of 87 
protocol and Informed Consent documents. The trial will not be initiated until IRB/EC approval 
of the protocol, the Informed Consent document, and all recruiting materials are obtained in 
writing by the Investigator and copies are received by the Sponsor. Appropriate reports on the 
progress of the study will be made to the IRB/EC and the Sponsor by the Principal Investigator 
in accordance with applicable governmental regulations and in agreement with the policy 
established by the Sponsor. 
10.1.6. 
Safety Oversight and Data Monitoring Committee 
The study Medical Monitor will review aggregate blinded safety data regularly over the course 
of the study according to the Safety Monitoring Plan. The Medical Monitor will keep the 
Sponsor’s Medical Director apprised of all relevant safety findings over the course of the study. 
In addition to continuous safety monitoring by the Medical Monitor and clinical staff, an external 
Data Monitoring Committee (DMC) will monitor the safety of subjects over the course of the 
study. The DMC will consist of external physicians and a biostatistician, with at least one 
member being a dermatologist knowledgeable in HS. Members of the DMC will be independent 
from the study conduct and free of conflict of interest. A DMC charter will be developed and the 
DMC will function according to the charter. 
It is anticipated that the DMC will have regular meetings as specified by the DMC Charter 
depending on study enrollment rate. Ad hoc meetings may be scheduled if unanticipated safety 
events occur. After review of data at each meeting, the DMC will make recommendations about 
further conduct of the study. 
Safety data from the study will be summarized for review by the DMC at various points over the 
course of the study. 
No Type I error adjustment will be made based on the DMC review of the data, since results 
from these analyses will be kept confidential and not be shared with the study team, 
Investigators, or subjects. 
10.1.7. 
Study Monitoring 
The Sponsor has ultimate responsibility to take all reasonable steps to ensure proper conduct of 
the study with respect to subject rights and safety, adherence to the currently approved 
protocol/amendment, compliance with ICH GCP and applicable regulatory requirements, and 
data validity and integrity. 
Study monitoring responsibility may be transferred to a Sponsor representative or CRO, who will 
be held to execute the study with high standards. 
The study will be closely monitored throughout its duration, in the form of personal visits with 
the study investigator/site staff as well as appropriate communications by telephone, fax, mail, or 
email. The purpose of these contacts is to review study progress, Investigator and subject 
adherence to the protocol, to identify and mitigate any risk of subject safety, and to evaluate data 
integrity. 
The following key areas will be assessed as part of study site monitoring on an ongoing basis, in 
addition to the details provided in the Clinical Monitoring Plan: 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 80 of 87 
• Continued suitability and qualification of the site to conduct the study, including proper 
training of the Investigator and site staff; 
• Informed consent and other regulatory documentation; 
• Subject accrual and follow up; 
• Continued compliance with protocol, including documentation of protocol deviations and 
implementation of corrective and preventive measures; 
• Documentation of all adverse events and concomitant medications, and proper reporting 
of all serious adverse events; 
• Timely data entry, accuracy, completeness and 100 % verifiability of data when 
compared to source documents, and 
• Study drug accountability. 
The Investigator and their staff are expected to cooperate and support monitors during their visits 
and provide access to relevant study documents and systems. A monitoring report and visit 
follow up communication will be generated for every visit and filed in the trial master files. 
10.1.8. 
Quality Assurance and Quality Control 
Clinical sites are responsible for quality management of the study and proper documentation. 
Quality control (QC) procedures to ensure data quality will be accomplished through 
implementation of a validated data entry system and data QC checks that will be run on the study 
database. As part of monitoring, any missing data or data anomalies will be communicated to the 
site(s) for clarification/resolution. 
Following written SOPs, the monitors will verify that the clinical trial is conducted, data are 
generated and biological specimens are collected, documented (recorded), and reported in 
compliance with the protocol, ICH GCP, and applicable regulatory requirements (e.g., Good 
Laboratory Practices, Good Manufacturing Practices). 
All study site documentation pertaining to this clinical study may be subject to quality assurance 
audits by personnel designated by ChemoCentryx, the FDA, and/or other regulatory agencies 
with similar responsibilities. Upon request, the auditor will have access to inspect, copy, review 
and audit all source documentation and eCRFs. Other documentation subject to quality assurance 
audits include the Investigator’s IRB files, study staff training and delegation records, laboratory 
certifications, pharmacy processes and standard operating procedures for study management 
processes. In addition, the Sponsor or designee may inspect conditions of storage of study drug, 
and observe any aspect of the clinical study or its supporting activities both from within and 
outside of the Investigative site. 
10.1.9. 
Data Handling and Record Keeping 
10.1.9.1. Data Collection and Management Responsibilities 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the Investigator. The Investigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 81 of 87 
All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data. 
Data recorded in the electronic data capture (EDC) system must be consistent with the data 
recorded on the source documents. 
Clinical data (including disease characteristics, medical history, subject-reported outcome 
measures, AEs, and concomitant medications) will be entered into the CRO’s database, a 21 
CFR Part 11-compliant data capture system. The data system includes password protection and 
internal quality checks, such as automatic range checks, to identify data that appear inconsistent, 
incomplete, or inaccurate. Clinical data will be entered directly from the source documents. 
Central laboratory data will be captured and transferred directly from the laboratory database. 
Upon completion of the study, electronic copies of the CRFs will be provided to the Investigators 
and should be included as part of his/her study files and retained as per FDA or local regulations. 
10.1.9.2. Study Records Retention 
Study documents should be retained for a minimum of 2 years after the last approval of a 
marketing application in an ICH region, and until there are no pending or contemplated 
marketing applications in an ICH region, or until at least 2 years have elapsed since the formal 
discontinuation of clinical development of the study intervention. These documents should be 
retained for a longer period, however, if required by local regulations. No records will be 
destroyed without the written consent of the Sponsor. The Sponsor will inform the Investigator 
when these documents no longer need to be retained. 
10.1.10. 
Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol or ICH GCP 
requirements. The noncompliance may be either on the part of the participant, the Investigator, 
or the study site staff. As a result of deviations, corrective actions must be developed by the site 
and implemented promptly. 
It is the responsibility of the Investigator to use continuous vigilance to identify and report 
significant protocol deviations to the Clinical Research Associate (CRA) as soon as possible 
upon identification of the protocol deviation. All deviations must be addressed in study source 
documents. Protocol deviations must be sent to the IRB/EC per their policies. The Investigator is 
responsible for knowing and adhering to the reviewing IRB/EC requirements. 
Significant protocol deviations will be listed and summarized by deviation category in the 
Clinical Study Report. 
The Sponsor will assess any protocol deviations and decide whether any of these should be 
reported to CAs as a serious breach of GCP and the protocol. Protocol waivers are not 
acceptable. 
10.1.11. 
Protocol Modifications 
Only the Sponsor may modify the protocol. The only exception is when the Investigator 
considers that a subject’s safety would be compromised without immediate action. In this 
circumstance, immediate approval of the chairperson of the IRB/EC must be sought, and the 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 82 of 87 
Investigator should inform the Sponsor’s Medical Monitor and the full IRB/EC within five 
working days after the emergency occurred. 
All other amendments that have an impact on subject risk or the study objectives, and/or that 
require revision of the ICF, must receive approval from the IRB/EC prior to their 
implementation, except when the changes involve only logistical or administrative aspects of the 
trial. The IRB/EC must be notified of changes that are made to study contact personnel, but 
IRB/EC review or approval of these changes is not required. If protocol amendments are 
substantial and are likely to have an impact on the safety of the trial subjects or to change the 
interpretation of the scientific documents in support of the conduct of the trial, or if they are 
otherwise significant, the Sponsor shall notify the FDA and other CAs concerned of the reasons 
for, and content of, these amendments according to the European Directive “Detailed guidance 
on the request to the CAs for authorization of a clinical trial on a medical products for human 
use, the notification of substantial amendments and the declaration of the end of trial (CT 
1)(2010/C 82/01)” and other regulatory guidance. In case of a substantial amendment to the 
protocol, approval will be sought from CAs before implementation. 
10.1.12. 
Study Registration, Use of Information and Publication 
The study will be registered in clinicaltrials.gov and other country-specific registries, as required, 
prior to initiation. 
It is understood by the Investigator that the information generated in this study will be used by 
the Sponsor in connection with the development of the product and therefore may be disclosed to 
government agencies in various countries. To allow for the use of information derived from the 
study, it is understood that the Investigator is obliged to provide the Sponsor with complete test 
results, all study data, and access to all study records. 
The Sponsor recognizes the importance of communicating study data and will disclose or publish 
the results in a suitable form regardless of outcome. The Sponsor will publish the results of this 
study in scientific journals, at seminars or conferences, and/or in other manner(s) it so chooses. 
Results from this study shall not be made available to any third party by the investigating team 
without the express permission of the Sponsor. 
11. 
BENEFIT/RISK ASSESSMENT 
11.1. Non-Clinical Evaluation 
Single-dose and repeat-dose toxicology, safety pharmacology, and genotoxicity studies have 
been conducted with avacopan. General toxicity studies of up to 26-week duration in rats and 44-
week duration in cynomolgus monkeys have been conducted at avacopan doses up to 200 and 45 
mg/kg/day, respectively, significantly higher than the highest human daily dose of 30 mg twice 
daily (b.i.d.) being tested in this clinical trial and other indications. 
Based on in vivo safety pharmacology studies, which included neuropharmacology, pulmonary, 
and renal safety studies in rats, and a cardiovascular safety study in conscious telemetered 
cynomolgus monkeys, there was no evidence of toxicity of avacopan. No evidence of 
electrocardiographic alterations was seen in the monkey 4-week, 20-week, or 44-week studies or 
in in vitro cardiovascular safety studies (IC50 values for hERG inhibition was determined to be 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 83 of 87 
>2.3 µM for avacopan and >3.0 µM for its metabolite CCX168-M1, the limit of solubility for 
both compounds). A safety margin for avacopan and metabolite CCX168-M1 of at least 3,500 
fold relative to expected steady state human unbound maximum plasma is projected. 
Genotoxicity studies, including in vitro bacterial mutagenicity (Ames test) and in vitro 
mammalian cell mutagenicity (mouse lymphoma) studies, in vivo bone marrow rat micronucleus 
and in silico mutagenicity evaluation of starting materials, intermediates and chemical impurities 
utilized and formed during the synthesis of avacopan were also conducted and did not identify 
any safety concerns or significant potential for drug-drug interactions. In an acute toxicology 
study, single doses of avacopan up to 100 mg/kg in rats produced no remarkable effects. No 
effects on IgG and IgM antibody production in rats or monkeys were noted following 
immunization with keyhole limpet hemocyanin antigen. Immunophenotypic analyses performed 
in the 44-week monkey study did not reveal any avacopan-related effects. No phototoxicity 
potential was observed for avacopan in the in vitro 3T3 assay. 
Avacopan was well tolerated in studies up to 26 and 44 weeks in rats and cynomolgus monkeys, 
respectively, up to the highest doses tested (200 mg/kg/day in rats and 45 mg/kg/day in 
cynomolgus monkeys). These doses provide an exposure margin of ~19-fold and ~6-fold, 
respectively, compared to the projected avacopan steady-state exposure with the 30 mg twice 
daily therapeutic dose in humans. There were no significant toxicological findings of concern in 
these chronic studies or the preceding sub-chronic studies. Metabolite CCX168-M1 (which has 
been identified in humans) was present in samples collected in the rat 26-week and the monkey 
44-week studies at relatively high levels indicating that this metabolite has been qualified. 
No avacopan-related effects were observed upon pregnancy or embryo-fetal development in 
studies at doses up to 1000 mg/kg and 200 mg/kg in hamsters and rabbits, respectively. No 
evidence of histopathological alterations to the male or female reproductive system was seen in 
rats or monkeys in toxicology studies. A pre and post-natal development study (Segment III) in 
hamsters with avacopan given at doses up to 1,000 mg/kg/day (500 mg/kg b.i.d.) from GD 6-12 
and through lactation until weaning of the offspring, resulted in no adverse findings in either the 
F0 dams or the F1 offspring, including developmental, behavioral, immunological or reproductive 
measures (PC0673_168). Analysis of avacopan plasma levels in the lactating dams and the 
plasma levels in nursing offspring showed the presence of avacopan, suggesting avacopan is 
likely excreted into the milk of lactating hamsters. 
In summary, no safety findings in toxicology studies in rats, cynomolgus monkeys, rabbits and 
hamsters have been observed that would preclude dosing to humans at the 30 mg twice daily 
dose in this clinical trial. 
11.2. Clinical Evaluation 
Five Phase 1 studies have been completed at avacopan doses ranging from 1 mg up to 100 mg 
(CL001_168, CL004_168, CL007_168, CL008_168, and CCX1101). Avacopan was generally 
well tolerated in these studies. 
The most frequently reported adverse events in subjects receiving avacopan in Phase 1 clinical 
studies were headache (14.6% vs. 14.3% for placebo), diarrhea (6.7% vs. 7.1% for placebo), 
dizziness (4.5% vs. 0% for placebo), upper respiratory tract infection (4.5% vs. 0% for placebo), 
nausea (3.4% vs. 0% for placebo), oropharyngeal pain (3.4% vs. 7.1% for placebo), and WBC 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 84 of 87 
count decreased (3.4% vs. 0% for placebo). All other adverse events occurred at an incidence 
less than 3%. 
In addition, a Phase 1 study in subjects with mild (N=8) or moderate (N=8) hepatic impairment 
(as defined using Child-Pugh [C-P] Classification of the Severity of Liver Disease criteria) 
compared to healthy matched controls (N=8) studying a single dose of 30 mg avacopan was 
completed. The single dose of 30 mg avacopan was well tolerated in all subjects and there was 
no pharmacokinetically relevant impact on avacopan exposure. As a result, no dose adjustment is 
necessary for subjects with mild to moderate hepatic impairment. 
An ethno-bridging Phase 1 study (CCX1101) was conducted in 40 healthy, male Japanese 
subjects. The study was conducted to test the safety and PK of avacopan and its major metabolite 
CCX168-M1 in the Japanese subjects compared to 24 Caucasian healthy adult males. 
In addition, two Phase 2 clinical trials (CL002_168 and CL003_168) have been conducted in 
109 subjects with AAV; 73 of these were randomized to receive avacopan in these trials. A total 
of 60 subjects received 30 mg avacopan twice daily and 13 subjects received 10 mg avacopan 
twice daily for 12 weeks. 
As anticipated, since all subjects received rituximab or cyclophosphamide, and most also 
received glucocorticoids, serious infections were the most common serious adverse event. The 
incidence of serious infections was similar in subjects receiving avacopan compared to the 
control group. Vasculitis or renal vasculitis (worsening) was also reported at a similar incidence 
in the two groups. 
The most commonly reported treatment-emergent adverse events in subjects with AAV receiving 
avacopan in studies CL002_168 and CL003_168 combined were hypertension (17.8% vs. 16.7% 
in the control group), nausea (17.8% vs. 19.4% in the control group), vomiting (13.7% vs. 0.0% 
in the control group), headache (11.0% vs. 11.1% in the control group), nasopharyngitis (11.0% 
vs. 8.3% in the control group), peripheral edema (9.6% vs. 11.1% in the control group), 
arthralgia (8.2% vs. 2.8% in the control group), and diarrhea (8.2% vs. 2.8% in the control 
group). Grade 3 lymphopenia has been observed in more subjects receiving avacopan plus 
cyclophosphamide or rituximab compared to cyclophosphamide or rituximab alone. This 
lymphopenia occurred within the first 2 weeks of treatment, and was not progressive with 
continued treatment. Avacopan did not show evidence of pro-arrhythmic potential in an intensive 
ECG study (CL007_168). 
Caution should be exercised when avacopan is given with potent CYP3A4 inhibitors such as 
itraconazole, since the avacopan plasma exposure may increase approximately two-fold. 
Avacopan has shown evidence of efficacy in Phase 2 study CL002_168 based on BVAS, quality 
of life measurements, renal response, urinary albuminuria, and urinary MCP-1:creatinine results. 
This efficacy was demonstrated across a number of relevant immunological and clinical 
subgroups, i.e., subjects with MPO ANCA-positive disease vs. PR3 ANCA-positive disease, 
newly diagnosed vs. relapsing subjects, subjects on cyclophosphamide vs. those on rituximab.  
It is of note that as avacopan is a selective C5aR blocker, it does not appear to affect the 
formation of C5b and the membrane attack complex (MAC) or terminal complement complex 
(TCC) which is needed to protect against Neisseria infections. Nevertheless, subjects should 
adhere to all local vaccination program requirements, Investigators should be vigilant in 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 85 of 87 
reporting all infections occurring during clinical trials and should attempt to identify the 
organisms involved in all infections. 
In an ongoing Phase 3 study (CL010_168) of approximately 300 subjects with AAV, subjects 
receive avacopan and background therapy of cyclophosphamide followed by azathioprine, or in 
combination with rituximab. The control group receives high dose glucocorticoids on 
background therapy with cyclophosphamide followed by azathioprine, or in combination with 
rituximab. The study remains blinded to the Sponsor, Investigators and subjects. An unblinded 
Data Monitoring Committee (DMC) of study CL010_168 recommended notification be sent to 
Investigators with the following observations: (a) urticaria with angioedema in two subjects, and 
(b) elevated liver transaminases in several subjects on blinded study drug (with one event of 
biopsy consistent-hepatocellular damage in a subject receiving active study drug in combination 
with immunosuppressive and other drugs), and (c) events of nausea, vomiting, and diarrhea. 
Informed Consent Form(s) were also updated. 
Therefore, the Reference Safety Information section of the Investigator’s Brochure has been 
updated to include the potential risk of urticaria, angioedema, and of hepatotoxicity, and to state 
that general gastrointestinal adverse events (e.g., nausea, diarrhea) observed in Phase 2 AAV 
studies have been observed in the ongoing Phase 3 CL010_168 study at approximately the same 
frequency and severity. 
Further, as a result of the DMC review of safety data from all completed and ongoing studies of 
avacopan, the frequency of monitoring of hematology has been increased to monthly and rules 
for pausing administration of blinded study drug have been modified. These changes to the 
protocol were based on observations of neutropenia and neutropenic sepsis in a blinded study in 
a subject with C3 glomerulopathy (CL011_168) and agranulocytosis in the ongoing and blinded 
Phase 3 study of avacopan in subjects with AAV (ADVOCATE, CL010_168). In all reported 
cases, subjects were receiving multiple immunosuppressants (e.g., cyclophosphamide, rituximab, 
mycophenolate mofetil, others) in addition to study medication. 
11.3. Summary Benefit-Risk Statement 
Based on the nonclinical and clinical study results, the potential benefits of testing avacopan in 
subjects with HS outweigh the potential risks. 
Subjects participating in clinical trials must be closely monitored for any adverse events, and 
laboratory, physical examination, or vital signs abnormalities. WBC and differential counts, and 
liver enzyme values must be monitored over the course of the studies. 
As with all investigational compounds, the potential exists for unanticipated serious or life-
threatening toxicities or adverse events not predicted by the animal toxicology or clinical studies 
conducted to date. Investigators should exercise vigilance in the monitoring of subjects involved 
in this clinical trial with avacopan. 
For additional details, please refer to the current version of the Investigator’s Brochure.


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 86 of 87 
12. 
REFERENCES 
1. Bekker P, et al. Characterization of pharmacologic and pharmacokinetic properties of 
CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based 
on preclinical evaluation and randomized phase 1 clinical study. PLoS ONE 11: e0164646. 
doi:10.1371/journal.pone.0164646. 
2. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. Food and 
drug administration, July 2009. 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf. 
3. Guo R, et al. IFX-1 blocking the anaphylatoxin C5a – an anti-inflammatory effect in subjects 
with hidradenitis suppurativa. Poster presentation at the 16th European Meeting on 
Complement in Human Disease (EMCHD2017), Copenhagen, Sep 2017. 
https://www.inflarx.de/dam/jcr:ec982d1e-f82b-4992-a1b0 
ff6e69a04b6b/Guo_2017_poster.pdf 
4. Jayne DRW, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated 
vasculitis. J Am Soc Nephrol 2017;28:2756-2767. 
5. Johnson TN, et al. Prediction of the clearance of eleven drugs and associated variability in 
neonates, infants and children. Clin Pharmacokinet 2006;45:931-956. 
6. Kanni T, et al. Complement activation in hidradenitis suppurativa: a new pathway of 
pathogenesis? Br J Dermatol 2018;179:413-419.  
7. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe 
hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012;157:846-855. 
8. Kimball AB, et al. Assessing the validity, responsiveness and meaningfulness of the 
Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis 
suppurativa treatment. Br J Dermatol 2014;171:1434-1442.  
9. Kimball AB, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J 
Med 2016a;375:422-434. 
10. Kimball AB, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical 
endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the 
placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol 
2016b;30:989-994. 
11. Napolitano M, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. 
Clin Cosmet Investig Dermatol 2017;10:105-115. 
12. Prens E and Deckers I. Pathophysiology of hidradenitis suppurativa: An update. J Am Acad 
Dermatol 2015;73:S8-S11. 
13. Radtke F, et al. Notch signaling in the immune system. Immunity 2010;32:14-27.  
14. Sartorius K, et al. Suggestions for uniform outcome variables when reporting treatment 
effects in hidradenitis suppurativa. Br J Dermatol 2003;149:211-213. 


Avacopan (CCX168) 
 
Protocol CL016_168 
31 July 2019 
 
Amendment 2.0 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Page 87 of 87 
15. Sartorius K, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco 
smoking and obesity. Br J Dermatol 2009;161:831-839. 
16. Wang B, et al. Gamma-secretase gene mutations in familial acne inversa. Science. 2010; 
330:1065. 
17. Xiao H, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc 
Nephrol 2014;25:225-231. 
18. Zouboulis CC, et al. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity 
assessment, classification and disease evaluation. Dermatology 2015;231:184-190. 
19. Zouboulis CC, et al. Development and validation of the International Hidradenitis 
Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS 
severity. Br J of Dermatol 2017 Nov;177:1401-1409. 

SAP_001.pdf: 
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
C he m o Ce ntr y x, I nc  
Pr ot oc ol #: C L 0 1 6 _ 1 6 8  
 
A R a n d o mize d, D o u ble- Bli n d, pl ace b o - C o ntr olle d, P ar allel Gr o u p, 
P h ase 2 St u d y t o E v al u ate t he S afet y a n d Effic ac y of A v ac o p a n i n S u bjects wit h 
M o der ate t o Se vere Hi dr a de nitis S u p p ur ati v a  
 
St atistic al A n al ysis Pl a n  
 
Versi o n 7. 0  
D oc u me nt last sa ve d:  1- Dec - 2 0 2 0 1 0: 1 0 A M 
 
 Pre p are d f o r:  
C he m o Ce ntr y x, I n c.  
M o u ntai n Vie w, Calif or nia 9 4 0 4 3, U S A  
P h o ne: + 1 ( 6 5 0) 2 1 0- 2 9 0 0 
 
 
Pre p are d b y:  
 
 
 
 
 
 
 
 
 
 
 
 
 
P P D
P P D
P P D
P P D


C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
L I S T O F A B B R E VI A T I O N S A N D A C R O N Y M S  
A A V  
A N C A -ass ociat e d vasc ulitis 
A E  
a d verse e ve nt  
A E SI  
a d verse e ve nt of s p ecial i nterest  
A L T  
ala ni ne a mi n otra nsferas e  
A N  
a bscess a n d i nfl a m mat or y n o d ule (c o u nt)  
A N A  
a nti n uclear a nti b o dies  
A N C  
a bs ol ute ne utr o p hil c o u nt  
A N C A  
a nti-ne utr o p hil c yt o plas mic a ut oa nti b o d y  
A N C O V A  
a nal ysis of c o varia nce  
A S T  
as partate a mi n otra nsferas e  
A T  
A mi n otra nsfer ase  
A T C  
A nat o mic T her a pe utic C he mistr y  
A U C  
area u n d er t he pl as ma c o nce ntrati o n -ti me c ur ve 
b.i. d.  
t wice dail y 
C 5a  
c o m ple me nt c o m p o ne nt 5a fra g m e nt  
C 5a R  
rece pt or f or C 5a 
C 5 b -9  
me m bra ne attac k c o m ple x or ter mi nal c o m ple me nt c o m ple x  
C A  
c o m pete nt a ut h orit y  
C ma x  
ma xi m u m ( ma xi mal) plas ma c o nce ntrati o n  
C mi n  
mi ni m u m plas ma c o nce ntrati o n  
C M H  
C oc hra n -Ma nt el -Hae nszel  
C O VI D -1 9  
C or o na vir us Disease 2 0 1 9  
C P K  
creati ne p h os p h o ki n ase  
C R A  
Cli nical Researc h Ass o ciate  
C R F  
Case Re p ort F or m  
C R O  
cli nical researc h or ga nizati o n  
C S R  
cli nical st u d y re p ort  
C Y P 3 A 4  
c yt oc hr o me P 4 5 0 3 A 4  
D L QI   
Der mat ol o g y Life Q u alit y I n d e x  
D M C  
data m o nit ori n g c o m mittee  
E C G  
Electr ocar di o gra m  
e C R F 
electr o nic case re p ort f or m  
E D C  
electr o nic d ata ca pt ure  
E Q -5 D -5 L  
E ur o Q ualit y of Life -5 D o mai ns -5 Le vels  
F D A  
F o o d a n d Dr u g A d mi nistrati o n  
g  
Gra m  
H B V  
he patitis B vir us  
H C V  
he patitis C vir us  
Hi S C R  
hi dra de nitis s u p p urati va cli nical res p o nse  
Hi S Q O L  
Hi dra de nitis S u p p urati va Q ualit y of Life  
HI V  
h u ma n i m m u n o deficie nc y vir us 
H S  
hi dra de nitis s u p p urati va  
H S -P G A  
Hi dra de nitis S u p p urati va -P h ysicia n Gl o bal Assess me nt  
I g 
I m m u n o gl o b uli n 
I g A N 
i m m u n o gl o b uli n A ne p hr o pat h y 
P P D
P P D
P P D


C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
I G R A 
i nterfer o n γ release ass a y 
I H S 4 
I nter nati o nal H S Se verit y Sc ori n g S yste m 
I N D 
I n v esti gati o nal Ne w Dr u g 
I N R 
I nter nati o nal n or malize d rati o 
I R T 
i nteracti ve r es p o nse tec h n ol o g y 
I T T 
i nte nt-t o-treat 
I V 
i ntra ve n o us 
k Da  
Kil o dalt o n  
k g  
Kil o gra m  
L O R  
l oss of res p o nse 
Me d D R A  
Me dical Dicti o nar y f or R e g ulat or y Acti vities  
M g  
Milli gra m  
m L  
Milliliter  
M P O  
m yel o per o xi dase  
M S S  
m o difie d Sart ori us sc ore  
N  
N u m ber  
N F  
Nati o nal F or m ular y  
N RI  
N o n -Res p o n der I m p ut ati o n  
N R S  
n u meric rati n g scale  
N R S 3 0  
pr o p orti o n of s u bjects ac hie vi n g at least 3 0 % re d u cti o n a n d at least 1 u nit 
re d ucti o n fr o m bas eli ne i n t he s u bject’s gl o bal ass ess me nt of s ki n pai n o n 
a n u meric r ati n g scale  
P K  
p har mac o ki netic(s)  
P P  
Per -pr ot oc ol  
P T  
pr ot hr o m bi n ti me  
Q A  
q ualit y ass ura nce  
Q C  
q ualit y c o ntr ol  
Q T/ Q Tc  
Q -T i nter val o n E C G; c orrect e d Q -T i nter v al 
R B C  
re d bl o o d cell(s) 
R N A  
ri b o n ucleic aci d 
S A E  
seri o us a d vers e e v e nt 
S A P  
statistical a nal ysis pla n 
S A R  
seri o us a d vers e reacti o n 
S D  
sta n dar d de viati o n 
S E M  
sta n dar d err or of t h e mea n 
S F -3 6 v 2  
S h ort F or m -3 6 versi o n 2. 0  
S O P  
sta n dar d o per ati n g pr oce d ure  
S U S A R  
s us pecte d u ne x p ecte d seri o us a d verse reacti o n 
T B  
t u berc ul osis 
T Bili  
t otal bilir u bi n 
T E A E  
Treat me nt e mer ge nt a d v erse e ve nt  
U L N  
u p per li mit of n or mal  
W B C  
w hite bl o o d cell  
W H O D D  
W orl d Healt h Or ga nizati o n Dr u g Dicti o nar y  
W P AI: S H P  
W or k Pr o d ucti vit y a n d A cti vit y I m pair me nt Q u esti o n naire: S pecific 
Healt h Pr o ble m  
P P D
P P D
P P D


C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
C o nte nts 
I.I ntr o d u cti o n ............................................................................................................................ 6 
A
Bac k gr o u n d ............................................................................................................. 6 
B.
Pr ot oc ol a n d A me n d me nt Hist or y .......................................................................... 6 
II.Pr ot oc ol O bjecti ves ............................................................................................................... 6 
A.
Pri mar y  .................................................................................................................... 6
B.
Sec o n dar y  ................................................................................................................ 7
III.S t u d y E n d p oi nts ................................................................................................................... 7 
A.
Efficac y E n d p oi nts .................................................................................................. 7 
B.
Safet y E n d p oi nts ..................................................................................................... 9 
I V.St u d y Desi g n ...................................................................................................................... 1 0  
A.
Desi g n O ver vie w .................................................................................................. 1 0  
B.
St u d y P o p ulati o n ................................................................................................... 1 1  
C.
Sa m ple Size Esti mati o n  ........................................................................................ 1 1 
D.
Treat me nt Ra n d o mizati o n  ..................................................................................... 1 1 
E.
Assess me nt Sc he d ule  ............................................................................................ 1 3 
V. I nter ve nti o ns........................................................................................................................ 1 7 
A.
Cli nical Trial Material ........................................................................................... 1 7  
VI. Ge ner al A nal ytical C o nsi derati o ns  .................................................................................... 1 7 
A.
Baseli ne a n d St u d y Da y ........................................................................................ 1 7  
B.
A nal y sis Visit Wi n d o w ......................................................................................... 1 7 
C.
Missi n g Data  ......................................................................................................... 2 0 
D.
M ulti ple St u d y Ce nters ......................................................................................... 2 2  
E.
C o variate A dj ust me nt i n Pri mar y A nal ysis  .......................................................... 2 2 
F.
Sa m ple Size Reassess me nt  ................................................................................... 2 2 
G.
I nteri m A nal yses or Ti mi n g of A nal yses .............................................................. 2 2 
H.
Test Sizes  .............................................................................................................. 2 2 
I.
M ulti ple C o m paris o ns/ M ulti plicit y  ...................................................................... 2 2 
J.
A nal ysis P o p ulati o ns ............................................................................................. 2 3  
K.
S u b gr o u p A nal ysis ................................................................................................ 2 5  
L.
Data Dis pla y C har acteristics  ................................................................................. 2 5 
VII. S u bject Acc o u nta bilit y ..................................................................................................... 2 6  
A.
S u bject Dis p ositi o n  ............................................................................................... 2 7 
B.
Pr ot oc ol De viati o ns ............................................................................................... 2 7  
C.
S u bject C haracteristics  .......................................................................................... 2 7 
VIII. Efficac y A nal yses  ........................................................................................................... 3 0 
A.
Ti mi n g of A nal yses ............................................................................................... 3 0  
B.
Efficac y E n d p oi nts ................................................................................................ 3 0  
C.
Ge ner al A p pr oac h  ................................................................................................. 4 2 
P P D


C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
D.  Pri mar y Efficac y E n d p oi nt A nal ysis .................................................................... 4 3  
E.  Sec o n dar y a n d Ot her Efficac y E n d p oi nts A nal yses ............................................. 4 6  
I X.Safet y A nal yses  ................................................................................................................. 4 9 
A.  A d verse E v e nts  ..................................................................................................... 4 9 
B.  Cli nical La b orat or y Res ults  .................................................................................. 5 1 
C.  Vital Si g ns  ............................................................................................................. 5 3 
D.  1 2- Lea d Electr o car di o gra m ( E C G) ....................................................................... 5 3  
E.  P h ysical E xa mi nati o n ............................................................................................ 5 3  
F.  P har mac o ki netic A n al ysis  ..................................................................................... 5 4 
G.  Bi o mar ker Assess me nts  ........................................................................................ 5 7 
H.  P h ot o gra p hic Assess me nts .................................................................................... 5 7  
I. S u p ple me ntar y A nal yses Relate d t o C O VI D- 1 9 .................................................. 5 7  
X. C ha n ges fr o m t he Pr ot oc ol Pla n ne d A nal yses .................................................................... 5 9  
 
P P D


 
C O N FI D E N TI A L  
Pa ge 6  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
I. 
I ntr o d ucti o n 
 
A.  B ac k gr o u n d 
 
T he p ur p ose of t his d oc u me nt is t o pr o vi de a descri pti o n of t he statistical met h o ds a n d 
pr oce d ures t o be i m ple me nte d f or t he a nal ysis of data fr o m C he m o Ce ntr y x, I nc. 
Pr ot oc ol C L 0 1 6 _ 1 6 8. T his d oc u me nt is base d o n Pr ot oc ol A me n d me nt 2. 0 
( 3 1J U L Y 2 0 1 9). If circ u msta nces arise d uri n g t he st u d y s uc h t hat m ore a p pr o priate 
a nal ytic pr oce d ures bec o me a vaila ble, t he statistical a nal ysis pla n ( S A P) ma y be 
re vise d. T he statistical defi niti o ns a n d a nal ytical met h o ds descri be d i n t his S A P 
s u perse de t hat i n t he pr ot oc ol. An y re visi o ns t o t he pri mar y e n d p oi nt a nal yses a n d 
si g nifica nt re visi o ns t o t he sec o n dar y e n d p oi nt a nal yses will be ma de pri or t o t he 
data base freeze f or t he data i n t he d o u ble - bli n d treat me nt peri o d t hr o u g h Wee k 1 2. 
Reas o ns f or s uc h re visi o ns will be descr i be d i n t he fi nal Cli nical St u d y Re p ort ( C S R).  
 
B.  Pr ot oc ol a n d A m e n d me nt Hist or y 
   
T his Statistical A nal ysis Pla n ( S A P) is base d o n 3 1J U L 2 0 1 9 of Pr ot oc ol C L 0 1 6 _ 1 6 8, 
A me n d me nt 2. 0. 
 
Versi o n  
A p pr o v al D ate 
Ori gi nal Pr ot oc ol 
1 9 Oct o ber 2 0 1 8 
A me n d me nt 1 
1 9 Marc h  2 0 1 9 
A me n d me nt 2 
3 1 J ul y 2 0 1 9 
 
II. 
Pr ot oc ol O bjecti ves  
 
T he st u d y is a ra n d o mize d, d o u ble- bli n d, place b o-c o ntr olle d, t hree- gr o u p P hase 2 trial 
i n a p pr o xi matel y 3 9 0 s u bjects wit h m o derate t o se vere hi dra de nitis s u p p urati va 
( H urle y Sta ge II or III). S u bjects will be ra n d o mize d 1: 1: 1 t o a treat me nt of 1 0 m g 
a vac o p a n t wice d ail y, 3 0 m g a vac o pa n t wi ce dail y or place b o f or 1 2 w ee ks. S u bjects 
treate d wit h 1 0 m g or 3 0 m g t wice dail y d uri n g t he bli n de d, place b o-c o ntr olle d 1 2-
wee k treat me nt peri o d ( P eri o d 1, da y 1 t o wee k 1 2) will be f oll o we d b y a n a d diti o nal 
2 4- wee k, acti ve tr eat me nt peri o d ( Peri o d 2 , wee k 1 2 t o wee k 4 4) d uri n g w hic h t he y 
will c o nti n ue t o recei ve t he sa me d ose re gi me n, eit her 1 0 m g or 3 0 m g a vac o pa n t wice 
dail y. 
 
A.  Pri m ar y  
1)  E va l uati o n of t he efficac y of a vac o p a n  c o m pare d t o p lace b o i n s u bjects wit h 
H urle y Sta ge II or III hi dra de nitis s u p p urati va ( H S) base d o n s u bjects ac hie vi n g a 
Hi dra de nitis S u p p urati va Cli nical Res p o nse ( Hi S C R) after 1 2 w ee ks of treat me nt. 
Hi S C R is defi ne d as at least a 5 0 % re d ucti o n i n a bscess a n d i nfla m mat or y n o d ule 
( A N) c o u nt a n d n o i ncr ease i n a bscess c o u nt a n d n o i ncreas e i n drai ni n g fist ula 
c o u nt at Wee k 1 2 relati v e t o baseli ne.  
P P D


 
C O N FI D E N TI A L  
Pa ge 7  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
2)  E val uati o n of t he saf et y of a vac o p a n  c o m pare d t o place b o i n t hese s u bjects base d 
o n t he a d vers e e ve nt i nci de nce, c ha n ges fr o m bas eli ne i n la b orat or y p ara m eters, 
a n d vital si g ns 
 
B.  Sec o n d ar y  
 
1)  E val uati o n of t he efficac y of a vac o p a n c o m pare d t o p lace b o i n t hese s u bjects 
i ncl u de: 
a. T he s u bject’s gl o bal ass ess me nt of s ki n pai n n u meric rati n g scal e ( N R S),  
b.  T he m o difie d Sart ori us s c ore, a n d 
c. Ac hie vi n g a n A N  c o u nt of 0, 1, or 2. 
 
2)  Assess me nt of s u bject-re p orte d o utc o mes i ncl u di n g healt h-rel ate d q ualit y-of -life 
c ha n ges bas e d o n t he S h ort F or m- 3 6 v ersi o n 2 ( S F- 3 6 v 2), t he E ur o Q O L- 5 D- 5 L 
( E Q- 5 D- 5 L), t he Hi dr a de nitis S u p p urati va Q ualit y of Life ( Hi S Q O L) I n de x, t he 
Der mat ol o g y Life Q u alit y I n d e x ( D L QI), a n d t he W or k Pr o d ucti vit y a n d A cti vit y 
I m pair me nt Q uesti o n naire: S pecific Healt h Pr o ble m ( W P AI: S H P) wit h a vac o pa n  
c o m pare d t o place b o .  
3)  E val uati o n of t he p har m ac o ki netic pr ofile of a vac o pa n i n s u bjects wit h H S.  
4)  E val uati o n of t he saf et y a n d efficac y of a vac o p a n  treat me nt fr o m Da y 1 b y eac h 
ti me p oi nt u p t o Wee k 4 4 i n s u bjects wit h H S. 
5)  E val uati o n of t he efficac y of a vac o p a n  c o m pare d t o place b o i n t hese s u bjects 
i ncl u de: 
a. T he Sart ori us sc ore, I nter nati o nal H S Se verit y Sc ori n g S yste m (I H S 4) 
sc ore, H S P h ysicia n Gl o bal Assess me nt ( H S-P G A),  
b.  Pr o p orti o n of s u bjects w h o e x perie n ce d fl are, w h o e x perie n ce d l oss of 
res p o nse d uri n g Peri o d 2, w h o recei ve d oral a nti bi otic resc ue t h era p y or 
lesi o n i nter ve nti o n, a n d w h o recei ve d disall o we d o pi oi d pai n t hera p y, a n d 
c. T he d urati o n of fl are i n d a ys.   
 
6)  E val uati o n of healt h- ec o n o mic i nf or mati o n. 
 
III.      St u d y E n d p oi nts  
 
A.  Effic ac y E n d p oi nt s 
 
•  Pri m ar y  Effic ac y E n d p oi nt  
 
T he pri mar y efficac y e n d p oi nt is t he pr o p orti o n of s u bjects ac hie vi n g Hi dra de nitis 
S u p p urati va Cli nical Res p o nse ( Hi S C R) at Wee k 1 2. A res p o nse is defi ne d as a 
re d ucti o n of at least 5 0 % i n a bscess  a n d i nfla m mat or y n o d ule c o u nt wit h n o i ncreas e i n 
a bscess c o u nt a n d n o i ncr ease i n drai ni n g fist ula c o u nt c o m pare d t o bas eli ne. 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 8  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
•  Sec o n d ar y  Effic ac y E n d p oi nt s 
 
T he f oll o wi n g sec o n dar y efficac y e n d p oi nts will be a nal yze d acc or di n g t o t he ra n k 
or der as t he f oll o ws: 
1.  C ha n ge fr o m Baseli ne  i n t otal AN c o u nt at Wee k 1 2; 
2.  Pr o p orti o n of s u bjects ac hie vi n g at least 3 0 % re d u cti o n a n d at least 1 u nit re d ucti o n 
fr o m Baseli ne  i n t he s u bject’s gl o bal assess me nt of s ki n pai n ( N R S 3 0) i n s u bjects wit h 
a Baseli ne N R S of at least 3, e val uate d at Wee k 1 2; wee kl y a ver a ges of dail y pai n will 
be calc ul ate d base d o n s u bjects’ dail y diar y rec or di n g of t he w orst pai n e x p erie nce d i n 
t he pre vi o us 2 4 h o urs. 
3.  Pr o p orti o n of s u bjects wit h baseli ne H urle y Sta ge II w h o ac hie ve d a n a bscess a n d 
i nfla m mat or y n o d ule c o u nt of 0, 1, or 2 at Wee k 1 2. 
4.  Re d ucti o n of I H S 4 sc or e relati ve t o baseli ne at Wee k 1 2. 
5.  C ha n ge fr o m Baseli ne  i n i nfla m mat or y n o d ule c o u nt at Wee k 1 2. 
6.  C ha n ge fr o m Baseli ne  i n a bscess c o u nt at Wee k 1 2. 
7.  C ha n ge fr o m Baseli ne  i n drai ni n g fist ula c o u nt at Wee k 1 2. 
8.  C ha n ge fr o m Baseli ne  t o Wee k 1 2 i n t he m o difie d Sart ori us sc ore t o q ua ntif y t he 
se verit y c ha n g e of H S; 
 
•  Ot her Effic ac y E n d p oi nts 
T he f oll o wi n g effi cac y e n d p oi nts will be a nal yze d fr o m Baseli ne  t o eac h ti me p oi nt u p t o 
Wee k 4 4 , w h ere a p plica ble : 
1.  Pr o p orti o n of s u bjects ac hie vi n g Hi S C R , Hi S C R 7 5, a n d Hi S C R 9 0; 
2.  Pr o p orti o n of s u bjects ac hie vi n g at least 3 0 % re d u cti o n a n d at least 1 u nit re d ucti o n 
fr o m Baseli ne  i n t he s u bject’s gl o bal assess me nt of s ki n pai n ( N R S 3 0), i n s u bjects 
wit h a Baseli ne  N R S of at least 3;  
3.  Pr o p orti o n of s u bjects wit h baseli ne H urle y Sta ge II w h o ac hie ve d a n a bscess a n d 
i nfla m mat or y n o d ule c o u nt of 0, 1, or 2; 
4.  C ha n ge fr o m Baseli ne  i n i nfla m mat ory n o d ule c o u nt, a bscess c o u nt, n o n- i nfla m mat or y 
c o u nt, drai ni n g fist ula, n o n- drai ni n g fist ula, t otal fist ula c o u nt, a n d t otal A N c o u nt; 
5.  % C ha n ge fr o m B as eli ne  i n i nfla m mat or y n o d ule c o u nt, a bscess c o u nt, n o n-
i nfla m mat or y c o u nt, drai ni n g fist ula, n o n- drai ni n g fist ula, t otal fist ula c o u nt, a n d t otal 
A N c o u nt a m o n g s u bjects w h o ha ve at least o ne c orres p o n di n g lesi o n at Baseli ne ; 
6.  C ha n ge fr o m Baseli ne  i n t he Sart ori us sc ore, m o difie d Sart ori us sc ore, I H S 4 sc ore, 
a n d H S- P G A t o q ua ntif y t he se verit y c h a n ge of H S; 
7.  C ha n ge fr o m Baseli ne  i n s u bject-re p orte d o utc o mes: S F- 3 6 v 2, E Q- 5 D-5 L, Hi S Q O L 
a n d D L QI; 
P P D


 
C O N FI D E N TI A L  
Pa ge 9  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
8.  Pr o p orti o n of s u bjects w h o e x perie n ce d fl are, d efi ne d b y at lea st a 2 5 % i ncrease i n A N 
c o u nts wit h a mi ni m u m i ncreas e of 2 A N lesi o ns relati ve t o Baseli ne ; 
9.  D urati o n of flare i n da ys (calc ulat e d fr o m t he d a y w he n flare is o bser v e d t o t he da y 
pri or t o t he o bser vati o n t hat flare is n o l o n g er pres e nt; of n ote, t here c o ul d be m ulti ple 
peri o ds t hat flar es ar e o bser ve d, i n w hic h case, t h e t otal da ys fr o m t he m ulti ple peri o ds 
will be use d); 
1 0.  Pr o p orti o n of s u bjects w h o e x perie n ce at least 2 5 % i ncrease i n drai ni n g fist ula c o u nts 
wit h a mi ni m u m i ncrease of 2 drai ni n g fist ula c o u nt s relati ve t o Baseli ne ; 
1 1.  D uri n g Peri o d 2, pr o p orti o n of s u bjects wit h a l oss of res p o nse, ( L O R) defi ne d as l oss 
of at least 5 0 % of A N c o u nt i m pr o ve me nt ac hie ve d fr o m Wee k 1 2 i n Peri o d 1; 
1 2.  Ti me t o L O R d uri n g Peri o d 2;  
1 3.  Pr o p orti o n of s u bjects w h o recei v e d a d d- o n a nti bi otic or ot her t hera p y d uri n g Peri o d 1 
a n d Peri o d 2 i ncl u di n g t he f oll o w- u p peri o d se paratel y; 
1 4.  Pr o p orti o n of s u bjects w h o start disall o we d o pi oi d pai n t hera p y d uri n g Peri o d 1 a n d 
Peri o d 2 i ncl u di n g t he f oll o w- u p peri o d se p aratel y ; 
1 5.  Pr o p orti o n of s u bjects w h o u n der g o lesi o n i nter ve nti o n d ue t o H S d uri n g Peri o d 1 a n d 
Peri o d 2 i ncl u di n g t he f oll o w- u p peri o d se p aratel y ; 
1 6.  N u m ber of lesi o n i nter v e nti o ns d ue t o H S d uri n g Peri o d 1 a n d Peri o d 2 i ncl u di n g t he 
f oll o w- u p peri o d se p arat el y; 
1 7.  Healt h -ec o n o mic i nf or m ati o n: 
a. W P AI: S H P: C h a n ge fr o m Baseli ne  t o eac h ti me p oi nt d uri n g Peri o d 1 a n d C ha nge 
fr o m Wee k 1 2  t o eac h ti me p oi nt d uri n g Peri o d 2 a n d i ncl u di n g t he f oll o w- u p 
peri o d; 
b.  H os pitalizati o ns (c u m ulati ve): N u m ber of H os pitalizati o ns t otal a n d d ue t o H S, 
N u m ber of da ys h os pitali ze d, N u m ber of da ys misse d fr o m w or k d uri n g Peri o d 1 
a n d Peri o d 2 i ncl u di n g t he f oll o w- u p peri o d se paratel y ;  
c. E mer ge nc y or Ur g e nt Care visits (c u m ulati ve): N u m ber of visits t otal a n d d ue t o 
H S, N u m ber of da ys ( or h o urs w here a p plica ble) misse d fr o m w or k d uri n g Peri o d 
1 a n d Peri o d 2 i ncl u di n g t he f oll o w- u p peri o d se p aratel y ; 
d.  Lesi o n i nter ve nti o ns f or H S: N u m ber of da ys ( or h o urs w here a p plica ble) misse d 
fr o m w or k d ue t o H S lesi o n i nter ve nti o ns d uri n g Peri o d 1 a n d Peri o d 2 i ncl u di n g 
t he f oll o w-u p peri o d se p aratel y . 
 
B.  S afet y E n d p oi nts  
 
1.  S u bject  i nci de nce of treat me nt-e mer ge nt  seri o us a d verse e ve nts, a d verse 
e ve nts, a n d wit h dra wals  d ue t o a d verse e ve nts; 
2.  C ha n ge fr o m Baseli ne  a n d s hifts fr o m Baseli ne  i n all safet y la b orat or y para meters;  
3.  C ha n ge fr o m Bas eli n e  i n vital  si g ns a n d si g nifica nt c ha n ges i n p h ysical  
e xa mi nati o n a b n or malities. 
P P D


 
C O N FI D E N TI A L  
Pa ge 1 0  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
 
I V. 
St u d y Desi g n  
 
A.  
Desi g n O ver vie w   
 
T he st u d y is a ra n d o mize d, d o u ble- bli n d, p lace b o-c o ntr olle d, t hree- gr o u p P hase 2 
trial i n a p pr o xi matel y 3 9 0 s u bjects wit h m o derate t o se vere hi dra de nitis 
s u p p urati va ( H url e y Sta ge II or III). S u bjects will be ra n d o mize d 1: 1: 1 t o a 
treat me nt of 1 0 m g a v ac o pa n  t wice dail y, 3 0 m g a vac o pa n  t wice dail y or pl ace b o  
f or 1 2 wee ks. Ot her s yste mic treat me nts f or H S i n cl u di n g a nti-T N F -α  treat me nts 
are pr o hi bite d. Sta ble a nti bi otic t hera p y wit h d o x yc ycli ne or mi n oc ycli ne is 
all o we d as s pecifie d i n t he pr ot oc ol. S u bjects treat e d wit h 1 0 m g or 3 0 m g t wice 
dail y d uri n g t he bli n de d, p lace b o-c o ntr olle d 1 2-w ee k treat me nt peri o d ( Peri o d 1) 
will be f oll o we d b y a n a d diti o nal 2 4- wee k,  acti ve treat me nt peri o d ( Peri o d 2) 
d uri n g w hic h t he y will c o nti n ue t o recei ve t h e sa me d ose re gi me n, eit her 1 0 m g or 
3 0 m g a vac o pa n  t wi ce dail y. S u bjects o n place b o  w h o c o m plete Peri o d 1 will be 
re-r a n d o mize d 1: 1 t o recei ve 1 0 m g or 3 0 m g a vac o pa n  t wice d ail y i n Peri o d 2. 
D uri n g Peri o d 2 t he treat me nt assi g n me nt t o 1 0 m g or 3 0 m g t wice dail y will n ot 
be discl ose d t o t he s u bject, st u d y site pers o n nel or t he S p o ns or. T hereafter, all 
s u bjects will be f oll o we d f or 8 wee ks wit h o ut st u d y dr u g bef ore t he y e xit t h e 
st u d y. 
T o o btai n bala nce acr oss treat me nt gr o u ps, a stratifie d ra n d o mizati o n sc he me will 
be i m ple me nte d. T he stratificati o n fact ors a n d strata wit hi n eac h fact or are liste d 
bel o w. 
  
  
 
1.  H urle y Sta ge ( Sta ge II vs. III):  
a. Sta ge II diseas e: o ne or m ore wi del y se parate d rec urre nt a bscesses wit h 
tract f or mati o n a n d s cars, or 
b.  Sta ge III disease: m ulti ple i nter c o n necte d tracts a n d a bscesses acr oss a n 
e ntire ar ea, wit h diff us e or near diff use i n v ol ve m e nt. 
 
2.  C o nc o mita nt a nti bi otic t hera p y ( Yes vs. N o) 
a. C o nc o mita ntl y treate d wit h d o x yc ycli ne or mi n oc ycli ne as t he o nl y 
all o we d a nti bi otic treat m e nt f or H S, or  
b.  N o c o nc o mita nt a nti bi otic t hera p y. 
 
       3.    A nti -T N F -α treat me nt ( Treat me nt naï ve vs. Pre vi o us treat me nt): 
a. Di d n ot pre vi o usl y recei v e a nti- T N F - α dr u g s uc h as a dali m u ma b or 
i nfli xi ma b (a nti-T N F -α dr u g  naï ve), or 
b.  Pre vi o usl y ( b ut n o l o n ger) recei ve d a n a nti-T N F - α dr u g a n d 
•  c o m plete d a nti-T N F -α treat me nt  b ut ma y ha ve rel a pse d , or 
•  was i nt olera nt t o a nti-T N F - α treat me nt, or 
•  pre vi o usl y faile d t o res p o n d or i na de q uatel y res p o n de d t o a nti-T N F -
α treat me nt. 
P P D


 
C O N FI D E N TI A L  
Pa ge 1 1  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
N ot m ore t ha n 2 0 % of s u bjects will be i n strat u m 2a.  
 
F o r eac h s u bject, t he st u d y will c o nsist of 4 peri o ds: 
•  Scree ni n g Peri o d ( ≤ 4 w ee ks) 
•  D o u ble- Bli n d Treat me nt Peri o d ( 1 2 wee ks)  
•  Acti ve Treat me nt Peri o d ( 2 4 wee ks)  
•  F oll o w- u p Peri o d ( 8 w ee ks) 
 
S u bjects will be scree n e d f or eli gi bilit y base d o n t he sta ge of t he di sease a n d t heir 
healt h stat us. T he scr ee ni n g peri o d will be u p t o 2 8 da ys. T he pri mar y effi cac y 
a nal ysis will occ ur w he n t he last e nr olle d s u bject h as c o m plete d t he Wee k 1 2 visit. 
After t he bli n de d 1 2- wee k treat me nt peri o d, all s u bjects will c o nti n ue a n a d diti o nal 
2 4- wee k tr eat me nt wit h eit her 1 0 m g or 3 0 m g a vac o pa n  t wice d ail y. T he 
treat me nt assi g n me nt t o 1 0 m g or 3 0 m g t wice dail y will n ot be discl ose d t o t he 
s u bject, st u d y pers o n nel at t he site or t he s p o ns or. T hereafter, all s u bjects will be 
f oll o we d f or 8 w ee ks.  
 
B.  St u d y P o p ul ati o n 
 
Eli gi ble a d ult s u bjects (at least 1 8 years of a ge) wit h m o derate t o se vere 
hi dra de ni tis s u p p urati va ( H urle y sta ge II or III) o n sta n dar d- of-care t hera p y as 
s pecifie d b y t he i ncl usi o n a n d e xcl usi o n criteria i n t he pr ot oc ol Secti o n 4 , are 
all o wed t o e nter t he st u d y. 
 
C.  S a m ple Size Esti m ati o n  
 
T he st u d y will e nr oll a p pr o xi matel y 3 9 0 s u bjects. I n t w o P has e 3 cli nical trials 
wit h a dali m u ma b ( PI O N E E R I a n d II; Ki m ball et al, 2 0 1 6a), t he pr o p orti o ns of 
s u bjects i n t he place b o  c o ntr ol gr o u p ac hie vi n g a Hi S C R at Wee k 1 2 were 2 6. 0 % 
a n d 2 7. 6 %, res p ecti vel y. He nce, if t h e c o ntr ol gr o u p o nl y recei ves pl ace b o , o ne 
ma y ass u me a n Hi S C R at Wee k 1 2 of a p pr o xi matel y 3 0 %. T he a vera ge Hi S C R 
at Wee k 1 2 i n t he a dali m u ma b gr o u ps i n PI O N E E R I a n d II w ere 4 1. 8 % a n d 
5 8. 9 %, res pecti vel y wit h a n a vera ge of a p pr o xi mat el y 5 0 % ( Ki m ball et al, 
2 0 1 6a). T he attriti o n rate t hr o u g h o ut t he trial is esti mate d t o be a p pr o xi mat el y 
7 %. A sa m ple size of a p pr o xi matel y 1 3 0 s u bjects per treat me nt gr o u p ( 3 9 0 i n 
t otal) at a t y pe I err or rat e of α = 0. 0 5 (t w o-si de d) pr o vi des a p pr o xi matel y 9 0 % 
p o wer t o detect a 2 0 % s u peri orit y of a vac o pa n  c o m pare d t o t he place b o  c o ntr ol 
gr o u p i n Hi S C R at Wee k 1 2, ass u mi n g a n Hi S C R at Wee k 1 2 of 5 0 % i n t he 
a vac o p a n  gr o u p. 
 
D.  
Tre at m e nt R a n d o miz ati o n 
 
S u bjects will be r a n d o mize d 1: 1: 1 t o o ne of t he t hree treat me nt g r o u ps wit hi n eac h 
strat u m base d o n a n o n-d y na mic, list - base d bl oc ke d ra n d o mizati o n sc he m e 
P P D


 
C O N FI D E N TI A L  
Pa ge 1 2  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
recei v e 1 0 m g a vac o pa n t wice dail y, 3 0 m g a vac o pa n  t wice dail y or mat c hi n g 
p lace b o f or 1 2 wee ks i n a d o u ble- bli n d, place b o-c o ntr olle d ma n ner stratifie d b y: 
1)  H urle y sta ge ( Sta g e II vs III)  
2)  C o nc o mita nt a nti bi otic t hera p y ( Yes vs N o) 
3)  A nti -T N F - α treat me nt ( Treat me nt nai ve vs Pre vi o us treat me nt) 
  
 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 1 3  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
 
E.  Assess m e nt Sc he d ule  
 
S u bject s will u n der g o a Scree ni n g Peri o d, D o u ble-Bli n d Treat me nt Peri o d, Acti ve 
Treat me nt Peri o d  a n d F oll o w - u p Peri o d. Please see bel o w f or a detaile d St u d y 
sc he d ule, i ncl u di n g all meas ure m e nts a n d e val u ati o ns f or t he e ntire st u d y p eri o d 
prese nte d i n ta b ular f or m. 
 
 
 
 
 
 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 1 4  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
 
St u d y Sc he d ule  
 
 
Scree ni n g  
Peri o d 1  
D o u ble -Bli n d Tre at m e nt  
Peri o d 2  
Acti ve Tre at m e nt  
F oll o w -
u p  
St u d y Wee k
1 
≤4 wee ks 1  
 
2  
4  
8  
1 2  
1 6  
2 0  
2 4  
2 8  
3 2  
3 6  
4 4  
St u d y D a y 1 
≤2 8 d a ys 1  
1  
1 5  
2 9  
5 7  
8 5  
1 1 3  
1 4 1  
1 6 9  
1 9 7  
2 2 5  
2 5 3  
3 0 9  
 
-7 
d a ys  
 
 
 
 
 
 
 
 
 
 
 
 
I nf or me d c o nse nt 
X  
 
 
 
 
 
 
 
 
 
 
 
 
 
Re vie w 
i ncl usi o n/e xcl usi o n 
criteria 
X  
 
 
 
 
 
 
 
 
 
 
 
 
 
De m o gra p hics, 
me dical hist or y, 
pri or treat me nts  
X  
 
 
 
 
 
 
 
 
 
 
 
 
 
P h ysical 
e xa mi nati o n 2 
X  
 
X 3 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Vital si g ns  
X  
 
X 3 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Ser u m pre g na nc y 
test f or w o me n of 
c hil d beari n g 
p ote ntial  
X  
 
X  
 
X  
X  
X  
X  
X  
X  
X  
X  
X  
  
Uri ne pre g na nc y 
test f or w o me n of 
c hil d beari n g 
p ote ntial  
 
 
X 3  
 
 
 
 
 
 
 
 
 
 
 
HI V, H B V, H C V 
testi n g 
X  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scree ni n g f or 
t u berc ul osis4 
X  
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 -Lea d E C G  
X  
 
 
 
 
 
X  
 
 
 
 
 
 
X  
Ser u m c he mistr y 
i ncl. Li ver 
F u ncti o n Tests, 
H e mat ol o g y  
X  
 
X 3 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Uri nal ysis  
X  
 
X 3 
 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Bi o mar ker plas ma 
sa m ple c ollecti o n 1 5 
 
 
X 1 5 
 
 
 
X  
 
 
 
 
 
X  
 
Stratificati o n a n d 
ra n d o mizati o n 
 
 
X  
 
 
 
X 1 0 
 
 
 
 
 
 
 
Rec or d l ocati o n 
a n d n u m ber of H S 
i nfla m mat or y 
n o d ules, a bscesses, 
fist ulae, a n d scars 
X  
 
X 3 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Rec or d H urle y 
Sta ge  
X  
 
 
 
 
 
 
 
 
 
 
 
 
 
S u bject gl o bal 
assess me nt of s ki n 
pai n dail y diar y 
rec or di n g5  
 
X 3→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→ 
→X  
P P D


 
C O N FI D E N TI A L  
Pa ge 1 5  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
 
Scree ni n g  
Peri o d 1  
D o u ble -Bli n d Tre at m e nt  
Peri o d 2  
Acti ve Tre at m e nt  
F oll o w -
u p  
St u d y Wee k
1 
≤4 wee ks 1  
 
2  
4  
8  
1 2  
1 6  
2 0  
2 4  
2 8  
3 2  
3 6  
4 4  
St u d y D a y 1 
≤2 8 d a ys 1  
1  
1 5  
2 9  
5 7  
8 5  
1 1 3  
1 4 1  
1 6 9  
1 9 7  
2 2 5  
2 5 3  
3 0 9  
 
-7 
d a ys  
 
 
 
 
 
 
 
 
 
 
 
 
Rec or d ite ms f or 
t he Sart ori us a n d 
m o difie d Sart ori us 
sc ores calc ulati o n 6 
 
 
X 3 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
P h ot o gra p h 
selecte d lesi o ns1 2  
 
 
X 1 2 
X  
X 1 2 
X  
X 1 2 
X 1 2 
X  
X  
X 1 2 
X  
X 1 2 
X  
Rec or d I H S 4 
sc ore7  
 
 
X 3 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
H S -P G A 1 4 
 
 
X 3 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
S F -3 6 v 2 a n d E Q -
5 D -5 L Patie nt -
Re p orte d 
O utc o mes 8  
 
 
X 3 
 
X  
 
X  
X  
 
 
X  
 
X  
X  
Hi S Q O L I n de x 8  
 
 
X 3  
 
X  
 
X  
X  
 
 
X  
 
X  
X  
Healt h -Ec o n o mic 
I nf or mati o n1 3 
 
 
X 3 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
St u d y dr u g 
dis pe nsi n g  
 
 
X 3 
 
  
  
X  
  
  
X  
 
  
 
 
St u d y dr u g 
c o m plia nce 
 
 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
 
St u d y dr u g 
acc o u nta bilit y 1 1 
 
 
 
 
 
 
X 1 1 
 
 
X 1 1 
 
 
X 1 1 
 
P K plas ma sa m ple 
c ollecti o n 9 
 
 
X  
X  
X  
X  
X  
X  
X  
 
X  
 
X  
X  
C o nc o mita nt 
me dicati o ns  
X  
 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
A d verse e ve nt 
assess me nt 
X  
 
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
1Scree ni n g peri o d ma y be e xcee de d b y u p t o 3 da ys. Wee k 1 t hr o u g h 3 6 visits ma y occ ur wit hi n a ± 2- da y 
wi n d o w. T he Wee k 4 4 visit ma y occ ur wit hi n a ± 4- da y wi n d o w.  
2P h ysical e xa mi nati o n will i ncl u de b o d y wei g ht meas ure me nts. Hei g ht will be meas ure d o nl y at Scree ni n g.  
3T hese pr oce d ures m ust be perf or me d bef ore ta ki n g t he first d ose of bli n de d st u d y dr u g ( A vac o pa n  or place b o ). 
4Scree ni n g f or t u berc ul osis : see e xcl usi o n criteria f or s pecifics . 
5S u bjects will rec or d t he ma xi m u m se verit y pai n o n a n u meric rati n g scale fr o m 0 ( n o s ki n pai n) t o 1 0 (s ki n pai n 
as ba d as ca n be i ma gi ne d) i n a dail y diar y fr o m o ne wee k pri or t o Da y 1 t hr o u g h t he Wee k 4 4 visit.  
6T wel ve b o d y areas will be e val uate d t o calc ulate t he Sart ori us a n d m o difie d Sart ori us sc ores: left a n d ri g ht 
a xillae, left a n d ri g ht i nfra ma m mar y areas, i nter ma m mar y area, left a n d ri g ht b utt oc ks, left a n d ri g ht i n g ui n o -
cr ural f ol ds, peria nal area, peri neal area, a n d ot her. T he prese nce of n o d ules, a bscesses, fist ulae, scars, a n d 
ot her fi n di n gs will be rec o r de d. T he l o n gest dista nce bet wee n t w o lesi o ns a n d w het her lesi o ns are se parate d b y 
n or mal s ki n will be rec or de d.  
7I H S 4 sc ore ( p oi nts) = ( n u m ber of n o d ules m ulti plie d b y 1) + ( n u m ber of a bscesses m ulti plie d b y 2) + [ n u m ber 
of drai ni n g t u n nels (fist ulae/si n uses) m ulti plie d b y 4]. A sc ore of 3 or less si g nifies mil d H S, a sc ore of 4– 1 0 
si g nifies m o derate H S a n d a sc ore of 1 1 or hi g her si g nifies se vere H S.  
8“ Patie nt-re p orte d o utc o mes” ( P R Os) i ncl u de t he S F-3 6 v 2, E Q -5 D -5 L, Hi S Q O L, D L QI, a n d W P AI - SH P 
q uesti o n naires.  The S F -3 6 v 2 a n d E Q -5 D -5 L i nstr u me nts are wi del y acce pte d gl o bal n o n -disease -s pecific t o ols 
t o meas ure c ha n ges i n s u bjects’ healt h-relate d q ualit y of life. T he Hi S Q O L i n de x (a n H S-s pecific i nstr u me nt) 
a n d D L QI i nstr u me nts are desi g ne d t o  meas ure t he i m pact of H S or s ki n disease o n s u bjects’ q ualit y of life. 
T he W P AI: S H P assesses t he effect of ge neral a n d s pecific healt h c o n diti o ns o n pr o d ucti vit y l osses.  
P P D


 
C O N FI D E N TI A L  
Pa ge 1 6  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
9 P K bl o o d sa m ple will be c ollecte d pri or t o t he m or ni n g d ose o n Da y 1 a n d at 0. 5, 1,  2, a n d 3 ( +/ - 5 mi n utes) 
h o urs f oll o wi n g d osi n g. Si n gle P K sa m ples will be c ollecte d pre -d osi n g at t he s u bse q ue nt visits as i n dicate d. 
T he date a n d ti me of t he P K sa m ple c ollecti o n will be rec or de d. T he date a n d ti me of t he last d ose of st u d y 
dr u g pri or t o t he P K sa m ple c ollecti o n will als o be rec or de d. O n st u d y visit da ys w he n P K sa m ples are 
c ollecte d, it is prefera ble t hat t he s u bjects ta ke t he m or ni n g d ose of st u d y dr u g at t he site f oll o wi n g t he 
c ollecti o n of P K sa m ples. P K will be perf or me d i n u p t o 1 5 0 s u bjects partici pati n g i n t he st u d y. T he S p o ns or 
will c o nti n u o usl y assess t he n u m ber of s u bjects e nr olle d i n t he P K gr o u p. If at a n y p oi nt d uri n g e nr oll me nt, t he 
n u m ber of P K s u bjects is bel o w t he re q uire d n u m ber, P K sa m ples will be c o nsi dere d ma n dat or y f or t he 
re mai ni n g s u bjects t o be e nr olle d i n t he st u d y. A d diti o nal c o nse nti n g will be re q ueste d fr o m s u bject f or 
c ollecti o n of P K sa m ples . 
1 0 S u bjects o n place b o  w h o c o m plete t he bli n de d, place b o -c o ntr olle d 1 2 -wee k peri o d ( Peri o d 1) will be re -
ra n d o mize d 1: 1 t o recei ve 1 0 m g or 3 0 m g A vac o pa n  t wice dail y d uri n g t he 2 4-wee k acti ve treat me nt peri o d  
( Peri o d 2). 
1 1At  Wee k 1 2, 2 4, a n d 3 6 visits, f ull dr u g acc o u nta bilit y will be c o n d ucte d o n ret ur ne d st u d y dr u g . 
1 2If c o nse nte d, p h ot o gra p h y will be use d f or t he p ur p ose of p u blicati o ns a n d lesi o n assess me nt c o m paris o n. If 
feasi ble, it is rec o m me n de d t hat p h ot o gra p hs be ta ke n at e ver y visit. 
1 3Healt h -ec o n o mic i nf or mati o n i ncl u des h os pitalizati o ns, e mer ge nc y or ur ge nt care visits, a n d lesi o n 
i nter ve nti o ns d ue t o H S. The W P AI: S H P q uesti o n naire a d mi nistrati o n will f oll o w t he Patie nt -Re p orte d 
O utc o mes sc he d ule.  
1 4H S -P G A is a n or di nal scale s pecific t o H S t hat cate g orizes s u bjects i nt o clear, mi ni mal, mil d, m o derate, se vere, 
or ver y se vere disease . 
1 5Bi o mar ker plas ma sa m ple will be c ollecte d at Da y 1, Wee k 1 2, a n d Wee k 3 6 or Earl y Ter mi nati o n visits i n 
s u bjects w h o c o nse nte d a n d at st u d y sites a de q uatel y e q ui p pe d t o perf or m t he c ollecti o n. F or Da y 1, t he 
bi o mar ker sa m ple c ollecti o n m ust be d o ne bef ore t he s u bject ta kes  t he first d ose of st u d y dr u g. 
 
 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 1 7  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
 
V.  
I nter ve nti o ns 
 
A.  Cli nic al Tri al M ateri al  
 
St u d y s u bjects will  recei ve acti ve a vac o pa n  or place b o  ca ps ules  as st u d y dr u g. 
T he  st u d y dr u g  c o nsists of har d  gelati n  ca ps ules  c o ntai ni n g 1 0 m g  a vac o pa n  or 
place b o  a d mi nistere d  orall y. A vac o pa n  a n d place b o  b ottles  a n d ca ps ules  will  be 
i de ntical i n a p peara nce. 
S u bjects  will  be as ke d t o ta ke 3 ca ps ules  of st u d y dr u g orall y  wit h  water a n d  
prefera bl y  wit h  f o o d e ver y m or ni n g, a n d 3 ca ps ules  wit h  water  a n d prefera bl y  
wit h  f o o d i n t he e ve ni n g  a p pr o xi matel y 1 2 h o urs after t he m or ni n g d ose,  as 
i nstr ucte d. St u d y dr u g will  be ta ke n f or 3 6 wee ks  ( 2 5 2 da ys) c o nti n u o usl y. 
 
VI.  
Ge ner al A n al ytic al C o nsi der ati o ns  
 
A.  B aseli ne a n d St u d y D a y  
 
Baseli ne  
Baseli ne f or a n al ysis p ur p oses is defi ne d as t he last assess me nt pri or t o treat me nt 
start date/ti me.  
 
F or S u bject 's Gl o bal Ass ess me nt of S ki n Pai n ( N u merical Rati n g Scale, S ki n Pai n 
N R S), t he a ver a ge of t he last 7 assess me nts pri or t o  t he date of first d ose of st u d y 
dr u g will be use d as Baseli ne.  If t here are o nl y 3 t o 6 dail y assess me nts a vaila ble, 
t he a ver a ge of t h e a vaila ble assess me nts will be use d.  If t here are 2 or less 
assess me nts a vaila ble, t h e s u bject's Baseli ne will be c o nsi dere d as missi n g.  
 
C ha n ge fr o m Ba seli ne 
C ha n ge fr o m bas eli ne is defi ne d as t h e p ost  baseli ne val ue mi n us t he bas eli ne val ue. 
Perce nt c h a n ge fr o m bas eli ne is calc ulate d as f oll o ws: Perce nt c h a n ge = ( C ha n ge 
fr o m baseli ne / Baseli ne) * 1 0 0. 
 
Re d ucti o n fr o m Baseli ne 
Re d ucti o n fr o m baseli ne is defi ne d as t he baseli n e val ue mi n us t he p ost b aseli ne 
val ue. Perce nt r e d ucti o n fr o m baseli ne is calc ulate d as f oll o ws: Perce nt re d ucti o n = 
( Re d ucti o n fr o m baseli ne / Baseli ne) * 1 0 0. 
 
St u d y Da y 
St u d y da y f or a nal ysis p ur p oses is defi ne d as ( date of e ve nt – treat me nt start date) 
( + 1 if t he e v e nt occ urs after treat me nt start date). 
 
B.  A n al ysis Visit Wi n d o w  
 
P P D


 
C O N FI D E N TI A L  
Pa ge 1 8  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
All visits i ncl u di n g sc he d ule d, u nsc he d ule d a n d earl y ter mi nati o n visits will be 
assi g ne d t o a nal ysis visits usi n g a nal ysis visit wi n d o ws base d o n t he act ual date t he 
assess me nt t o o k place. T he start da y of t he a nal ysis wi n d o w will be calc ulate d as 
t he mi d p oi nt bet wee n t he sc he d ule d ass ess me nt a n d pre vi o usl y sc he d ule d 
assess me nt f or t hat para meter. T he e n d da y of t h e a nal ysis wi n d o w will be 
calc ulate d as t he mi d p oi nt bet wee n t he sc h e d ule d assess me nt a n d t he ne xt 
sc he d ule d ass ess me nt f or t hat para meter. W here m ulti ple meas ure me nts f or a 
partic ular p ara met er a p p ear wit hi n a n a nal ysis wi n d o w, t he sc he d ule d visit will be 
use d. If n o sc h e d ule d visit a p pears i n t he a nal ysis wi n d o w, t he res ult cl osest t o t he 
tar get da y will be use d. If e q ui dista nt a n d b ot h are u nsc he d ule d a n d/ or earl y 
ter mi nati o n visits, t he later res ult will be use d f or t he s u m mar y meas ure. 
T h o u g h all meas ures ma y n ot be use d i n data s u m maries (e. g., t w o la b m eas ures 
wit hi n t h e sa me a nal ysis visit wi n d o w), all meas ure me nts a p pear i n t he datasets 
a n d listi n gs. F or s u bjects w here t he e ve nt dat e is missi n g, t he st u d y da y a n d 
a nal ysis wi n d o w will als o be missi n g.  See Ta bles 1 - 3 b el o w f or t h e a nal ysis 
wi n d o ws. 
 
T a ble 1  M a p pi n g f or E n d p oi nts M e as ure d at St u d y D a y 1, Wee ks 2, 4, 8, 
1 2, 1 6, 2 0, 2 4, 2 8, 3 2, 3 6, a n d 4 4 
 
Sc he d ule d  
Visit  
T ar get  
St u d y D a y  
Visit Wi n d o w 
(St u d y D a y ) 
Peri o d 1 : St u d y Da y = visit date  - d ate of first d ose of st u d y dr u g i n Peri o d 
1 + 1 
Baseli ne  
1 
≤ 1  
Wee k 2  
1 5 
2 t o 2 2 
Wee k 4  
2 9 
2 3 t o 4 3 
Wee k 8  
5 7 
4 4 t o 7 1 
Wee k 1 2  
8 5 
7 2 t o mi n ( 1 1 4, t he 
st u d y da y of t he 
ra n d o mizati o n date 
f or Peri o d  2)  
 
Peri o d 2: St u d y Da y = visit date  - d ate of first d ose of st u d y dr u g i n Peri o d 
2 + 1  
E ntr y of Peri o d 2 
1 
≤ 1  
Wee k 1 6  
2 9 
2 t o 4 3 
Wee k 2 0  
5 7 
4 4 t o 7 1 
Wee k 2 4  
8 5 
7 2 t o 9 9 
P P D


 
C O N FI D E N TI A L  
Pa ge 1 9  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
Sc he d ule d  
Visit  
T ar get  
St u d y D a y  
Visit Wi n d o w 
(St u d y D a y ) 
Wee k 2 8  
1 1 3 
1 0 0 t o 1 2 7 
Wee k 3 2  
1 4 1 
1 2 8 t o 1 5 5 
Wee k 3 6  
1 6 9 
1 5 6 t o 1 8 3 
Wee k 4 4  
1 9 7 
≥ 1 8 4  
 
 
T a ble 2   M a p pi n g f or S ki n P ai n N R S  
 
Sc he d ule d  
Visit  
T ar get  
St u d y D a y  
Visit Wi n d o w 
(St u d y D a y) 
Peri o d 1: St u d y Da y = visit date  - d ate of first d ose of st u d y dr u g i n Peri o d 
1 + 1 
Baseli ne  
- 1 
< 1  
Wee k 2  
1 4 
1 t o 2 1 
Wee k 4  
2 8 
2 2 t o 4 2 
Wee k 8  
5 6 
4 3 t o 7 0 
Wee k 1 2  
8 4 
7 1 t o mi n ( 1 1 3, t he 
st u d y da y of t he 
ra n d o mizati o n date 
f or Peri o d  2 - 1) 
 
Peri o d 2: St u d y Da y = visit date  - d ate of first d ose of st u d y dr u g i n Peri o d 
2 + 1  
E ntr y of Peri o d 2 
- 1 
< 1 
Wee k 1 6  
2 8 
1 t o 4 2 
Wee k 2 0  
5 6 
4 3 t o 7 0 
Wee k 2 4  
8 4 
7 1 t o 9 8 
Wee k 2 8 
1 1 2 
9 9 t o 1 2 6 
Wee k 3 2  
1 4 0 
1 2 7 t o 1 5 4 
Wee k 3 6  
1 6 8 
1 5 5 t o 1 8 2 
Wee k 4 4  
1 9 6 
≥ 1 8 3  
 
P P D


 
C O N FI D E N TI A L  
Pa ge 2 0  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
T a ble 3  M a p pi n g f or E n d p oi nts M e as ure d at St u d y D a y 1, Wee ks 4, 1 2, 1 6, 
2 8, 3 6, a n d 4 4 
 
Sc he d ule d  
Visit  
T ar get  
St u d y D a y  
Visit Wi n d o w 
(St u d y D a y) 
Peri o d 1: St u d y Da y = visit d ate  - d ate of first d ose of st u d y dr u g i n Peri o d 1 
+ 1  
Baseli ne  
1 
≤ 1  
Wee k 4  
2 9 
2 t o 4 3 
Wee k 1 2  
8 5 
4 4 t o mi n ( 1 1 4, t he 
st u d y da y of t he 
ra n d o mizati o n date 
f or Peri o d  2) 
 
Peri o d 2: St u d y Da y = visit d ate  - d ate of first d ose of st u d y dr u g i n Peri o d 2 
+ 1  
E ntr y of Peri o d 2 
1 
≤ 1  
Wee k 1 6  
2 9 
2 t o 4 3 
Wee k 2 8  
1 1 3 
4 4 t o 1 5 5 
Wee k 3 6  
1 6 9 
1 5 6 t o 1 9 7 
Wee k 4 4  
2 2 5 
≥ 1 9 8 
 
Data c ollecte d at all visits will be i ncl u de d i n t he data listi n gs wit h visit prese nte d 
as re p orte d b y t he site.  
 
C.  
Missi n g D at a 
 
I m p ut ati o n f or Effic acy v ari a bles:  
 
T he a p pr o ac hes liste d bel o w will be use d f or h a n dli n g missi n g data: 
•  N o n -res p o n d er i m p utati o n ( N RI): S u bjects w h o ha ve missi n g data at t he 
ti me p oi nt of i nterest are treate d as t h o u g h t he y di d n ot res p o n d t o t he 
treat me nt.  
•  Last O bser vati o n Carrie d F or w ar d ( L O C F): T he L O C F a nal yses will use 
t he last o bser ve d n o n- missi n g e val uati o n (last c o m plete d n o n-missi n g 
e val uati o n, fr o m c o m p osite e n d p oi nt) fr o m t he pre vi o us visit wit hi n t he 
partic ular p eri o d f or efficac y meas ures assess e d t o i m p ute missi n g data at 
later visits i n t he sa me peri o d. Baseli ne effi cac y e v al uati o ns will n ot be 
P P D


 
C O N FI D E N TI A L  
Pa ge 2 1  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
carri e d f or w ar d. L O C F will be t he pri mar y a p pr o ac h i n t he a nal ysis of 
c o nti n u o us varia ble. 
•  O bser ve d case ( O C): Missi n g data are n ot i m p ute d. O nl y s u bjects wit h 
a vaila ble data at t he gi ve n ti me p oi nt are c o nsi dere d.  
•  M ulti ple I m p utati o n ( MI) – Mar k o v C hai n M o nte Carl o ( M C M C) 
i m p utati o n: Usi n g m ulti ple i m p utati o n met h o d ol o g y, missi n g data i n Peri o d 
1 are i mp ute d bas e d o n t he M C M C met h o d, please see Secti o n VIII D  f or 
details.  
T he  f oll o win g ta ble de pi cts w hic h missi n g data ha n dli n g a p pr oac h es s h o ul d be 
use d base d o n varia ble pri orit y ( pri mar y, sec o n d ar y, ot her) a n d v aria ble t y p e 
( bi nar y, c o nti n u o us).  
 
E n d p oi nts  
V ari a ble 
T y pe  
Missi n g D at a H a n dli n g A p pr o ac h  
N RI  
 
MI  
L O C F  
O C  
Pri mar y Efficac y  Bi nar y  
P 
S E N  
S E N  
 
Pri mar y Efficac y  
( C O VI D-1 9)  
Bi nar y  
P 
 
S E N  
 
Sec o n dar y/  
Ot her Efficac y  
(selecte d o n es 
o nl y , see Pa ge  
4 7 ) 
Bi nar y  
P 
S E N  
 
 
C o nti n u o us 
 
 
P 1  
S E N  
              P = Pri mar y met h o d, S E N = Se nsiti vit y met h o d  
            1 = F or s electe d e n d p oi nts 
  
 
I m p ut ati o n f or A E a n d Co nc o mit a nt Me dic ati o n S t art D ates : 
 
F or a n al yses of A Es a n d c o nc o mita nt me dicati o n usa ge, a c o m plet e date m ust be 
esta blis he d i n or der t o c orrectl y i de ntif y t he A E or me dicati o n as occ urri n g d uri n g 
treat me nt or n ot. F or p ur p oses of i m p uti n g missi n g c o m p o ne nts of partiall y-
re p orte d start a n d st o p dates f or A Es a n d f or me di cati o n use, t he al g orit h ms liste d 
bel o w will be  f oll o we d. Start a n d st o p dates of A Es or c o nc o mita nt me dicati o n 
will be dis pla ye d as re p orte d i n t he s u bject data listi n gs (i.e., n o i m p ute d val ues 
will be dis pla ye d i n data listi n gs).  
 
Partial A E a n d c o n c o mita nt me dicati o n start dates will be i m p ute d as f oll o ws: 
•  If year is missi n g, n o i m p utati o n will be perf or me d.  
•  If b ot h da y a n d m o nt h of t he start d ate are missi n g, t he da y a n d m o nt h will 
be i m p ute d wit h t he da y a n d m o nt h of t he first st u d y d ose date if t h e year is 
e q ual t o t he year of first d ose. Ot her wise, t he m o nt h a n d da y is i m p ute d as 
t he first da y of t he y ear ( 0 1 Ja n).  
P P D


 
C O N FI D E N TI A L  
Pa ge 2 2  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
•  If o nl y da y is missi n g, a n d if t he year a n d m o nt h are e q u al t o t he first d os e 
date, t he da y will be i m p ute d as da y of t he first d ose date. Ot her wise, t h e 
da y will be i m p ute d as “ 0 1”.  
 
D.  
M ulti ple St u d y Ce nters  
 
N o a dj ust me nt f or stratifi cati o n b y t he st u d y ce nters is pla n ne d.  H o we v er, ce nters 
will be gr o u pe d b y ge o gra p hic re gi o n a n d a s u b gr o u p a nal ysis will be c o n d ucte d 
t o deter mi ne if re gi o n i m pacts t he pri mar y e n d p oi nt. 
 
E.  
C o v ari ate A dj ust m e nt i n Pri m ar y A n al ysis 
 
C o nti n u o us varia bles of t he sec o n dar y/ ot her efficac y e n d p oi nts, c ha n ge fr o m 
Baseli ne  t o Wee k 1 2 i n t he Sart ori us sc ore, m o difie d Sart ori us sc ore, I H S 4 sc ore, 
H S -P G A, i nfla m mat or y a n d n o n-i nfla m mat or y n o d ule c o u nt, a bscess c o u nt, 
drai ni n g, n o n- drai ni n g a n d t otal fist ula c o u nt, t otal A N c o u nt, S F- 3 6 v 2 ( d o mai ns 
a n d c o m p o ne nt sc or es) a n d E Q- 5 D- 5 L ( vis ual a nal o g ue scale a n d i n d e x), 
Hi S Q O L , D L QI,  a n d W P AI: S H P will be a nal yze d usi n g a mi xe d effects m o del 
f or re p eate d meas ures. T his m o del will i ncl u de treat me nt gr o u p, visit, treat me nt-
b y- visit i nteracti o n, a n d ra n d o mizati o n strata ( H urle y Sta ge II or H urle y Sta ge III, 
a nti- T N F dr u g use or a nti- T N F dr u g nai ve) as fact ors, a n d c orres p o n di n g b aseli ne 
as c o vari ate.  
 
C ha n ge fr o m Baseli ne  t o Wee k 1 2 i n W P AI: S H P will be a nal yze d usi n g a n 
A N C O V A m o del w hic h i ncl u des treat me nt gr o u p, ra n d o mizati o n strata ( H urle y 
Sta ge II or H urle y Sta ge III, a nti -T N F d r u g us e or a nti- T N F dr u g nai ve) as f act ors, 
a n d c orr es p o n di n g baseli ne as c o variate.  
 
 
F.  S a m ple Size Re assess me nt  
 
N o sa m ple size r eassess me nt is pla n ne d. 
 
G.  
I nteri m A n al yses or Ti mi n g of A n al yses 
 
N o i nteri m a nal yses pla n ne d. 
 
H.  
Test Sizes  
 
All c o nfi de nce i nter vals will be t w o -si de d wit h 9 5 % c o vera ge. 
 
I. 
M ulti ple C o m p aris o ns/ M ulti plicit y  
 
F or t he pri mar y  efficac y e n d p oi nt testi n g, t he a vac o pa n 3 0 m g vs. place b o i n 
Hi S C R ( H 1 1) a n d t he a vac o pa n 1 0 m g vs. place b o i n Hi S C R ( H1 2), a hierarc hical 
pr oce d ur e will be use d t o c o ntr ol t he o verall α at 0. 0 5 le vel. 
P P D


 
C O N FI D E N TI A L  
Pa ge 2 3  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
T hat is i f H 1 1 is rejecte d at a 2-si de d al p h a le vel of 0. 0 5, t he n t he H1 2 will be teste d 
at 2-si de d al p ha le v el of 0. 0 5.   
F or sec o n dar y effi cac y e n d p oi nt testi n g, t he a vac o pa n 3 0 m g vs. place b o or  t he 
a vac o p a n 1 0 m g vs. place b o will be teste d se parat el y wit h t he α = 0. 0 5 le v el , 
pr o vi de d t hat t he c orres p o n di n g pri mar y e n d p oi nt testi n g of t he sa me d ose l e vel is 
si g nifica nt.  As t he t w o dr u g d oses are t w o i n de pe n de nt fa milies, a n d t he o utc o me 
of t he st u d y is t o select o ne d ose, n ot 2 d oses.  A fi xe d hierarc hical testi n g 
se q ue nce will be e m pl o ye d, as f oll o wi n g:  
H 2 : C ha n ge fr o m Baseli ne  i n t otal A N c o u nt at Wee k 1 2 
H 3 : N R S 3 0 at Wee k 1 2  
H 4 : % s u bjects wit h baseli ne H urle y Sta ge II w h o ac hie ve d A N c o u nt of 0, 1, or 2  
      at Wee k 1 2        
H 5 : Re d ucti o n of I H S 4 at Wee k 1 2  
H 6 : C ha n ge fr o m Baseli ne  i n i nfla m mat or y n o d ule c o u nt at Wee k 1 2 
H 7 : C ha n ge fr o m Baseli ne  i n a bscess c o u nt at Wee k 1 2 
H 8:  C ha n ge fr o m Baseli ne  i n drai ni n g fist ula c o u nt at Wee k 1 2 
H 9 : C ha n ge fr o m Baseli ne  i n M o difie d Sart ori us sc ore at Wee k 1 2 
 
C o m paris o ns i n v ol vi n g ot her effi cac y e n d p oi nts a n d ti me p oi nts are c o nsi dere d 
s u p p orti ve or e x pl orat or y a n d will be ma de at α = 0. 0 5 0 le vel (t w o -si de d). N o 
m ulti plicit y a dj ust me nt will be ma de f or t hes e c o m paris o ns.      
 
J.  
A n al ysis P o p ul ati o ns  
 
A nal ysis p o p ulati o ns will be defi ne d f or use wit h v ari o us a nal yses. 
 
  
       I nte nt-t o-Tre at  P o p ul ati o n  
T he I nte nt -t o- Treat (I T T) P o p ulati o n will i ncl u de all s u bjects w h o are ra n d o mize d 
a n d ha ve r ecei ve d at least o ne d ose of st u d y dr u g, a n d w h o are n ot fr o m st u d y Site 
1 3 8. S u bjects fr o m Site 1 3 8 will be  e xcl u de d fr o m t he I T T P o p ulati o n d ue t o 
p ote ntial misc o n d uct a n d n o n- c o m plia nce at site 1 3 8 . 
T he I T T p o p ulati o ns are defi ne d f or t h e t w o treat me nt peri o ds as t he f oll o wi n g: 
•  T he I T T 1 P o p ulati o n i n Peri o d 1 is defi ne d as all s u bjects w h o are 
ra n d o mize d at b aseli ne a n d ha ve recei ve d at least o ne d ose of st u d y dr u g 
d uri n g Peri o d 1. 
•  T he I T T 2 P o p ulati o n i n Peri o d 2 is defi ne d as all s u bjects w h o ha ve 
recei v e d at least o ne d ose of st u d y dr u g d uri n g Peri o d 2. 
Per Pr ot oc ol P o p ul ati o n  
P P D


 
C O N FI D E N TI A L  
Pa ge 2 4  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
T he per pr ot o c ol ( P P) p o p ulati o n f or peri o d 1 will c o nsist of I T T1 a n d d o n ot 
ha ve pr ot oc ol de vi ati o ns t hat c o ul d si g nifica ntl y affect t he i nter pretati o n of t he 
res ults f or t he pri mar y e n d p oi nts. S u bjects’ i ncl usi o n/e xcl usi o n fr o m t he P P 
p o p ulati o n will be deter mi ne d a n d d oc u me nte d pri or t o t he data bas e l oc k a n d 
u n bli n di n g.  
Per - Pr ot oc ol P o p ulati o n i n Peri o d 1 ( P P 1) will i ncl u de s u bjects i n I T T 1 w h o meet 
all t he f oll o wi n g criteria:  
–  Recei ve at least 7 0 % of t he pla n ne d st u d y dr u g i n Peri o d 1 f or s u bjects 
w h o c o m plete Peri o d 1 or r ecei ve at least o ne d os e of st u d y dr u g a n d 
disc o nti n ue Peri o d 1 
–  Pr o vi de at least o ne p ost Baseli ne assess me nt o n l esi o n c o u nt 
–  Meet t he H url y sta ge II: T otal S C A R a n d Fist ula c o u nts > 0 at eit her 
scree ni n g or Da y 1 . 
–  Ha ve Baseli ne A N c o u nt ≥ 3 
–  Ha ve Baseli ne drai ni n g fist ula c o u nt ≤ 2 0 
–  D o n ot ta ke t he f oll o wi n g e xcl usi o nar y me dicati o ns d uri n g t he 
e xcl usi o nar y scree ni n g p eri o d or d uri n g Peri o d 1: 
–  A n y c o nc o mita nt a nti bi otics f or t he treat me nt of H S (e xce pt t he pr ot o c ol 
all o we d res c ue me dicati o n w hic h will res ult i n c o u nti n g t he s u bjects as 
n o n-res p o n ders, or ha vi n g t he last o bser vati o n pri or t o t he use of t hese 
treat me nts carrie d f or war d). 
–  A nti -T N F - a ( H u mira), M et h otre xate ( M T X), c y cl os p ori n, c ortic oster oi ds, 
a n d reti n oi ds f or a n y reas o n, or ot her me dicati o n f or treat me nt of t heir H S 
t hat will c o nf o u n d t he efficac y e v al uati o n (t o be d eter mi ne d a n d 
d oc u me nte d i n t he classificati o n res ults pri or t o bli n d brea k). 
 
Per -Pr ot oc ol P o p ulati o n i n Peri o d 2 ( P P 2 ) will be defi ne d se p aratel y.  
S u bjects i ncl u de d i n t he Per- Pr ot oc ol P o p ulati o n will be a nal yze d as treate d.  T hat 
is, if a s u bject recei ves t h e treat me nt t hat is n ot t he ra n d o mize d assi g n me nt d uri n g 
t heir e ntire partici pati o n of a peri o d, t he s u bject will be a nal yze d acc or di n g t o t he 
treat me nt t hat t he s u bject act uall y recei ve d i n t he peri o d. 
 
S afet y  P o p ul ati o n 
T he S afet y P o p ulati o n will i ncl u de  all s u bjects w h o are ra n d o mize d a n d ha ve 
recei v e d at least o ne d ose of st u d y dr u g, e xcl u di n g t h ose s u bjects w h o are fr om 
st u d y Site 1 3 8. D ue t o t he reas o ns stat e d a b o ve safet y data of s u bjects fr o m site 
1 3 8, i ncl u di n g a d verse e ve nts, will be liste d se paratel y o nl y a n d n ot be i ncl u de d 
i n t he s u m mar y ta bles: 
P P D


 
C O N FI D E N TI A L  
Pa ge 2 5  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
•  T he Safet y P o p ulati o n i n Peri o d 1 ( Safet y 1) is defi ne d as all s u bjects w h o 
are r a n d o mize d at baseli ne a n d ha v e recei ve d at least o ne d ose of st u d y 
dr u g d uri n g Peri o d 1. 
•  T he Safet y P o p ulati o n i n Peri o d 2 ( Safet y 2) is defi ne d as all s u bjects w h o 
recei v e d at least o ne d ose of a vac o p a n  d uri n g Peri o d 2. 
•  T he All A vac o p a n Treate d P o p ulati o n is defi ne d as all s u bjects w h o recei ve 
at least o ne d ose of a vac o pa n i n a n y treat me nt p eri o d. 
T he Safet y P o p ulati o ns will be a nal yze d a cc or di n g t o t he assi g ne d treat m e nt 
gr o u p. I n t he e v e nt t hat a s u bject recei ves a trea t m e nt re gi me n t hat d oes n ot 
c orres p o n d t o t he assi g ne d treat me nt c o nsiste ntl y , t he s u bject will be i ncl u de d i n 
t he a nal ysis gr o u p of t he treat me nt act u all y recei ve d. 
 
P h ar m ac o ki netic P o p ul ati o n 
 
P har mac o ki netic ( P K) p o p ulati o n is a s u bset of t he Safet y  p o p ulati o n a n d i n cl u des 
all s u bjects wit h at least o ne meas ura bl e plas ma p har mac o ki netic c o nce ntrati o n of 
a vac o p a n  or its meta b olite M 1 . 
 
T he P K  p o p ulati o ns are d efi ne d f or t h e t w o treat me nt peri o ds as t he f oll o wi n g: 
•  T he P K 1  P o p ulati o n i n Peri o d 1 is a s u bset of t he Safet y 1  p o p ulati o n a n d 
i ncl u des all s u bjects wit h at least o ne m eas ura ble plas ma  p har mac o ki netic 
c o nce ntr ati o n of a vac o pa n or its meta b olite M 1 i n Peri o d 1. 
•  T he P K 2  P o p ulati o n i n Peri o d 2 is a s u bset of t he Safet y 2  p o p ulati o n a n d 
i ncl u des all s u bjects wit h at least o ne m eas ura ble plas ma p har mac o ki netic 
c o nce ntr ati o n of a vac o pa n or its meta b olite M 1 i n Peri o d 2. 
 
S u bjects  wit h  maj or  pr ot oc ol  de viati o n  i ncl u di n g  P K  de viati o n  or  c o m plia nce 
iss ues  ma y  be  e xcl u de d  fr o m  t he  P K  a nal yses  (i.e.  descri pti ve  statistics)  u p o n 
a gree m e nt wit h t he S p o ns or o n cas e b y case b asis b ut all data will be liste d. Val ues 
t hat are e x cl u de d fr o m t he a nal ysis will be f o ot n ote d a p pr o pri atel y. 
 
K.  
S u b gr o u p  A n al ysis   
 
 Please see secti o n VIII D f or s u b gr o u p a n al ysis. 
L.  
D at a Dis pl a y C h ar acteristics 
 
Data dis pla ys pr o d uce d f or t his st u d y will i ncl u de t hree t y pes : s u m mar y ta bles, 
data listi n gs, a n d fi g ures.   
 
Data listi n gs will si m pl y list t he data rec or d e d o n t he case re p ort f or m ( C R F ) or 
deri ve d f or eac h s u bject.  T he y will be or dere d b y treat me nt, s u bject n u m ber, a n d 
P P D


 
C O N FI D E N TI A L  
Pa ge 2 6  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
ti me of assess me nt.  A d diti o nal le vels of or deri n g ma y be e m pl o ye d as 
a p pr o priate.  Data listi n gs will n ot dis pla y s u bject i nitials.  
 
I n g e ner al, s u m mar y ta bl es f or t he d o u ble- bli n d treat me nt peri o d ( Peri o d 1) will be 
prese nte d b y tr eat me nt  gr o u p: 
•  P lace b o 
•  A vac o pa n 1 0 m g 
•  A vac o pa n 3 0 m g 
•  A vac o pa n T ot al (i.e., A v ac o pa n 1 0 m g + A vac o p a n 3 0 m g) 
 
S u m mar y ta bles f or t he 2 4 -wee k acti ve treat me nt peri o d ( Peri o d 2 ) will be 
prese nte d b y t he f oll o wi n g treat me nt gr o u p: 
•  P lace b o t o A vac o p a n 1 0 m g 
•  P lace b o t o A vac o p a n 30 m g  
•  A vac o pa n 1 0 m g  
•  A vac o pa n 3 0 m g 
•  A vac o pa n T ot al (i.e., P lace b o t o A vac o pa n 1 0 m g + P laceb o t o  
                          A vac o pa n 3 0 m g + A vac o p a n 1 0 m g + A vac o p a n 3 0 m g) 
 
S u m mar y ta bles f or t he c o m bi ne d peri o ds usi n g t he All A vac o p a n Treate d 
P o p ulati o n will be prese nte d b y t he f oll o wi n g treat me nt gr o u p: 
•  Place b o t o A vac o p a n 1 0 m g 
•  Place b o t o A vac o p a n 3 0 m g  
•  A vac o pa n 1 0 m g  
•  A vac o pa n 3 0 m g 
•  A vac o pa n T ot al (i.e., Place b o t o A vac o pa n 1 0 m g + Place b o t o  
                          A vac o pa n 3 0 m g + A vac o p a n 1 0 m g + A vac o p a n 3 0 m g) 
 
C o nti n u o us data will be s u m marize d wit h t he n u m ber of n o n- missi n g val ues, 
mea n, sta n dar d d e viati o n, mi ni m u m, me dia n, a n d ma xi m u m.  Cate g orical data 
will be s u m marize d wit h t he n u m ber of n o n- missi n g val ues a n d t he n u m bers o f 
val ues e q ual t o eac h of t h e p ossi ble val ues.  Perce nta ges of s u bjects wit h eac h of 
t he p ossi ble val ues will be calc ul ate d fr o m t he n u m ber of s u bjects i n t he rele va nt 
c o h ort of t he c orres p o n di n g a nal ysis p o p ulati o n, u nless state d ot her wise.  S o me 
c o nti n u o us varia bles ma y als o be gr o u pe d i nt o cate g orical le v els a n d e val u ate d i n 
fre q ue n c y ta bles. F or effi cac y e n d p oi nts, s uc h as c ha n ge a n d p erce nt c ha n g e fr o m 
baseli ne, if t he dat a is n ot n or mal distri b ute d, t he l o garit h mic tra nsf or mati o n of 
t he data will be perf or me d pri or t o a nal ysis, a n d g e o metric mea n will be 
prese nte d.  
 
All statistical a nal yses will be perf or me d usi n g S A S   s oft ware, Versi o n 9. 3, or 
hi g her. 
 
VII.  S u bject Acc o u nt a bilit y  
 
P P D


 
C O N FI D E N TI A L  
Pa ge 2 7  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
A.  S u bject Dis p ositi o n   
 
T he n u m ber of s u bjects w h o were scree ne d, w h o scree n faile d ( b y reas o n), w h o 
were ra n d o mize d, w h o c o m plete d Wee k 1 2, Wee k 3 6, a n d Wee k 4 4 of t he st u d y, 
res pecti vel y, a n d w h o wit h dre w earl y fr o m t he st u d y, al o n g wit h t he reas o ns f or 
wit h dra wal, will be pr ese nte d b y treat me nt gr o u p a n d peri o d.  A se p arate ta ble f or 
a nal ysis p o p ulati o ns will als o be pr o vi de d b y treat me nt gr o u p. 
Patie nt dis p ositi o n data will be pr o vi de d i n a listi n g. A se parate listi n g descri bi n g 
eac h s u bject’s i ncl usi o n or e xcl usi o n stat us f or eac h of t he a n al ysis sets will als o 
be pr o vi de d. 
 
B.  Pr ot oc ol D e vi ati o ns 
 
Pr ot oc ol de viati o ns will be ca pt ure d b y t he site a n d re vie we d b y me dical m o nit or  
d uri n g t he st u d y . Classificati o n bet wee n C S R re p orta ble a n d n o n -C S R re p orta bl e  
pr ot oc ol de viati o ns will be deci de d b y t he st u d y tea m pri or t o data bas e l oc k.  All 
pr ot oc ol  de viati o ns  will  be  liste d  a n d  s u m marize d  b y  t y pe , treat me nt  gr o u p a n d 
peri o d. 
A listi n g of pr ot oc ol de viati o ns will be i ncl u de d.  
 
C.  
S u bject C h ar act eristics   
 
 
De m o gr a p hic a n d B aseli ne C h ar acteristics  
 
De m o gra p h ic a n d baseli n e i nf or mati o n will be s u m marize d f or t h e  I T T 1 b y 
treat me nt gr o u p: 
 
•  A ge   
•  Se x ( Male, Fe male)  
•  Et h nicit y ( His pa nic or Lati n o, N ot His pa nic or Lati n o, N ot Re p orte d) 
•  Race ( W hite, Blac k or Africa n A m erica n, Nati ve Ha waiia n or Ot her Pacific 
Isla n d er, Asia n, A merica n I n dia n or Alas k a n Nati ve, Ot her, N ot Re p orte d) 
•  Hei g ht (c m)  
•  Wei g ht ( k g) 
•  B MI ( k g/ m 2) 
•  H urle y  Sta ge  of H S  
•  H S  disease  d urati o n  (fr o m ti me of dia g n osis)  
•  H S lesi o n c o u nts:  
o  N u m ber of A N c o u nts 
o  N u m ber  of i nfla m mat or y n o d ules 
P P D


 
C O N FI D E N TI A L  
Pa ge 2 8  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
o  N u m ber of a bscesses  
o  N u m ber of drai ni n g  fist ulae  
o  N u m ber of A N c o u nt cate g ories:   < 5 , 5- 1 0,  ≥1 0 
o  N u m ber of  h y pertr o p hic scars 
•  Sart ori us  a n d m o difie d  Sart ori us  sc ores  
•  I H S 4 sc ore 
•  H S -P G A  
•  A nat o mic  l ocati o n of H S  
•  S u bject’s  gl o bal assess me nt  of s ki n pai n  N R S  
•  Pre vi o us s yste mic H S treat me nt (i ncl u des T N F i n hi bit or use b ut e xcl u des 
a nti bi otic use) 
•  Pre vi o us  T N F   i n hi bit or use 
•  Pre vi o us  a nti bi otic treat me nt f or H S 
•  Pri or  s ur ger y f or H S  
•  S F -3 6 v 2  
•  E Q - 5 D- 5 L i n de x  
•  Hi S Q O L  i n de x  
•  D L QI i n de x 
•  Healt h Ec o n o mics W P AI: S H P  
A listi n g of de m o gra p hic a n d baseli ne i nf or m ati o n will be pr o vi de d. 
T he stratificati o n f act or v al ues as c ollecte d i n t he electr o nic case re p ort f or ms will 
be use d f or t h e s u m maries of baseli ne c h aracteristi cs. 
 
Me dic al Hist o ry a n d C o nc urre nt Pr oce d ures  
 
 
T he Me dical Dicti o nar y f or Re g ulat or y Acti vities ( Me d D R A; Versi o n  2 1. 1) will be 
use d t o c o d e all me dical hist or y ter ms or c o nc urre nt pr oce d ures t o a S yste m Or ga n 
Class ( S O C) a n d Pr eferre d Ter m ( P T).  M e dical Hist or y /c o nc urre nt pr oce d ures will 
be s u m marize d b y S O C i n al p ha betical or d er, preferre d ter m  i n al p ha b etical or der, 
a n d b y tr eat me nt gr o u p .  S u bjects re p orti n g m ore t ha n o ne P T  wit hi n a S O C  will 
be c o u nte d o nl y o nce f or t hat S O C.  
 
All m e dical hist or y a n d c o nc urre nt pr o ce d ures will be pr o vi de d i n a listi n g 
se parat el y. 
 
  
       Pri or a n d C o nc o mit a nt Me dic ati o ns 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 2 9  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
Pri or me dicati o ns are d efi ne d as a n y me dicati o n ta ke n pri or t o t he first d ose of 
bli n d st u d y me dicati o n. C o nc o mita nt me dicati o ns are defi ne d as a n y me di cati o n 
ta ke n o n or after t he first d ose of bli n d st u d y me dicati o n. A me dicati o n is 
classifie d as b ot h pr i or a n d c o nc o mita nt if it starte d pri or t o t he first d ose of bli n d 
st u d y me dicati o n date  a n d c o nti n ue d i nt o t he treat me nt peri o d. 
 
Pri or /c o nc o mita nt me dicati o ns will be c o de d t o t hera pe utic class a n d preferre d 
ter m usi n g t he W orl d Healt h Or ga nizati o n Dr u g Dicti o nar y  ( W H O-D D), Versi o n  
Se pte m ber 2 0 1 8. 
 
T he n u m ber a n d p erce nta ge of s u bjects w h o h a d ta ke n p ri or/c o nc o mita nt 
me dicati o ns will be s u m marize d b y t hera pe utic class a n d preferre d ter m , a n d b y 
treat me nt gr o u p. S u bjects ta ki n g t he sa me me dicati o n m ulti ple ti mes will o nl y be 
c o u nte d o nce f or t hat t hera pe utic cl ass a n d preferre d ter m . A s u bject le v el listi n g 
will als o be prese nte d.  
 
St u dy Dr u g E x p os ure a n d C o m pli a nce 
 
St u d y dr u g  e x p os ure will  be deter mi ne d usi n g t he m or ni n g/e ve ni n g dr u g diar y, 
st u d y dr u g dis pe nsi n g a n d ret ur n rec or ds. T he  st u d y dr u g e x p os ure i ncl u di n g 
d urati o n, t otal d ose,  a vera ge dail y  d ose a n d c o m plia nce will be s u m marize d f or 
Peri o d 1 a n d Peri o d 2  se paratel y f or t he safet y p o p ulati o n. I n di vi d ual s u bject 
data  listi n gs will  als o be pr o vi de d. If date of last d ose is n ot a vaila ble, t he date 
of disc o nti n uati o n fr o m st u d y will be use d . 
 
T he f oll o wi n g are t h e defi niti o ns of t he dr u g e x p os ure meas ures: 
•  D urati o n of St u d y Dr u g: Defi ne d as L ast D ose D ate – First D ose D ate + 1 . 
•  T otal D ose: Defi ne d as t otal d ose of A vac o pa n ta ke n i n m g. 
•  A vera ge  Dail y  D ose  ( m g/ da y): Defi n e d as [t otal d ose  of a vac o pa n  ta k e n 
( m g) / treat me nt d urati o n ( da ys)] . 
•  Perce nt c o m plia nce  
 
  C o m plia nce ( %)
= 1 0 0 × (T ot al  # of  c a ps ul es dis p e ns e d −T ot al  # of  c a ps ul es r et ur n e d)
D ur ati o n of Tr e at m e nt * 6
 
 
D urati o n o n treat me nt will be calc ulate d usi n g t he last d ose date – first d ose date 
+ 1 .  T he first d ose d ate i n Peri o d 1 a n d t he last d ose date i n Peri o d 2 will be 
c ollecte d fr o m E D C, t he last d ose date i n Peri o d 1 a n d t he first d ose dat e i n Peri o d 
2 will be deter mi ne d fr o m t he dr u g acc o u nt a bilit y f or m ( D A). If t he last d ose date 
i n Peri o d 1 is missi n g f or s u bjects wit h earl y ter mi nati o n, t he n t he date of last visit 
will be use d as t he last d ose date i n Peri o d 1. F or s u bjects w h o di d n ot ret ur n data 
o n D A, t he date of last d ose a n d c o m plia nce will be calc ul ate d base d o n s u bjects’ 
dail y d osi n g d iar y. 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 3 0  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
VIII.  Effic ac y A n al yses  
 
All efficac y a n al yses will be perf or me d usi n g t he I T T p o p ulati o n u nless ot her wise 
n ote d. A ll statistical testi n g will be t w o-si de d, wit h t he T y pe I err or rate at α = 
0. 0 5. S u m mar y ta bles will be prese nte d f or t he Peri o d 1 a n d Peri o d 2 se paratel y. 
T he stratificati o n f act or v al ues as c ollecte d i n t he electr o nic case re p ort f or ms will 
be use d f or all stratifie d efficac y a nal yses, a n d s u b gr o u p a nal yses.  
 
A.  
Ti mi n g of A n al yses 
Pri m ary A n alysis:  T his st u d y c o nsists of a 1 2-wee k place b o -c o ntr olle d, d o u ble-
bli n d treat me nt peri o d ( P eri o d 1), f oll o we d b y a 2 4- wee k acti ve treat me nt peri o d 
( Peri o d 2). W h e n all s u bjects ha ve c o m plete d or dr o p pe d o ut of Peri o d 1, a n 
u n bli n de d a nal ysis of t he data c ollect e d fr o m Peri o d 1 ca n be c o n d ucte d. 
F oll o w- u p  A n alysis:  W he n all s u bjects ha ve c o m plete d all of t he Wee k 4 4 
assess me nts or ha ve dr o p pe d o ut of st u d y, t he f oll o w- u p a nal ysis will be c o n d ucte d 
o n all data c ollecte d i n t h e st u d y.  
 
B.  
Effic ac y E n d p oi nts  
 
•  Pri m ar y effic a c y e n d p oi nt  
 
Pri mar y efficac y e n d p oi nt is t he pr o p orti o n of s u bjects ac hie vi n g 
Hi dra de nitis S u p p urati va Cli nical Res p o nse ( Hi S C R) at Wee k 1 2. A 
res p o nse is defi n e d as a re d ucti o n of at least 5 0 % i n a bscess  a n d 
i nfla m mat or y n o d ule c o u nt ( A N) c o u nt wit h n o i ncreas e i n a bscess c o u nt 
a n d n o i ncrease i n drai ni n g fist ula c o u nt c o m pare d t o baseli ne.  
 
  % Re d ucti o n fr o m Baseli ne i n A N C o u nt
= 1 0 0 × (Baseli ne A N C o u nt −W e e k  1 2  A N C o u nt)
Baseli ne A N C o u nt
  
 
T he  pr o p orti o n of s u bjects ac hie vi n g Hi S C R  at Wee k  1 2 will  be calc ulate d  as 
t h ose s u bjects ha vi n g  % Re d ucti o n fr o m Baseli ne i n A N c o u nt ≥ 5 0 a n d 
(B as eli n e  A bsc ess C o u nt −W e e k  1 2  A bscess  C o u nt ≥ 0 )  a n d  
(B as eli n e  Dr ai ni n g  Fist ul a  C o u nt −W e e k  1 2  Dr ai ni n g  Fist ul a  C o u nt ) ≥ 0  at 
Wee k 1 2  di vi de d  b y  t he t otal n u m ber of s u bjects i n eac h treat me nt gr o u p. 
 
T he  l ocati o n a n d e xte nt of H S  will  be assesse d  at visits  i n t he Ti me  a n d E ve nts 
Ta ble  b y  rec or di n g t he a nat o mic l ocati o n(s) of t he disease, as  well  as t he 
n u m ber of H S  i nfla m mat or y n o d ules,  a bscesses, fist ulae, a n d scars i n eac h of 
t he l ocati o ns i n t he “A nat o mic L ocati o n a n d N u m ber of H S Lesi o ns ” C R F. 
T wel ve  b o d y areas will be  e val uate d: left a n d ri g ht a xillae,  left a n d ri g ht 
i nfra ma m mar y areas, i nter ma m mar y area, left a n d  ri g ht b utt oc ks, left a n d ri g ht 
P P D


 
C O N FI D E N TI A L  
Pa ge 3 1  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
i n g ui n o-cr ural f ol ds, peria nal  area, peri neal  area, a n d ot her. T otal n u m ber of 
n o d ules, a bscesses, fist ulae, a n d scars f or eac h s u bject will be calc ulate d 
res pecti vel y b y s u m of t he n u m ber acr oss t he l ocati o ns. 
 
•  Sec o n d ar y  Effic ac y E n d p oi nt s 
 
1)  C ha n ge fr o m Baseli ne i n  t otal A N c o u nt at Wee k 1 2. 
C ha n ge fr o m Baseli ne  = Wee k 1 2 C o u nt – Baseli ne  C o u nt 
 
2)  Pr o p orti o n of s u bjects ac hie vi n g at least 3 0 % re d u cti o n a n d at least 1 u nit 
re d ucti o n fr o m Baseli ne  i n t he s u bject’s gl o bal ass ess me nt of s ki n pai n 
( N R S 3 0) i n s u bjects wit h a Baseli ne  N R S of at least 3, e val uate d at Wee k 
1 2.  
 
S u bjects  will rec or d  t he ma xi m u m se verit y pai n o n a n u meric rati n g  scale fr o m 
0 ( n o s ki n pai n) t o 1 0 (s ki n pai n as ba d  as ca n be i ma gi ne d) i n a dail y diar y 
fr o m o ne wee k pri or  t o Da y 1  t hr o u g h t he Wee k 4 4  visit.  Wee kl y a vera ges of 
dail y pai n will be calc ulate d base d o n s u bjects’ d ail y diar y rec or di n g of t he 
w orst pai n e x perie nce d i n t he pre vi o us 2 4 h o urs. T he wee kl y a vera ge sc ore 
will be calc ulate d b ase d o n t he 7  a vaila ble d ail y sc ores fr o m t he da ys wit hi n 
eac h visit wi n d o w t hat are cl osest t o t he tar get d a y.  If t here are 3 t o 6 
assess me nts i n t he visit wi n d o w, t he a vera ge of t he a vaila ble assess me nts will 
be use d. If m or e t ha n o ne assess me nt is i ncl u de d o n t he sa me da y, t he w orst 
assess me nt o n t hat da y will be c h ose n as t he dail y sc ore.  If t here are m ore t ha n 
7 dail y sc ores a v aila ble a n d t he 7t h a n d 8t h o bser v ati o ns (ra n ke d b ase d o n 
dista nce fr o m t he n o mi nal da y) are e q ui dista nt t o t he n o mi nal da y, t he o ne after 
t he n o mi nal da y will be use d t o calc ulate t h e wee kl y sc ore.  F or a n y visit wit h 
less t ha n 3 3 diar y e ntries wit hi n t he visit wi n d o w, t he wee kl y a v era g e will be 
rec or d e d as missi n g. 
 
% Re d ucti o n fr o m B as eli n e i n N R S = 1 0 0 ×
( B as eli n e N R S   − W e e k  1 2  N R S )
B as eli n e N R S
  
T he  pr o p orti o n of s u bjects ac hie vi n g N R S 3 0  at Wee k  1 2 will  be calc ulate d  as 
t h ose s u bjects ha vi n g  % Re d ucti o n fr o m B as eli n e i n N R S  ≥ 3 0 a n d 
(B as eli n e  N R S −W e e k 1 2  N R S ≥ 1 )  at Wee k 1 2 di vi de d  b y  t he t otal n u m ber 
of s u bjects ha vi n g B as eli n e  N R S  ≥ 3 i n eac h treat me nt gr o u p. 
 
3)  Pr o p orti o n of s u bjects wit h baseli ne H urle y Sta ge II w h o ac hie ve d a n a bscess 
a n d i nfla m mat or y n o d ule c o u nt of 0, 1, or 2 at Wee k 1 2. 
N u m ber of a bscess a n d i nfla m mat or y  n o d ules is c ollecte d i n t he “ A nat o mic 
L ocati o n a n d N u m ber of H S Lesi o ns” C R F, pl ease see  t he Pri mar y E n d p oi nt f or 
details.  
T he  pr o p orti o n of s u bjects wit h baseli ne H urle y Sta ge II  ac hie vi n g A N c o u nt of 
0, 1, or 2 at Wee k  1 2 will  be calc ulate d  as t h ose s u bjects  ha vi n g baseli ne 
P P D


 
C O N FI D E N TI A L  
Pa ge 3 2  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
H urle y Sta ge II  a n d A N C o u nt = 0, 1, or 2  at Wee k 1 2 di vi de d  b y  t he t otal 
n u m ber of s u bjects ha vi n g baseli ne H urle y Sta ge II  i n eac h treat me nt gr o u p. 
4)  Re d ucti o n a n d % re d u cti o n of I H S 4 sc ore relati ve t o baseli ne at Wee k 1 2  
 
T he  I nter nati o nal Hi dra de nitis  S u p p urati va Se verit y  Sc ore  (I H S 4) is calc ulate d 
as t he f oll o wi n g: 
 
I H S 4 sc ore ( p oi nts) = ( n u m ber of n o d ules m ulti plie d  b y 1) + ( n u m ber of  
a bscesses  m ulti plie d  b y 2) + [ n u m ber of drai ni n g t u n nels (fist ulae/si n uses) 
m ulti plie d  b y 4] 
 
A sc or e of 3 or less si g nifies mil d  H S,  a sc ore of 4 – 1 0 si g nifies m o derate H S  
a n d a sc or e of  1 1 or hi g her si g nifies se vere H S.  
 
Re d ucti o n i n I H S 4 = B as eli n e  Sc or e −P ost  B as eli n e  Sc or e  
% Re d ucti o n i n I H S 4 = 1 0 0 ∗Re d ucti o n i n I H S 4 / B as eli n e  Sc or e  
 
5)  C ha n ge fr o m Baseli ne i n i nfla m mat or y n o d ule c o u nt at Wee k 1 2. 
C ha n ge fr o m Baseli ne  = Wee k 1 2 C o u nt – Baseli ne C o u nt  
 
6)  C ha n ge fr o m Baseli ne i n a bscess c o u nt at Wee k 1 2.  
C ha n ge fr o m Baseli ne  = Wee k 1 2 C o u nt – Baseli ne C o u nt  
 
7)  C ha n ge fr o m Baseli ne i n drai ni n g fist ula c o u nt at Wee k 1 2.  
C ha n ge fr o m Baseli ne  = Wee k 1 2 C o u n t – Baseli ne C o u nt  
 
8)  C ha n ge fr o m Baseli ne  t o Wee k 1 2 i n t he m o difie d Sart ori us sc ore t o q ua ntif y 
t he se verit y c h a n ge of H S. 
T wel ve  b o d y areas will  be  e val uate d at visits  s pecifie d i n t he St u d y  Sc he d ule t o 
calc ulate t he Sart ori us  (i n ot her effic ac y e n d p oi nts) a n d m o difie d  Sart ori us  
[ 2 0 0 9] sc ores: 
 
•  left a n d ri g ht a xillae, 
•  left a n d ri g ht i nfra ma m mar y areas, 
•  i nter ma m mar y area, 
•  left a n d ri g ht b utt oc ks,  
•  left a n d ri g ht i n g ui n o-cr ural f ol ds, 
•  peria nal  area a nd  peri neal  area, a n d 
•  ot her (s pecif y). 
P P D


 
C O N FI D E N TI A L  
Pa ge 3 3  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
A sc ore of 4 i n dicates t he least se vere disease,  a n d hi g her sc ores i n dicate 
i ncreasi n gl y se vere disease.  T here  is n o u p per li mit i n t he sc ore. 
T he  prese nce  of n o d ules, a bscesses,  fist ulae, scars, a n d ot her  fi n di n gs will  
be rec or de d i n t he E D C.  T he  l o n gest dista nce  bet wee n  t w o lesi o ns a n d 
w het her  lesi o ns are se parate d b y  n or mal s ki n will  als o be rec or de d. T he 
fi nal Sart ori us  a n d m o difie d Sart ori us  [ 2 0 0 9] sc ores will be t he s u m of eac h 
re gi o nal sc ore. 
C ha n ge fr o m Baseli ne  i n M o difie d Sart ori us Sc ore  = Wee k 1 2 Sc ore – 
Baseli ne  Sc ore  
 
T he f oll o wi n g are t h e al g orit h ms o n h o w t o calc ulate t he Sart ori us  a n d 
m o difie d  Sart ori us  [ 2 0 0 9] sc ores f or eac h re gi o nal sc ore: 
 
 
 
Sart ori us ( 2 0 0 3) 
 
 
M o difie d Sart ori us [ 2 0 0 9] 
 
 
F or eac h a n at o mic re gi o n, calc ulate 
t he re gi o nal sc ore as f oll o ws: 
F or eac h a n at o mic re gi o n, s u m u p t he 
f oll o wi n g t o o btai n t he s u bjects sc ore:  
 
1  
3 p oi nts per re gi o n i n v ol ve d.  
 
3 p oi nts per re gi o n i n v ol ve d.  
 
2  
N u m ber a n d sc ores of l esi o ns  
 
2 p oi nts per n o d ule ( or a bscess) 
4 p oi nts per fist ula 
1 p oi nt per scar 
1 p oi nt per “ ot her” lesi o n 
N u m bers a n d sc ores of lesi o ns  
 
1 p oi nt per n o d ule ( or a bscess)  
6 p oi nt per fist ula  
 
N ote: A bscesses are c o nsi dere d t he 
sa me as n o d ules si nce t h e y are h ar d t o 
disti n g uis h fr o m t he ot her.  Scars a n d 
ot her lesi o ns are n ot c o nsi dere d.  
3  
T he l o n gest dista nce bet wee n t w o 
rele va nt lesi o ns, or size if o nl y o ne 
lesi o n  
 
< 5 c m, 2 p oi nts 
< 1 0 c m, 4 p oi nts 
> 1 0 c m, 8 p oi nts  
T he l o n gest dista nce bet wee n t w o 
rele va nt lesi o ns ( or si ze of lesi o n if 
si n gle) i n eac h re gi o n  
 
< 5 c m = 1 p oi nt  
5 – 1 0 c m = 3 p oi nts 
> 1 0 c m = 9 p oi nts  
4  
Are all lesi o ns clearl y se parate d b y 
n or mal s ki n? I n eac h re gi o n  
yes = 0; n o = 6 
 
Are all lesi o ns cl earl y se parate d b y 
n or mal s ki n? I n eac h re gi o n  
yes = 0; n o = 9  
 
 
•  Ot her  Effic ac y E n d p oi nt s 
P P D


 
C O N FI D E N TI A L  
Pa ge 3 4  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
T he f oll o wi n g effi cac y e n d p oi nts will be a nal yze d fr o m Baseli ne  t o eac h 
ti me p oi nt u p t o Wee k 4 4, w here a p plica ble : 
1)  C ha n ge fr o m Baseli ne  i n i nfla m mat or y n o d ule c o u nt, a bscess c o u nt, drai ni n g 
fist ula c o u nt, t otal A N c o u nt, a n d n o n-i nfla m mat or y n o d ule c o u nt, n o n-
drai ni n g a n d t otal fist ula c o u nt. 
C ha n ge fr o m Baseli ne  = P ost Baseli ne C o u nt – Baseli ne  C o u nt 
2)  % c ha n ge fr o m Baseli ne i n i nfla m mat or y n o d ule c o u nt, a bscess c o u nt, drai ni n g 
fist ula c o u nt, t otal A N c o u nt, a n d n o n-i nfla m mat or y n o d ule c o u nt, n o n-
drai ni n g a n d t otal fist ula c o u nt a m o n g s u bjects w h o ha ve at least o ne 
c orres p o n di n g lesi o n at Da y 1. 
% C h a n g e fr o m B as eli n e = 1 0 0* C h a n g e fr o m B as eli n e / B as eli n e C o u nt  
 
3)  Pr o p orti o n of s u bjects ac hie vi n g Hi S C R, Hi S C R 7 5, a n d Hi S C R 9 0. 
Please see t he d escri pti o n of t he Pri mar y E n d p oi nt f or details.  
 
% Re d ucti o n fr o m Baseli ne  i n A N C o u nt
= 1 0 0 × (Baseli ne A N C o u nt −P ost  B as eli n e  A N C o u nt)
Baseli ne A N C o u nt
  
 
T he  pr o p orti o n of s u bjects ac hie vi n g Hi S C R  at P ost Baseli ne visits  will  be 
calc ulate d as t h ose s u bjects ha vi n g  % Re d ucti o n fr o m Baseli ne i n A N c o u nt ≥ 
5 0 a n d (B as eli n e  A bsc ess C o u nt −P ost  B as eli n e  A bscess  C o u nt ≥ 0 )  a n d  
(B as eli n e  Dr ai ni n g  Fist ul a  C o u nt −
P ost  B as eli n e  Dr ai ni n g  Fist ul a  C o u nt ) ≥ 0   
at P ost Baseli ne visits di vi de d b y  t he t otal n u m ber of s u bjects i n eac h treat me nt  
gr o u p. 
Hi S C R 7 5 or Hi S C R 9 0 de n otes 7 5 % re d u cti o n or 9 0 % re d ucti o n f or t he Hi S C R 
defi niti o n i nstea d of 5 0 % re d ucti o n wit h n o i ncrease i n t he n u m ber of 
a bscesses or drai ni n g fist ulas  c o u nt. 
4)  Pr o p orti o n of s u bjects ac hie vi n g at least 3 0 % re d u cti o n a n d at least 1 u nit 
re d ucti o n fr o m Baseli ne  i n t he s u bject’s gl o bal ass ess me nt of s ki n pai n 
( N R S 3 0), i n s u bjects wit h a Baseli ne  N R S of at least 3 . 
Please see t he d escri pti o n of ite m 2) i n Sec o n dar y E n d p oi nts f or details. 
% Re d ucti o n fr o m B as eli n e i n N R S = 1 0 0 ×
B as eli n e  N R S −P o st  B a s eli n e  N R S
B as eli n e  N R S
  
T he  pr o p orti o n of s u bjects ac hie vi n g N R S 3 0  at P ost Baseli ne visits  will  be 
calc ulate d as t h ose s u bjects ha vi n g  % Re d ucti o n fr o m Baseli ne i n N R S ≥ 3 0 
a n d (B as eli n e  N R S −P ost  B as eli n e  N R S ≥ 1 )  at P ost  B as eli n e  visits di vi de d 
P P D


 
C O N FI D E N TI A L  
Pa ge 3 5  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
b y  t he t otal n u m ber of s u bjects ha vi n g Baseli ne  N R S ≥ 3 i n eac h treat me nt 
gr o u p. 
 
5)  Pr o p orti o n of s u bjects wit h baseli ne H urle y Sta ge II w h o ac hie ve d a n a bscess 
a n d i nfla m mat or y n o d ule c o u nt of 0, 1, or 2. 
Please see t he d escri pti o n of ite m 4) i n Sec o n dar y E n d p oi nts f or details. 
T he  pr o p orti o n of s u bjects wit h baseli ne H urle y Sta ge II  ac hie vi n g A N c o u nt of 
0, 1, or 2 at P ost Baseli ne visits wil l be calc ulate d as t h ose s u bjects ha vi n g  
baseli ne H urle y Sta g e II  a n d A N C o u nt = 0, 1, or 2  at P ost Baseli ne visits 
di vi de d b y  t he t otal n u m ber of s u bjects ha vi n g baseli ne H urle y Sta ge II  i n eac h 
treat me nt gr o u p.  
6)  C ha n ge fr o m Baseli ne  i n t he Sart ori us sc ore, m o difie d Sart ori us sc ore, I H S 4 
sc ore, a n d H S- P G A t o q ua ntif y t he se verit y c h a n g e of H S. 
Sart ori us sc ore, m o difie d Sart ori us sc ore, a n d I H S 4 sc ore has b ee n d escri be d i n 
ite ms 1) a n d 3) of Sec o n dar y E n d p oi nts. 
T he  Hi dra de nitis  S u p p urati va- P h ysicia n’s Gl o bal Assess me nt ( H S -P G A)  is a n 
or di nal scale s pecific t o H S  t hat cate g orizes  s u bjects i nt o clear, mi ni mal,  mil d,  
m o derate,  se vere, or ver y  se vere disease, a n d it was use d s uccessf ull y i n a 
p hase 2 i nter ve nti o nal cli nical trial.   A rece ntl y de vel o pe d  si x sta ge P G A  was  
defi ne d  as f oll o ws: 
 
Hi dr a de nitis  S u p p ur ati v a -P h ysici a n’s  Gl o b al  Assess me nt  
Sc ore  
S h ort 
Descri pt or  
Defi niti o n  
0  
Clear  
0 a bscesses, 0 drai ni n g fist ulas, 0 
i nfla m mat or y n o d ules, a n d 0 n o n-
i nfla m mat or y n o d ules 
1  
Mi ni mal  
0 a bscesses, 0 drai ni n g fist ulas, 0 
i nfla m mat or y n o d ules, a n d o nl y prese nce of 
n o n -i nfla m mat or y n o d ules 
2  
Mil d  
0 a bscesses, 0 drai ni n g fist ulas, a n d 1 t o 4 
i nfla m mat or y n o d ules 
or  
1 a bscess or drai ni n g fist ula (s u m of 
a bscesses a n d drai ni n g fist ulas is 1) a n d 0 
i nfla m mat or y n o d ules 
3  
M o derate  
0 a bscesses, 0 drai ni n g fist ulas, a n d ≥ 5 
i nfla m mat or y n o d ules 
or  
1 a bscess or drai ni n g fist ula a n d ≥1 
i nfla m mat or y n o d ule 
or  
P P D


 
C O N FI D E N TI A L  
Pa ge 3 6  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
2 t o 5 a bscesses or drai ni n g fist ulas (s u m of 
a bscesses a n d drai n i n g fist ulas is 2 t o 5) a n d 
< 1 0 i nfla m mat or y n o d ules  
4  
Se vere  
2 t o 5 a bscesses or drai ni n g fist ulas a n d ≥1 0 
i nfla m mat or y n o d ules 
5  
Ver y  se vere 
> 5 a bscess es or drai ni n g fist ulas (s u m of 
a bscesses a n d drai ni n g fist ulas > 5)  
H S -P G A is c ollecte d fr o m t he “ Hi dra de nitis  S u p p urati va- P h ysicia n’s Gl o bal  
Assess me nt ( H S -P G A)” C R F.   
C ha n ge fr o m Baseli ne  i n Sc ore = P ost Baseli ne Sc ore – Baseli ne  Sc ore  
 
7)  C ha n ge fr o m Baseli ne  i n s u bject-re p orte d o utc o mes: S F- 3 6 v 2, E Q- 5 D-5 L, 
Hi S Q O L a n d D L QI.  
T he S F - 3 6 v 2, is t he m ost wi del y use d healt h-relat e d q ualit y- of-life m eas ure i n 
researc h t o date. It meas ures t he f oll o wi n g 8 healt h d o mai ns as rate d b y t he 
s u bjects o ver t he past f o ur wee ks: P h ysical F u ncti o ni n g, R ole P h ysical, B o dil y 
Pai n, Ge neral Healt h, Vit alit y, S o cial F u ncti o ni n g, R ole E m oti o nal, a n d Me ntal 
Healt h.  
T he S F - 3 6 P h ysical a n d Me ntal C o m p o ne nt S u m mar y sc ores ( P C S a n d M C S, 
res pecti vel y) ar e use d t o meas ure t he t w o br oa d c o m p o ne nts, or as pects, of 
healt h - p h ysical a n d m e ntal. P C S a n d M C S are base d o n t he a g gre gate of 8 
healt h c o nce pts descri be d a b o ve a n d all of t he 8 h ealt h d o mai n scales are use d 
t o sc ore b ot h c o m p o ne nts s u m mar y meas ures. 
O ne a d diti o nal ite m as ks res p o n de nts a b o ut healt h c ha n ge o v er t he past y ear. 
T he S F - 3 6 will be use d usi n g Q ualit y Metric ’s Healt h O utc o mes ™ Sc ori n g 
S oft ware. T he s oft ware uses u p dates 2 0 0 9 U. S. p o p ulati o n n or ms a n d a p plies a 
F ull Missi n g Sc ore Esti mati o n ( F ull M S E) met h o d as f oll o ws:  
•  A healt h d o mai n sc ore (e xce pt t he P F d o mai n) will be esti mate d pr o vi de d 
t hat at least o ne no n- missi n g res p o nse is a vaila ble wit hi n t hat d o mai n  
•  F or t he P F d o m ai n ite m res p o nse t he or y will be us e d t o de vel o p a m o del 
f or esti mates of t he missi n g sc ore 
•  Re gressi o n met h o ds are t he n a p plie d t o esti mate t he P C S a n d t he M C S o n 
t he basis of t he a vaila bl e d o mai ns. 
 
T he E Q - 5 D- 5 L ( E ur o Q ualit y of Life- 5 D o mai ns-5 Le vels)  is a self-
assesse d, healt h relate d, q ualit y of life q uesti o n naire. T he scale meas ures 
q ualit y of life o n a 5-c o m p o ne nt scale i ncl u di n g m o bilit y, self- care, us ual 
acti vities, pai n/ disc o mf ort, a n d a n xiet y/ de pressi o n. Eac h le vel is rate d o n 
scale t hat descri bes t he de gree of pr o ble ms ra n gi n g fr o m 1 t o 5 i n t hat 
area: n o pr o ble ms, sli g ht pr o ble ms, m o derate pr o ble ms, se vere pr o ble ms, 
P P D


 
C O N FI D E N TI A L  
Pa ge 3 7  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
a n d e xtre me pr o ble ms . E Q - 5 D- 5 L healt h states, defi ne d b y t he E Q- 5 D-5 L 
descri pti ve s yste m, will be c o n verte d i nt o a si n gle i n de x val u e.  
 
T his t o ol als o has a n o verall healt h scale calle d vis ual a nal o g scale  w here 
t he rater selects a n u m ber fr o m 0 ( w orst healt h state p ossi ble) t o 1 0 0 ( best 
healt h state p ossi ble).  
 
T he Hi dra d e nitis S u p p urati va Q ualit y of Life ( Hi S Q O L) is a si m ple, s u bjec t-
a d mi nistere d, q ualit y - of-life q uesti o n naire t hat c o v ers 9 d o mai ns i ncl u di n g 
p h ysica l fu ncti o ns, a cti vities of dail y li vi n g , cl ot hi n g c h oices d ue t o H S, 
s y m pt o ms d ue t o H S, e m oti o nal c o nse q ue nces, se x ual f u ncti o ni n g, social 
c o nse q ue nces, c o n ce ntrati o n c o nse q ue nces, a n d i nfl ue nces o n w or k a n d st u d y 
as assesse d o v er t he past 7 da ys. T he  Hi S Q O L  i n de x has  bee n  de vel o pe d as a n 
H S -s pecific i nstr u me nt t o meas ure  t he i m pact of H S  o n s u bjects’ q ualit y  of  
life. F or ms f or  t hese i nstr u me nts will  be c o m plete d b y st u d y s u bjects at visits  
s pecifie d i n t he Ti me  a n d E ve nts Ta ble . 
T he sc ori n g of eac h a ns w er f or t he Hi S Q O L is as f oll o ws: 
Hi S Q O L S c ori n g 
Res p o nse 
Sc ore  
E xtre mel y / 
U na ble t o d o d ue t o m y H S 
4 
Ver y m uc h  
3 
M o deratel y  
2 
Sli g htl y  
1 
N ot at all / 
I d o n ot n or m all y d o t his/ 
I a m n ot se x uall y acti ve/ 
I d o n ot w or k or st u d y 
0 
Q uesti o n u na ns were d 
0 
 
T he Hi S Q O L t otal sc ore is calc ulate d b y s u m mi n g t he sc ore of eac h q uesti o n. 
S u bscale sc or es ar e t he t otal sc ore f or t he ite ms i n eac h s u b - d o m ai n. T he 
hi g her t he sc or e, t he m ore q ualit y of life is i m paire d b y hi dra de nitis 
s u p p urati va.  
 
Der mat ol o g y Life Q u alit y I n d e x ( D L QI), 
P P D


 
C O N FI D E N TI A L  
Pa ge 3 8  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
T he D L QI is a si m ple, s u bject-a d mi nistere d, 1 0- q uesti o n, vali date d, q ualit y- of-
life q uesti o n naire t hat c o vers 6 d o mai ns i ncl u di n g s y m pt o ms a n d feeli n gs, 
dail y acti vi ties, leis ure, w or k a n d sc h o ol, pers o nal relati o ns hi ps, a n d treat me nt, 
as assesse d o v er t he past wee k.   
T he sc ori n g of eac h a ns w er f or t he D L QI is as f oll o ws: 
D L QI Sc ori n g  
Res p o nse 
Sc ore  
Ver y m uc h  
3 
A l ot  
2 
A little  
1 
N ot at all  
0 
N ot rele va nt  
0 
Q uesti o n u na ns were d 
0 
Q 7: ‘ pre ve nt e d w or k or st u d yi n g’ 
= yes  
3 
S pecificall y:  
•  If o ne q uesti o n is left u na ns were d t his is sc ore d 0 a n d t he sc ores are s u m me d 
a n d e x press e d as us ual o ut of a ma xi m u m of 3 0. 
•  If t w o or m ore q u esti o ns are left u na ns w ere d t he q uesti o n naire is n ot sc ore d. 
•  If q uesti o n 7 is a ns w ere d ‘ yes’ t his is sc ore d 3. If q uesti o n 7 is a ns w ere d 
‘ n o’ b ut t he n eit her ‘a l ot’ or ‘a little’ is tic ke d t his is t he n sc ore d 2 or 1. If 
“ N ot rele va nt” is tic ke d, t he sc ore f or Q uesti o n 7 is 0. If it is a ns were d ‘ n o’, 
b ut t he sec o n d half is left i nc o m plete, t he sc ore wil l re mai n 0. 
•  If  t w o  or  m ore  res p o nse  o pti o ns  are  tic ke d,  t he  res p o nse  o pti o n  wit h  t he 
hi g hest sc ore s h o ul d be rec or de d. 
•  If t her e is a res p o nse bet wee n t w o tic k b o xes, t h e l o wer of t he t w o sc ore 
o pti o ns s h o ul d be rec or d e d. 
T he D L QI is calc ulate d b y a d di n g t he sc ore of eac h q uesti o n. T he ma xi m u m 
sc ore is 3 0, a n d t he mi ni m u m sc ore is 0. T he hi g h er t he sc ore, t he m ore q u alit y 
of life is i m paire d.  
Me a ni n g of D L QI Sc ores  
0- 1 = n o effect at all o n s u bject ’s life 
P P D


 
C O N FI D E N TI A L  
Pa ge 3 9  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
2- 5 = s mall eff ect o n s u bject ’s life 
6- 1 0 = m o der ate effect o n s u bject ’s life 
1 1- 2 0 = ver y l ar ge effect o n s u bject ’s life 
2 1- 3 0 = e xtr e mel y lar ge effect o n s u bject ’s life 
C ha n ge fr o m Baseli ne  i n Sc ore = P ost Baseli ne Sc ore – Baseli ne  Sc or e 
 
8)  
Pr o p orti o n of s u bjects w h o e x perie n ce d fl are, d efi ne d b y at least a 2 5 % 
i ncreas e i n A N c o u nts wit h a mi ni m u m i ncrease of 2 A N c o u nts relati ve t o 
Baseli ne .  
T he A N c o u nt is t he s u m of all a bscess es a n d  i nfla m mat or y n o d ules c o u nts 
acr oss all r e gi o ns.  
% I ncre as e i n A N c o u nts
= 1 0 0 × (A N  C o u nts  at  D a y  x−A N  C o u nts  at  B as eli n e )
A N  C o u nt  at  B as eli n e
 
T he  pr o p orti o n of s u bjects w h o e x perie n ce d flare  at P ost Baseli ne visits  will  
be calc ulate d as t h ose s u bjects ha vi n g  % I ncrease i n A N c o u nts ≥ 2 5 a n d 
(P ost  B as eli n e  A N  C o u nts −B as eli n e  A N  C o u nts ) ≥2 at P ost  B as eli n e  
visits di vi de d  b y  t he t otal n u m ber of s u bjects i n eac h treat me nt gr o u p.  
 
9)  
D urati o n of flare i n da ys ( O bser v e d cas e o nl y) 
D urati o n of flare i n da ys is calc ulate d fr o m t he da y w he n flare is o bser v e d t o 
t he da y pri or t o t he o bser vati o n t hat flare is n o l o n ger pres e nt; of n ote, t here 
c o ul d be m ulti ple peri o ds t hat flares are o bser ve d, i n w hic h case, t he t otal d a ys 
fr o m t he m ulti ple peri o ds will be use d. 
 
1 0)  
Pr o p orti o n of s u bjects w h o e x perie n ce at least 2 5 % i ncrease i n drai ni n g fist ula 
c o u nts wit h a mi ni m u m i ncreas e of 2 drai ni n g fist ula c o u nts relati ve t o Bas eli ne . 
% I ncr e as e i n Dr ai ni n g Fist ul a C o u nts
= 1 0 0 × (P ost  B as eli n e  Dr ai ni n g Fist ul a  C o u nts −B as eli n e  Dr ai ni n g Fist ul a  C o u nts )
Dr ai ni n g Fist ul a  C o u nt  at  B as eli n e
 
T he  pr o p orti o n of s u bjects w h o e x perie n ce d at least 2 5 % i ncreas e i n drai ni n g 
fist ula c o u nts wit h a mi ni m u m i ncrease of 2 drai ni n g fist ula c o u nts relati ve t o 
Baseli ne  at P ost Baseli ne visits  will  be calc ulate d  as t h ose s u bjects ha vi n g 
% I ncr e as e i n Dr ai ni n g Fist ul a C o u nts ≥ 2 5 a n d 
(P ost  B as eli n e  Dr ai ni n g Fist ul a   C o u nts −
B as eli n e  Dr ai ni n g Fist ul a   C o u nts ) ≥2 at P ost  B as eli n e  visits di vi de d  b y  t he 
t otal n u m ber of s u bjects i n eac h treat me nt gr o u p. 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 4 0  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
1 1)  D uri n g Peri o d 2, pr o p orti o n of s u bjects wit h a l oss of res p o nse, ( L O R) defi ne d 
as l oss of at least 5 0 % of A N c o u nt i m pr o ve me nt ac hie ve d at Wee k 1 2 fr o m 
Peri o d 1. 
A N  i n P eri o d  2−W e e k  1 2  A N >
1
2 (B as eli n e  A N −Wee k 1 2 A N)  
i.e., A N  i n P eri o d  2  >
1
2 (B as eli n e  A N + Wee k 1 2 A N)  
Pr o p orti o n of s u bjects wit h a L O R  i n Peri o d 2 is calc ulate d as t h ose s u bjects 
ha vi n g A N  C o u nts  i n P eri o d  2  >  0. 5  × (B as eli n e  A N  c o u nts −Wee k 1 2 A N 
c o u nts)  di vi de d b y  t he t otal n u m ber of s u bjects i n eac h treat me nt gr o u p in 
Peri o d 2. 
 
1 2)  Ti me t o L O R d uri n g Peri o d 2. 
F or s u bjects wit h L O R, ti me t o L O R ( da ys) = date of L O R – date of t he first 
d ose of st u d y dr u g i n Peri o d 2 + 1; F or S u bjects wit h o ut L O R or l ost f oll o w-
u p, s u bjects will be ce ns ore d at t he dat e of t he last assess me nt of n u m ber of H S 
lesi o ns, i.e., ti me t o L O R ( da ys) = d ate of last ass ess me nt of n u m ber of H S 
lesi o ns – date of t he first d ose of st u d y dr u g i n Peri o d 2 + 1. 
 
1 3)  Pr o p orti o n of s u bjects w h o recei v e d a d d- o n a nti bi otic or ot her t hera p y f or H S 
d uri n g Peri o d 1 a n d Peri o d 2 se parat el y . 
A d d - o n a nti bi otic or ot her t hera pies f or H S are ca pt ure d i n t he C o nc o mita nt 
Me dicati o n C R Fs.  
Pr o p orti o n of s u bjects w h o recei v e d a d d- o n a nti bi otic or ot her t hera p y will be 
calc ulate d as t h ose  s u bjects w h o recei ve d a d d- o n a nti bi otic or ot her t hera p y 
d oc u me nte d i n t he C M C R F p ost baseli ne di vi de d b y  t he t otal n u m ber of 
s u bjects i n eac h treat me nt gr o u p i n t he safet y p o p ulati o n. 
 
1 4)  Pr o p orti o n of s u bjects w h o start disall o we d o pi oi d pai n t hera p y d uri n g Peri o d 1 
a n d Peri o d 2 se paratel y. 
Oral a n d tr a ns der mal o pi oi d a nal gesics (e x ce pt f or tra ma d ol) f or a n y reas o n  are 
disall o we d. Disall o we d o pi oi d pai n t hera p y are ca pt ure d i n t he C o nc o mita nt 
Me dicati o n ( C M) C R Fs.  
Pr o p orti o n of s u bjects w h o start disall o we d o pi oi d pai n t hera p y wil l be 
calc ulate d as t h ose  s u bjects w h o start disall o we d o pi oi d pai n t hera p y 
d oc u me nte d i n t he C M C R F p ost baseli ne di vi de d b y  t he t otal n u m ber of 
s u bjects i n eac h treat me nt gr o u p i n safet y p o p ulati o n. 
1 5)  Pr o p orti o n of s u bjects w h o u n der g o lesi o n i nter ve nti o n d ue t o H S d uri n g 
Peri o d 1 a n d Peri o d 2 se paratel y. 
Lesi o n i nter ve nti o n d ue t o H S is c ollecte d i n A E a n d C o nc urre nt Pr oce d ures 
C R Fs.   
P P D


 
C O N FI D E N TI A L  
Pa ge 4 1  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
O nl y t w o t y pes of i nter ve nti o ns are all o we d: i njecti o n wit h i ntralesi o nal 
tria mci n ol o ne acet o ni de s us pe nsi o n (intralesi o nal Ke nal o g  resc u e i njecti o ns, 
i.e., tria mci n ol o ne acet o ni de, 1 0 m g t otal ma xi m u m per s u bject wit hi n a peri o d 
n o l o n ger t ha n 1 wee k) a n d i ncisi o n a n d drai na ge. A n y disall o we d lesi o ns 
i nter ve nti o ns d ue t o H S ot her t ha n t he t w o t y pes d escri be d a b o ve will als o be 
c o u nte d as “ L esi o n i nter ve nti o n d ue t o H S” a n d will be rec or d e d as maj or 
( = C S R re p orta ble) pr ot oc ol de viati o n. 
D uri n g Peri o d 1, a t otal of t w o pr ot oc ol-all o we d i nter ve nti o ns are p er missi ble . 
A n  i nter ve nti o n ca n o cc ur o n ma xi mall y t w o differe nt lesio ns at t he sa me visit 
or o n t he sa me lesi o n at t w o differe nt st u d y visits. T he sa me lesi o n ca n n ot be 
treate d t w o ti mes at t he s a me visit. If a s u bject re q uires m ore t ha n t w o 
i nter ve nti o ns wit hi n t he first 1 2 wee ks, t he n t he y m ust disc o nti n ue ta ki n g bli n d 
st u d y me dicati o n. H o we ver, t hese s u bjects will be re q uest e d t o re mai n i n t he 
st u d y a n d t o c o m plete all st u d y pr oce d ures if p ossi ble. 
D uri n g Peri o d 2, ma xi mall y t w o i nter ve nti o ns e ver y 4 wee ks are p er mitte d. A n 
i nter ve nti o n ca n occ ur o n t w o differe nt lesi o ns at t he sa me visit or o n t he sa me 
lesi o n at t w o differ e nt st u d y visits. Wit hi n eac h 4- wee k peri o d, t he sa me t y pe 
of i nter ve nti o n ca n n ot b e use d t w o ti mes o n t he sa me lesi o n. If a s u bject 
re q uires m or e t ha n t w o i nter ve nti o ns wit hi n a 4- wee k peri o d or has t w o of t he 
sa me i nter ve nti o ns o n t he sa me lesi o n wit hi n t hat peri o d, t he s u bject m ust 
disc o nti n ue ta ki n g bli n d st u d y me dicati o n. H o we ver, t hese s u bjects will be 
re q ueste d t o r e mai n i n t he st u d y a n d t o c o m plete all st u d y pr oce d ures if 
p ossi ble. 
Pr o p orti o n of s u bjects w h o u n der g o lesi o n i nter ve nti o n d ue t o H S will be 
calc ulate d as t h ose  s u bjects w h o ha ve lesi o n i nter ve nti o n d ue t o H S 
d oc u me nte d i n t he A E/ C o nc urre nt Pr o ce d ure C R F p ost baseli ne di vi de d b y 
t he t otal n u m ber of s u bjects i n eac h treat me nt gr o u p i n t he safet y p o p ulati o n. 
Pr o p orti o n of s u bjects w h o recei v e d oral a nti bi otic resc u e t hera p y will be 
calc ulate d as t h ose  s u bjects w h o recei ve d oral a nti bi otic resc ue t hera p y 
d oc u me nte d i n t he C M C R F p ost baseli ne di vi de d b y  t he t otal n u m ber of 
s u bjects i n each treat me nt gr o u p i n safet y p o p ulati o n. 
 
1 6)  N u m ber of lesi o n i nter v e nti o ns d ue t o H S d uri n g Peri o d 1 a n d Peri o d 2 
se parat el y. 
Lesi o n i nter ve nti o n d ue t o H S is c ollecte d i n C o nc urre nt Pr oce d ures C R Fs. 
N u m ber of lesi o n i nter v e nti o ns d ue t o H S per s u bject will be calc ul ate d b y 
peri o d. 
 
1 7)  Healt h -ec o n o mic i nf or m ati o n: 
a. W P AI: S H P: C ha n ge fr o m Baseli ne  t o eac h ti me p oi nt d uri n g Peri o d 1 a n d 
C ha n ge fr o m Wee k 1 2 t o eac h ti me p oi nt d uri n g Peri o d 2 a n d i ncl u di n g t he 
f oll o w- u p peri o d; 
P P D


 
C O N FI D E N TI A L  
Pa ge 4 2  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
 
W or k Pr o d ucti vit y a n d A cti vit y I m pair me nt Q u esti o n naire  (W P AI: S H P ) 
assesses t he effect of ge n eral a n d s p ecific h ealt h c o n diti o ns o n pr o d ucti vit y 
l osses. Sc ores are cal c ulate d f or f o ur areas: perce nt w or k ti me misse d d ue 
t o H S, perce nt i m pair me nt w hile w or ki n g d ue t o H S, perce nt o v erall w or k 
i m pair me nt d ue t o H S, a n d perce nt acti vit y i m pair me nt d ue t o H S. F or ms 
f or t his i nstr u me nt will be c o m plete d b y st u d y s u bjects at visits s pecifie d i n 
t he Ti me  a n d E ve nts Ta ble t o meas ure c ha n ges fr o m baseli ne i n w or k 
pr o d ucti vit y a n d acti vit y i m pair me nt. 
 
b.  H os pitalizati o ns (c u m ulati ve)  b y peri o d: N u m ber of H os pitalizati o ns t otal 
a n d d ue t o H S, N u m ber of da ys h os pitalize d, N u m ber of da ys misse d fr o m 
w or k .  
 
H os pitalizati o n s are ca pt ure d i n Heat h E c o n o mics I nf or mati o n C R Fs, 
c u m ulati ve n u m ber will  be calc ul ate d b y s u m of t he n u m bers fr o m eac h 
visit.  
 
c. E mer ge nc y or Ur g e nt Care visits (c u m ulati ve)  b y peri o d : N u m ber of visits 
t otal a n d d ue t o H S, N u m ber of da ys ( or h o urs w h ere a p plica ble) misse d 
fr o m w or k. 
 
E mer ge nc y or Ur g e nt Care visits  are ca pt ure d i n Heat h Ec o n o mics 
I nf or mati o n C R Fs, c u m ulati ve n u m ber will be cal c ulate d b y s u m of t he 
n u m bers fr o m eac h visit. 
 
d.  Lesi o n i nter ve nti o ns f or H S b y peri o d: N u m ber of da ys ( or h o urs w h ere 
a p plica ble) misse d fr o m w or k d ue t o H S lesi o n i nter ve nti o ns. 
 
Lesi o n i nter ve nti o ns f or H S are ca pt ure d i n H eat h Ec o n o mics I nf or mati o n 
C R Fs, c u m ulati ve n u m ber of da ys misse d fr o m w or k d ue t o H S lesi o n 
i nter ve nti o ns will be calc ulate d b y s u m of t he n u m bers fr o m eac h visit. 
 
C.  
Ge ner al A p pr o ac h  
Lesi o ns t hat recei ve d i nter ve nti o n (i ncisi o n a n d drai na ge, or i ntralesi o nal i njecti o n 
of c ortic oster oi d) will be c o u nte d as per ma ne ntl y prese nt fr o m t he d ate of t he 
i nter ve nti o n. 
I n or der t o a dj ust f or t he i m pact of maj or pr ot oc ol disall o we d treat me nts o n t he 
res ults of t he trial, efficac y assess me nts o btai ne d after t he start of maj or pr ot oc ol 
disall o we d treat me nts will be e xcl u de d fr o m t he a nal ysis  ( u nless ot her wise 
s pecifie d). S u bject will b e c o u nte d as n o n-res p o n d ers f or t he cate g orical varia bles 
a n d ha ve t heir l ast o bser v ati o n carri e d f or w ar d f or c o nti n u o us varia bles. 
 
C o nc o mita nt t hera p y t hat w o ul d q ualif y as a resc u e me dicati o n will be re vi e we d 
pri or t o data base l o c k. 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 4 3  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
A d diti o nal a nal yses ma y be perf or me d f or t h e pri mar y effi cac y v aria ble a dj usti n g 
f or Baseli ne c o v ariates in a d diti o n t o Baseli ne H urle y Sta ge, if necessar y. R es ults 
fr o m a n y a d diti o nal a n al yses will n ot be use d as a s u bstit ute f or t he pla n ne d 
a nal yses, b ut ma y be use d as s u p ple me ntal i nf or m ati o n f or t he st u d y re p ort. 
 
D.  
Pri m ar y Effic ac y E n d p oi nt A n al ysis 
 
Pri m ar y A n alysis 
 
T he  pri mar y  efficac y o bj ecti ve is t o e val uate t he efficac y of a vac o pa n  c o m pare d  t o 
place b o  i n s u bjects wit h  H urle y  Sta ge  II or III H S  base d  o n s u bjects ac hie vi n g  a 
Hi dra de nitis  S u p p urati va Cli nical  Res p o nse ( Hi S C R) after 1 2 wee ks  of treat me nt. 
T o  a d dress t his o bjecti ve, t he f oll o wi n g h y p ot heses will be teste d usi n g t he data 
c ollecte d fr o m Peri o d 1 after t he last s u bject h as c o m plete d Peri o d 1: 
•  T he  n ull h y p ot hesis ( H0) is t hat t he a vac o pa n  gr o u p is n ot differe nt  fr o m 
t he place b o c o ntr ol gr o u p w he n  c o m pari n g t he Hi S C R  rate at Wee k 1 2. 
•  T he  alter nati ve h y p ot hesis ( H1) is t hat t he a vac o pa n  gr o u p is differe nt  fr o m 
t he place b o c o ntr ol gr o u p w he n  c o m pari n g t he Hi S C R  rate at Wee k 1 2. 
 
T o a d dress t he m ulti plicit y iss ue wit h t w o d ose gr o u ps, a fi xe d hierarc hi cal testi n g 
pr oce d ur e will be use d f or t he c o m paris o ns of t he A vac o pa n 1 0 m g vs. Place b o 
a n d A vac o p a n  3 0 m g vs. Place b o  t o mai ntai n t he o verall T y pe I err or at 0. 0 5. T he 
h y p ot hesis testi n g will test t he A vac o pa n 3 0 m g vs. Place b o f irst: if t he p-v al ue is 
≤ 0. 0 5, t he n 1 0 m g A vac o pa n vs. Place b o  will be teste d at t he α = 0. 0 5 l e v el. If t he 
test of A vac o p a n  3 0 m g vs. Place b o  is n ot si g nifica nt at t he α = 0. 0 5 le vel, t he 1 0 
m g A vac o pa n  vs. Place b o  will be teste d as a n e x pl orat or y a nal ys is. 
 
T o c o m pare tr eat me nt gr o u ps, t he pr o p orti o n of s u bjects ac hie vi n g Hi S C R  at 
Wee k  1 2 will  be teste d usi n g t he C oc hra n -Ma ntel -Hae nszel  ( C M H) test, stratifie d 
b y H url e y  Sta ge  ( Sta ge II vs. III), c o nc o mita nt  a nti bi otic t hera p y wit h  all o we d 
a nti bi otics ( Yes vs. N o)  a n d pri or a nti-T N F  dr u g use ( Treat me nt naï ve vs. 
Pre vi o us treat me nt). T he  t w o-si de d 9 5 % c o nfi de nce i nter vals f or t he differe nce  i n 
pr o p orti o ns ( a vac o pa n  mi n us  place b o  c o ntr ol) will  be calc ulate d usi n g t he 
stratifie d Ne wc o m be  h y bri d-sc ore met h o d.  If t he sa m ple bec o mes s parse i n o ne 
of t he strata, t he str atificati o n fact or will be re m o v e d fr o m t he stratifie d a nal ysis.  
 
T he pri mar y efficac y a n al ysis will be carrie d o ut i n t he I T T 1 P o p ulati o n. I n 
a d diti o n, t he pri mar y efficac y e n d p oi nt will be a nal yze d i n t he P P 1  P o p ulati o n. 
 
T he f ol l o wi n g pr o vi des s a m ple c o de f or i m ple me nti n g t he C M H  a nal ysis f or 30 
m g a vac o pa n  vs. place b o  :  
 
     o d s  o u t p u t  c o m m o n p d i f f = p d i f f 1 ;  
            p r o c  f r e q  d a t a = t e s t ( w h e r e = ( t r t  i n  ( 0 ,  2 ) ) ) ;   
P P D


 
C O N FI D E N TI A L  
Pa ge 4 4  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
                 t a b l e  h s * a n t i b * a n t i t n f * t r t * r e s p / c m h 1  r i s k d i f f  ( c o m m o n   
                       c l = N e w c o m b e )  n o p r i n t ;  
            r u n ;  
 
w here  
•  H S is t he varia ble f or H urle y  Sta ge  ( Sta ge II vs. III) 
•  A N TI B is t he varia ble f or all o we d a nti bi otics ( Yes vs. N o)  
•  A N TI T N F a nti-T N F  dr u g use ( Treat me nt nai ve vs. Pre vi o us treat me nt)  
•  T R T is t he varia ble f or treat me nt ( 0 f or pl ace b o ; 1 f or a vac o pa n  1 0 m g; 2 
f or a vac o pa n  3 0 m g) 
•  R E S P is t he res p o nse varia ble f or ac hie vi n g Hi S C R  at Wee k  1 2 ( 0 f or N o, 
1 f or Yes).  
 
Missi n g assess me nts were ha n dle d wit h t he use of N RI  as t he pri mar y a p pr oac h t o 
ha n dli n g missi n g data. 
 
Se nsitivity A n alyses  
 
Se veral se nsiti vity a nal ys es will be c o n d ucte d o n t he pri mar y efficac y e n d p oi nt i n 
t he I T T1 P o p ulati o n .  Eac h are d escri b e d bel o w: 
 
1)  I m p ut ati o n of M issi n g V al ues wit h M ulti ple I m p ut ati o n ( MI)  A n al ysis 
 
T he M ulti ple I m p utati o n a nal ysis will be carrie d o ut i n t hree ste ps ; 
 
•  I m p utati o n of missi n g data.  T he i m p utati o n will be ge nerate d f or t he t hree 
c o m p o ne nts of Hi S C R (a bscess, drai ni n g fist ula, i nfla m mat or y n o d ule 
c o u nts).  T he varia bles t o be i ncl u de d i n t he i m p utati o n m o del are: B aseli ne 
H urle y Sta ge, Baseli ne a nti bi otic t hera p y, Baseli ne a nti -T N F -α treat me nt , 
treat me nt gr o u p, a n d v al ues at eac h visit fr o m Baseli ne u p t o Wee k 1 2.  F or 
eac h HiS C R c o m p o ne nt, 1 0 0 'c o m plete' data sets will be ge nerat e d usi n g 
S A S P R O C MI utilizi n g t he M C M C al g orit h m.  T he see d s f or t he 
i m p utati o n will be s pecifie d as t he val ue “1 2 0 6 1”, “ 3 6 1 0 2”, a n d “ 9 4 2 1 8” 
f or i m p utati o n of a bscess, drai ni n g fist ula, a n d i nfl a m mat or y n o d ule 
c o u nts, res pecti vel y. T h e 'c o m plete' data sets f or t he i n di vi d ual c o m p o ne nts 
of t he Hi S C R will be mer ge d b y i m p utati o n n u m ber t o all o w cal c ulati o n of 
t he Hi S C R a n d creati o n of 1 0 0 'c o m plete' data s ets f or e val uati o n of 
Hi S C R.  S u bjects w h o recei ve d c o n c o mita nt a nti-T N F -α treat m e nt or ot her 
treat me nts wit h cli nicall y rele va nt i m pact o n H S will be f orce d as n o n-
res p o n ders f or all of 1 00 'c o m plete' data sets . 
 
•  A nal ysis of i m p ute d data sets.  A C M H test, stratifie d b y Baseli ne H urle y 
Sta ge (II vs. III), Bas eli ne a nti bi otic t hera p y ( Yes vs. N o), Baseli ne a nti-
T N F --α treat me nt  ( Treat me nt naï ve vs. Pre vi o us treat me nt) will be use d t o 
a nal yze eac h 'c o m plete' Hi S C R data set.  
 
P P D


 
C O N FI D E N TI A L  
Pa ge 4 5  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
•  S y nt hesis of i m p utati o n a n d a nal ysis res ults.  S A S P R O C MI A N A L Y Z E 
will be use d t o ge nerate t he fi nal esti mate of t he pr o p orti o n differe nce 
bet wee n a vac o p a n  a n d pl ace b o  gr o u ps a n d t he c orres p o n di n g 9 5 % 
c o nfi de nce i nter val. 
 
2)  N o n- R es p o n der Im p ut ati o n f or A n y A d d - o n Anti bi otics / Ot her 
C o nc o mit a nt Me dic ati o ns U se 
 
All s u bjects wit h a n y a d d- o n a nti bi otics (a n y a nti bi otics ot her t ha n t he 
c o nc o mita nt at Baseli ne) or wit h d ose i ncrease fr o m b aseli ne c o nc o mita nt 
a nti bi otics pri or t o Wee k 1 2, re gar dl ess t he reas o n f or use; or ot her 
c o nc o mita nt me dicati o ns liste d bel o w will  be i m p ute d as n o n-res p o n d ers: 
1.  A d d - o n anti bi otics  
2.  C o nc o mita nt A nti- T N F -α treat me nt  
3.  C o nc o mita nt ot her s yste mic treat me nt f or H S.   E. g., met h otre xate, 
c ycl os p ori ne, reti n oi ds, a n d f u maric aci d esters, etc. 
 
3)  L O C F f or Hi S C R  
 
 
S u b gr o u p A n alysis   
 
S u b gr o u p a nal yses will be perf or me d f or t h e pri m ar y efficac y e n d p oi nt i n t he I T T1 
P o p ulati o n.  
T he s u b gr o u ps ar e defi n e d as f oll o ws: 
 
• 
Ra n d o mizati o n stratificati o n varia bles  
− H urle y Sta ge (II, III) 
− C o nc o mita nt a nti bi otic t hera p y ( Y es, N o)  
− A nti- T N F -α tr eat me nt  ( Treat me nt n aï ve, Pre vi o us treat me nt)  
• 
Se x ( Male , Fe male)  
• 
B MI cate g or y :  N or mal ( < 2 5 k g/ m2) , O ver wei g ht ( 2 5 – < 3 0 k g/ m2), o bese 
( 3 0 – < 4 0 k g/ m2), M or bi d o besit y ( ≥ 4 0 k g/ m2) 
• 
A ge at dia g n osis of H S ( < me dia n ,  ≥ me dia n ) 
• 
A ge at st u d y e ntr y ( < 6 5 years vs. ≥ 6 5 years) 
• 
D urati o n of H S ( < m e dia n ,  ≥ me dia n ) 
• 
Race ( W hite vs. N o ne-W hite ) 
• 
Baseli ne A N c o u nt ( <  5,  5- 1 0,  > 1 0 ) 
• 
Baseli ne i nfla m mat or y n o d ule c o u nt ( < me dia n ,  ≥ me dia n ) 
• 
Baseli ne a bscess c o u nt (< me dia n ,  ≥ me dia n ) 
P P D


 
C O N FI D E N TI A L  
Pa ge 4 6  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
• 
Basel i ne drai ni n g fist ula c o u nt (< me dia n ,  ≥ me di a n ) 
• 
Baseli ne m o difie d Sart ori us sc ore (< m e dia n ,  ≥ me dia n ) 
• 
Pre vi o us s yste mic H S treat me nt (i ncl u des T N F i n hi bit or use b ut e xcl u des 
a nti bi otic use) 
• 
Ge o gra p hic distri b uti o n ( N ort heaster n R e gi o n, S o ut heaster n Re gi o n, Wester n 
Re gi o n, Mi d wester n Re gi o n, a n d S o ut h wester n Re gi o n) 
T hese s u m maries will be base d o n  i m p ute d data ( N RI f or bi nar y v aria bles). If t he 
sa m ple bec o mes s parse i n o ne of t he s u b gr o u p strata, t he s u b gr o u p varia bl e will be 
c olla pse d or r e m o ve d fr o m t he s u b gr o u p a nal ysis. 
 
E x pl or at ory A n alysis  
T he avac o pa n  1 0  m g  vs.  3 0  m g  gr o u ps  will  be  teste d  f or t he  pri mar y  efficac y 
e n d p oi nt if t he pri mar y efficac y e n d p oi nt t ests of b ot h a vac o pa n 1 0 m g vs place b o  
a n d  avac o pa n  3 0  m g  gr o u ps  vs place b o  are  statisticall y  si g nifica nt  i n  t he  I T T 1 
P o p ulati o n. 
 
E.  
Sec o n d ar y  a n d Ot her  Effic ac y E n d p oi nts A n al yses 
 
 T he f oll o wi n g missi n g data ha n dli n g r ules will a p pl y: 
 Sec o n d ar y / Ot her Effic ac y E n d p oi nts   
•  F or  bi nar y efficac y varia bles,  N RI  i m p utati o n met h o d will  be use d  f or 
missi n g  data.  F or N R S 3 0  i n Peri o d 1, m ulti ple i m p utati o n met h o d will be 
a p plie d si milarl y as t he pri mar y e n d p oi nt.    
•  F or  c o nti n u o us  efficac y varia bles,  O C  met h o d will  be perf or me d.  
•  F or % c ha n ge fr o m bas eli ne i n i nfla m mat or y n o d ule c o u nt, a bscess c o u nt, 
n o n-i nfla m mat or y c o u nt, drai ni n g fist ula, n o n- drai ni n g fist ula, t otal fist ula 
c o u nt, a n d t otal A N c o u nt, n o statistical testi n g will be perf or me d, o nl y 
s u m mar y statistics will be pr o vi de d. 
F or t he sec o n dar y e n d p oi nts, m ulti plicit y iss ue has bee n a d dresse d i n Secti o n  
VI.I  
1.  A n al ysis of Sec o n d ar y a n d Ot her Effic ac y E n d p oi nts i n Peri o d  1 
 
T he Sec o n dar y Efficac y E n d p oi nts f or Peri o d 1 will be teste d f or t he a v ac o pa n  3 0 
m g vs. place b o , a n d a v ac o pa n  1 0 m g vs. place b o  at T y pe I err or at 0. 0 5. T h e 
a nal yses will be carrie d o ut i n t he I T T 1  a n d P P p o p ulati o n. A nal ysis of ot her 
efficac y e n d p oi nt s wi ll be c o n d ucte d fr o m Baseli ne  t o eac h ti me p oi nt i n t he I T T 1 
p o p ulati o n. 
Cate g orical varia bles of c ha n ge fr o m Baseli ne  t o Wee k 1 2 will be a nal yze d usi n g 
C M H test stratifie d f or b aseli ne H urle y Sta g e ( Sta ge II vs. III), c o nc o mita nt 
a nti bi otic t hera p y wit h al l o we d a nti bi otics ( Yes vs. N o) a n d a nti-T N F - α dr u g use 
P P D


 
C O N FI D E N TI A L  
Pa ge 4 7  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
( Treat me nt n aï ve vs. Pre vi o us treat me nt) si milar t o t he a nal ysis of t he pri m ar y 
efficac y e n d p oi nt. 
C o nti n u o us varia bles will be a nal yze d usi n g a mi xe d effects m o del f or re p eate d 
meas ures  ( M M R M). T his mo del will i ncl u de treat me nt gr o u p, visit, treat me nt - b y-
visit i nteracti o n, a n d ra n d o mizati o n strata ( H url e y Sta ge II or H urle y Sta ge III, 
pre vi o us a nti- T N F - α dr u g use or a nti-T N F - α dr u g naï ve, c o nc o mita nt a nti bi otic 
t hera p y use or n ot) as fact ors, a n d c orres p o n di n g b aseli ne as c o v ariate. S u bj ect s 
will be c o nsi dere d as re p eate d meas ure u nits o ver visits. A T oe plitz c o varia nce 
matri x will be use d t o m o del t he wit hi n -s u bject v aria nce-c o v aria n ce str uct ure f or 
t he m o del err ors. If t he m o del d oes n ot c o n ver g e usi n g t he u nstr uct ure d ( U N) 
c o varia n ce matri x, T o e plitz ( T O E P H)  c o v aria nce matri x will be use d. If 
c o n ver ge n ce is still n ot met, t he n A R( 1)  or c o m p o u n d s y m metr y ( C S) will be 
use d . Testi n g p- val ues, p oi nt esti mates a n d c orres p o n di n g 9 5 % c o nfi de nce 
i nter vals will be esti mate d f or t he differe n ce bet w ee n t he a v ac o p a n gr o u p a n d t he 
place b o  c o ntr ol gr o u p acr oss 1 2 wee ks usi n g li near c o ntrast fr o m t he m o d el.  
T he f oll o wi n g pr o vi des s a m ple c o de f or i m ple me nti n g t he M M R M a nal ysis:  
 
o d s  o u t p u t  l s m e a n s = l s m e a n s  d i f f s = d i f f s ;  
p r o c  m i x e d  d a t a = t e s t ;  
c l a s s  s u b j i d  t r t  v i s i t  a n t i t n f  h s ;  
m o d e l  c h  =  t r t  v i s i t  t r t * v i s i t  h s  a n t i b  a n t i t n f        
           b a s e / d d f m = k r  c l  a l p h a = 0 . 0 5  s o l u t i o n ;  
r e p e a t e d  v i s i t /  t y p e = U N  s u b = s u b j i d  ;  
l s m e a n s  t r t * v i s i t / c l  d i f f = c o n t r o l ( " 0 " ) ;  
r u n ;  
q u i t ;  
 
w here  
•  C H is t he varia ble f or c h a n ge fr o m b aseli ne  
•  T R T is t he varia ble f or treat me nt ( 0 f or pl ace b o ; 1 f or a vac o pa n  1 0 m g; 2 
f or a vac o pa n  3 0 m g) 
•  H S is t he H urle y  Sta ge  (II vs. III) 
•  VI SI T is t he varia ble f or st u d y visit  
•  A N TI B is t he varia ble f or c o nc o mita nt  a nti bi otic t hera p y wit h  all o we d 
a nti bi otics ( 0 f or N o; 1 f or Yes) 
•  A N TI T N F is t he vari a ble f or a nti-T N F  dr u g use ( Treat me nt nai ve vs. 
Pre vi o us treat me nt) 
•  B A S E is t he varia ble f or t he c orres p o n di n g baseli ne  val ue  
•  S U BJI D is f or s u bject 
 
F or t he a nal ysis of s u bject’s gl o bal assess me nt of s ki n pai n ( N R S 3 0) u p t o Wee k 
1 2, s u bjects w h o recei ve d a nal gesics (t o be d eter mi ne d b y classificati o n pri or t o 
data base l oc k), f or s ki n p ai n, or ha ve u n d er g o ne i nter ve nti o n will be c o u nte d as 
n o n- res p o n der f or cate g orical vari a bles, a n d ha v e t heir last pai n assess me nt bef ore 
t he start of t he a n al gesic or date of t he i n cisi o n a n d drai na ge (I & D) carrie d f or war d 
P P D


 
C O N FI D E N TI A L  
Pa ge 4 8  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
f or c o nti n u o us varia bl es, fr o m t he start da y of t h e a nal gesics or d a y of t he I & D 
u ntil 1 4 da ys after t he st o p of a nal gesic us e or da y of t he I & D. 
L O C F a n d as o bs er ve d a nal ysis will be t he se nsiti vit y a nal yses f or cate g ori cal 
varia bles a n d f or c o nti n u o us varia bles, res pecti vel y 
 
Disall o we d pai n t her a p y will be deter mi ne d b y a bli n de d data re vie w pri or t o 
data base l oc k.  
 
I n a d diti o n, as a se nsiti vit y a nal ysis f or Peri o d 1, f or selecte d s ec o n dar y efficac y 
e n d p oi nts (c o nti n u o us varia bles) , a n A N C O V A m o del wit h treat me nt, baseli ne 
val ue, H urle y Sta ge  ( Sta ge II vs. III),  c o nc o mita nt a nti bi otic t hera p y wit h  all o we d 
a nti bi otics ( Yes vs. N o)  a n d a nti-T N F  dr u g use ( Treat me nt naï ve vs. Pre vi o us 
treat me nt) will be als o a p plie d  base d o n O C; f or selecte d sec o n d ar y efficac y 
e n d p oi nts ( bi nar y vari a bles), M ulti ple i m p utati o n ( MI) met h o d will be a p plie d.  
T he f oll o wi n g are s elect e d sec o n dar y effi cac y e n d p oi nts: 
 
•  Re d ucti o n of I H S 4 sc ore relati ve t o baseli ne o v er ti me ( M M R M m o del, a n d 
A N C O V A m o del) ; L o g rati o of I H S 4 sc ore t o b as eli ne o ver ti me ( M M R M 
m o del). 
•  Pr o p orti o n of s u bjects ac hie vi n g at least 3 0 % re d u cti o n a n d at least 1 u nit  
re d ucti o n fr o m Baseli ne  i n t he s u bject’s gl o bal ass ess me nt of s ki n pai n 
( N R S 3 0) i n s u bjects wit h a Baseli ne  N R S of at least 3, e val uate d at eac h ti me 
p oi nt t o Wee k 1 2 ( N RI, a n d MI).  
•  C ha n ge fr o m Baseli ne  i n t he m o difie d Sart ori us sc ore t o q ua ntif y t he se v erit y 
c ha n ge of H S ( M M R M m o del, a n d A N C O V A m o del) 
•  T he S h ort F or m- 3 6 v ersi o n 2 ( S F- 3 6 v 2)  ( M M R M m o del, a n d A N C O V A 
m o del) 
•  T he E Q - 5 D-5 L ( E Q - 5 D-5 L)  ( M M R M m o del, a n d A N C O V A m o del) 
•  T he Hi dra d e nitis S u p p urati va Q ualit y of Life ( Hi S Q O L) I n de x ( M M R M 
m o del, a n d A N C O V A m o del) 
•  t he Der mat ol o g y Life Q u alit y I n de x ( D L QI)  ( M M R M m o del, a n d A N C O V A 
m o del) 
•  T he W or k Pr o d u cti vit y a n d Acti vit y I m pair m e nt Q uesti o n naire : S pecific 
Healt h Pr o ble m ( W P AI: S H P), c ha n ge fr o m baseli ne t o Wee k 1 2 ( M M R M 
m o del, A N C O V A m o del)  
 
F or t he ot her e n d p oi nts, o nl y t he pri mar y a nal ysis will be a p plie d. 
F or t he a nal ysis o f varia bles i n Peri o d 1, n ot b y visit, s uc h as: d urati o n of flare, 
healt h-ec o n o mic i nf or mati o n o n h os pital izati o ns, e mer ge n c y or ur g e nt care visits, 
P P D


 
C O N FI D E N TI A L  
Pa ge 4 9  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
a n d lesi o n i nter ve nti o ns f or H S, a n a nal ysis of c o v aria nce ( A N C O V A) m o d el wit h 
treat me nt, baseli ne v al ue, H urle y  Sta ge  ( Sta ge II vs. III), c o nc o mita nt  a nti bi otic 
t hera p y wit h  all o we d a nti bi otics  ( Yes vs. N o) , a n d a nti-T N F  dr u g use ( Treat me nt 
naï ve vs. Pre vi o us treat me nt) will be a p plie d.  Treat me nt c o m paris o ns bet wee n t he 
a vac o p a n  gr o u p a n d t he place b o  c o ntr ol gr o u p will be prese nte d . 
 
2.  A n al ysis of Sec o n d ar y a n d Ot her Effic ac y E n d p oi nts i n Peri o d 2  
T he effi cac y d ata f or sec o n dar y a n d ot her e n d p oi nts b y ti me p oi nt i n Peri o d 2 will 
be s u m marize d usi n g des cri pti ve statistics i n t he I T T2 p o p ulati o n.   
F or bi nar y v aria bles, N o n - Res p o n der I m p utati o n will be use d;  f or c ha n g e f r o m 
baseli ne vari a bles, ot her t ha n lesi o n c o u nts e n d p oi nts, n o missi n g data i m p utati o ns 
will be perf or me d. 
F or selecte d sec o n dar y efficac y e n d p oi nts s pecifie d a b o ve, a M M R M m o del 
i ncl u di n g treat me nt gr o u p, visit, treat me nt- b y- visit i nteracti o n, a n d ra n d o mizati o n 
strata ( H url e y Sta ge II or H urle y Sta ge III, pre vi o us a nti-T N F - α dr u g use or a nti-
T N F - α dr u g naï v e, c o nc o mita nt a nti bi otic t hera p y use or n ot) as fact ors, a n d 
c orres p o n di n g b aseli ne as c o variate will be a p plie d i n Peri o d 2. Testi n g p- val ues, 
p oi nt esti mates a n d c orres p o n di n g 9 5 % c o nfi de nce i nter vals will be esti mate d f or 
t he differ e nce t h e a vac o p a n 3 0 m g vs. t otal place b o t o a vac o pa n gr o u p, a n d 
a vac o p a n 1 0 m g vs. t otal place b o t o a v ac o pa n gr o u p acr oss visits i n Peri o d 2 usi n g 
li near c o ntr ast fr o m t he m o del.  
F or t he a nal ysis of ti me t o l oss of res p o nse ( L O R), t he treat me nt differe n ce 
bet wee n t he a vac o pa n  3 0 m g vs. place b o t o a vac o pa n 3 0 m g, a vac o p a n  1 0 m g vs. 
p lace b o t o a v ac o pa n 1 0 m g,  a vac o pa n  3 0 m g gr o u p vs. a vac o p a n  1 0 m g gr o u p, 
a n d  place b o t o a vac o p a n 3 0 m g vs. place b o t o a vac o pa n 1 0 m g will be a nal yze d 
usi n g t he stratifie d l o g -ra n k test wit h t he baseli ne H urle y Sta ge  ( Sta ge II vs. III), 
c o nc o mita nt a nti bi otic t hera p y wit h  all o we d a nti bi otics  ( Yes vs. N o) , a n d a nti-T N F  
dr u g use  ( Treat me nt naï ve vs. Pre vi o us treat me nt) as t he stratificati o n vari a bles . 
S u bjects wit h o ut L O R or l ost f oll o w- u p will be ce ns ore d at t he dat e of t he l ast 
assess me nt of n u m ber of H S lesi o ns. Ka pla n - Meier c ur ves will be pr o vi de d b y 
treat me nt gr o u p. 
 
I X. 
S afet y A n al yses  
 
Safet y a nal yses will be perf or me d i n t he Safet y A nal ysis Set usi n g t he act ual treat me nt 
gr o u p.    
 
A.  A d verse E ve nts  
 
All s u bjects will be assesse d re g ularl y f or p ote ntial occ urre nce of a d verse e ve nts 
(A E s) t hr o u g h o ut t he st u d y u ntil t he s u bject is off st u d y. T he Me dical Dicti o nar y 
f or Re g ulat or y A cti vities ( Me d D R A; Versi o n 2 1. 1) will be use d t o c o de all a d verse 
e ve nts t o a S yste m Or ga n Class ( S O C) a n d Preferre d Ter m ( P T).   
P P D


 
C O N FI D E N TI A L  
Pa ge 5 0  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
 
A treat me nt - e mer ge nt A E ( T E A E) i n Peri o d 1 is defi ne d as a n y A E t hat o cc urs 
after t he first d ose of st u d y treat me nt i n Peri o d 1 a n d bef ore t he dat e of first d ose 
of st u d y treat me nt i n Peri o d 2.  
 
A tr eat me nt- e mer ge nt A E ( T E A E) i n Peri o d 2 is defi ne d as a n y A E t hat o cc urs 
after t he first d ose of st u d y treat me nt i n Peri o d 2. 
 
A treat me nt -e mer ge nt A E ( T E A E)  for all a v ac o p a n, is defi ne d as a n y A E t hat 
occ urs after t he first d ose of avac o p a n  treat me nt i n st u d y. 
 
T he i nci de nce of T E A Es will be s u m marize d  a n d t a b ulate d b y treat me nt gr o u p a n d 
peri o d. 
 
T he se verit y  of eac h A E  will be assesse d  as mil d, m o derate , se v ere, life-
t hreate ni n g, f atal, or deat h. Se veral occ urre nces of t he sa me A E i n o ne s u bj ect will 
be c o u nte d o nce a n d t he o ne wit h ma xi m u m se verit y will be c o u nte d.  
 
T he relati o ns hi p of eac h A E t o t he bli n d st u d y me dicati o n will be classifie d  as 
pr o ba bl y n ot relate d or p ossi bl y relate d. Se veral occ urre nces of t he sa me A E i n 
o ne s u bject will be c o u nt e d o nce a n d t he o ne wit h t he ma xi m u m  relati o ns hi p t o 
bli n d st u d y me dicati o n will be c o u nte d. If a n A E is missi n g t he relati o ns hi p t o 
bli n d st u d y me dicati o n , t he e ve nt will be ass u me d to be pr o ba bl y rel ate d f or 
a nal ysis a n d s u m marizati o n. 
 
A d verse E v e nts of S peci al I nt erest ( A E SI) i ncl u d e i nfecti o ns, he p atic e nz y me 
ele vati o ns, ne utr o pe ni a a n d l y m p h o pe nia, h y perse nsiti vit y/a n gi oe de ma, c reati ne 
p h os p h o ki nase ele vati o n, mali g na ncies, a n d H S L esi o n i nter ve nti o ns. 
 
I nfecti o ns: T he s u bject i nci de nce of seri o us i nfecti o ns, se vere i nfecti o ns (i.e., 
Gra de 3 +), a n d i nfecti o ns lea di n g t o s u bject wit h dra wal fr o m t he st u d y will be 
s u m marize d b y treat me nt gr o u p. I nfecti o ns will be i de ntifie d b y selecti n g ter ms 
wit h t he A d verse E v e nt S yste m Or ga n Class of ‘I nfecti o ns a n d I nfestati o ns’.  
 
He p atic tr a ns a mi n ase ele v ati o ns:   
T he f oll o wi n g la b a b n or malities will be i ncl u de d i n t his cate g or y: 
•  Gra de 3 or greater i ncrease d A L T or A S T ( > 5 ti mes t he u p per li mit o f 
n or mal) 
•  Gra de 2 or greater i ncrease d A L T or A S T ( > 3 ti mes t he u p per li mit of 
n or mal) wit h ele vati o n of bilir u bi n t o > 2 ti mes t he u p per li mit of n or mal or 
I N R > 1. 5 
 
Ne utr o pe ni a, l y m p h o pe ni a a n d le u k o pe ni a:   
T he f oll o wi n g la b a b n or malities will be i ncl u de d  i n t his cate g or y: 
•  Gra de 3 or greater n e utr o pe nia ( < 1 x 1 0 9/ L) 
P P D


 
C O N FI D E N TI A L  
Pa ge 5 1  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
•  Gra de 4 l y m p h o pe nia ( < 0. 2 x 1 0 9/ L) 
•  Gra de 3 or greater le u k o pe nia ( W B C c o u nt < 2 x 1 0 9/ L) 
 
 
H y perse nsiti vit y re acti o ns:  T he s u bject i nci de nce of a d verse e v e nts ass ociate d 
wit h h y perse nsiti vit y/a n gi oe de ma a n d urticaria will be s u m marize d b y treat me nt 
gr o u p. Ter ms will be bas e d o n t he Sta n dar dize d Me d D R A Q uer y f or 
h y perse nsiti vit y.  
 
Cre ati ne P h os p h o ki n ase Ele v ati o n : 
Gra de 3 or greater C P K i ncreas e ( > 5 ti mes t he u p per li mit of n or mal)  
M ali g n a ncies : A n y mali g na ncies will be re p orte d as A Es.  
H S Lesi o n I nter ve nti o ns : Lesi o n i nter ve nti o ns d ue t o H S  will be rec or d e d i n C P.  
 
T he f oll o wi n g s u m maries will be prese nte d  i n ta bles: 
 
•  O verall s u m mar y of T E A Es  
•  T E A Es b y S O C a n d P T. ( T he n u m ber a n d per ce nt a ge of s u bjects wit h at 
least o ne T E A E, as classifie d b y s yste m or ga n cl ass ( S O C) a n d preferre d 
ter m ( P T), will be s u mmarize d b y treat me nt recei ve d i n t he peri o d of o nset.  
F or t hese s u m maries, s u bjects wit h m ulti ple e ve nts will be c o u nte d o nl y 
o nce pe r S O C a n d preferre d ter m. ) 
•  T E A Es  b y S O C, P T  a n d ma xi m u m relati o ns hi p t o st u d y dr u g 
•  T E A Es b y S O C , P T  a n d ma xi m u m Se verit y 
•  Seri o us T E A Es b y S O C a n d P T 
•  T E A Es lea di n g t o wit h dra wal t he st u d y dr u g b y S O C a n d P T 
•  T E A Es of s peci al i nterest  b y S O C a n d P T 
•  T E A Es b y P T i n desce n di n g or der 
•  S A Es b y P T i n desce n di n g or der 
 
T he A E listi n gs will be pre pare d, s orte d c hr o n ol o gicall y wit hi n s u bjects f or t he 
f oll o wi n g t y pes of A Es. Eac h listi n g will i ncl u de s yste m or ga n class, preferre d 
ter m, o nset a n d e n d d ate , se verit y, relati o n t o st u d y dr u g, acti o n ta ke n, o utc o me, 
a n d S A E stat us. 
•  All A Es  
•  Seri o us A Es 
•  T E A Es lea di n g t o deat h  
•  T E A Es lea di n g t o wit h dra wal  t he st u d y dr u g 
•  T E A Es of s peci al i nterest  
 
B.  
Cli nic al L a b or at or y Res ults 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 5 2  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
La b orat or y test r es ults i ncl u de: 
 
•  He mat ol o g y: he m o gl o bi n, he mat ocrit, R B C c o u nt, W B C c o u nt wit h 
differe ntial, plat elet c o u nt, mea n cell he m o gl o bi n, mea n cell he m o gl o bi n 
c o nce ntr ati o n, mea n c or p usc ular v ol u me.  
•  Ser u m C he mistr y: li ver pa nel (t otal bilir u bi n, lactate de h y dr o ge n ase, as p art ate 
a mi n otra nsfer ase [ A S T], ala ni ne a mi n otra nsferas e [ A L T]), re nal p a nel ( bl o o d 
urea nitr o ge n, creati ni ne), creati ne p h os p h o ki n ase ( C P K), al b u mi n, s o di u m, 
p otassi u m, ma g nesi u m, bicar b o nate, c hl ori de, calci u m, i n or ga nic p h os p h or us, 
gl uc ose, t otal pr otei n, al k ali ne p h os p hatase, t otal c h olester ol, uric aci d, ser u m 
a m ylase, a n d ser u m li pase.  
•  Uri nal ysis: nitrite, bl o o d, a n d pr otei n. If p ositi ve, micr osc o p y will be 
perf or me d;  
•  Vir ol o g y ( meas ur e d o nl y at scree ni n g a n d ma y be meas ure d at t he l ocal 
la b orat or y): he p atitis B s urface a nti ge n, h e patitis C a nti b o dies, HI V 1 a n d 2 
a nti b o dies. 
•  
T B scree n: interfer o n γ release assa y (I G R A).   
•  
Pre g na nc y test: ser u m pre g na nc y test  
All la b orat or y val ues will be c o n verte d t o I nter nati o nal S yste m of U nits ( SI u nits). 
La b res ults will be gra d e d b y t he l o w/ n or mal/ hi g h classificati o ns base d o n n or mal 
ra n ges. 
La b orat or y dat a  (act ual val ues  a n d c ha n ge fr o m baseli ne)  will  be s u m marize d 
wit h t he mea n, sta n dar d de viati o n a n d me dia n b y treat me nt gr o u p a n d st u d y 
visit.  La b orat or y data  will  be liste d b y treat me nt gr o u p, s u bject, a n d st u d y visit.  
T he C T C A E  gra des will be pr o vi de d f or selecte d La b para meters. A b n or mal 
la b orat or y val ues  will  be fla g ge d. 
T he s u bject i nci de nce of ele vate d la b orat or y val ues of A L T, A S T, t otal bilir u bi n, 
al kali ne p h os p hatase as assesse d b y t he Ce ntral La b orat or y, will be s u m marize d  
b y treat me nt gr o u p a n d Gra de, as defi ne d per C o m m o n Ter mi n ol o g y Criteria f or 
A d verse E ve nts  ( C T C A E) Versi o n 5. S hift fr o m baseli ne t o hi g hest C T C A E 
gra de d uri n g t he st u d y peri o d  will  als o be pr o d uce d f or t hese la b orat or y 
para meters base d o n t he Ce ntral La b orat or y meas ure me nts.  
T he sa me s u m mar y b y treat me nt a n d C T C A E gra de will be pr o d uce d f or s u bject 
i nci de nce of ele vate d creati ne p h os p h o ki nase ( C P K), l o w ne utr o p hils, l o w 
l y m p h ocytes, l o w le u k oc ytes, l o w  he m o gl o bi n, a n d l o w platelets. S hift fr o m 
baseli ne t o hi g hest C T C A E gra de d uri n g t he st u d y  peri o d will als o be pr o d uce d 
f or t hese la b orat or y para meters. A b y-s u bject listi n g i ncl u di n g all data f or t hese 
la b orat or y para meters i ncl udi n g C T C A E gra de f or s u bjects wit h a n y a b n or malit y  
will be pr o vi de d 
P P D


 
C O N FI D E N TI A L  
Pa ge 5 3  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
Uri ne a n d ser u m pre g n a n c y test res ults  f or fe male o nl y, HI V scree ni n g res ults, 
He patitis B/ C scree ni n g res ults, a n d t u berc ul osis scree ni n g res ults will be 
liste d. 
  
  
 
C.  
Vit al Si g ns  
 
T he f oll o wi n g vital si g ns varia bles will be s u m marize d: s yst olic bl o o d press ure 
( m m H g), diast olic bl o o d press ure ( m m H g), te m perat ure (° C) a n d heart rat e 
( beats/ mi n) a n d wei g ht ( k g). T he f oll o wi n g s u m maries will be pr o vi de d: 
•  A s u m mar y of t he a bs ol ute a n d c ha n g e fr o m Bas eli ne val ue f or eac h vital si g n 
varia ble b y tr eat me nt gr o u p, visit , a n d peri o d. 
•  A s u m mar y of t he n u m ber a n d perce nta g e of s u bjects e x perie n ci n g at least o ne 
P ote ntiall y Cli nicall y Si g nifica nt Vital Si g n Fi n di n gs  b y treat me nt gr o u p a n d 
visit . 
Defi niti o ns of P ote nti all y Cli nic all y Si g nific a nt Vit al Si g n Fi n di n gs  
 
Para meter 
( u nit) 
Cate g or y  
Mar ke dl y A b n or m al Val ues  
S yst olic 
Bl o o d 
Press ure 
( m m H g) 
L o w 
Val ue  
≤ 9 0 m m H g or decrease ≥ 2 0 m m H g fr o m 
Baseli ne  
Hi g h 
Val ue  
≥1 8 0 m m H g or i ncreas e ≥ 2 0 m m H g fr o m 
Baseli ne  
Diast olic 
Bl o o d 
Press ure 
( m m H g) 
L o w 
Val ue  
≤ 5 0 m m H g or decrease ≥ 1 5 m m H g fr o m 
Baseli ne  
Hi g h 
Val ue  
≥1 0 5 m m H g or i ncreas e ≥ 1 5 m m H g fr o m 
Baseli ne  
Heart Rate  
( b p m) 
L o w 
Val ue  
≤ 5 0 b p m or decrease ≥ 1 5 b p m fr o m 
Baseli ne  
Hi g h 
Val ue  
≥ 1 2 0 b p m or i ncreas e ≥ 1 5 b p m fr o m 
Baseli ne  
A b y -s u bject listi n g of all vital si g ns data will be pr o vi de d. T his listi n g will be 
prese nte d b y tr eat me nt gr o u p wit h a b n or mal vital si g n val ues fla g ge d as “ L” or 
“ H” acc or di n gl y. 
 
D.  
1 2- Le a d Electr oc a r di o gr a m ( E C G)  
 
E C G res ults will be liste d i n t he data listi n gs. A b n or mal E C G fi n di n gs will be 
liste d b y treat me nt gr o u p a n d st u d y visit, a n d cli nical si g nifica nce of a b n or malities 
i n dicate d.  
 
 
E.  
P h ysic al E x a mi n ati o n 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 5 4  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
P h ysical e xa mi nati o n will i ncl u de assess me nt of a p peara n ce/ me ntal stat us, hea d, 
e yes, ears, n ose, t hr o at, a n d t he f oll o wi n g b o d y s yste ms: der mat ol o gic, 
car di o vas c ular, r es pirat or y, gastr oi ntesti nal, m usc ul os keletal a n d ne ur ol o gic.  
 
A listi n g will be pr o vi de d f or p h ysical e x a mi nati o n fi n di n gs (i.e., n ormal or 
a b n or mal a n d w h et her eac h a b n or malit y was cli nicall y si g nifica nt) b y treat me nt, 
visit, b o d y s yste m. 
 
F.  
P h ar m ac o ki netic A n al ysi s 
 
Sa m ple C ollecti o ns  
 
P K bl o o d sa m ple will be c ollecte d pri or t o t he m or ni n g d ose o n Da y 1 a n d at 0. 5, 
1, 2, a n d 3 ( +/- 5 mi n utes) h o urs ( per pr ot oc ol 1 9 Oct o ber 2 0 1 8 a n d a me n d me nt 
2. 0) or at 0. 5, 1, 2, 3, a n d 6 ( +/- 5 mi n utes) h o urs ( per pr ot oc ol 1 9 O ct o ber 2 0 1 8 
a n d a me n d me nt 1. 0) f oll o wi n g d osi n g . Si n gle P K sa m ples will be c ollecte d pre-
d osi n g at t he s u bse q ue nt visits at Wee ks 2, 4, 8, 1 2, 1 6, 2 0, 2 8, 3 6, a n d 4 4. T he 
date a n d ti me of t he P K s a m ple c ollecti o n will be rec or de d. T he dat e a n d ti me of 
t he last d ose of st u d y dr u g pri or t o t he P K sa m ple c ollecti o n will als o be rec or de d.  
 
F or plas ma c o nce ntr ati o ns a n d P K para met ers  of a vac o pa n ( C C X 1 6 8) or 
meta b olite  M 1 , descri pti ve statistics will i ncl u de t he n u m ber of v al ues, arit h metic 
mea n, sta n dar d d e viati o n, a n d c oefficie nt of v ariati o n ( C V %), ge o metric m ea n 
( G M), C V % G M a n d 9 0 % c o nfi de n ce i nter v als, mi ni m u m, me dia n, a n d ma xi m u m. 
 
Data A sse m bl y 
T he  c o nce ntr ati o n  data of a vac o pa n   a n d met a b olite  M 1  as  re p orte d  b y  t he 
bi oa nal ytical la b orat or y will be use d wit h o ut r o u n di n g f or all a nal ysis.  
S u bjects wit h maj or pr ot oc ol de viati o n s uc h as P K de viati o n or c o m plia n ce iss ues 
ma y be e xcl u de d fr o m t he P K a nal yses (i.e. , descri pti ve statistics) u p o n a gree me nt 
wit h t he S p o ns or o n a case– b y- cas e basis b ut all data will be liste d. Val ues t hat are 
e xcl u de d fr o m t he a nal ysis will be f o ot n ote d a p pr o priatel y. 
 
T he f oll o wi n g ge n eral r ules will a p pl y f or ha n dli n g missi n g data or c o nce ntrati o n 
bel o w t he l o wer li mit of q ua nt ificati o n ( B L Q):  
•  All B L Qs  will be set t o “ 0” f or D a y 1 visit.  
•  If t he B L Q occ urs bet w ee n 2 q ua ntifia bl e dr u g c o nce ntrati o ns wit hi n a f ull 
P K pr ofile f or D a y 1 visi t, t he B L Q is e xcl u de d fr o m all P K assess me nts. 
•  All B L Q will n ot be i m p ute d f or P ost -Da y 1 Visits a n d will be e x cl u de d fr o m 
t he descri pti ve s u m mar y. 
P P D


 
C O N FI D E N TI A L  
Pa ge 5 5  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
•  Missi n g pre- d ose c o nce ntr ati o ns o n Da y 1 will be set as “ 0” a n d i ncl u de d i n 
P K e val uati o n  
•  Missi n g p ost -d ose val ues o n Da y 1 or missi n g tr o u g h val ues f or p ost -D a y 1 
visits will n ot be i m p ute d a n d will be e xcl u de d fr o m P K e val uati o n  
•  Val ues t hat are e xcl u de d fr o m t he a nal ysis will b e d oc u me nte d a p pr o priatel y.  
•  Pre -d ose  v al ues  o n  Da y  1  t hat  are  greater  t h a n  5 %  of  C ma x  will  be 
d oc u me nte d.  A  se nsiti vit y  a nal ysis  ( wit h  i ncl usi o n  a n d  e x cl usi o n  of  t he 
s u bjects wit h t he pre-d ose c o nce ntrati o n > 5 % of C ma x ) will be prese nte d a n d 
d oc u me nte d i n t he st u d y re p ort. 
 
T he sa m ple ti me of t he pre -d ose s a m ples o n Da y 1 will be u nif or ml y c o nsi dere d as 
ti me “ 0”.  
F or D a y 1 visit, i n di vi d ual P K pl ots or i n di vi d ual P K para meters, si nce t here is n o 
c ollecti o n wi n d o w s pecifie d f or p ost- d ose P K sa m pli n g, will b e base d o n act ual 
ti mes rec or de d.  F or c o nce ntrati o n vers us ti me des cri pti ve statistical s u m maries 
a n d mea n pl ot pre p arati o n, n o mi nal ti me p oi nts will be use d. If t he differe n ce of 
p ost- d ose sa m pli n g ti me is >  5 mi n utes fr o m t he n o mi nal sa m pli n g ti mes f or ti me 
p oi nts < 2 h o urs or > 5 % f or ti me p oi nts ≥2 h o urs, t he c orres p o n di n g c o nce ntrati o n 
data will be e xcl u d e d fr o m t he c o nce ntrati o n s u m mar y a n d mea n pl ot pre p arati o n, 
b ut will still be use d i n t he i n di vi d ual pl ots a n d t he calc ulati o n of P K para m eter. 
F or  D a y  1  visit,  if  t h e  pre -d ose  P K  s a m ple  is  c ollecte d  after  d osi n g,  t he 
c orres p o n di n g c o n ce ntrati o n will be treate d as a p ost -d ose val ue a n d will be use d 
f or i n di vi d ual pl otti n g a n d P K para meter cal c ulati o n.  
P ost- Da y 1 a vac o p a n  a n d its meta b olite M 1  plas ma c o nce ntrati o n res ults will be 
use d t o calc ulate tr o u g h plas ma c o nce ntrati o ns ( C mi n ) o ver t he c o urse of t he cli nical 
trial.  
F or p ost -D a y 1 visits (i.e. Wee ks 2, 4, 8, 1 2, 1 6, 2 0, 2 8, 3 6, a n d 4 4), t he all o wa ble 
ti me wi n d o w f or P K sa m pli n g is ± 3 h o urs (i.e. 2 5 % of d osi n g i nter val of 1 2 h o urs) 
f or  Cmi n .  If  t he  e xact  ti me  ( meas ure d  fr o m  d osi n g)  is  o utsi de  of  t he  c ollecti o n 
wi n d o w, t here is n o d osi n g ti me, or t here is a c o m plia nce  iss ue, t he c orres p o n di n g 
c o nce ntr ati o n will be e x cl u de d fr o m tr o u g h c o nce ntrati o n v ers us ti me des cri pti ve 
statistical  s u m maries  a n d  me dia n  pl ot  pre parati o n,  b ut  will  still  be  use d  i n  t he 
i n di vi d ual pl ots.   
N o n -n u merical  rea d o uts  e xce pt  B L Q  [e. g. , N A  ( n ot  a vaila ble)  or  N R E  ( n ot 
relia ble)] will be set as missi n g a n d will n ot be i ncl u de d in t he P K e val uati o n. 
 
P har mac o ki netic C o nce ntrati o n  
F or s u bjects wit h serial sa m ples c ollecte d o n D a y 1: 
I n di vi d ual plas ma c o nce ntrati o ns of a vac o pa n  a n d its meta b o lite M 1  will be liste d, 
pl otte d, a n d s u m marize d descri pti vel y a n d gra p hicall y b y treat me nt gr o u p. 
P P D


 
C O N FI D E N TI A L  
Pa ge 5 6  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
•  I n di vi d ual  plas m a  c o n ce ntrati o ns  of  a vac o pa n  a n d  its  meta b olite  M 1  will  be 
pl otte d  o n  a  li near  a n d  se mi -l o garit h mic  scale  a gai nst  act ual  sa m pli n g  ti me 
p oi nts;  
•  C o nce ntrati o n data will b e s u m marize d b y treat me nt at eac h n o mi nal ti me p oi nt 
descri pti vel y;  
•  Mea n ( ± S D) plas ma c o n ce ntrati o ns of a v ac o pa n a n d its meta b olite M 1 will be 
pl otte d o n a li near a n d s e mi -l o garit h mic scale a g ai nst n o mi nal ti me p oi nts b y 
treat me nt. 
F or  s u bjects wit h pr e-d os e sa m ple c ollect e d o n P ost- Da y 1 visits: 
•  I n di vi d ual  plas m a  c o n ce ntrati o ns  of  a vac o pa n  a n d  its  meta b olite  M 1  will  be 
pl otte d b y treat me nt o n a li near scal e a gai nst visits;  
•  Tr o u g h c o nce ntrati o n dat a, wit hi n all o wa ble ti me wi n d o ws, will  be s u m marize d 
b y treat me nt at eac h visit descri pti vel y.  
•  I n a d diti o n, me dia n tr o u g h c o nce ntrati o ns ( C mi n ) of a vac o p a n a n d its 
meta b olite M 1 will be pl otte d o verlai d wit h t he scatter pl ot of i n di vi d ual 
tr o u g h c o nce ntr ati o ns b y treat me nt o n a li near scal e a gai nst visits. 
F or s u bjects w h o recei ve d acti ve treat me nt i n Peri o d 1, t his pl ot will i ncl u de 
visits i n b ot h Peri o d 1 a n d Peri o d 2. 
•  T he a ver a ge stea d y stat e tr o u g h c o nce ntrati o n of a v ac o pa n  or its meta b olite M 1 
f or eac h i n di vi d ual s u bject will be calc ulate d f or a t o- be-d efi ne d  stea d y-state 
ti me peri o d (eac h s u bject nee ds t o ha v e at least 3 ti me p oi nts i n t his stea d y st ate 
peri o d f or t he calc ulati o n). T he gl o bal a vera ge stea d y state tr o u g h c o nce ntrati o n 
of a vac o p a n  or its meta b olite M 1 will be liste d a n d s u m marize d descri pti vel y.  
•  F or s u bjects w h o r ecei ve d place b o i n Peri o d 1 ( Wee k 1 t hr o u g h Wee k 1 2), t he 
Peri o d  2  c o nce ntrati o n  data  ( Wee k  1 6  t hr o u g h  Wee k  3 6)  will  be  a nal yze d 
se parat el y fr o m t he s u bjects w h o recei ve d acti ve treat me nt i n Peri o d 1. 
 
P har mac o ki ne tic Par a meter 
P K a nal ysis will be perf or me d i n t he P K p o p ulati o n. T he f oll o wi n g para m eters f or 
a vac o p a n ( C C X 1 6 8) or meta b olite M 1  will be deter mi ne d, w here p ossi ble: 
•  C ma x  
Ma xi m u m plas ma c o nce ntrati o n  
•  T ma x  
Ti me of ma xi m u m plas ma c o nce ntrati o n  
•  A U C 0- 3 h  Area u n d er t he plas ma c o nce ntrati o n -ti me c ur ve fr o m Ti me 0        
                 t o H o ur 3 o n Da y 1 
•  A U C 0- 6 h Area u n d er t he plas ma c o nce ntrati o n -ti me c ur ve fr o m Ti me 0        
                 t o H o ur 6 o n Da y 1 
•  C mi n   
Tr o u g h le vel plas ma c o n ce ntrati o ns at p ost-D a y 1 visits  
P P D


 
C O N FI D E N TI A L  
Pa ge 5 7  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
P K para meter cal c ulati o ns will be base d o n c o nti n u o us ti me p oi nts fr o m Da y 1 
(i ncl u di n g Ti me 0).  
Plas ma P K para meters will be calc ulate d b y sta n d ar d n o n -c o m p art me ntal a nal ysis. 
T he act ual c ollecti o n ti mes will be use d f or P K para meter calc ulati o n. T h e li n ear 
tra pez oi dal r ule met h o d (e q ui vale nt t o t he Li near Tra pez oi dal Li near I nter p olati o n 
i n Wi n N o nli n ® Pr ofessi o nal) will be use d i n t he c o m p utati o n of A U Cs. 
P K para meters will be liste d a n d s u m marize d b y treat me nt descri pti vel y.  
T he deri ve d P K p ara met ers  ( Cma x , A U C, Tma x  a n d Cmi n ) will be r o u n de d t o t hree 
si g nifica nt di gits. 
T he relati o ns hi p bet wee n P K para meters a n d efficac y e n d p oi nts s uc h as Hi S C R 
ma y als o be e val u ate d.  
 
G.  
Bi o m ar ker Assess m e nts  
A s u m mar y of t he a bs ol ute a n d c ha n g e fr o m Bas eli ne val ue f or eac h a vaila ble 
bi o mar ker varia ble will b e prese nt e d b y treat me nt gr o u p, visit, a n d peri o d. 
A listi n g will be pr o vi de d f or s u bjects w h o ha v e bi o mar ker ass ess me nts. 
 
H.  
P h ot o gr a p hic Assess me nts  
 
A lis ti n g will be pr o vi de d f or s u bjects w h o recei ve d p h ot o gra p h y b y visit. 
 
I. 
S u p ple m e nt ar y A n al yses Rel ate d t o C O VI D - 1 9 
 
I n or d er t o descri b e t he i m pact of C O VI D-1 9 o n t he c urre nt st u d y, t he f oll o wi n g will 
be s u m marize d i n t he ta bles /listi n gs: 
•  S u bjects disc o nti n ue d fr o m t he st u d y d ue t o  C O VI D - 1 9 relate d o n t he st u d y e xit 
f or m.  
•  A d d a ne w ta bl e f or pr ot oc ol de viati o ns d ue t o C O VI D - 1 9. 
•  A d d i nf or mati o n f or T E A E  ( C O VI D- 1 9) i n O verall A E s u m mar y ta ble. 
•  S u bjects  wit h  st u d y  visits  misse d  or  altere d  (i ncl u di n g  h o me healt h  visit, 
p h o ne/ vi de o  c o nf ere n ci n g,  ot her)  d ue  t o  C O VI D - 1 9. T his  ma y  i ncl u de  altere d  or 
ca ncelle d st u d y visits a n d data c ollecti o ns beca use of a te m p orar y st u d y site cl os ure 
d uri n g certai n ti me peri o ds of t he C O VI D - 1 9 p a n de mic.  
•  A n a d diti o nal se nsiti vit y a nal ysis of t he pri mar y e n d p oi nt will be perf or me d i n 
t he I T T p o p ulati o n base d o n t he L O C F a n d N RI i m p utati o n met h o d.  
o  L O C F: F or a n y wee k 1 2  assess me nts perf or me d via altere d st u d y visits  or 
missi n g d ue t o C O VI D 0 1 9, last pri or u naffecte d lesi o n assess me nt will b e 
carri e d f or w ar d t o wee k 1 2, 
P P D


 
C O N FI D E N TI A L  
Pa ge 5 8  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
o  N RI: i m p ute  a n y wee k 1 2  assess me nts perf or me d via altere d st u d y visits  or 
missi n g d ue t o C O VI D 0 1 9 as n o n-res p o n d ers. 
 
 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 5 9  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
X.  
C h a n ges fr o m t he Pr ot oc ol Pl a n ne d A n al yses 
 
T h e f oll o wi n g c ha n g es fr o m t he pr ot oc ol pla n ne d a nal yses are n ote d i n t his pla n: 
 
 
C h a n ges  
 
Pr ot oc ol  
 
S A P  
U p date d A d verse 
E ve nts of S pecial 
I nterest ( A E SI) 
defi niti o n  
Pa ge 6 3:  
7. 2. 3. 3. A d verse E ve nts of S pecial 
I nterest ( A E SI) 
T he f oll o wi n g fi n di n gs, as defi ne d 
bel o w, m ust be re p orte d as A Es a n d 
will be c o nsi dere d a d verse e ve nts of 
i nterest ( A E SI): 
I nfecti o ns:  
F or me dicall y i m p orta nt i nfecti o ns, t he 
or ga nis ms i n v ol ve d i n t he i nfecti o n 
nee d t o be deter mi ne d w he ne ver 
p ossi ble a n d be d oc u me nte d i n t he 
E D C. All l ocal a n d nati o nal 
vacci nati o n rec o m me n dati o ns s h o ul d 
be f oll o we d.  
He patic Tra nsa mi nase Ele vati o n:  
• Gra de 3 or greater i ncrease d A L T or 
A S T ( > 5 ti mes t he u p per li mit of 
n or mal)  
• Gra de 2 or greater i ncrease d A L T or 
A S T ( > 3 ti mes t he u p per li mit of 
n or mal) wit h ele vati o n of  bilir u bi n t o 
> 2 ti mes t he u p per li mit of n or mal or 
I N R > 1. 5 
Ne utr o pe nia, L y m p h o pe nia, a n d 
Le u o k o pe nia:  
• Gra de 3 or greater ne utr o pe nia ( < 1 x 
1 0 9/ L)  
• Gra de 4 l y m p h o pe nia  ( < 0. 2 x 1 0 9/ L) 
• Gra de 3 or greater le u k o pe nia ( W B C 
c o u nt < 2 x 1 0 9/ L) 
Creati ne P h os p h o ki nase Ele vati o n:  
• Gra de 3 or greater C P K i ncrease ( > 5 
ti mes t he u p per li mit of d osi n g) 
H y perse nsiti vit y Reacti o ns:  
• urticaria  
• a n gi oe de ma 
Mali g na ncies:  
• A n y mali g na ncies will be re p orte d as 
A Es.  
H S Lesi o n I nter ve nti o ns:  
• Lesi o n i nter ve nti o ns as descri be d i n 
Secti o n 5. 7 will be rec or de d as A E.  
A d verse E ve nts of S pecial I nterest 
( A E SI) i ncl u de i nfecti o ns, he patic 
e nz y me ele vati o ns, ne utr o pe nia a n d 
l y m p h o pe nia, 
h y perse nsiti vit y/a n gi oe de ma, creati ne 
p h os p h o ki nase ele vati o n, 
mali g na ncies, a n d H S Lesi o n 
i nter ve nti o ns. 
 
I nfecti o ns: T he s u bject i nci de nce of 
i nfecti o ns, seri o us i nfecti o ns, se vere 
i nfecti o ns (i.e., Gra de 3 +), a n d 
i nfecti o ns lea di n g t o s u bject 
wit h dra wal fr o m t he st u d y will be 
s u m marize d b y treat me nt gr o u p. 
I nfecti o ns will be i de ntifie d b y 
selecti n g ter ms wit h t he A d verse 
E ve nt S yste m Or ga n Class of 
‘I nfecti o ns a n d I nfestati o ns’.  
 
He p atic tr a ns a mi n ase ele v ati o ns :   
T he f oll o wi n g la b a b n or malities will be 
i ncl u de d i n t his cate g or y: 
•  
Gra de 3 or greater i ncrease d 
A L T or A S T ( > 5 ti mes t he 
u p per li mit of n or mal)  
•  
Gra de 2 or greater i ncrease d 
A L T or A S T ( > 3 ti mes t he 
u p per li mit of n or mal) wit h 
ele vati o n of bilir u bi n t o > 2 
ti mes t he u p per li mit of 
n or mal or I N R > 1. 5  
 
Ne utr o pe ni a, l y m p h o pe ni a a n d 
le u k o pe ni a:  
T he f oll o wi n g la b a b n or malities wil l be 
i ncl u de d i n t his cate g or y: 
•  
Gra de 3 or greater 
ne utr o pe nia ( < 1 x 1 0 9/ L)  
•  
Gra de 4 l y m p h o pe nia ( < 0. 2 x 
1 0 9/ L)  
•  
Gra de 3 or greater le u k o pe nia 
( W B C c o u nt < 2 x 1 0 9/ L) 
 
P P D


 
C O N FI D E N TI A L  
Pa ge 6 0  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
H y perse nsiti vit y re acti o ns:  T he 
s u bject i nci de nce of a d verse e ve nts 
ass ociate d wit h 
h y perse nsiti vit y/a n gi oe de ma a n d 
urticaria will be s u m marize d b y 
treat me nt gr o u p. Ter ms will be base d 
o n t he Sta n dar dize d Me d D R A Q uer y 
f or h y perse nsiti vit y.  
Cre ati ne P h os p h o ki n ase Ele v ati o n : 
Gra de 3 or greater C P K 
i ncrease ( > 5 ti mes t he u p per 
li mit of n or mal) 
M al i g n a ncies: A n y mali g na ncies will 
be re p orte d as A Es.  
H S Lesi o n I nter ve nti o ns: Lesi o n 
i nter ve nti o ns d ue t o H S  will be 
rec or de d i n C P. 
T he ha n dli n g of 
m ulti plicit y iss ues has 
bee n m o difie d   
Pa ge 6 7:  
T o a d dress t he m ulti plicit y iss ue wit h 
t w o d ose gr o u ps, a fi xe d hierarc hical 
testi n g se q ue nce will be e m pl o ye d. 
T he h y p ot hesis testi n g will test t he 
a vac o pa n 3 0 m g vs. place b o first. If 
t he test is si g nifica nt at t he α = 0. 0 5 
le vel, t he a vac o pa n 1 0 m g vs. place b o 
will be teste d at t he α = 0. 0 5 le vel. If  
t he test of a vac o pa n 3 0 m g vs. place b o 
is n ot si g nifica nt at t he α = 0. 0 5 le vel, 
t he a vac o pa n 1 0 m g vs. place b o will 
be teste d as a n e x pl orat or y a nal ysis.  
F or t he pri mar y  efficac y e n d p oi nt 
testi n g, t he a vac o pa n 3 0 m g vs. 
place b o i n Hi S C R ( H 1 1) a n d t he 
a vac o pa n 1 0 m g vs. place b o i n Hi S C R 
( H1 2), a hierarc hical pr oce d ure will be 
use d t o c o ntr ol t he o verall α at 0. 0 5 
le vel. 
T hat is if H 1 1 is rejecte d at a 2-si de d 
al p ha le vel of 0. 0 5, t he n t he H1 2 will 
be teste d at 2 -si de d al p ha le vel of 0. 0 5.   
F or sec o n dar y efficac y e n d p oi nt 
testi n g, t he a vac o pa n 3 0 m g vs. 
place b o or t he a vac o pa n 1 0 m g vs. 
place b o will be teste d se paratel y wit h 
t he α = 0. 0 5 le vel, pr o vi de d t hat t he 
c orres p o n di n g pri mar y e n d p oi nt testi n g 
of t he sa me d ose le vel is si g nifica nt.  
As t he t w o dr u g d oses are t w o 
i n de pe n de nt fa milies. A n d t he o utc o me 
of t he st u d y is t o select o ne d ose, n ot 2 
d oses.  A fi xe d hierarc hical testi n g 
se q ue nce will be e m pl o ye d. 
T he pri mar y a nal ysis 
p o p ulati o n ’s na me has 
bee n c ha n ge d  fr o m 
mI T T t o I T T  
Pa ge 6 8:  
M o difie d I nte nt -t o-Treat ( mI T T) 
P o p ulati o n  
 
 
I nte nt-t o-Treat (I T T) P o p ulati o n  
Defi niti o ns of I T T, 
Safet y a n d Per Pr ot oc ol 
P o p ulati o ns.  
Pa ge 6 8:  
 
 
I nte nt-t o-Tre at P o p ul ati o n  
T he I nte nt -t o-Treat (I T T) P o p ulati o n 
will i ncl u de all s u bjects w h o are 
P P D


 
C O N FI D E N TI A L  
Pa ge 6 1  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
8 . 4. 1 M o difie d I nte nt -t o-Tre at 
P o p ul ati o n  
F or t he p ur p oses of efficac y data 
a nal ysis, t he M o difie d I nte nt-t o-Treat 
( mI T T) p o p ulati o n will be use d. T his 
p o p ulati o n will i ncl u de all s u bjects 
w h o are ra n d o mize d a n d recei ve d at 
least o ne d ose of st u d y dr u g. T he 
efficac y p o p ulati o n will be a nal yze d 
acc or di n g t o t he treat me nt gr o u p eac h 
s u bject is ra n d o mize d t o. T he mI T T 
p o p ulati o n will be t he pri mar y a nal ysis 
p o p ulati o n f or t he efficac y a nal ysis.  
T he mI T T p o p ulati o ns are defi ne d f or 
t he t w o treat me nt peri o ds as t he 
f oll o wi n g: 
•  
T he mI T T 1 P o p ulati o n i n 
Peri o d 1 is defi ne d as all 
s u bjects w h o are 
ra n d o mize d at baseli ne 
a n d ha ve recei ve d at least 
o ne d ose of st u d y dr u g 
d uri n g Peri o d 1.  
•  
T he mI T T 2 P o p ulati o n i n 
Peri o d 2 is defi ne d as all 
s u bjects w h o ha ve 
recei ve d at least o ne d ose 
of st u d y dr u g d uri n g 
Peri o d 2.  
8. 4. 2    Per -Pr ot oc ol P o p ul ati o n  
T he Per -Pr ot oc ol ( P P) p o p ulati o n will 
c o nsist of all ra n d o mize d s u bjects w h o 
recei ve at least o ne d ose of st u d y dr u g 
a n d d o n ot ha ve pr ot oc ol de viati o ns 
t hat c o ul d si g nifica ntl y affect t he 
i nter pretati o n of t he res ults f or t he 
pri mar y e n d p oi nts. S u bjects’ 
i nclusi o n/e xcl usi o n fr o m t he P P 
p o p ulati o n will be deter mi ne d a n d 
d oc u me nte d pri or t o t he data base l oc k 
a n d u n bli n di n g. 
8. 4. 3     S afet y P o p ul ati o n  
ra n d o mize d a n d ha ve recei ve d at least 
o ne d ose of st u d y dr u g, a n d w h o are 
n ot fr o m st u d y Site 1 3 8. S u bjects fr o m 
Site 1 3 8 will be e xcl u de d fr o m t he I T T 
P o p ulati o n d ue t o p ote ntial misc o n d uct 
a n d n o n -c o m plia nce at site 1 3 8 . 
T he I T T p o p ulati o ns are defi ne d f or 
t he t w o treat me nt peri o ds as t he 
f oll o wi n g: 
•  
T he I T T 1 P o p ulati o n i n 
Peri o d 1 is defi ne d as all s u bjects w h o 
are ra n d o mize d at baseli ne a n d ha ve 
recei ve d at least o ne d ose of st u d y 
dr u g d uri n g Peri o d 1.  
•  
T he I T T 2 P o p ulati o n i n 
Peri o d 2 is defi ne d as all s u bjects w h o 
ha ve recei ve d at least o ne d ose of 
st u d y dr u g d uri n g Peri o d 2. 
Per Pr ot oc ol P o p ul ati o n  
T he per pr ot oc ol ( P P) p o p ulati o n f or 
peri o d 1 will c o nsist of I T T 1 a n d d o 
n ot ha ve pr ot oc ol de viati o ns t hat c o ul d 
si g nifica ntl y affect t he i nter pretati o n of 
t he res ults f or t he pri mar y e n d p oi nts. 
S u bjects’ i ncl usi o n/e xcl usi o n fr o m t he 
P P p o p ulati o n will be deter mi ne d a n d 
d oc u me nte d pri or t o t he data base l oc k 
a n d u n bli n di n g.  
Per -Pr ot oc ol P o p ulati o n i n Peri o d 1 
( P P 1) will i ncl u de s u bjects i n I T T 1 
w h o meet all t he f oll o wi n g criteria:  
–  
Recei ve at least 7 0 % of t he 
pla n ne d st u d y dr u g i n Peri o d 1 f or 
s u bjects w h o c o m plete Peri o d 1 or 
recei ve at least o ne d ose of st u d y dr u g 
a n d disc o nti n ue Peri o d 1  
–  
Pr o vi de at least o ne p ost 
Baseli ne assess me nt o n lesi o n c o u nt  
–  
Meet t he H url y sta ge II: T otal 
S C A R a n d Fist ula c o u nts > 0 at eit her 
scree ni n g or Da y 1. 
–  
Ha ve Baseli ne A N c o u nt ≥ 3  
–  
Ha ve Baseli ne drai ni n g fist ula 
c o u nt ≤ 2 0 
P P D


 
C O N FI D E N TI A L  
Pa ge 6 2  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
T he  Safet y P o p ulati o ns are defi ne d as 
t he f oll o wi n g: 
•  
T he Safet y P o p ulati o n i n 
Peri o d 1 is defi ne d as all 
s u bjects w h o are 
ra n d o mize d at baseli ne 
a n d ha ve recei ve d at least 
o ne d ose of st u d y dr u g 
d uri n g Peri o d 1.  
•  
T he Safet y P o p ulati o n i n 
Peri o d 2 is defi ne d as all 
s u bjects w h o recei ve d at 
least o ne d ose of 
a vac o pa n d uri n g Peri o d 
2.  
•  
T he All A vac o pa n 
Treate d P o p ulati o n  is 
defi ne d as all s u bjects 
w h o recei ve at least o ne 
d ose of a vac o pa n i n a n y 
treat me nt peri o d. 
T he Safet y P o p ulati o ns will be 
a nal yze d acc or di n g t o t he assi g ne d 
treat me nt gr o u p. I n t he e ve nt t hat a 
s u bject recei ves a treat me nt re gi me n 
t hat d oes n ot c orres po n d t o t he 
assi g ne d treat me nt, t he s u bject will be 
i ncl u de d i n t he a nal ysis gr o u p of t he 
treat me nt act uall y recei ve d. 
 
–  
D o n ot ta ke t he f oll o wi n g 
e xcl usi o nar y me dicati o ns d uri n g t he 
e xcl usi o nar y scree ni n g peri o d or 
d uri n g Peri o d 1:  
–  
A n y c o nc o mita nt a nti bi o tics 
f or t he treat me nt of H S (e xce pt t he 
pr ot oc ol all o we d resc ue me dicati o n 
w hic h will res ult i n c o u nti n g t he 
s u bjects as n o n-res p o n ders, or ha vi n g 
t he last o bser vati o n pri or t o t he use of 
t hese treat me nts carrie d f or war d). 
–  
A nti -T N F -a ( H u mira), 
Met h otre xat e ( M T X), c ycl os p ori n, 
c ortic oster oi ds, a n d reti n oi ds f or a n y 
reas o n, or ot her me dicati o n f or 
treat me nt of t heir H S t hat will 
c o nf o u n d t he efficac y e val uati o n (t o be 
deter mi ne d a n d d oc u me nte d i n t he 
classificati o n res ults pri or t o bli n d 
brea k).  
 
Per -Pr ot oc o l P o p ulati o n i n Peri o d 2 
( P P 2) will be defi ne d se paratel y. 
S u bjects i ncl u de d i n t he Per -Pr ot oc ol 
P o p ulati o n will be a nal yze d as treate d.  
T hat is, if a s u bject recei ves t he 
treat me nt t hat is n ot t he ra n d o mize d 
assi g n me nt d uri n g t heir e ntire 
partici pati o n o f a peri o d, t he s u bject 
will be a nal yze d acc or di n g t o t he 
treat me nt t hat t he s u bject act uall y 
recei ve d i n t he peri o d. 
 
S afet y P o p ul ati o n  
T he Safet y P o p ulati o n will i ncl u de all 
s u bjects w h o are ra n d o mize d a n d ha ve 
recei ve d at least o ne d ose of st u d y 
dr u g, e xcl u di n g t h ose s u bjects w h o are 
fr o m st u d y Site 1 3 8. D ue t o t he 
reas o ns state d a b o ve safet y data of 
s u bjects fr o m site 1 3 8, i ncl u di n g 
a d verse e ve nts, will be liste d 
se paratel y o nl y a n d n ot be i ncl u de d i n 
t he s u m mar y ta bles: 
•  
T he Safet y P o p ulati o n i n 
Peri o d 1 ( Safet y 1) is defi ne d as all 
s u bjects w h o are ra n d o mize d at 
P P D


 
C O N FI D E N TI A L  
Pa ge 6 3  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
b aseli ne a n d ha ve recei ve d at least o ne 
d ose of st u d y dr u g d uri n g Peri o d 1.  
•  
T he Safet y P o p ulati o n i n 
Peri o d 2 ( Safet y 2) is defi ne d as all 
s u bjects w h o recei ve d at least o ne d ose 
of a vac o pa n d uri n g Peri o d 2.  
•  
T he All A vac o pa n Treate d 
P o p ulati o n is defi ne d as all s u bjects 
w h o recei ve at least o ne d ose of 
a vac o pa n i n a n y treat me nt peri o d.  
T he Safet y P o p ulati o ns will be 
a nal yze d acc or di n g t o t he assi g ne d 
treat me nt gr o u p. I n t he e ve nt t hat a 
s u bject recei ves a treat me nt re gi me n 
t hat d oes n ot c orres p o n d t o t he 
assi g ne d treat me nt c o nsiste ntl y, t he 
s u bject will be i ncl u de d i n t he a nal ysis 
gr o u p of t he treat me nt act uall y 
recei ve d. 
 
A d di n g Ra n ke d 
Sec o n dar y E n d p oi nts  
Pa ge 6 9:  
•  
Sec o n dar y Efficac y E n d p oi nts  
Sec o n dar y efficac y e n d p oi nts 
i ncl u de: 
 
1.  Re d ucti o n of I H S 4 sc ore 
relati ve t o baseli ne at Wee k 
1 2;  
2.  Pr o p orti o n of s u bjects 
ac hie vi n g at least 3 0 % 
re d ucti o n a n d at least 1 u nit 
re d ucti o n fr o m Da y 1 i n t he 
s u bject’s gl o bal assess me nt of 
s ki n pai n ( N R S 30) i n s u bjects 
wit h a baseli ne N R S of at 
least 3, e val uate d at Wee k 1 2; 
wee kl y a vera ges of dail y pai n 
will be calc ulate d base d o n 
s u bjects’ dail y diar y 
rec or di n g of t he w orst pai n 
e x perie nce d i n t he pre vi o us 
2 4 h o urs;  
3.  C ha n ge fr o m Da y 1 t o Wee k 
1 2 i n t he m o difie d Sart ori us 
sc ore t o q ua ntif y t he se verit y 
c ha n ge of H S;  
 
T he f oll o wi n g sec o n dar y efficac y 
e n d p oi nts will be a nal yze d  acc or di n g t o 
t he ra n k or der as t he f oll o ws: 
1.  C ha n ge fr o m Baseli ne  i n t otal 
A N c o u nt at Wee k 1 2; 
2.  Pr o p orti o n of s u bjects 
ac hie vi n g at least 3 0 % 
re d ucti o n a n d at least 1 u nit 
re d ucti o n fr o m Baseli ne  i n 
t he s u bject’s gl o bal 
assess me nt of s ki n pai n 
( N R S 3 0) i n s u bjects wit h a 
Baseli ne  N R S of at least 3, 
e val uate d at Wee k 1 2; wee kl y 
a vera ges of dail y pai n w ill be 
calc ulate d base d o n s u bjects’ 
dail y diar y rec or di n g of t he 
w orst pai n e x perie nce d i n t he 
pre vi o us 2 4 h o urs;  
3.  Pr o p orti o n of s u bjects wit h 
baseli ne H urle y Sta ge II w h o 
ac hie ve d a n a bscess a n d 
P P D


 
C O N FI D E N TI A L  
Pa ge 6 4  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
4.  Pr o p orti o n of s u bjects wit h 
baseli ne H urle y Sta ge II w h o 
ac hie ve d a n a bscess a n d 
i nfla m mat or y n o d ule c o u nt of 
0, 1, or 2 at Wee k 1 2.  
 
i nfla m mat or y n o d ule c o u nt of 
0, 1, or 2 at Wee k 1 2 ; 
4.  Re d ucti o n of I H S 4 sc ore 
relati ve t o baseli ne at Wee k 
1 2 ; 
5.  C ha n ge fr o m Baseli ne  i n 
i nfla m mat or y n o d ule c o u nt at 
Wee k 1 2 ; 
6.  C ha n ge fr o m Baseli ne  i n 
a bscess c o u nt at Wee k 1 2 ; 
7.  C ha n ge fr o m Baseli ne  i n 
drai ni n g fist ula c o u nt at Wee k 
1 2 ; 
8.  C ha n ge fr o m Baseli ne  t o 
Wee k 1 2 i n t he m o difie d 
Sart ori us sc ore t o q ua ntif y t he 
se verit y c ha n ge of H S. 
A d de d ot her efficac y 
e n d p oi nts 
Pa ge 6 9  
•  
Ot her Efficac y E n d p oi nts  
T he f oll o wi n g efficac y e n d p oi nts will 
be a nal yze d fr o m Da y 1 t o eac h 
ti me p oi nt u p t o Wee k 4 4, w here 
a p plica ble: 
1.  Pr o p orti o n of s u bjects ac hie vi n g 
Hi S C R;  
2.  Pr o p orti o n of s u bjects ac hie vi n g at 
least 3 0 % re d ucti o n a n d at least 1 
u nit re d ucti o n fr o m Da y 1 i n 
s u bject’s gl o bal assess me nt of 
s ki n pai n ( N R S 3 0), i n s u bjects 
wit h a Da y 1 N R S of at least 3;  
3.  Pr o p orti o n  of s u bjects wit h 
baseli ne H urle y Sta ge II w h o 
ac hie ve d a n a bscess a n d 
i nfla m mat or y n o d ule c o u nt of 0, 
1, or 2;  
4.  C ha n ge fr o m Da y 1 i n 
i nfla m mat or y n o d ule c o u nt, 
a bscess c o u nt, drai ni n g fist ula 
c o u nt, a n d t otal A N c o u nt; 
 
•  Ot her Efficac y E n d p oi nts  
T he f oll o wi n g efficac y e n d p oi nts will 
be a nal yze d fr o m Baseli ne  t o eac h 
ti me p oi nt u p t o Wee k 4 4, w here 
a p plica ble: 
1.  Pr o p orti o n of s u bjects 
ac hie vi n g Hi S C R, Hi S C R 7 5, 
a n d Hi S C R 9 0; 
2.  Pr o p orti o n of s u bjects 
ac hie vi n g at least 3 0 % 
re d ucti o n a n d at least 1 u nit 
re d ucti o n fr o m Baseli ne  i n 
t he s u bject’s gl o bal 
assess me nt of s ki n pai n 
( N R S 3 0), i n s u bjects wit h a 
Baseli ne  N R S of at least 3;  
3.  Pr o p orti o n of s u bjects wit h 
baseli ne H urle y Sta ge II w h o 
ac hie ve d a n a bscess a n d 
i nfla m mat or y n o d ule c o u nt of 
0, 1, or 2;  
4.  C ha n ge fr o m Baseli ne  i n 
i nfla m mat or y n o d ule c o u nt, 
P P D


 
C O N FI D E N TI A L  
Pa ge 6 5  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
5.  C ha n ge fr o m Da y 1 i n t he 
Sart ori us sc ore, m o difie d Sart ori us 
sc ore, I H S 4 sc ore, a n d H S-P G A t o 
q ua ntif y t he se verit y c ha n ge of 
H S;  
6.  C ha n ge fr o m Da y 1 i n patie nt -
re p orte d o utc o mes: S F-3 6 v 2, E Q -
5 D -5 L, Hi S Q O L, a n d  D L QI;  
7.  Pr o p orti o n of s u bjects w h o 
e x perie nce d flare, defi ne d as a n at 
least 2 5 % i ncrease i n A N c o u nts 
wit h a mi ni m u m i ncrease of 2 A N 
lesi o ns relati ve t o Da y 1; 
8.  D urati o n of flare i n da ys 
(calc ulate d fr o m t he da y w he n 
flare is o bser ve d t o t he da y pri or 
t o t he o bser vati o n t hat flare is n o 
l o n ger prese nt; of n ote, t here 
c o ul d be m ulti ple peri o ds t hat 
flares are o bser ve d, i n w hic h case, 
t he t otal da ys fr o m t he m ulti ple 
peri o ds will be use d);  
9.  Pr o p orti o n of s u bjects w h o 
e x perie nce at least 2 5 % i ncrease 
i n drai ni n g fist ula c o u nts wit h a 
mi ni m u m i ncrease of 2 drai ni n g 
fist ula c o u nts relati ve t o Da y 1; 
1 0.  D uri n g Peri o d 2, Pr o p orti o n of 
s u bjects wit h a l oss of res p o nse 
( L O R), defi ne d as l oss of at least 
5 0 % of A N c o u nt i m pr o ve me nt 
ac hie ve d fr o m Da y 1 t o Wee k 1 2;  
1 1.  Ti me t o L O R d uri n g Peri o d 2;  
1 2.  Pr o p orti o n of s u bjects w h o 
recei ve d oral a nti bi otic resc ue 
t hera p y; 
1 3.  Pr o p orti o n of s u bjects w h o start 
disall o we d o pi oi d pai n t hera p y;  
1 4.  Pr o p orti o n of s u bjects w h o 
u n der g o lesi o n i nter ve nti o n d ue t o 
H S;  
a bscess c o u nt, n o n-
i nfla m mat or y c o u nt, drai ni n g 
fist ula, n o n-drai ni n g fist ula, 
t otal fist ula c o u nt, a n d t otal 
A N c o u nt;  
5.  % C ha n ge fr o m Baseli ne  i n 
i nfla mmat or y n o d ule c o u nt, 
a bscess c o u nt, n o n-
i nfla m mat or y c o u nt, drai ni n g 
fist ula, n o n-drai ni n g fist ula, 
t otal fist ula c o u nt, a n d t otal 
A N c o u nt a m o n g s u bjects 
w h o ha ve at least o ne 
c orres p o n di n g lesi o n at 
Baseli ne . 
6.  C ha n ge fr o m Baseli ne  i n t he 
Sart ori us sc ore, m o difie d 
Sart ori us sc ore, I H S 4 sc ore, 
a n d H S-P G A t o q ua ntif y t he 
se verit y c ha n ge of H S; 
7.  C ha n ge fr o m Baseli ne  i n 
s u bject-re p orte d o utc o mes: 
S F -3 6 v 2, E Q -5 D -5 L, 
Hi S Q O L a n d D L QI;  
8.  Pr o p orti o n of s u bjects w h o 
e x perie nce d flare, defi ne d b y 
at least a 2 5 % i ncrease  i n A N 
c o u nts wit h a mi ni m u m 
i ncrease of 2 A N lesi o ns 
relati ve t o Baseli ne ; 
9.  D urati o n of flare i n da ys 
(calc ulate d fr o m t he da y 
w he n flare is o bser ve d t o t he 
da y pri or t o t he o bser vati o n 
t hat flare is n o l o n ger prese nt; 
of n ote, t here c o ul d be 
m ulti ple peri o ds t hat flares 
are o bser ve d, i n w hic h case, 
t he t otal da ys fr o m t he 
m ulti ple peri o ds will be 
use d);  
1 0.  Pr o p orti o n of s u bjects w h o 
e x perie nce at least 2 5 % 
P P D


 
C O N FI D E N TI A L  
Pa ge 6 6  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
1 5.  N u m ber of lesi o n i nter ve nti o ns 
d ue t o H S;  
1 6.  Healt h -ec o n o mic i nf or mati o n: 
a. 
W P AI: S H P: C ha n ge fr o m 
Da y 1 t o eac h ti me p oi nt 
d uri n g Peri o d 1 a n d C ha n ge 
fr o m Wee k 1 2 t o eac h 
ti me p oi nt d uri n g Peri o d 2 
a n d i ncl u di n g t he f oll o w -u p 
peri o d;  
b.  H os pitalizati o ns 
(c u m ulati ve): N u m ber of 
H os pitalizati o ns t otal a n d 
d ue t o H S, N u m ber of da ys 
h os pitalize d, N u m ber of 
da ys misse d fr o m w or k;  
c. 
E mer ge nc y or Ur ge nt Care 
visits (c u m ulati ve): 
N u m ber of visits t otal a n d 
d ue t o H S, N u m ber of da ys 
( or h o urs w here a p plica ble) 
misse d fr o m w or k;  
d.  Lesi o n i nter ve nti o ns f or H S 
(c u m ulati ve): N u m ber of 
da ys ( or h o urs w here 
a p plica ble) misse d fr o m 
w or k d ue t o H S lesi o n 
i nter ve nti o ns. 
 
i ncrease i n drai ni n g fist ula 
c o u nts wit h a mi ni m u m 
i ncrease of 2 drai ni n g fist ula 
c o u nts relati ve t o Bas eli ne; 
1 1.  D uri n g Peri o d 2, pr o p orti o n 
of s u bjects wit h a l oss of 
res p o nse, ( L O R) defi ne d as 
l oss of at least 5 0 % of A N 
c o u nt i m pr o ve me nt ac hie ve d 
fr o m Wee k 1 2 i n Peri o d 1; 
1 2.  Ti me t o L O R d uri n g Peri o d 2;  
1 3.  Pr o p orti o n of s u bjects w h o 
recei ve d oral a nti bi otic resc ue 
t hera p y d uri n g Peri o d 1 a n d 
Peri o d 2 i ncl u di n g t he f oll o w -
u p peri o d se paratel y;  
1 4.  Pr o p orti o n of s u bjects w h o 
start disall o we d o pi oi d pai n 
t hera p y d uri n g Peri o d 1 a n d 
Peri o d 2 i ncl u di n g t he f oll o w -
u p peri o d se paratel y;  
1 5.  Pr o p orti o n of s u bjects w h o 
u n der g o lesi o n i nter ve nti o n 
d ue t o H S d uri n g Peri o d 1 
a n d Peri o d 2 i ncl u di n g t he 
f oll o w-u p peri o d se paratel y;  
1 6.  N u m ber of lesi o n 
i nter ve nti o ns d ue t o H S 
d uri n g Peri o d 1 a n d Peri o d 2 
i ncl u di n g t he f oll o w-u p 
peri o d se paratel y;  
1 7.  Healt h -ec o n o mic i nf or mati o n: 
a. 
W P AI: S H P: C ha n ge  
fr o m Baseli ne  t o eac h 
ti me p oi nt d uri n g 
Peri o d 1 a n d C ha n ge 
fr o m Wee k 1 2 t o eac h 
ti me p oi nt d uri n g 
Peri o d 2 a n d i ncl u di n g 
t he f oll o w-u p peri o d;  
b.  H os pitalizati o ns 
(c u m ulati ve): N u m ber 
of H os pitalizati o ns 
t otal a n d d ue t o H S, 
N u m ber of da ys 
P P D


 
C O N FI D E N TI A L  
Pa ge 6 7  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
h os pitalize d, N u m be r 
of da ys misse d fr o m 
w or k d uri n g Peri o d 1 
a n d Peri o d 2 i ncl u di n g 
t he f oll o w-u p peri o d 
se paratel y;  
c. 
E mer ge nc y or Ur ge nt 
Care visits 
(c u m ulati ve): N u m ber 
of visits t otal a n d d ue 
t o H S, N u m ber of da ys 
( or h o urs w here 
a p plica ble) misse d 
fr o m w or k d uri n g 
Peri o d 1 a n d Peri o d 2 
i ncl u di n g t he f oll o w-u p 
peri o d se paratel y;  
d.  Lesi o n i nter ve nti o ns 
f or H S: N u m ber of 
da ys ( or h o urs w here 
a p plica ble) misse d 
fr o m w or k d ue t o H S 
lesi o n i nter ve nti o ns 
d uri n g Peri o d 1 a n d 
Peri o d 2 i ncl u di n g t he 
f oll o w-u p peri o d  
se paratel y. 
U p date d t he defi niti o n  
of n o n -res p o n ders 
Pa ge 7 1:  
T he f oll o wi n g are e xa m ples f or 
s u bjects w h o will be c o u nte d as n o n-
res p o n der:  
• C o nc o mita nt a nti-T N F -α treat me nt or 
ot her treat me nts wit h cli nicall y 
rele va nt i m pact o n H S; 
• A nti bi otic resc ue t hera p y; 
• No n -pr ot oc ol s pecifie d lesi o n 
i nter ve nti o n, or hi g her t ha n per mitte d 
fre q ue nc y or n u m ber of pre-s pecifie d 
lesi o n i nter ve nti o ns. Pr ot oc ol-s pecifie d 
lesi o n i nter ve nti o ns will n ot be 
c o u nte d as N o n -res p o n der. 
Lesi o ns t hat recei ve d i nter ve nti o n 
(i ncisi o n a n d drai na ge, or i ntralesi o nal 
i njecti o n of c ortic oster oi d) will be 
c o u nte d as per ma ne ntl y prese nt fr o m 
t he date of t he i nter ve nti o n. 
I n or der t o a dj ust f or t he i m pact of 
maj or pr ot oc ol disall o we d treat me nts 
o n t he res ults of t he trial, efficac y 
assess me nts o bta i ne d after t he start of 
maj or pr ot oc ol disall o we d treat me nts 
will be e xcl u de d fr o m t he a nal ysis. 
S u bject will be c o u nte d as n o n -
res p o n ders f or t he cate g orical 
varia bles a n d ha ve t heir last 
o bser vati o n carrie d f or war d f or 
c o nti n u o us varia bles.  
 
P P D


 
C O N FI D E N TI A L  
Pa ge 6 8  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
Missi n g data 
i m p utati o n met h o d has 
bee n u p date d  
Pa ge 7 1:  
Missi n g Data A nal ysis: F or missi n g 
data a nal ysis, t he f oll o wi n g i m p utati o n 
r ules will be a p plie d t o cate g orical a n d 
c o nti n u o us efficac y varia bles, 
res pecti vel y: 
• Cate g orical Efficac y Varia bles: N RI 
will be t he pri mar y a p pr oac h f or 
cate g orical varia bles. T he N RI a nal ysis 
will c o u nt s u bjects w h o ha ve missi n g 
val ues at a s pecific visit as n o n -
res p o n ders f or t hat visit. L O C F will be 
t he sec o n dar y a p pr oac h f or t he missi n g 
data a nal ysis.  
• C o nti n u o us Efficac y Varia bles: 
L O C F will be t he pri mar y a p pr oac h 
f or c o nti n u o us efficac y varia bles of 
missi n g data. T he L O C F a nal yses will 
ha ve t heir vali d efficac y assess me nts 
fr o m t he pre vi o us visits t o i m p ute 
missi n g data at later visits. Baseli ne 
efficac y e val uati o ns will n ot be carrie d 
f or war d. 
 
1)  A d d e d MI met h o d f or 
selecte d bi nar y sec o n dar y 
efficac y e n d p oi nts. 
2)  A d d e d  A N C O V A m o del f or 
selecte d bi nar y sec o n dar y 
efficac y e n d p oi nts. 
  
A d de d C T C A E gra des 
f or la b para meters 
Pa ge 7 3:  
N o C T C A E was me nti o ne d i n t he 
pr ot oc ol.  
A d d e d a nal yses b y  C T C A E gra des.  
A d d e d m ore  s ub gr o u p  
a nal yses.  
Pa ge 7 5:  
T he a nal ysis of t he efficac y e n d p oi nts 
ma y be a dj uste d b y t he f oll o wi n g 
varia bles i n t he f or m of c o variate 
a nal ysis, stratifie d a nal ysis, a n d/ or 
s u b gr o u p a nal ysis: 
• Ra n d o mizati o n stratificati o n 
varia bles  
- H urle y Sta ge II vs. H urle y Sta ge III  
- C o nc o mita nt  a nti bi otic t hera p y ( Yes 
vs. N o)  
- A nti -T N F -α treat me nt ( Treat me nt 
naï ve vs. Pre vi o us treat me nt)  
• Se x 
• B MI 
• Baseli ne wei g ht 
• A ge at dia g n osis of H S 
• A ge at st ud y e ntr y  
• D urati o n of H S 
• S u bject’s a ge, race, a n d et h nicit y  
• Baseli ne i nfla m mat or y n o d ule c o u nt 
• Baseli ne a bscess c o u nt 
• Baseli ne drai ni n g fist ula c o u nt 
• Baseli ne Sart ori us a n d m o difie d   
Sart ori us sc ores  
• Baseli ne A N c o u nt 
• Ge o gra p hic distri b utio n  
T he s u b gr o u ps are defi ne d as f oll o ws:  
•  
Ra n d o mizati o n stratificati o n 
varia bles  
− 
H urle y Sta ge (II, III)  
− 
C o nc o mita nt 
a nti bi otic t hera p y 
( Yes, N o)  
− 
A nti -T N F -α 
treat me nt ( Treat me nt 
naï ve, Pre vi o us 
treat me nt)  
•  
Se x ( Male, Fe male)  
•  
B MI cate g or y:  N or mal ( < 2 5 
k g/ m 2) , O ver wei g ht ( 2 5 – < 
3 0 k g/ m 2), o bese ( 3 0 – < 4 0 
k g/ m 2), M or bi d o besit y ( ≥ 4 0 
k g/ m 2) 
•  
A ge at dia g n osis of H S ( < 
me dia n,  ≥ me dia n)  
•  
A ge at st u d y e ntr y ( < 6 5 years 
vs. ≥ 6 5 years)  
•  
D urati o n of H S ( < me dia n,  ≥ 
me dia n)  
•  
Race ( W hite vs. N o ne -W hite)  
P P D


 
C O N FI D E N TI A L  
Pa ge 6 9  of 6 9  
C he m o Ce ntr y x, I nc. / Pr ot oc ol: C L 0 1 6 _ 1 6 8  
( C o nfi de ntial) Pr oject # B Z A 5 2 2 2 7 
 
•  
Baseli ne A N c o u nt ( < 5,  5 -
1 0,  > 1 0)  
•  
Baseli ne i nfla m mat or y 
n o d ule c o u nt ( < me dia n,  ≥ 
me dia n)  
•  
Baseli ne a bscess c o u nt ( < 
me dia n,  ≥ me dia n)  
•  
Baseli ne drai ni n g fist ula 
c o u nt ( < me dia n,  ≥ me dia n)  
•  
Baseli ne m o difie d Sart ori us 
sc ore ( < me dia n,  ≥ me dia n) 
•  
Pre vi o us s yste mic H S 
treat me nt (i ncl u des T N F 
i n hi bit or use b ut e xcl u des 
a nti bi otic use) 
•  
Ge o gra p hic distri b uti o n 
( N ort heaster n Re gi o n, 
S o ut heaster n Re gi o n, 
Wester n R e gi o n, Mi d wester n 
Re gi o n, a n d S o ut h wester n 
Re gi o n)  
 
P P D


P P D
P P D
P P D
P P D
P P D